PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
11798159-4	2002	Bradykinin elicited endothelium-dependent relaxations and hyperpolarizations in the presence of indomethacin and N(omega)-nitro-l-arginine, which thus were attributed to EDHF, in human mesenteric arteries.	Nitroarginine	113-138	kininogen 1	Homo sapiens	0-10
11786479-8	2002	However, when endothelial nitric oxide synthase (eNOS) was blocked with N(G)-nitro-L-arginine, the sensitivity and maximum relaxant response to ACh was significantly higher in intact females compared with males and ovariectomized females.	Nitroarginine	72-93	nitric oxide synthase 3	Rattus norvegicus	14-47
11786479-8	2002	However, when endothelial nitric oxide synthase (eNOS) was blocked with N(G)-nitro-L-arginine, the sensitivity and maximum relaxant response to ACh was significantly higher in intact females compared with males and ovariectomized females.	Nitroarginine	72-93	nitric oxide synthase 3	Rattus norvegicus	49-53
11853122-1	2002	This study was designed to determine the possible potentiation of catalepsy behavior after coadministration of N(G)-nitro-L-arginine (L-NOARG), an inhibitor of nitric oxide synthase (NOS), and tiapride, a specific antagonist for D2 receptors, in male mice.	Nitroarginine	111-132	nitric oxide synthase 1, neuronal	Mus musculus	160-181
11773322-4	2002	In isolated smooth muscle cells from wild-type, eNOS knockout and nNOS knockout mice, the relaxation induced by VIP (10(-9) M) was inhibited by approximately 70-95 % by both the non-selective NOS inhibitor N(G)-nitro-L-arginine (L-NA; 10(-4) M) and the selective inducible NOS inhibitor N-(3-(aminomethyl)-benzyl)acetamidine (1400W; 10(-6) M).	Nitroarginine	206-227	nitric oxide synthase 1, neuronal	Mus musculus	66-70
11773322-4	2002	In isolated smooth muscle cells from wild-type, eNOS knockout and nNOS knockout mice, the relaxation induced by VIP (10(-9) M) was inhibited by approximately 70-95 % by both the non-selective NOS inhibitor N(G)-nitro-L-arginine (L-NA; 10(-4) M) and the selective inducible NOS inhibitor N-(3-(aminomethyl)-benzyl)acetamidine (1400W; 10(-6) M).	Nitroarginine	206-227	vasoactive intestinal polypeptide	Mus musculus	112-115
12112002-5	2002	L-Arginine analogs N-nitro-L-arginine methyl ester (L-NAME) and N-nitro-L-arginine (NLA) significantly block HO-1 protein induced by LPS/IFN-gamma associated with a decrease in NO (not PGE(2)) production.	Nitroarginine	19-37	heme oxygenase 1	Homo sapiens	109-113
12112002-5	2002	L-Arginine analogs N-nitro-L-arginine methyl ester (L-NAME) and N-nitro-L-arginine (NLA) significantly block HO-1 protein induced by LPS/IFN-gamma associated with a decrease in NO (not PGE(2)) production.	Nitroarginine	19-37	interferon regulatory factor 6	Homo sapiens	133-136
12112002-5	2002	L-Arginine analogs N-nitro-L-arginine methyl ester (L-NAME) and N-nitro-L-arginine (NLA) significantly block HO-1 protein induced by LPS/IFN-gamma associated with a decrease in NO (not PGE(2)) production.	Nitroarginine	19-37	interferon gamma	Homo sapiens	137-146
12112002-5	2002	L-Arginine analogs N-nitro-L-arginine methyl ester (L-NAME) and N-nitro-L-arginine (NLA) significantly block HO-1 protein induced by LPS/IFN-gamma associated with a decrease in NO (not PGE(2)) production.	Nitroarginine	84-87	heme oxygenase 1	Homo sapiens	109-113
12112002-5	2002	L-Arginine analogs N-nitro-L-arginine methyl ester (L-NAME) and N-nitro-L-arginine (NLA) significantly block HO-1 protein induced by LPS/IFN-gamma associated with a decrease in NO (not PGE(2)) production.	Nitroarginine	84-87	interferon regulatory factor 6	Homo sapiens	133-136
12112002-5	2002	L-Arginine analogs N-nitro-L-arginine methyl ester (L-NAME) and N-nitro-L-arginine (NLA) significantly block HO-1 protein induced by LPS/IFN-gamma associated with a decrease in NO (not PGE(2)) production.	Nitroarginine	84-87	interferon gamma	Homo sapiens	137-146
11853122-1	2002	This study was designed to determine the possible potentiation of catalepsy behavior after coadministration of N(G)-nitro-L-arginine (L-NOARG), an inhibitor of nitric oxide synthase (NOS), and tiapride, a specific antagonist for D2 receptors, in male mice.	Nitroarginine	134-141	nitric oxide synthase 1, neuronal	Mus musculus	160-181
11910991-4	2001	NG-nitro-L-arginine methyl ester, NG-nitro-L-arginine and NG-monomethyl-L-arginine were used to inhibit NO synthase, VIP (10-28) and [D-p-Cl-Phe6, Leu17] VIP to block VIP receptors, and suramin to block ATP receptors.	Nitroarginine	0-19	vasoactive intestinal peptide	Rattus norvegicus	117-120
12435435-3	2002	The present study tests the hypothesis that inhibition of NOS by N-nitro-L-arginine (NNLA) will prevent the hypoxia-induced increased phosphorylation of CREB protein in neuronal nuclei of newborn piglets.	Nitroarginine	65-83	cAMP responsive element binding protein 1	Homo sapiens	153-157
12435435-3	2002	The present study tests the hypothesis that inhibition of NOS by N-nitro-L-arginine (NNLA) will prevent the hypoxia-induced increased phosphorylation of CREB protein in neuronal nuclei of newborn piglets.	Nitroarginine	85-89	cAMP responsive element binding protein 1	Homo sapiens	153-157
11910991-4	2001	NG-nitro-L-arginine methyl ester, NG-nitro-L-arginine and NG-monomethyl-L-arginine were used to inhibit NO synthase, VIP (10-28) and [D-p-Cl-Phe6, Leu17] VIP to block VIP receptors, and suramin to block ATP receptors.	Nitroarginine	0-19	vasoactive intestinal peptide	Rattus norvegicus	154-157
11910991-4	2001	NG-nitro-L-arginine methyl ester, NG-nitro-L-arginine and NG-monomethyl-L-arginine were used to inhibit NO synthase, VIP (10-28) and [D-p-Cl-Phe6, Leu17] VIP to block VIP receptors, and suramin to block ATP receptors.	Nitroarginine	0-19	vasoactive intestinal peptide	Rattus norvegicus	154-157
11689192-9	2001	The exogenous orexin A-induced relaxation was completely inhibited by L-NOARG.	Nitroarginine	70-77	hypocretin	Mus musculus	14-22
11714881-7	2001	L-NOARG (100 microM) caused an inhibition of VIP-induced relaxation that was reversed by L-arginine (1 mM) but not by D-arginine (1 mM).	Nitroarginine	0-7	vasoactive intestinal polypeptide	Mus musculus	45-48
11711216-4	2001	Application of NG-Nitro-L-arginine (L-NNA), an inhibitor of all NO synthetases (NOS), prevented CBF stimulation by acetazolamide.	Nitroarginine	15-34	CCAAT/enhancer binding protein zeta	Rattus norvegicus	96-99
11711216-4	2001	Application of NG-Nitro-L-arginine (L-NNA), an inhibitor of all NO synthetases (NOS), prevented CBF stimulation by acetazolamide.	Nitroarginine	36-41	CCAAT/enhancer binding protein zeta	Rattus norvegicus	96-99
11711216-5	2001	Continuous infusion of the exogenous NO donor SIN-1 (3-morpholinosydnonimine) suppressed L-NNA induced increases of mean arterial blood pressure without effect on rCBF in comparison to baseline.	Nitroarginine	89-94	MAPK associated protein 1	Homo sapiens	46-51
11733865-4	2001	Rat beta-cells were cultured for 24 h with or without IL-1 beta and the inducible-nitric-oxide-synthase (iNOS) inhibitor N(G)-methyl-L-arginine (NMA).	Nitroarginine	121-143	nitric oxide synthase 2	Rattus norvegicus	72-103
11733865-4	2001	Rat beta-cells were cultured for 24 h with or without IL-1 beta and the inducible-nitric-oxide-synthase (iNOS) inhibitor N(G)-methyl-L-arginine (NMA).	Nitroarginine	121-143	nitric oxide synthase 2	Rattus norvegicus	105-109
11733865-7	2001	The suppressive effects of IL-1 beta on proinsulin synthesis and conversion were prevented by addition of NMA.	Nitroarginine	106-109	interleukin 1 beta	Rattus norvegicus	27-36
11985333-5	2001	Enzymatic studies revealed that N(G)-nitro-L-arginine and its methyl ester blocked the activity of brain kynurenine aminotransferase (KAT) I.	Nitroarginine	32-53	kynurenine aminotransferase 1	Homo sapiens	105-140
11985333-6	2001	The activity of KAT II was diminished only by N(G)-nitro-L-arginine.	Nitroarginine	46-67	aminoadipate aminotransferase	Homo sapiens	16-22
11985333-7	2001	Kinetic analyses have shown that N(G)-nitro-L-arginine and its methyl ester reduce Vmax and increase Km of KAT I, whereas N(G)-nitro-L-arginine diminishes Vmax of KAT II.	Nitroarginine	33-54	kynurenine aminotransferase 1	Homo sapiens	107-112
11985333-7	2001	Kinetic analyses have shown that N(G)-nitro-L-arginine and its methyl ester reduce Vmax and increase Km of KAT I, whereas N(G)-nitro-L-arginine diminishes Vmax of KAT II.	Nitroarginine	33-54	aminoadipate aminotransferase	Homo sapiens	163-169
11985333-7	2001	Kinetic analyses have shown that N(G)-nitro-L-arginine and its methyl ester reduce Vmax and increase Km of KAT I, whereas N(G)-nitro-L-arginine diminishes Vmax of KAT II.	Nitroarginine	122-143	aminoadipate aminotransferase	Homo sapiens	163-169
11787760-18	2001	The pretreatment with L-NNA to inhibit NO-synthase activity attenuated significantly the protective and hyperemic effects of CCK but not those of leptin while capsaicin denervation counteracted leptin-induced protection and rise in the GBF but attenuated significantly those of CCK.	Nitroarginine	22-27	cholecystokinin	Rattus norvegicus	125-128
11787760-18	2001	The pretreatment with L-NNA to inhibit NO-synthase activity attenuated significantly the protective and hyperemic effects of CCK but not those of leptin while capsaicin denervation counteracted leptin-induced protection and rise in the GBF but attenuated significantly those of CCK.	Nitroarginine	22-27	leptin	Rattus norvegicus	194-200
11787760-18	2001	The pretreatment with L-NNA to inhibit NO-synthase activity attenuated significantly the protective and hyperemic effects of CCK but not those of leptin while capsaicin denervation counteracted leptin-induced protection and rise in the GBF but attenuated significantly those of CCK.	Nitroarginine	22-27	cholecystokinin	Rattus norvegicus	278-281
11876023-11	2001	On the other hand, L-NOARG intensified stereotypy and catalepsy but inhibited CAR.	Nitroarginine	19-26	nuclear receptor subfamily 1, group I, member 3	Rattus norvegicus	78-81
11588525-4	2001	In the presence of Nomega-nitro-L-arginine, acetylcholine caused endothelium-dependent contractions, which were greater in vim -/- than in vim +/+ and vim +/- aortas.	Nitroarginine	19-42	vimentin	Mus musculus	123-126
11903503-5	2001	Cd2+ did block the EFS-evoked guanethidine-sensitive contraction in the presence of N(G)-nitro-L-arginine.	Nitroarginine	84-105	CD2 antigen	Mus musculus	0-3
11588525-4	2001	In the presence of Nomega-nitro-L-arginine, acetylcholine caused endothelium-dependent contractions, which were greater in vim -/- than in vim +/+ and vim +/- aortas.	Nitroarginine	19-42	vimentin	Mus musculus	139-142
11588525-4	2001	In the presence of Nomega-nitro-L-arginine, acetylcholine caused endothelium-dependent contractions, which were greater in vim -/- than in vim +/+ and vim +/- aortas.	Nitroarginine	19-42	vimentin	Mus musculus	139-142
11553364-4	2001	The suppressing action of 17beta-estradiol on the N(G)-nitro-L-arginine and indomethacin-resistant relaxation induced by isoprenaline disappeared after pretreatment with N,N-diethylaminoethyl-2,2-diphenylvalerate hydrochloride (SKF 525A), an inhibitor of cytochrome P450 (CYP).	Nitroarginine	50-71	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	255-270
11566193-3	2001	NO derived from lipopolysaccharide-stimulated J774 A-1 cells also decreased the binding of EC-SOD to HUVEC, and this decrease was blocked by N(G)-nitro-L-arginine, a nitric oxide synthase inhibitor.	Nitroarginine	141-162	superoxide dismutase 3, extracellular	Mus musculus	91-97
11567657-7	2001	These protective and hyperemic effects of standard preconditioning were significantly attenuated by pretreatment with cyclooxygenase-2 and cyclooxygenase-1 inhibitors, such as indomethacin, Vioxx, resveratrol and nitric oxide (NO)-synthase inhibitor, N(G)-nitro-L-arginine (L-NNA).	Nitroarginine	251-272	prostaglandin-endoperoxide synthase 2	Homo sapiens	118-134
11567657-7	2001	These protective and hyperemic effects of standard preconditioning were significantly attenuated by pretreatment with cyclooxygenase-2 and cyclooxygenase-1 inhibitors, such as indomethacin, Vioxx, resveratrol and nitric oxide (NO)-synthase inhibitor, N(G)-nitro-L-arginine (L-NNA).	Nitroarginine	251-272	prostaglandin-endoperoxide synthase 1	Homo sapiens	139-155
11567657-7	2001	These protective and hyperemic effects of standard preconditioning were significantly attenuated by pretreatment with cyclooxygenase-2 and cyclooxygenase-1 inhibitors, such as indomethacin, Vioxx, resveratrol and nitric oxide (NO)-synthase inhibitor, N(G)-nitro-L-arginine (L-NNA).	Nitroarginine	274-279	prostaglandin-endoperoxide synthase 2	Homo sapiens	118-134
11567657-7	2001	These protective and hyperemic effects of standard preconditioning were significantly attenuated by pretreatment with cyclooxygenase-2 and cyclooxygenase-1 inhibitors, such as indomethacin, Vioxx, resveratrol and nitric oxide (NO)-synthase inhibitor, N(G)-nitro-L-arginine (L-NNA).	Nitroarginine	274-279	prostaglandin-endoperoxide synthase 1	Homo sapiens	139-155
11553364-4	2001	The suppressing action of 17beta-estradiol on the N(G)-nitro-L-arginine and indomethacin-resistant relaxation induced by isoprenaline disappeared after pretreatment with N,N-diethylaminoethyl-2,2-diphenylvalerate hydrochloride (SKF 525A), an inhibitor of cytochrome P450 (CYP).	Nitroarginine	50-71	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	272-275
11522609-5	2001	In the presence of 10 microM indomethacin and 30 microM N(G)-nitro-L-arginine (L-NOARG), both bradykinin and substance P induced a transient decrease in [Ca(2+)]i and tension in arterial strips contracted with 100 nM U46619 (thromboxane A2 analogue).	Nitroarginine	56-77	kininogen 1	Homo sapiens	94-104
11522609-5	2001	In the presence of 10 microM indomethacin and 30 microM N(G)-nitro-L-arginine (L-NOARG), both bradykinin and substance P induced a transient decrease in [Ca(2+)]i and tension in arterial strips contracted with 100 nM U46619 (thromboxane A2 analogue).	Nitroarginine	56-77	tachykinin precursor 1	Homo sapiens	109-120
11522609-5	2001	In the presence of 10 microM indomethacin and 30 microM N(G)-nitro-L-arginine (L-NOARG), both bradykinin and substance P induced a transient decrease in [Ca(2+)]i and tension in arterial strips contracted with 100 nM U46619 (thromboxane A2 analogue).	Nitroarginine	79-86	kininogen 1	Homo sapiens	94-104
11522609-5	2001	In the presence of 10 microM indomethacin and 30 microM N(G)-nitro-L-arginine (L-NOARG), both bradykinin and substance P induced a transient decrease in [Ca(2+)]i and tension in arterial strips contracted with 100 nM U46619 (thromboxane A2 analogue).	Nitroarginine	79-86	tachykinin precursor 1	Homo sapiens	109-120
11522609-10	2001	The indomethacin/L-NOARG-resistant relaxation induced by bradykinin was completely inhibited by 3 mM tetrabutylammonium (non-specific Ca(2+)-activated K(+) channel blocker), while that induced by substance P was not inhibited by 3 mM tetrabutylammonium or 1 mM 4-aminopyridine (voltage-dependent K(+) channels blocker) alone, but completely inhibited by their combination.	Nitroarginine	17-24	kininogen 1	Homo sapiens	57-67
11522609-10	2001	The indomethacin/L-NOARG-resistant relaxation induced by bradykinin was completely inhibited by 3 mM tetrabutylammonium (non-specific Ca(2+)-activated K(+) channel blocker), while that induced by substance P was not inhibited by 3 mM tetrabutylammonium or 1 mM 4-aminopyridine (voltage-dependent K(+) channels blocker) alone, but completely inhibited by their combination.	Nitroarginine	17-24	tachykinin precursor 1	Homo sapiens	196-207
11476748-6	2001	RESULTS: CNP reduced perfusion pressure from 134 +/- 2 mmHg (baseline) to 71 +/- 1 mmHg (-48%) and this effect was significantly attenuated by L-NNA (-37%) or HS-142-1 (-19%).	Nitroarginine	143-148	natriuretic peptide C	Rattus norvegicus	9-12
11507004-3	2001	Maximal contraction to epidermal growth factor [EGF; percentage of phenylephrine (PE; 10 umol/l)-induced contraction] was greater in strips from L-NNA (32 +/- 5%) and SHR (53 +/- 8%) rats compared with sham and WKY rats (17 +/- 1 and 12 +/- 4%, respectively).	Nitroarginine	145-150	epidermal growth factor	Rattus norvegicus	48-51
11476748-8	2001	Basal release of cGMP was increased up to 4-fold by CNP and this increase was reduced (-50%) in presence of L-NNA or HS-142-1 (-68%).	Nitroarginine	108-113	natriuretic peptide C	Rattus norvegicus	52-55
11444496-6	2001	In rings of coronary artery precontracted with U46619, bradykinin and cyclopiazonic acid produced endothelium-dependent relaxations even in the presence of N(G)-nitro-L-arginine and indomethacin.	Nitroarginine	156-177	kininogen 1	Homo sapiens	55-65
11461931-4	2001	Luminal application of the nonselective NOS inhibitor nitro-L-arginine (10(-3) and 10(-2) M) enhanced the perfusion-dependent fall in stop-flow pressure in nNOS +/+ (7 +/- 1 to 13 +/- 2 mmHg; P < 0.05) but not in nNOS -/- (7 +/- 1 to 8 +/- 1 mmHg; not significant) mice.	Nitroarginine	54-70	nitric oxide synthase 1, neuronal	Mus musculus	156-160
11461931-4	2001	Luminal application of the nonselective NOS inhibitor nitro-L-arginine (10(-3) and 10(-2) M) enhanced the perfusion-dependent fall in stop-flow pressure in nNOS +/+ (7 +/- 1 to 13 +/- 2 mmHg; P < 0.05) but not in nNOS -/- (7 +/- 1 to 8 +/- 1 mmHg; not significant) mice.	Nitroarginine	54-70	nitric oxide synthase 1, neuronal	Mus musculus	216-220
11331078-7	2001	Furthermore, N-nitro-L-arginine (NLA) and N-nitro-L-arginine methyl ester (L-NAME) pretreatment enhanced LPS-induced iNOS (but not COX-2) protein expression, which was inhibited by these three polyphenolic compounds.	Nitroarginine	13-31	nitric oxide synthase 2, inducible	Mus musculus	117-121
11331078-7	2001	Furthermore, N-nitro-L-arginine (NLA) and N-nitro-L-arginine methyl ester (L-NAME) pretreatment enhanced LPS-induced iNOS (but not COX-2) protein expression, which was inhibited by these three polyphenolic compounds.	Nitroarginine	33-36	nitric oxide synthase 2, inducible	Mus musculus	117-121
11369112-18	2001	L-NOARG potentiated the A II induced vasoconstriction only in cadmium poisoned rats, also indicating a greater influence of nitric oxide in cadmium treated rat vasculature.	Nitroarginine	0-7	angiotensinogen	Rattus norvegicus	24-28
11417334-1	2001	PURPOSE: It has been reported that intravenous injection of the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine methyl esther (L-NAME) causes a rapid decrease of intraocular pressure (IOP) in rabbits.	Nitroarginine	102-121	nitric oxide synthase, brain	Oryctolagus cuniculus	64-85
11179776-5	2001	At 1 mg x kg(-1) N(omega)-nitro-L-arginine (L-NNA) blocked the GLP-1 response up to a dose of 10 pmol x kg(-1) x min(-1) (P<0.05), while higher doses were able to overcome L-NNA-induced disinhibition of the GLP-1 response (P<0.05).	Nitroarginine	18-42	glucagon	Rattus norvegicus	63-68
11179776-5	2001	At 1 mg x kg(-1) N(omega)-nitro-L-arginine (L-NNA) blocked the GLP-1 response up to a dose of 10 pmol x kg(-1) x min(-1) (P<0.05), while higher doses were able to overcome L-NNA-induced disinhibition of the GLP-1 response (P<0.05).	Nitroarginine	18-42	glucagon	Rattus norvegicus	210-215
11179776-5	2001	At 1 mg x kg(-1) N(omega)-nitro-L-arginine (L-NNA) blocked the GLP-1 response up to a dose of 10 pmol x kg(-1) x min(-1) (P<0.05), while higher doses were able to overcome L-NNA-induced disinhibition of the GLP-1 response (P<0.05).	Nitroarginine	44-49	glucagon	Rattus norvegicus	63-68
11179776-5	2001	At 1 mg x kg(-1) N(omega)-nitro-L-arginine (L-NNA) blocked the GLP-1 response up to a dose of 10 pmol x kg(-1) x min(-1) (P<0.05), while higher doses were able to overcome L-NNA-induced disinhibition of the GLP-1 response (P<0.05).	Nitroarginine	44-49	glucagon	Rattus norvegicus	210-215
11179776-6	2001	Similarly, L-arginine at 300 mg x kg(-1) prevented L-NNA-induced disinhibition of the GLP-1 response (P<0.05).	Nitroarginine	51-56	glucagon	Rattus norvegicus	86-91
11283844-9	2001	Incubation with NNA, INDO, or both significantly enhanced the response of collaterals to ET-1 (P < .05).	Nitroarginine	16-19	endothelin 1	Rattus norvegicus	89-93
11257085-8	2001	Although high [Ca(2+)] perfusion increased E(max) and the intercept to the same extent as ET-1, it did not change S. N(G)-Nitro-L-arginine (an inhibitor of nitric oxide synthase) increased the coronary perfusion pressure as much as ET-1, but S again remained unchanged.	Nitroarginine	117-138	endothelin 1	Rattus norvegicus	232-236
11323004-10	2001	Pretreatment with the nitric oxide (NO)-synthase inhibitor N(G)-nitro-L-arginine-methylester (L-NAME) suppressed the dose-dependent vasodilator effects of thrombin.	Nitroarginine	59-80	coagulation factor II	Rattus norvegicus	155-163
11230999-13	2001	The treatment with tyrphostin or N(G)-nitro-L-arginine reversed in part the acceleration of ulcer healing by leptin and CCK.	Nitroarginine	33-54	leptin	Rattus norvegicus	109-115
11230999-13	2001	The treatment with tyrphostin or N(G)-nitro-L-arginine reversed in part the acceleration of ulcer healing by leptin and CCK.	Nitroarginine	33-54	cholecystokinin	Rattus norvegicus	120-123
11208599-8	2001	Addition of 5 x 10(-3) M L-arginine to the peritubular perfusate overcame the inhibitory effect of L-NNA on high-eta-induced increase in H+ flux.	Nitroarginine	99-104	endothelin receptor type A	Homo sapiens	113-116
11162595-4	2001	N(G)-nitro-l-arginine significantly increased ET-1 concentration and reduced hemoglobin stimulation of ET-1 release.	Nitroarginine	0-21	endothelin 1	Bos taurus	46-50
11162595-4	2001	N(G)-nitro-l-arginine significantly increased ET-1 concentration and reduced hemoglobin stimulation of ET-1 release.	Nitroarginine	0-21	endothelin 1	Bos taurus	103-107
11162595-9	2001	Ferrous hemoglobin increases ET-1 by binding nitric oxide and abolishing this inhibitory pathway although other mechanisms are involved since N(G)-nitro-l-arginine reduces hemoglobin-induced ET-1 release.	Nitroarginine	142-163	endothelin 1	Bos taurus	191-195
11120633-10	2001	A two- to threefold increase in eNOS activity was observed upon activation by bradykinin which was completely inhibited in L-NNA-treated samples.	Nitroarginine	123-128	kininogen 1	Homo sapiens	78-88
11179602-2	2001	VIP reduced motor activity and this inhibitory effect was not altered by either atropine, hexamethonium, tetrodotoxin (TTX) nor TTX plus acetylcholine (ACh), but was completely antagonized by NO synthase inhibitor N(G)-nitro-L-arginine (L-NA) and by VIP receptor antagonist, VIP(10-28).	Nitroarginine	214-235	vasoactive intestinal peptide	Rattus norvegicus	0-3
11269922-6	2000	Vagal stimulation elicited frequency-dependent relaxations of the LOS that were abolished by tetrodotoxin (1 microM) and markedly reduced following L-NNA pretreatment (100 microM), but unaltered following pretreatment with the selective VIP or PACAP receptor antagonists VIP (10-28) or PACAP (6-38), respectively (each at 5 microM).	Nitroarginine	148-153	VIP peptides	Mustela putorius furo	237-240
11269922-6	2000	Vagal stimulation elicited frequency-dependent relaxations of the LOS that were abolished by tetrodotoxin (1 microM) and markedly reduced following L-NNA pretreatment (100 microM), but unaltered following pretreatment with the selective VIP or PACAP receptor antagonists VIP (10-28) or PACAP (6-38), respectively (each at 5 microM).	Nitroarginine	148-153	VIP peptides	Mustela putorius furo	271-274
11078448-4	2000	IL-1beta-induced NO production was prevented by incubation of islets in arginine-free medium supplemented with the arginine analog NG-nitro-L-arginine.	Nitroarginine	131-150	interleukin 1 beta	Rattus norvegicus	0-8
11025451-2	2000	The induction can be suppressed by N(G)-methyl-L-arginine, a specific inhibitor of nitric oxide synthase (NOS).	Nitroarginine	35-57	nitric oxide synthase 2	Homo sapiens	83-104
11009479-7	2000	Dilation to ACh was inhibited by N(G)-nitro-L-arginine, an inhibitor of NOS in control and eNOS -/- mice.	Nitroarginine	33-54	nitric oxide synthase 3, endothelial cell	Mus musculus	91-95
10980246-1	2000	The function of the neuronal isoform of nitric oxide synthase (nNOS) was studied by comparing the effects of the specific nNOS blocker 7-nitro indazole monosodium salt (7-NINA) with that of the general NOS inhibitor N(G)-nitro-L-arginine (L-NA) in isolated rat basilar arteries (BAs).	Nitroarginine	216-237	nitric oxide synthase 1	Rattus norvegicus	63-67
11016327-5	2000	The rings were isometrically contracted with potassium chloride (30 mmol/L) and the response to BK (1 to 1,000 nmol/L)-induced relaxation was investigated in the presence of nitric oxide synthase inhibitor Nomega-nitro-L-arginine (300 micromol/L) alone and in combination with the cyclooxygenase inhibitor indomethacin (10 micromol/L), and that of the inhibitor of calcium-dependent potassium channels tetraethylammonium (7 mmol/L).	Nitroarginine	206-229	kininogen 1	Homo sapiens	96-98
10963751-5	2000	Finally, increased IL-1 beta gene expression in the PVN of LPS-treated rats receiving N(G)-nitro-L-arginine showed that NO regulates brain IL-1 beta gene expression.	Nitroarginine	86-107	interleukin 1 beta	Rattus norvegicus	19-28
10963751-5	2000	Finally, increased IL-1 beta gene expression in the PVN of LPS-treated rats receiving N(G)-nitro-L-arginine showed that NO regulates brain IL-1 beta gene expression.	Nitroarginine	86-107	interleukin 1 beta	Rattus norvegicus	139-148
10952674-2	2000	The cyclic GMP elevation produced by 100 microM NMDA was blocked by 100 microM of the NO synthase inhibitor N(G)-nitro-L-arginine (L-NOARG) or by 10 microM of the soluble guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-alpha] quinoxaline-1-one (ODQ).	Nitroarginine	108-129	5'-nucleotidase, cytosolic II	Homo sapiens	11-14
10952674-2	2000	The cyclic GMP elevation produced by 100 microM NMDA was blocked by 100 microM of the NO synthase inhibitor N(G)-nitro-L-arginine (L-NOARG) or by 10 microM of the soluble guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-alpha] quinoxaline-1-one (ODQ).	Nitroarginine	131-138	5'-nucleotidase, cytosolic II	Homo sapiens	11-14
10919570-4	2000	RESULTS: In the rings (normalized diameter: 200-500 microM) precontracted by U46619, EDHF-mediated relaxation and hyperpolarization were initiated by bradykinin (BK) or A23187 in the presence of indomethacin and NG-nitro-L-arginine.	Nitroarginine	212-231	kininogen 1	Homo sapiens	150-160
10919570-4	2000	RESULTS: In the rings (normalized diameter: 200-500 microM) precontracted by U46619, EDHF-mediated relaxation and hyperpolarization were initiated by bradykinin (BK) or A23187 in the presence of indomethacin and NG-nitro-L-arginine.	Nitroarginine	212-231	kininogen 1	Homo sapiens	162-164
10902810-8	2000	To examine whether the insulin-induced inhibition of ICAM-1 was mediated by nitric oxide (NO) from increased endothelial NOS, HAEC were treated with N(omega)-nitro-L-arginine, a NOS inhibitor.	Nitroarginine	149-174	insulin	Homo sapiens	23-30
10902810-9	2000	N(omega)-Nitro-L-arginine inhibited the insulin-induced decrease in ICAM-1 expression in HAEC at the messenger ribonucleic acid and protein levels.	Nitroarginine	0-25	insulin	Homo sapiens	40-47
10902810-9	2000	N(omega)-Nitro-L-arginine inhibited the insulin-induced decrease in ICAM-1 expression in HAEC at the messenger ribonucleic acid and protein levels.	Nitroarginine	0-25	intercellular adhesion molecule 1	Homo sapiens	68-74
10839919-11	2000	The NO synthase inhibitors Nomega-nitro-l-arginine-methyl-esther and Nomega-nitro-l-arginine completely abolished the morphine-induced attenuation of NF-kappaB nuclear binding, demonstrating that the inhibitory action is mediated by NO release.	Nitroarginine	27-50	nuclear factor kappa B subunit 1	Homo sapiens	150-159
10912465-5	2000	L-NNA treatment significantly reduced the BK-stimulated rise in [NO] to 32.1+/-11.3 nM but did not affect the hyperpolarization.	Nitroarginine	0-5	kininogen 1	Homo sapiens	42-44
10912465-11	2000	CONCLUSIONS: In porcine coronary arteries, both EDHF and NO contribute to BK-induced relaxation resistance to indomethacin and L-NNA.	Nitroarginine	127-132	kininogen 1	Homo sapiens	74-76
10781015-8	2000	Relaxations to thrombin, SFLLRN, trypsin and SLIGRL were significantly inhibited (P<0.05) to similar extents by the nitric oxide (NO) synthase inhibitor N(G)-nitro-L-arginine (L-NOARG; 100 microM) and the NO scavenger oxyhaemoglobin (20 microM), both separately and in combination.	Nitroarginine	156-177	coagulation factor II, thrombin	Homo sapiens	15-23
10781015-10	2000	In the presence of the L-type voltage-operated calcium channel (L-VOCC) inhibitor nifedipine (0.3 microM), K(+) (67 mM) abolished the L-NOARG-resistant relaxations to thrombin, SFLLRN, trypsin and SLIGRL.	Nitroarginine	134-141	coagulation factor II, thrombin	Homo sapiens	167-175
10781015-12	2000	Furthermore, L-NOARG-resistant relaxations to thrombin were abolished by nifedipine, whereas relaxations to SFLLRN, trypsin or SLIGRL were not further inhibited by combined treatment with nifedipine and L-NOARG, than they were with L-NOARG treatment alone.	Nitroarginine	13-20	coagulation factor II, thrombin	Homo sapiens	46-54
10781015-14	2000	Similar selective inhibition of the L-NOARG-resistant relaxation to thrombin, but not SFLLRN, occurred with verapamil (1 microM) and diltiazem (3 microM).	Nitroarginine	36-43	coagulation factor II, thrombin	Homo sapiens	68-76
10832602-9	2000	It is concluded that: (a) PACAP(6-38) is a VIP/PACAP antagonist in the guinea-pig taenia caeci; (b) a release of a VIP/PACAP-like substance from enteric nerves is involved in the NANC relaxation in this preparation, but its contribution is relatively small and seems to depend on the functional integrity of the PPADS-sensitive inhibitory mechanism; (c) the PPADS- plus L-NOARG-resistant NANC relaxation probably involves apamin-sensitive K+ channels.	Nitroarginine	370-377	VIP peptides	Cavia porcellus	115-118
10769287-11	2000	Intracoronary N(omega)-nitro-L-arginine (2 mg/kg) decreased the CD effect of bradykinin and prevented the CBFv and CD effects of des-Arg(9)-bradykinin.	Nitroarginine	14-39	kininogen 1	Canis lupus familiaris	77-87
10769287-11	2000	Intracoronary N(omega)-nitro-L-arginine (2 mg/kg) decreased the CD effect of bradykinin and prevented the CBFv and CD effects of des-Arg(9)-bradykinin.	Nitroarginine	14-39	kininogen 1	Canis lupus familiaris	140-150
10758772-3	2000	In addition, intraperitoneal injection of NG-nitro-L-arginine (CAS 2149-70-4) 100 mg/kg for 5 days improved the retention impairment induced by IL-6 and meanwhile antagonized the increase in nitrite levels.	Nitroarginine	42-61	interleukin 6	Rattus norvegicus	144-148
10666511-3	2000	In the presence of either tetrodotoxin or Nomega-nitro-L-arginine, nociceptin was unable to cause a further contraction, whereas the muscarinic receptor agonist carbachol elicited a contractile response.	Nitroarginine	42-65	prepronociceptin	Homo sapiens	67-77
10657552-4	2000	In circular muscle of Sprague-Dawley rats, in which participation of both nitric oxide and VIP in the relaxation was suggested, inhibition of descending relaxation by N(G)-nitro-L-arginine (L-NOARG) together with VIP-(10-28) was similar to that by either of the antagonists, and exogenous VIP-induced relaxation was not affected by L-NOARG, but exogenous nitric oxide-induced relaxation was partly inhibited by VIP-(10-28).	Nitroarginine	167-188	vasoactive intestinal peptide	Rattus norvegicus	91-94
10657552-4	2000	In circular muscle of Sprague-Dawley rats, in which participation of both nitric oxide and VIP in the relaxation was suggested, inhibition of descending relaxation by N(G)-nitro-L-arginine (L-NOARG) together with VIP-(10-28) was similar to that by either of the antagonists, and exogenous VIP-induced relaxation was not affected by L-NOARG, but exogenous nitric oxide-induced relaxation was partly inhibited by VIP-(10-28).	Nitroarginine	190-197	vasoactive intestinal peptide	Rattus norvegicus	91-94
10625313-10	2000	In the setting of tolerance, however, L-NNA decreased steady-state O(2)(.-) levels, indicating the involvement of NOS III in O(2)(.-) formation.	Nitroarginine	38-43	nitric oxide synthase 3	Rattus norvegicus	114-121
10805410-6	2000	Both the antihypotensive effects of adaptation and HSP70 accumulation were completely prevented by L-NNA, an inhibitor of NO synthesis, or quercetin, an inhibitor of HSP70 synthesis.	Nitroarginine	99-104	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	51-56
10672628-1	2000	RATIONALE: NG-nitro-L-arginine (L-NOARG), an inhibitor of nitric-oxide synthase (NOS), induces catalepsy in mice.	Nitroarginine	11-30	nitric oxide synthase 1, neuronal	Mus musculus	58-79
10672628-1	2000	RATIONALE: NG-nitro-L-arginine (L-NOARG), an inhibitor of nitric-oxide synthase (NOS), induces catalepsy in mice.	Nitroarginine	32-39	nitric oxide synthase 1, neuronal	Mus musculus	58-79
10594341-6	1999	Angiotensin I-induced contractions was less reduced by captopril when the strips were pretreated with Nomega-nitro-L-arginine.	Nitroarginine	102-125	angiotensinogen	Homo sapiens	0-13
10558999-8	1999	In functional experiments with endothelium-denuded rat aortic rings (that contained no NOS III), contractions induced by KCl were markedly increased in the presence of the NOS inhibitor N(G)-nitro-L-arginine.	Nitroarginine	186-207	nitric oxide synthase 3	Rattus norvegicus	87-94
10514420-1	1999	Using a murine breast cancer model, we earlier found a positive correlation between the expression of nitric oxide synthase (NOS) and tumor progression; treatment with inhibitors of NOS, N(G)-methyl-L-arginine (NMMA) and N(G)-nitro-L-arginine methyl ester (L-NAME), had antitumor and antimetastatic effects that were partly attributed to reduced tumor cell invasiveness.	Nitroarginine	187-209	nitric oxide synthase 1, neuronal	Mus musculus	102-123
10556500-4	1999	Pretreatment with a NO synthase inhibitor, N(G)-nitro-L-arginine, significantly increased the angiotensin II-induced vasoconstriction in young rats.	Nitroarginine	43-64	angiotensinogen	Rattus norvegicus	94-108
10556501-6	1999	The stimulation of cyclic GMP production could be inhibited by the bradykinin B(2) receptor antagonist icatibant, the NO synthase inhibitor N-omega-nitro-L-arginine, the serine protease inhibitor 3, 4-dichloroisocoumarin and the selective plasma kallikrein inhibitor Pefabloc PK, suggesting activation of the plasma kallikrein-kinin system.	Nitroarginine	140-164	5'-nucleotidase, cytosolic II	Homo sapiens	26-29
11715524-10	1999	Furthermore, L-NNA decreased iNOS-specific protein expression in DPDPE-induced tolerance and naloxone-precipited withdrawal cells.	Nitroarginine	13-18	nitric oxide synthase 2, inducible	Mus musculus	29-33
10510194-4	1999	Pretreatment of the animals with atropine, haloperidol or the nitric oxide synthase inhibitor nitro-L-arginine abolished the action of CNP.	Nitroarginine	94-110	natriuretic peptide C	Rattus norvegicus	135-138
10462538-8	1999	When this overproduction of NO in the LPS-treated rats was inhibited in vivo by a single or repeat doses of either a general NOS inhibitor N(G)-nitro-L-arginine or a specific iNOS inhibitor aminoguanidine, the FMO1 mRNA levels were not severely depressed (70-85% of the control level).	Nitroarginine	139-160	flavin containing dimethylaniline monoxygenase 1	Rattus norvegicus	210-214
10444505-8	1999	In vessels from eNOS -/- mice that were transduced with eNOS, N(omega)-nitro-L-arginine (10(-4) M) inhibited relaxation to ACh and A-23187 but not NP.	Nitroarginine	62-87	nitric oxide synthase 3, endothelial cell	Mus musculus	16-20
10444505-8	1999	In vessels from eNOS -/- mice that were transduced with eNOS, N(omega)-nitro-L-arginine (10(-4) M) inhibited relaxation to ACh and A-23187 but not NP.	Nitroarginine	62-87	nitric oxide synthase 3, endothelial cell	Mus musculus	56-60
10444508-3	1999	NO synthase (NOS) inhibition by N(omega)-nitro-L-arginine (L-NNA; topically) reduced the rCBF response to 9 +/- 4% and resting rCBF to 80 +/- 8%.	Nitroarginine	32-57	CCAAT/enhancer binding protein zeta	Rattus norvegicus	89-93
10444508-3	1999	NO synthase (NOS) inhibition by N(omega)-nitro-L-arginine (L-NNA; topically) reduced the rCBF response to 9 +/- 4% and resting rCBF to 80 +/- 8%.	Nitroarginine	32-57	CCAAT/enhancer binding protein zeta	Rattus norvegicus	127-131
10444508-3	1999	NO synthase (NOS) inhibition by N(omega)-nitro-L-arginine (L-NNA; topically) reduced the rCBF response to 9 +/- 4% and resting rCBF to 80 +/- 8%.	Nitroarginine	59-64	CCAAT/enhancer binding protein zeta	Rattus norvegicus	89-93
10444508-3	1999	NO synthase (NOS) inhibition by N(omega)-nitro-L-arginine (L-NNA; topically) reduced the rCBF response to 9 +/- 4% and resting rCBF to 80 +/- 8%.	Nitroarginine	59-64	CCAAT/enhancer binding protein zeta	Rattus norvegicus	127-131
10411696-12	1999	L-NNA treatment during four days resulted in a significant decrease in renal Ang II (183 +/- 32 vs. 454 +/- 40 fmol/g in control, P < 0.05).	Nitroarginine	0-5	angiotensinogen	Rattus norvegicus	77-83
10411696-14	1999	Blood Ang II was not significantly different from the control on days 4, 7, and 14 but was significantly increased after 21 days of L-NNA treatment (215 +/- 35 vs. 78 +/- 13 fmol/ml in control, P < 0.05).	Nitroarginine	132-137	angiotensinogen	Rattus norvegicus	6-12
10458643-11	1999	Inhibition of NO-synthase by L-NNA significantly delayed ulcer healing and reversed the CCK-8 induced acceleration of ulcer healing, hyperemia at the ulcer margin and luminal NO release, and these effects were restored by the addition to L-NNA of L-arginine but not D-arginine.	Nitroarginine	29-34	cholecystokinin	Rattus norvegicus	88-91
10320729-2	1999	In this study, we have examined the effect of drugs which spontaneously release NO (sodium nitroprusside, SNP) or inhibit the NO synthase (NOS) enzyme (Nomega-nitro-L-arginine, L-NA) on the activity of some hypothalamic and functionally associated nuclei using Fos expression as an index of neuronal activation.	Nitroarginine	152-175	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	261-264
10386227-5	1999	Endothelin-1 (10(-7) and 10(-10) mol/L) induced increases in intracellular cAMP concentrations, but only in the presence of N omega-nitro-L-arginine, a nitric oxide synthase (NOS) inhibitor.	Nitroarginine	124-148	endothelin 1	Rattus norvegicus	0-12
10215909-6	1999	Similarly, cerebroventricular administration of another NOS inhibitor, N-omega-nitro-L-arginine methylester (L-NAME), but not D-NAME or saline, increased BDNF content in the neocortex.	Nitroarginine	71-95	brain-derived neurotrophic factor	Rattus norvegicus	154-158
10215650-5	1999	Indomethacin (1 microM) and Nomega-nitro-L-arginine (100 microM) enhanced ET-1 and S6c responses.	Nitroarginine	28-51	endothelin-1	Cavia porcellus	74-78
10199846-5	1999	The arteriolar dilation to C-peptide in the presence of insulin was completely inhibited by administration of NG-nitro-L-arginine (10(-4) M).	Nitroarginine	110-129	insulin 2	Rattus norvegicus	27-36
10077589-10	1999	Use of the nitric oxide-specific dye diaminofluorescein shows that estradiol treatment increases nitric oxide generation by endothelial cells; this response is blocked by ICI 182,780 and by the eNOS inhibitor Nomega-nitro-L-arginine.	Nitroarginine	209-232	nitric oxide synthase 3	Bos taurus	194-198
11437984-2	2001	The interval between CMMCs was decreased from approximately 3 min in control solution, by approximately 55% in a nitric oxide synthase (NOS) inhibitor, N-nitro-L-arginine (L-NNA; 100 micromol L-1).	Nitroarginine	152-170	nitric oxide synthase 1, neuronal	Mus musculus	113-134
11437984-2	2001	The interval between CMMCs was decreased from approximately 3 min in control solution, by approximately 55% in a nitric oxide synthase (NOS) inhibitor, N-nitro-L-arginine (L-NNA; 100 micromol L-1).	Nitroarginine	172-177	nitric oxide synthase 1, neuronal	Mus musculus	113-134
11298788-5	2001	NMDA-induced phosphorylation of MAP-2 was inhibited by the nitric oxide synthase inhibitors nitroarginine and 7-nitroindazole and by PD098059 (an inhibitor of MAP kinase kinase), but was only slightly reduced by calphostin C or U-73122, inhibitors of protein kinase C and of phospholipase C, respectively.	Nitroarginine	92-105	microtubule-associated protein 2	Rattus norvegicus	32-37
11257143-7	2001	Inhibition of NOS II by N(G)-methyl-l-arginine (LNMMA) restores the killing obtained in the presence of interferon (IFN)-gamma plus lipolysaccharide (LPS), whereas the nitric oxide scavenger 2-(4-carboxyphenyl)-4,4,5,5,-tetramethylimidazoline-3-oxide-1-oxyl (carboxy-PTIO) was without effect.	Nitroarginine	24-46	nitric oxide synthase 2, inducible	Mus musculus	14-20
11238718-3	2001	The cytotoxicity of NMDA (30 microM) in single cultures was significantly attenuated by the nitric oxide synthase (NOS) inhibitor N(omega)-nitro-L-arginine (100 microM), whereas the toxicity in co-cultures was not.	Nitroarginine	130-155	nitric oxide synthase 2	Homo sapiens	92-113
11158972-3	2001	In porcine coronary artery precontracted with U-46619, bradykinin (BK) and cyclopiazonic acid (CPA) caused endothelium-dependent relaxations in the presence of N(G)-nitro-L-arginine (L-NNA).	Nitroarginine	160-181	kininogen 1	Homo sapiens	55-65
11158972-3	2001	In porcine coronary artery precontracted with U-46619, bradykinin (BK) and cyclopiazonic acid (CPA) caused endothelium-dependent relaxations in the presence of N(G)-nitro-L-arginine (L-NNA).	Nitroarginine	160-181	kininogen 1	Homo sapiens	67-69
11158972-3	2001	In porcine coronary artery precontracted with U-46619, bradykinin (BK) and cyclopiazonic acid (CPA) caused endothelium-dependent relaxations in the presence of N(G)-nitro-L-arginine (L-NNA).	Nitroarginine	183-188	kininogen 1	Homo sapiens	55-65
11158972-3	2001	In porcine coronary artery precontracted with U-46619, bradykinin (BK) and cyclopiazonic acid (CPA) caused endothelium-dependent relaxations in the presence of N(G)-nitro-L-arginine (L-NNA).	Nitroarginine	183-188	kininogen 1	Homo sapiens	67-69
11159833-4	2001	This is not due to desensitization of a SM NO pathway, as pretreatment with n-omega-nitro-L-arginine affected both wild-type and SMP8-IGF-I aortas to a similar degree.	Nitroarginine	76-100	insulin-like growth factor 1	Mus musculus	134-139
11210005-7	2001	By contrast, substance P (0.1 microM) induced an endothelium-dependent relaxation in both groups of vessels; this relaxation was prevented (p < 0.05) by L-NNA in vessels from ICM hearts but only reduced (p < 0.05) by L-NNA in vessels from DCM hearts.	Nitroarginine	156-161	tachykinin precursor 1	Homo sapiens	13-24
11210005-7	2001	By contrast, substance P (0.1 microM) induced an endothelium-dependent relaxation in both groups of vessels; this relaxation was prevented (p < 0.05) by L-NNA in vessels from ICM hearts but only reduced (p < 0.05) by L-NNA in vessels from DCM hearts.	Nitroarginine	223-228	tachykinin precursor 1	Homo sapiens	13-24
11210005-8	2001	In depolarized conditions, acetylcholine contracted (p < 0.05) whereas substance P induced a complete relaxation (p < 0.05) of vessels from both groups: substance P-induced relaxation was abolished (p < 0.05) by L-NNA.	Nitroarginine	221-226	tachykinin precursor 1	Homo sapiens	74-85
11210005-8	2001	In depolarized conditions, acetylcholine contracted (p < 0.05) whereas substance P induced a complete relaxation (p < 0.05) of vessels from both groups: substance P-induced relaxation was abolished (p < 0.05) by L-NNA.	Nitroarginine	221-226	tachykinin precursor 1	Homo sapiens	159-170
11905149-4	2001	L-Arginine, a substrate for NO synthesis and NG-Nitro-L-Arginine (L-NNA) an inhibitor of NO synthase (NOS), were administered systemically.	Nitroarginine	66-71	nitric oxide synthase, brain	Oryctolagus cuniculus	89-100
11697043-0	2001	Synthesis and evaluation of dipeptide amides containing N omega-nitroarginine and D-2,4-diaminobutyric acids as inhibitors of neuronal nitric oxide synthase.	Nitroarginine	56-77	nitric oxide synthase 1	Homo sapiens	135-156
11162200-6	2001	The coronary relaxant effect of CNP (0.1-3 micromol/L) was similarly attenuated by L-NNA and ODQ (n = 6).	Nitroarginine	83-88	natriuretic peptide C	Homo sapiens	32-35
11490203-6	2001	The AT1 receptor antagonist losartan (30 nmol/l) competitively blocked the AngII-induced contractions with an estimated pA(2) of 8.2 in both the control arteries and in arteries treated with indomethacin and NOLA.	Nitroarginine	208-212	angiotensinogen	Rattus norvegicus	75-80
12040419-1	2001	The inhibitive effect of N-nitro-L-arginine (L-NNA, a nitric oxide synthase inhibitor) on the excitation of cultured rat hippocampal CA1 neurons, stimulated by penicillin G(PG), was investigated.	Nitroarginine	25-43	carbonic anhydrase 1	Rattus norvegicus	133-136
12040419-1	2001	The inhibitive effect of N-nitro-L-arginine (L-NNA, a nitric oxide synthase inhibitor) on the excitation of cultured rat hippocampal CA1 neurons, stimulated by penicillin G(PG), was investigated.	Nitroarginine	45-50	carbonic anhydrase 1	Rattus norvegicus	133-136
12040419-4	2001	Meanwhile, L-NNA(1 and 10 &mgr;mol/L) also significantly inhibited the immunoreactive methionine enkephalin (ir-M-ENK) level.	Nitroarginine	11-16	proenkephalin	Rattus norvegicus	101-111
12040419-4	2001	Meanwhile, L-NNA(1 and 10 &mgr;mol/L) also significantly inhibited the immunoreactive methionine enkephalin (ir-M-ENK) level.	Nitroarginine	11-16	proenkephalin	Rattus norvegicus	118-121
12040419-6	2001	Finally, beta-FNA (100 &mgr;mol/L, an M-ENK receptor inhibitor) facilitated the inhibitive effect of L-NNA on the Glu level, while nor-BIN (100 &mgr;mol/L, a DYN receptor inhibitor) suppressed that effect.	Nitroarginine	105-110	proenkephalin	Rattus norvegicus	44-47
12040419-7	2001	In conclusion,L-NNA could inhibit NO production induced by PG (4 000 IU/ml) stimulation, thuslowering the M-ENK level and increasing the DYN-B level, and resulted in a down-regulation of the Glu level and the neuron excitation.	Nitroarginine	14-19	proenkephalin	Rattus norvegicus	108-111
11121042-5	2000	The IFN-gamma-induced suppression of JNK1 activation in BV-2, RAW264.7, or rat alveolar macrophage cells was completely prevented by N(G)-nitro-l-arginine, a NO synthase inhibitor.	Nitroarginine	133-154	interferon gamma	Mus musculus	4-13
11121042-5	2000	The IFN-gamma-induced suppression of JNK1 activation in BV-2, RAW264.7, or rat alveolar macrophage cells was completely prevented by N(G)-nitro-l-arginine, a NO synthase inhibitor.	Nitroarginine	133-154	mitogen-activated protein kinase 8	Mus musculus	37-41
11139441-7	2000	When the thrombin-induced contraction was inhibited by ONO-3708, either pretreatment with N(omega)-nitro-L-arginine methylester (L-NAME) or an increase in the amount of external K(+) to 40 mM did not abolish thrombin-induced relaxation during phenylephrine-induced sustained contraction.	Nitroarginine	90-115	coagulation factor II, thrombin	Homo sapiens	9-17
11025760-8	2000	The nitric oxide synthase inhibitor, N-nitro-L-arginine (L-NAME) or angiotensin II type I receptor blocker, losartan, inhibited nitric oxide and TGF-beta1 induced by angiotensin II.	Nitroarginine	37-55	transforming growth factor, beta 1	Rattus norvegicus	145-154
11025760-8	2000	The nitric oxide synthase inhibitor, N-nitro-L-arginine (L-NAME) or angiotensin II type I receptor blocker, losartan, inhibited nitric oxide and TGF-beta1 induced by angiotensin II.	Nitroarginine	37-55	angiotensinogen	Rattus norvegicus	166-180
11032727-8	2000	Pretreatment with gamma-tocopherol (but not alpha-tocopherol) afforded a partial protection against the inhibitory effects of NO, whereas specifically inhibiting inducible NO synthase with N-nitro-L-arginine completely reversed the IL-1beta effects.	Nitroarginine	189-207	interleukin 1 beta	Rattus norvegicus	232-240
11044768-6	2000	The tissue-associated myeloperoxidase activity was decreased in the liver by L-NNA and L-ARG.	Nitroarginine	77-82	myeloperoxidase	Rattus norvegicus	22-37
10996604-2	2000	Superfusing the cheek pouch microcirculation with 100-nM PAF elicited rapid leakage of FITC-dextran that was markedly inhibited by prior treatment with a nitric oxide synthase (NOS) inhibitor, N(omega)-nitro-L-arginine (L-NA; 1 microM).	Nitroarginine	193-218	PCNA clamp associated factor	Homo sapiens	57-60
10952787-10	2000	MPO activity was significantly increased in the presence of L-NNA, suggesting that the protective effect of NO against CA-4-P-induced vascular injury may be, at least partially, mediated by limiting neutrophil infiltration.	Nitroarginine	60-65	myeloperoxidase	Homo sapiens	0-3
10991930-8	2000	After inhibition of nitric oxide synthase (N(omega)-nitro-L-arginine 100 microM), and in the presence of peptidase inhibitors, nociceptin produced full inhibition of the pure adrenergic motor response (EC(50) 4 nM; pEC(50) 8.4+/-0.1, E(max) 98.3+/-1.2%, n=12).	Nitroarginine	43-68	prepronociceptin	Rattus norvegicus	127-137
10944233-5	2000	In the saline-perfused hindlimb of WT and eNOS -/- mice, marked N(omega)-nitro-l-arginine (l-NA, 300 micromol/liter)- and diclofenac-insensitive vasodilations in response to both bradykinin and acetylcholine (ACh) were observed, which were more pronounced than the agonist-induced vasodilation in the hindlimb of WT in the absence of l-NA.	Nitroarginine	64-89	nitric oxide synthase 3, endothelial cell	Mus musculus	42-46
10926966-7	2000	RESULTS: Infarct volume was significantly decreased (47%) in animals treated with the nonselective nitric oxide synthase (NOS) inhibitor N(omega)-nitro-L-arginine (L-NA) at reperfusion.	Nitroarginine	137-162	nitric oxide synthase 1, neuronal	Mus musculus	99-120
10988340-7	2000	L-NNA during 4 days decreased cardiac angiotensin II (23+/-4 versus 61+/-15 fmol/g; P<0.05).	Nitroarginine	0-5	angiotensinogen	Rattus norvegicus	38-52
10884482-13	2000	The involvement of iNOS in EC death was suggested by partial reduction of cell death by NO synthase inhibitors, including L-N(G)-(1-iminoethyl)ornithine and nitro-L-arginine, and an NO scavenger, the Fe(2+)-N-methyl-D-glucamine dithiocarbamate complex.	Nitroarginine	157-173	nitric oxide synthase 2	Bos taurus	19-23
10824696-10	2000	NNA dose dependently inhibited the pancreatic secretion of fluid and bicarbonate stimulated by duodenal acidification, exogenous secretin, and a meal.	Nitroarginine	0-3	secretin	Rattus norvegicus	129-137
10824696-11	2000	NNA dose dependently inhibited the pancreatic secretion of protein stimulated by duodenal infusion of casein, exogenous CCK, and a meal.	Nitroarginine	0-3	cholecystokinin	Rattus norvegicus	120-123
10754219-0	2000	Differential activation of Fos-like immunoreactivity in the arcuate nucleus and amygdala after intracerebroventricular injection of sodium nitroprusside and N omega nitro-L-arginine in conscious and urethane-anesthetized lactating rats.	Nitroarginine	157-181	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	27-30
10766457-5	2000	The ecNOS mRNA level was decreased by the ascitic fluids; ascitic fluids-induced expression of adhesion molecules and interleukin-8 as well as the nuclear translocation of NF-kappaB were attenuated by SNP, whereas L-NNA augmented them; and the effects on the endothelial activation were paralleled by the altered adhesion of U937 cells to endothelium.	Nitroarginine	214-219	nitric oxide synthase 3	Homo sapiens	4-9
10736288-9	2000	In these depolarizing conditions, nitric oxide-dependent relaxation to substance P was trivial after PTCA+ICRT and reduced after ICRT, whereas in the presence of physiological solution and N(omega)-nitro-L-arginine, substance P-induced relaxation was reduced after PTCA and abolished after PTCA+ICRT 6 weeks after intervention.	Nitroarginine	189-214	tachykinin precursor 1	Homo sapiens	216-227
10749148-6	2000	Nitric oxide synthase (NOS) inhibitors (N(omega)-nitro-L-arginine methyl ester and N(omega)-nitro-L-arginine) reduced tumor growth in vivo by approximately 50% in both tumor models.	Nitroarginine	40-65	nitric oxide synthase 1, neuronal	Mus musculus	0-21
10768853-14	2000	Pancreatic weight and plasma levels of amylase and TNFalpha significantly increased in the group of rats treated with combination of LPS+L-NNA as compared to the animals received LPS alone.	Nitroarginine	137-142	tumor necrosis factor	Rattus norvegicus	51-59
10662734-5	2000	In kidneys from Sham rats, afferent and efferent arteriolar responses to ANG II (0.1-10.0 nM) were exaggerated significantly by L-NNA.	Nitroarginine	128-133	angiotensinogen	Rattus norvegicus	73-79
10662734-6	2000	L-NNA also augmented efferent arteriolar ANG II responses in kidneys from STZ rats (high-glucose bath) but did not alter ANG II responses in afferent arterioles from STZ rats.	Nitroarginine	0-5	angiotensinogen	Rattus norvegicus	41-47
10662734-7	2000	L-NNA also accentuated efferent, but not afferent, arteriolar ANG II responses in STZ kidneys during acute restoration of bath glucose to normal levels.	Nitroarginine	0-5	angiotensinogen	Rattus norvegicus	62-68
10662734-8	2000	Superoxide dismutase (150 U/ml) restored the ability of L-NNA to allow exaggerated afferent arteriolar responses to ANG II in kidneys from STZ rats.	Nitroarginine	56-61	angiotensinogen	Rattus norvegicus	116-122
10679504-2	2000	We tested whether hypertension and renal dysfunction elicited by chronic inhibition of nitric oxide (NO) synthesis using N(G)-nitro-L-arginine (L-NNA) could be mediated in part by vasopressin V(1A) receptors.	Nitroarginine	144-149	arginine vasopressin	Rattus norvegicus	180-191
10679504-6	2000	L-NNA produced sustained hypertension, decreased glomerular filtration rate, and increased renal vascular resistance, plasma renin activity, and urinary albumin excretion.	Nitroarginine	0-5	renin	Rattus norvegicus	125-130
11310984-5	2000	The effect of A beta peptide was reduced by half by the nitric oxide synthase inhibitor N-nitro-L-arginine.	Nitroarginine	88-106	amyloid beta precursor protein	Rattus norvegicus	14-20
10694197-7	2000	L-NOARG-resistant relaxations were virtually abolished by VIP (100 nM) desensitization at all frequencies.	Nitroarginine	0-7	vasoactive intestinal peptide	Homo sapiens	58-61
10604965-9	2000	The NK-1 receptor-mediated relaxations could be blocked by removing the endothelium, or by a combination of N-nitro-L-arginine and indomethacin.	Nitroarginine	108-126	tachykinin receptor 1	Homo sapiens	4-17
10590407-6	2000	The higher affinity ((3)H)L-NNA binding site colocalized with nNOS and the lower affinity site with iNOS.	Nitroarginine	26-31	nitric oxide synthase 1, neuronal	Mus musculus	62-66
10590407-6	2000	The higher affinity ((3)H)L-NNA binding site colocalized with nNOS and the lower affinity site with iNOS.	Nitroarginine	26-31	nitric oxide synthase 2, inducible	Mus musculus	100-104
10805420-3	2000	In Experiment 1, long-term L-NNA application increased BP compared to the control group (group C1) (L-NNA1 = 131.4 +/- 6.3, n = 6; C1 = 82.7 +/- 4.7 mm Hg, n = 7) but decreased plasma noradrenaline and adrenaline levels and ACE activity (NA levels: C1 = 15.5 +/- 0.8, n = 7; L-NNA1 = 8.6 +/- 0.5 ng/ml, n = 7; A levels: C1 = 15.5 +/- 0.8, n = 7; L-NNA1 = 6.0 +/- 0.5 ng/ml, n = 7; ACE activities: C1 = 87.3 +/- 3.1, n = 6; L-NNA1 = 46.2 +/- 1.9 U/l, n = 5).	Nitroarginine	27-32	angiotensin I converting enzyme	Gallus gallus	224-227
10805420-3	2000	In Experiment 1, long-term L-NNA application increased BP compared to the control group (group C1) (L-NNA1 = 131.4 +/- 6.3, n = 6; C1 = 82.7 +/- 4.7 mm Hg, n = 7) but decreased plasma noradrenaline and adrenaline levels and ACE activity (NA levels: C1 = 15.5 +/- 0.8, n = 7; L-NNA1 = 8.6 +/- 0.5 ng/ml, n = 7; A levels: C1 = 15.5 +/- 0.8, n = 7; L-NNA1 = 6.0 +/- 0.5 ng/ml, n = 7; ACE activities: C1 = 87.3 +/- 3.1, n = 6; L-NNA1 = 46.2 +/- 1.9 U/l, n = 5).	Nitroarginine	27-32	angiotensin I converting enzyme	Gallus gallus	381-384
10805420-5	2000	In this series, long-term L-NNA application (group L-NNA2) did not change the BP, but surprisingly increased noradrenaline and ACE values (values of L-NNA2: BP = 165.7 +/- 15.6 mm Hg, n = 7; NA = 9.3 +/- 1.3 ng/ml, n = 8; ACE = 149.4 +/- 16 U/l, n = 8) while decreasing plasma adrenaline levels.	Nitroarginine	26-31	angiotensin I converting enzyme	Gallus gallus	127-130
10805420-5	2000	In this series, long-term L-NNA application (group L-NNA2) did not change the BP, but surprisingly increased noradrenaline and ACE values (values of L-NNA2: BP = 165.7 +/- 15.6 mm Hg, n = 7; NA = 9.3 +/- 1.3 ng/ml, n = 8; ACE = 149.4 +/- 16 U/l, n = 8) while decreasing plasma adrenaline levels.	Nitroarginine	26-31	angiotensin I converting enzyme	Gallus gallus	222-225
10805420-6	2000	L-arginine addition to L-NNA treatment completely reversed plasma noradrenaline and ACE activity values.	Nitroarginine	23-28	angiotensin I converting enzyme	Gallus gallus	84-87
12548860-3	1999	In the 2# clone expressing iNOS gene, iNOS catalytic activity in the cytosol fraction displayed to have an increasing trend, accompanying with the accumulation of NO2- content in the supernantant of cultured cells and the intracellular cGMP concentration, which suggested that NO-cGMP signal pathway was mediated by the expression of iNOS gene and blocked by NG-nitro-L-arginine (L-NNA) and methylene blue (MB).	Nitroarginine	359-378	nitric oxide synthase 2, inducible	Mus musculus	27-31
12548860-3	1999	In the 2# clone expressing iNOS gene, iNOS catalytic activity in the cytosol fraction displayed to have an increasing trend, accompanying with the accumulation of NO2- content in the supernantant of cultured cells and the intracellular cGMP concentration, which suggested that NO-cGMP signal pathway was mediated by the expression of iNOS gene and blocked by NG-nitro-L-arginine (L-NNA) and methylene blue (MB).	Nitroarginine	359-378	nitric oxide synthase 2, inducible	Mus musculus	38-42
12548860-3	1999	In the 2# clone expressing iNOS gene, iNOS catalytic activity in the cytosol fraction displayed to have an increasing trend, accompanying with the accumulation of NO2- content in the supernantant of cultured cells and the intracellular cGMP concentration, which suggested that NO-cGMP signal pathway was mediated by the expression of iNOS gene and blocked by NG-nitro-L-arginine (L-NNA) and methylene blue (MB).	Nitroarginine	359-378	nitric oxide synthase 2, inducible	Mus musculus	38-42
12548860-3	1999	In the 2# clone expressing iNOS gene, iNOS catalytic activity in the cytosol fraction displayed to have an increasing trend, accompanying with the accumulation of NO2- content in the supernantant of cultured cells and the intracellular cGMP concentration, which suggested that NO-cGMP signal pathway was mediated by the expression of iNOS gene and blocked by NG-nitro-L-arginine (L-NNA) and methylene blue (MB).	Nitroarginine	380-385	nitric oxide synthase 2, inducible	Mus musculus	27-31
12548860-3	1999	In the 2# clone expressing iNOS gene, iNOS catalytic activity in the cytosol fraction displayed to have an increasing trend, accompanying with the accumulation of NO2- content in the supernantant of cultured cells and the intracellular cGMP concentration, which suggested that NO-cGMP signal pathway was mediated by the expression of iNOS gene and blocked by NG-nitro-L-arginine (L-NNA) and methylene blue (MB).	Nitroarginine	380-385	nitric oxide synthase 2, inducible	Mus musculus	38-42
12548860-3	1999	In the 2# clone expressing iNOS gene, iNOS catalytic activity in the cytosol fraction displayed to have an increasing trend, accompanying with the accumulation of NO2- content in the supernantant of cultured cells and the intracellular cGMP concentration, which suggested that NO-cGMP signal pathway was mediated by the expression of iNOS gene and blocked by NG-nitro-L-arginine (L-NNA) and methylene blue (MB).	Nitroarginine	380-385	nitric oxide synthase 2, inducible	Mus musculus	38-42
12548860-4	1999	Activity of iNOS was concentration-dependently inhibited by NOS inhibitors such as L-NNA and aminoguanidine.	Nitroarginine	83-88	nitric oxide synthase 2, inducible	Mus musculus	12-16
10521782-5	1999	It also has been amply demonstrated that this entire process of neurohypophyseal regeneration and cell migration is completely inhibited by the introduction of the antagonist of nitric oxide, namely, nitroarginine (Scott et al., Exp Neurol, 1995;131-1:23-39; Scott and Hansen, Vir Med, 1997;124:249-261).	Nitroarginine	200-213	arginine vasopressin	Homo sapiens	64-80
10578147-3	1999	However, the concentration response curve was shifted rightward to higher concentrations of YC-1, when (i) the aortas were pre-treated with L-NG-nitroarginine methylester (L-NAME) or (ii) the endothelium was removed.	Nitroarginine	140-158	glutathione S-transferase alpha 1	Rattus norvegicus	92-96
10578147-11	1999	6 When HUVEC and RMCEC were pre-treated with L-NG-nitroarginine (L-NOARG), the maximum YC-1 stimulated cyclic GMP increase was reduced by >/=50%.	Nitroarginine	45-63	glutathione S-transferase alpha 1	Rattus norvegicus	87-91
10578147-11	1999	6 When HUVEC and RMCEC were pre-treated with L-NG-nitroarginine (L-NOARG), the maximum YC-1 stimulated cyclic GMP increase was reduced by >/=50%.	Nitroarginine	65-72	glutathione S-transferase alpha 1	Rattus norvegicus	87-91
10547273-10	1999	On the other hand, a blocker of inducible nitric oxide synthase (iNOS) activity (N(G)-methyl-L-arginine) did not prevent IL-1-induced SPI-3 expression.	Nitroarginine	81-103	nitric oxide synthase 2	Rattus norvegicus	32-63
10547273-10	1999	On the other hand, a blocker of inducible nitric oxide synthase (iNOS) activity (N(G)-methyl-L-arginine) did not prevent IL-1-induced SPI-3 expression.	Nitroarginine	81-103	nitric oxide synthase 2	Rattus norvegicus	65-69
10525092-6	1999	When combining reactive blue 2 and N(G)-nitro-L-arginine, the response to 50.8 mM K(+) was reduced by approximately 70% and was abolished by the concomitant administration of these antagonists and VIP(10-28).	Nitroarginine	35-56	vasoactive intestinal peptide	Rattus norvegicus	197-200
10527953-10	1999	Pretreatment of animals with Nw-nitro-L-arginine (L-NNA), an inhibitor of nitric oxide synthase, abolished the attenuating effects of FGF-1 on neutrophil infiltration, suggesting that nitric oxide might participate in the anti-inflammatory effects of FGF-1 in this experimental design.	Nitroarginine	50-55	fibroblast growth factor 1	Rattus norvegicus	134-139
10527953-10	1999	Pretreatment of animals with Nw-nitro-L-arginine (L-NNA), an inhibitor of nitric oxide synthase, abolished the attenuating effects of FGF-1 on neutrophil infiltration, suggesting that nitric oxide might participate in the anti-inflammatory effects of FGF-1 in this experimental design.	Nitroarginine	50-55	fibroblast growth factor 1	Rattus norvegicus	251-256
10491341-9	1999	EPO stimulated NO release from the resting HUVEC in a concentration- and time-dependent manner, an effect that was inhibited by the presence of N(G)-nitro-L-arginine.	Nitroarginine	144-165	erythropoietin	Homo sapiens	0-3
10523375-11	1999	Plasma renin activity was reduced at day 21 (L-NNA=9.6+/-2.1 and C=25.9+/-5 ng x mL(-1) x h(-1), P<0.05) and remained lower at postpartum day 7 x L-NNA rats exhibited glomerular lesions and tubular atrophy, particularly of connecting tubules that displayed reduced kallikrein staining.	Nitroarginine	45-50	renin	Rattus norvegicus	7-12
10502685-2	1999	Although the nitric oxide (NO) complex of the ferric heme was EPR-silent, photo-illumination at 5 K to the NO complex of the ferric nNOS in the substrate-free form produced a new high spin EPR signal similar to that of the ferric heme of N(omega)-nitro-L-arginine-bound nNOS, suggesting that the photo-dissociated NO might move away from the heme.	Nitroarginine	238-263	nitric oxide synthase 1	Rattus norvegicus	132-136
11270983-3	1999	RESULTS: In quiescent rings of the previously deendothelialized left anterior descending coronary artery treated with the NO-synthase inhibitor nitro-L-arginine, endothelin-1 caused contractions which were larger in rings with than that in those without endothelium.	Nitroarginine	144-160	endothelin 1	Homo sapiens	162-174
10510458-4	1999	The L-NOARG-resistant component of NANC inhibitory responses to higher frequencies of vagus nerve stimulation were significantly attenuated by the proteinase alpha-chymotrypsin (2 U/ml), suggesting that a neuropeptide such as VIP may contribute to NANC responses.	Nitroarginine	4-11	VIP peptides	Cavia porcellus	226-229
10462367-6	1999	Incubation with NNA, indomethacin, or both significantly potentiated the response of collaterals to vasopressin.	Nitroarginine	16-19	arginine vasopressin	Rattus norvegicus	100-111
10462367-7	1999	In addition, the pressor response to vasopressin in the combination group was significantly higher than that in the NNA-alone group.	Nitroarginine	116-119	arginine vasopressin	Rattus norvegicus	37-48
10461899-6	1999	It is interesting that the change in MBP phosphorylation was attenuated by the reactive oxygen species scavengers superoxide dismutase and catalase and the nitric oxide synthase inhibitor N-nitro-L-arginine.	Nitroarginine	188-206	myelin basic protein	Homo sapiens	37-40
10444477-7	1999	In vitro, increases in tension caused by N(omega)-nitro-L-arginine (L-NNA) or PGF(2alpha) in arterial rings were reduced by ET(A)- but not ET(B)-receptor blockade.	Nitroarginine	41-66	endothelin receptor type A	Homo sapiens	124-130
10444477-7	1999	In vitro, increases in tension caused by N(omega)-nitro-L-arginine (L-NNA) or PGF(2alpha) in arterial rings were reduced by ET(A)- but not ET(B)-receptor blockade.	Nitroarginine	68-73	endothelin receptor type A	Homo sapiens	124-130
10444520-9	1999	Nitric oxide synthase inhibition (0.2 mM N(omega)-nitro-L-arginine) reduced the SP relaxation by 36.5 +/- 12.5%, whereas the SP effect was abolished by eicosanoid inhibition (10 microM indomethacin).	Nitroarginine	41-66	tachykinin 1	Mus musculus	80-82
10474781-9	1999	In the presence of NG-nitro-L-arginine (NOARG; 40 micrograms/kg per min intrarenally), a nitric oxide (NO) synthase inhibitor, BK-induced renal vasodilative and natriuretic effects were markedly attenuated, although responses of UF and urine osmolality to BK remained unchanged.	Nitroarginine	19-38	kininogen 1	Canis lupus familiaris	127-129
10474781-9	1999	In the presence of NG-nitro-L-arginine (NOARG; 40 micrograms/kg per min intrarenally), a nitric oxide (NO) synthase inhibitor, BK-induced renal vasodilative and natriuretic effects were markedly attenuated, although responses of UF and urine osmolality to BK remained unchanged.	Nitroarginine	19-38	kininogen 1	Canis lupus familiaris	256-258
10474781-9	1999	In the presence of NG-nitro-L-arginine (NOARG; 40 micrograms/kg per min intrarenally), a nitric oxide (NO) synthase inhibitor, BK-induced renal vasodilative and natriuretic effects were markedly attenuated, although responses of UF and urine osmolality to BK remained unchanged.	Nitroarginine	40-45	kininogen 1	Canis lupus familiaris	127-129
10458643-11	1999	Inhibition of NO-synthase by L-NNA significantly delayed ulcer healing and reversed the CCK-8 induced acceleration of ulcer healing, hyperemia at the ulcer margin and luminal NO release, and these effects were restored by the addition to L-NNA of L-arginine but not D-arginine.	Nitroarginine	238-243	cholecystokinin	Rattus norvegicus	88-91
10593572-7	1999	In another series of experiments, EFS-induced relaxations were almost completely inhibited by the treatment of the segments with L-NOARG and VIP(10-28) in the jejunum, with L-NOARG, VIP(10-28) and PACAP(6-38) in the proximal colon, and with L NOARG and PACAP(6-38) in the distal colon.	Nitroarginine	129-136	vasoactive intestinal polypeptide	Mus musculus	182-185
10593572-7	1999	In another series of experiments, EFS-induced relaxations were almost completely inhibited by the treatment of the segments with L-NOARG and VIP(10-28) in the jejunum, with L-NOARG, VIP(10-28) and PACAP(6-38) in the proximal colon, and with L NOARG and PACAP(6-38) in the distal colon.	Nitroarginine	129-136	adenylate cyclase activating polypeptide 1	Mus musculus	253-258
10593572-7	1999	In another series of experiments, EFS-induced relaxations were almost completely inhibited by the treatment of the segments with L-NOARG and VIP(10-28) in the jejunum, with L-NOARG, VIP(10-28) and PACAP(6-38) in the proximal colon, and with L NOARG and PACAP(6-38) in the distal colon.	Nitroarginine	173-180	vasoactive intestinal polypeptide	Mus musculus	141-144
10593572-7	1999	In another series of experiments, EFS-induced relaxations were almost completely inhibited by the treatment of the segments with L-NOARG and VIP(10-28) in the jejunum, with L-NOARG, VIP(10-28) and PACAP(6-38) in the proximal colon, and with L NOARG and PACAP(6-38) in the distal colon.	Nitroarginine	241-248	vasoactive intestinal polypeptide	Mus musculus	141-144
10354348-8	1999	The effects of VIP and PACAPs were completely antagonized by nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (L-NA), suggesting that NO mediates the inhibitory effects of VIP and PACAPs on duodenal motility.	Nitroarginine	98-117	vasoactive intestinal peptide	Rattus norvegicus	15-18
10354348-8	1999	The effects of VIP and PACAPs were completely antagonized by nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (L-NA), suggesting that NO mediates the inhibitory effects of VIP and PACAPs on duodenal motility.	Nitroarginine	98-117	vasoactive intestinal peptide	Rattus norvegicus	180-183
10218957-6	1999	The endothelium-dependent component of PTHrP and PTH-induced aortic relaxations were unaffected by pretreatment with either L-NNA or indomethacin but were abolished by pretreatment with tetrabutyl ammonium.	Nitroarginine	124-129	parathyroid hormone-like peptide	Mus musculus	39-44
10218957-6	1999	The endothelium-dependent component of PTHrP and PTH-induced aortic relaxations were unaffected by pretreatment with either L-NNA or indomethacin but were abolished by pretreatment with tetrabutyl ammonium.	Nitroarginine	124-129	parathyroid hormone	Mus musculus	39-42
10200988-5	1999	Bradykinin, acetylcholine, and IL1B EC-dependent effects were reversed with the nitric oxide (NO) synthase inhibitor L-NNA.	Nitroarginine	117-122	Nitric oxide synthase	Drosophila melanogaster	80-106
10657484-5	1999	Inducible nitric oxide synthase (iNOS) inhibitors, S-methylisothiourea sulfate (SMT) and N(G)-nitro-L-arginine (L-NNA), completely eliminated long-term depressant effect of CGRP.	Nitroarginine	89-110	nitric oxide synthase 2	Rattus norvegicus	0-31
10657484-5	1999	Inducible nitric oxide synthase (iNOS) inhibitors, S-methylisothiourea sulfate (SMT) and N(G)-nitro-L-arginine (L-NNA), completely eliminated long-term depressant effect of CGRP.	Nitroarginine	89-110	nitric oxide synthase 2	Rattus norvegicus	33-37
10657484-5	1999	Inducible nitric oxide synthase (iNOS) inhibitors, S-methylisothiourea sulfate (SMT) and N(G)-nitro-L-arginine (L-NNA), completely eliminated long-term depressant effect of CGRP.	Nitroarginine	89-110	calcitonin-related polypeptide alpha	Rattus norvegicus	173-177
10657484-5	1999	Inducible nitric oxide synthase (iNOS) inhibitors, S-methylisothiourea sulfate (SMT) and N(G)-nitro-L-arginine (L-NNA), completely eliminated long-term depressant effect of CGRP.	Nitroarginine	112-117	nitric oxide synthase 2	Rattus norvegicus	0-31
10657484-5	1999	Inducible nitric oxide synthase (iNOS) inhibitors, S-methylisothiourea sulfate (SMT) and N(G)-nitro-L-arginine (L-NNA), completely eliminated long-term depressant effect of CGRP.	Nitroarginine	112-117	calcitonin-related polypeptide alpha	Rattus norvegicus	173-177
10070063-8	1999	Insulin-evoked dilation in both RGM and WGM arterioles was completely inhibited and converted to vasoconstriction by endothelium removal and administration of L-NNA.	Nitroarginine	159-164	insulin	Homo sapiens	0-7
10070063-8	1999	Insulin-evoked dilation in both RGM and WGM arterioles was completely inhibited and converted to vasoconstriction by endothelium removal and administration of L-NNA.	Nitroarginine	159-164	repulsive guidance molecule BMP co-receptor a	Homo sapiens	32-35
9887032-4	1999	Nomega-nitro-L-arginine methyl ester (L-NAME) and Nomega-nitro-L-arginine (L-NNA) inhibited the vasodilation to phenylarsine oxide; the effects of NO synthase inhibitors and indomethacin were additive.	Nitroarginine	0-23	nitric oxide synthase 2	Sus scrofa	147-158
9950809-10	1999	Changes in the cardiac force-frequency relationship (staircase effect) after L-NNA were consistent with NOS3 modulation of contractile function in both SO and PVS rats, but there was no between-group difference in the modulation.	Nitroarginine	77-82	nitric oxide synthase 3	Rattus norvegicus	104-108
10028935-9	1999	After combined administration of this low dose of aspirin and of the nitric oxide synthase (NOS) inhibitor, N(omega)-nitro-L-arginine (L-NNA, 30 mg/kg/day/7 days), reactive hyperemia decreased to the same extent as when L-NNA was administered alone.	Nitroarginine	108-133	nitric oxide synthase 3	Canis lupus familiaris	69-90
10028935-11	1999	), myocardial reactive hyperemia was markedly reduced, and this effect was still observed after previous blockade of NOS and cyclooxygenase by L-NNA and diclofenac, respectively.	Nitroarginine	143-148	prostaglandin-endoperoxide synthase 1	Canis lupus familiaris	125-139
10048598-3	1999	Bradykinin (1-1,000 pmol) elicited a prominent, endothelium-dependent, relaxant response, 50-60% of which was insensitive to combined blockade of cyclooxygenase with diclofenac (1 microM) and NO synthase with NG-nitro-L-arginine (50 microM).	Nitroarginine	209-228	kininogen 1	Bos taurus	0-10
9950605-5	1999	To inhibit cNOS, NG-nitro-L-arginine (L-NNA) was injected intraperitoneally four times (every 6 hours) beginning 2 hours after reperfusion, for a total dose of 80 mg/kg.	Nitroarginine	17-36	nitric oxide synthase 3	Rattus norvegicus	11-15
9950605-5	1999	To inhibit cNOS, NG-nitro-L-arginine (L-NNA) was injected intraperitoneally four times (every 6 hours) beginning 2 hours after reperfusion, for a total dose of 80 mg/kg.	Nitroarginine	38-43	nitric oxide synthase 3	Rattus norvegicus	11-15
10022602-6	1999	The adrenomedullin-induced response in left pulmonary artery blood flow was inhibited by N(omega)-nitro-L-arginine (inhibition rate 99%) and significantly attenuated by glibenclamide (inhibition rate 44%); however, no significant changes were found with CGRP receptor blocker or indomethacin (inhibition rate 0 and 17%, respectively).	Nitroarginine	89-114	pro-adrenomedullin	Ovis aries	4-18
9887083-3	1999	In kidneys from sham-operated rats, NO synthase inhibition [100 microM Nomega-nitro-L-arginine (L-NNA)] reduced afferent arteriolar diameter by 4.1 +/- 0.6 microm and enhanced ANG II responsiveness (10 nM ANG II decreased afferent diameter by 10.1 +/- 1.4 micrometer before and 12.8 +/- 1.6 micrometer during L-NNA treatment; P < 0.05).	Nitroarginine	71-94	angiotensinogen	Rattus norvegicus	176-182
9887083-3	1999	In kidneys from sham-operated rats, NO synthase inhibition [100 microM Nomega-nitro-L-arginine (L-NNA)] reduced afferent arteriolar diameter by 4.1 +/- 0.6 microm and enhanced ANG II responsiveness (10 nM ANG II decreased afferent diameter by 10.1 +/- 1.4 micrometer before and 12.8 +/- 1.6 micrometer during L-NNA treatment; P < 0.05).	Nitroarginine	71-94	angiotensinogen	Rattus norvegicus	205-211
9887083-3	1999	In kidneys from sham-operated rats, NO synthase inhibition [100 microM Nomega-nitro-L-arginine (L-NNA)] reduced afferent arteriolar diameter by 4.1 +/- 0.6 microm and enhanced ANG II responsiveness (10 nM ANG II decreased afferent diameter by 10.1 +/- 1.4 micrometer before and 12.8 +/- 1.6 micrometer during L-NNA treatment; P < 0.05).	Nitroarginine	96-101	angiotensinogen	Rattus norvegicus	176-182
9887083-3	1999	In kidneys from sham-operated rats, NO synthase inhibition [100 microM Nomega-nitro-L-arginine (L-NNA)] reduced afferent arteriolar diameter by 4.1 +/- 0.6 microm and enhanced ANG II responsiveness (10 nM ANG II decreased afferent diameter by 10.1 +/- 1.4 micrometer before and 12.8 +/- 1.6 micrometer during L-NNA treatment; P < 0.05).	Nitroarginine	96-101	angiotensinogen	Rattus norvegicus	205-211
9887032-4	1999	Nomega-nitro-L-arginine methyl ester (L-NAME) and Nomega-nitro-L-arginine (L-NNA) inhibited the vasodilation to phenylarsine oxide; the effects of NO synthase inhibitors and indomethacin were additive.	Nitroarginine	75-80	nitric oxide synthase 2	Sus scrofa	147-158
9920186-9	1999	NO synthase inhibitors such as N(G)-nitro-L-arginine, N(G)-monomethyl-L-arginine and N(G)-nitro-L-arginine methyl ester (L-NAME) enhanced prepro endothelin-1 mRNA expression and significantly increased endothelin-1 release from endothelial cells.	Nitroarginine	31-52	endothelin 1	Homo sapiens	145-157
9920186-9	1999	NO synthase inhibitors such as N(G)-nitro-L-arginine, N(G)-monomethyl-L-arginine and N(G)-nitro-L-arginine methyl ester (L-NAME) enhanced prepro endothelin-1 mRNA expression and significantly increased endothelin-1 release from endothelial cells.	Nitroarginine	31-52	endothelin 1	Homo sapiens	202-214
10634311-4	1999	Angiotensin II (10(-10) to 3x10(-7) M) also caused a dose-dependent vasoconstriction in control kidneys; this response was markedly enhanced by 10(-4) M L-NNA, and significantly inhibited by losartan (10(-5) M).	Nitroarginine	153-158	angiotensinogen	Rattus norvegicus	0-14
10226765-0	1999	Endothelin-1 and relaxation of the rat aorta during pregnancy in nitroarginine-induced hypertension.	Nitroarginine	65-78	endothelin 1	Rattus norvegicus	0-12
9916128-2	1999	L-arginine (L-ARG) given intravenously or interstitially enhanced net fluid absorption and cGMP formation, which were completely blocked by the nitric oxide (NO) synthase inhibitor, N-nitro-L-arginine methylester (L-NAME), but not by the specific AT2 receptor antagonist, PD-123319 (PD).	Nitroarginine	182-200	angiotensin II receptor, type 2	Rattus norvegicus	247-250
9884072-11	1998	The release of EDRF was blocked by 0.1 mM (omega)nitro-L-arginine-methylester (L-NAME).	Nitroarginine	42-65	alpha hemoglobin stabilizing protein	Homo sapiens	15-19
10027763-6	1999	The pretreatment with NG-nitro-L-arginine methylester (L-NAME) 10(-4) mol/L abolished the vasodilation induced by lecithinized SOD.	Nitroarginine	22-41	superoxide dismutase 1	Homo sapiens	127-130
10369180-6	1999	A course of L-NNA during adaptation hampered both accumulation of HSP70 and development of the antihypoxic effect.	Nitroarginine	12-17	heat shock protein family A (Hsp70) member 4	Homo sapiens	66-71
10422882-6	1999	The nitric oxide inhibitors L-NOARG and L-NAME, but not D-NAME, significantly inhibited SP-induced pleurisy.	Nitroarginine	28-35	tachykinin 1	Mus musculus	88-90
9928058-4	1998	Nitric oxide synthase inhibitor, NG-nitro-L-arginine, antagonized the inhibitory effects of VIP, PACAP 38 and 27, suggesting that nitric oxide seems to be essential to exert the inhibitory action of VIP and PACAPs on the release of 5HT into the intestinal lumen from the EC cells.	Nitroarginine	33-52	vasoactive intestinal peptide	Rattus norvegicus	92-95
9928058-4	1998	Nitric oxide synthase inhibitor, NG-nitro-L-arginine, antagonized the inhibitory effects of VIP, PACAP 38 and 27, suggesting that nitric oxide seems to be essential to exert the inhibitory action of VIP and PACAPs on the release of 5HT into the intestinal lumen from the EC cells.	Nitroarginine	33-52	adenylate cyclase activating polypeptide 1	Rattus norvegicus	97-102
9928058-4	1998	Nitric oxide synthase inhibitor, NG-nitro-L-arginine, antagonized the inhibitory effects of VIP, PACAP 38 and 27, suggesting that nitric oxide seems to be essential to exert the inhibitory action of VIP and PACAPs on the release of 5HT into the intestinal lumen from the EC cells.	Nitroarginine	33-52	vasoactive intestinal peptide	Rattus norvegicus	199-202
11367672-2	1998	Intravenous infusion of NG-nitro-L-arginine (L-NNA), an inhibitor of nitric oxide synthase (NOS), caused increase in SO phasic wave amplitude and arterial blood pressure.	Nitroarginine	24-43	nitric oxide synthase, brain	Oryctolagus cuniculus	69-90
10326832-7	1998	In isolated mesenteric artery preparations precontracted with U-46619 (10(-7) M), [Leu13]motilin (10(-8)-10(-5) M) induced an endothelium-dependent relaxation, and this was inhibited by a pretreatment with N(omega)-nitro-L-arginine, a competitive inhibitor of NO synthase (10(-4) M).	Nitroarginine	206-231	motilin	Canis lupus familiaris	89-96
10097598-4	1998	L-NNA significantly inhibited acetylcholine- and bradykinin-induced pulmonary vasodilation without affecting the vasodilatory responses to isoproterenol in pulmonary vessels preconstricted with thromboxane analogue U46619 or prostaglandin F2 alpha.	Nitroarginine	0-5	kininogen 1	Canis lupus familiaris	49-59
11367672-2	1998	Intravenous infusion of NG-nitro-L-arginine (L-NNA), an inhibitor of nitric oxide synthase (NOS), caused increase in SO phasic wave amplitude and arterial blood pressure.	Nitroarginine	45-50	nitric oxide synthase, brain	Oryctolagus cuniculus	69-90
10098210-7	1998	In addition, Ang II did not affect the diameter of isolated rabbit afferent arterioles, but after the treatment of L-NNA, Ang II exerted a dose-dependent vasoconstriction.	Nitroarginine	115-120	angiogenin	Oryctolagus cuniculus	122-125
9815026-5	1998	In muscle strips, VIP stimulated basal and augmented somatostatin-induced substance P (SP) release; the somatostatin-induced increase in SP release was inhibited by VIP-(10-28) and NG-nitro-L-arginine, implying that excitatory VIP neurons regulate tachykinin motoneurons innervating longitudinal muscle.	Nitroarginine	181-200	vasoactive intestinal peptide	Rattus norvegicus	18-21
9786989-6	1998	Nevertheless, blockade of NOS with daily injections of nitroarginine from P14 to P56 fails to prevent the formation of ocular dominance columns, although NOS activity is reduced by >98%.	Nitroarginine	55-68	S100 calcium binding protein A9 (calgranulin B)	Mus musculus	74-77
9756504-4	1998	The inhibitory effect caused by VIP, PACAP-38, and PACAP-27 was not affected by either atropine, hexamethonium, TTX, or TTX plus ACh, but it was completely antagonized by the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (L-NNA).	Nitroarginine	212-231	vasoactive intestinal peptide	Rattus norvegicus	32-35
9756504-4	1998	The inhibitory effect caused by VIP, PACAP-38, and PACAP-27 was not affected by either atropine, hexamethonium, TTX, or TTX plus ACh, but it was completely antagonized by the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (L-NNA).	Nitroarginine	212-231	adenylate cyclase activating polypeptide 1	Rattus norvegicus	51-56
9756504-4	1998	The inhibitory effect caused by VIP, PACAP-38, and PACAP-27 was not affected by either atropine, hexamethonium, TTX, or TTX plus ACh, but it was completely antagonized by the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (L-NNA).	Nitroarginine	233-238	vasoactive intestinal peptide	Rattus norvegicus	32-35
9756504-4	1998	The inhibitory effect caused by VIP, PACAP-38, and PACAP-27 was not affected by either atropine, hexamethonium, TTX, or TTX plus ACh, but it was completely antagonized by the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (L-NNA).	Nitroarginine	233-238	adenylate cyclase activating polypeptide 1	Rattus norvegicus	51-56
9750960-5	1998	Vasoconstriction responses to 5-hydroxytryptamine (5-HT) were potentiated in the presence of endothelin-1 (ET-1), the thromboxane A2-mimetic U46619 and a nitric oxide synthase inhibitor, N-nitro-L-arginine (NOLA), but not in the presence of angiotensin II.	Nitroarginine	187-205	endothelin 1	Homo sapiens	93-105
9781927-4	1998	Compared with control animals, low-dose infusion of the NOS-inhibitor nitro-L-arginine (NLA) increased MAP and RVR, decreased glomerular filtration rate, RBF, and sodium excretion, and had no effect on plasma and kidney ANG II content.	Nitroarginine	88-91	angiotensinogen	Rattus norvegicus	220-226
9781934-5	1998	When the experiment was performed in the presence of 10 microM indomethacin and 30 microM N(G)-nitro-L-arginine (L-NNA), which block the generation of prostaglandin I2 (PGI2) and NO, respectively, K(Ca) channel activity was stimulated by bradykinin, indicating the direct involvement of EDHF in K(Ca) channel stimulation.	Nitroarginine	90-111	casein kappa	Homo sapiens	197-202
9781934-5	1998	When the experiment was performed in the presence of 10 microM indomethacin and 30 microM N(G)-nitro-L-arginine (L-NNA), which block the generation of prostaglandin I2 (PGI2) and NO, respectively, K(Ca) channel activity was stimulated by bradykinin, indicating the direct involvement of EDHF in K(Ca) channel stimulation.	Nitroarginine	90-111	kininogen 1	Homo sapiens	238-248
9781934-5	1998	When the experiment was performed in the presence of 10 microM indomethacin and 30 microM N(G)-nitro-L-arginine (L-NNA), which block the generation of prostaglandin I2 (PGI2) and NO, respectively, K(Ca) channel activity was stimulated by bradykinin, indicating the direct involvement of EDHF in K(Ca) channel stimulation.	Nitroarginine	90-111	casein kappa	Homo sapiens	295-300
9781934-5	1998	When the experiment was performed in the presence of 10 microM indomethacin and 30 microM N(G)-nitro-L-arginine (L-NNA), which block the generation of prostaglandin I2 (PGI2) and NO, respectively, K(Ca) channel activity was stimulated by bradykinin, indicating the direct involvement of EDHF in K(Ca) channel stimulation.	Nitroarginine	113-118	casein kappa	Homo sapiens	197-202
9781934-5	1998	When the experiment was performed in the presence of 10 microM indomethacin and 30 microM N(G)-nitro-L-arginine (L-NNA), which block the generation of prostaglandin I2 (PGI2) and NO, respectively, K(Ca) channel activity was stimulated by bradykinin, indicating the direct involvement of EDHF in K(Ca) channel stimulation.	Nitroarginine	113-118	kininogen 1	Homo sapiens	238-248
9781934-5	1998	When the experiment was performed in the presence of 10 microM indomethacin and 30 microM N(G)-nitro-L-arginine (L-NNA), which block the generation of prostaglandin I2 (PGI2) and NO, respectively, K(Ca) channel activity was stimulated by bradykinin, indicating the direct involvement of EDHF in K(Ca) channel stimulation.	Nitroarginine	113-118	casein kappa	Homo sapiens	295-300
9750960-5	1998	Vasoconstriction responses to 5-hydroxytryptamine (5-HT) were potentiated in the presence of endothelin-1 (ET-1), the thromboxane A2-mimetic U46619 and a nitric oxide synthase inhibitor, N-nitro-L-arginine (NOLA), but not in the presence of angiotensin II.	Nitroarginine	207-211	endothelin 1	Homo sapiens	93-105
9630344-10	1998	The competitive nitric oxide synthase (NOS) inhibitor N(omega)-nitro-L-arginine (L-NOARG) not only blocked L-arginine-induced relaxations, but also significantly increased spontaneous contractile activity when added alone (P < 0.05); the inactive D-enantiomer of NOARG had no such effect.	Nitroarginine	54-79	nitric oxide synthase 2	Homo sapiens	16-37
9789575-9	1998	These results indicate that ET-1 contributes to the coronary vasoconstrictor effect of L-NNA in the isolated rat heart, and that this action of ET-1 is mediated through ETA receptor activation.	Nitroarginine	87-92	endothelin 1	Rattus norvegicus	28-32
9877233-2	1998	It was observed that the NO synthase (NOS) inhibitor N(G)-nitro-L-arginine methylester (L-NAME) markedly potentiated insulin release and modestly inhibited glucagon release induced by carbachol.	Nitroarginine	53-74	nitric oxide synthase 2	Homo sapiens	25-36
9877233-2	1998	It was observed that the NO synthase (NOS) inhibitor N(G)-nitro-L-arginine methylester (L-NAME) markedly potentiated insulin release and modestly inhibited glucagon release induced by carbachol.	Nitroarginine	53-74	insulin	Homo sapiens	117-124
9686762-9	1998	The thrombin-mediated increase in putrescine production was reversed by N(G)-methyl-L-arginine, a competitive inhibitor of cationic amino acid transport, or by alpha-difluoromethylornithine (DFMO), an ODC inhibitor.	Nitroarginine	72-94	coagulation factor II, thrombin	Homo sapiens	4-12
9622138-4	1998	Nitric oxide synthase inhibition with 100 micromol/L N(omega)-nitro-L-arginine (NLA) reduced resting afferent and efferent arteriolar diameters to 14.7+/-0.4 and 14.3+/-1.2 microm, respectively, and enhanced afferent but not efferent arteriolar reactivity to Ang II.	Nitroarginine	53-78	angiotensinogen	Rattus norvegicus	259-265
9622138-4	1998	Nitric oxide synthase inhibition with 100 micromol/L N(omega)-nitro-L-arginine (NLA) reduced resting afferent and efferent arteriolar diameters to 14.7+/-0.4 and 14.3+/-1.2 microm, respectively, and enhanced afferent but not efferent arteriolar reactivity to Ang II.	Nitroarginine	80-83	angiotensinogen	Rattus norvegicus	259-265
9622138-5	1998	The enhanced afferent arteriolar reactivity to Ang II was eliminated by addition of the nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP, 10 micromol/L), which reversed the NLA-induced decrease in diameter.	Nitroarginine	181-184	angiotensinogen	Rattus norvegicus	47-53
9576868-4	1998	Apparent Kd values for nNOS haem-domain-binding of arginine and Nomega-nitro-L-arginine (nitroarginine) were measured as 1.6 microM and 25 nM respectively.	Nitroarginine	64-87	nitric oxide synthase 1	Rattus norvegicus	23-27
9576868-4	1998	Apparent Kd values for nNOS haem-domain-binding of arginine and Nomega-nitro-L-arginine (nitroarginine) were measured as 1.6 microM and 25 nM respectively.	Nitroarginine	89-102	nitric oxide synthase 1	Rattus norvegicus	23-27
9743084-2	1998	L-Arginine increased ciliary beat frequency in vitro with a maximum response of 27.1% +/- 6.4% at 10(-3) mol/L, and this effect was reversibly blocked by pretreatment with the NO synthase (NOS) inhibitor N(G)-nitro-L-arginine, whereas D-arginine had no such effect.	Nitroarginine	204-225	nitric oxide synthase 2	Homo sapiens	176-187
9710445-6	1998	The NO synthase inhibitor Nomega-nitro- L-arginine (L-NNA) also blocked the response to GLP-1, whereas L-arginine restored the response.	Nitroarginine	26-50	glucagon	Rattus norvegicus	88-93
9710445-6	1998	The NO synthase inhibitor Nomega-nitro- L-arginine (L-NNA) also blocked the response to GLP-1, whereas L-arginine restored the response.	Nitroarginine	52-57	glucagon	Rattus norvegicus	88-93
9678642-2	1998	One pair of experiments demonstrated dose-related reductions in 2-deoxy-D-glucose (2DG)- and insulin-induced solid food intake with increasing dose (10, 25, and 50 mg/kg s.c.) of the NO-synthase (NOS) inhibitor, NG-nitro-L-arginine (L-NOARG), reaching statistical significance at 10 mg/kg L-NOARG when compared to vehicle controls.	Nitroarginine	212-231	nitric oxide synthase 1, neuronal	Mus musculus	183-194
9678642-2	1998	One pair of experiments demonstrated dose-related reductions in 2-deoxy-D-glucose (2DG)- and insulin-induced solid food intake with increasing dose (10, 25, and 50 mg/kg s.c.) of the NO-synthase (NOS) inhibitor, NG-nitro-L-arginine (L-NOARG), reaching statistical significance at 10 mg/kg L-NOARG when compared to vehicle controls.	Nitroarginine	233-240	nitric oxide synthase 1, neuronal	Mus musculus	183-194
9678642-2	1998	One pair of experiments demonstrated dose-related reductions in 2-deoxy-D-glucose (2DG)- and insulin-induced solid food intake with increasing dose (10, 25, and 50 mg/kg s.c.) of the NO-synthase (NOS) inhibitor, NG-nitro-L-arginine (L-NOARG), reaching statistical significance at 10 mg/kg L-NOARG when compared to vehicle controls.	Nitroarginine	289-296	nitric oxide synthase 1, neuronal	Mus musculus	183-194
9630344-10	1998	The competitive nitric oxide synthase (NOS) inhibitor N(omega)-nitro-L-arginine (L-NOARG) not only blocked L-arginine-induced relaxations, but also significantly increased spontaneous contractile activity when added alone (P < 0.05); the inactive D-enantiomer of NOARG had no such effect.	Nitroarginine	81-88	nitric oxide synthase 2	Homo sapiens	16-37
9630344-10	1998	The competitive nitric oxide synthase (NOS) inhibitor N(omega)-nitro-L-arginine (L-NOARG) not only blocked L-arginine-induced relaxations, but also significantly increased spontaneous contractile activity when added alone (P < 0.05); the inactive D-enantiomer of NOARG had no such effect.	Nitroarginine	83-88	nitric oxide synthase 2	Homo sapiens	16-37
9593832-9	1998	In opposite, a nitric oxide synthase (NOS) inhibitor, N-nitro-L-arginine (NNA)(25 mg/kg) decreased CBF by about 25% and increased time to seizure to 60+/-16 min.	Nitroarginine	54-72	nitric oxide synthase 2	Homo sapiens	15-36
9618239-4	1998	Exposure to IFN-gamma and LPS for 15 h in vitro significantly decreased the peak tension (PT for IFN-gamma + LPS, from 0.13 +/- 0.03 to 0.07 +/- 0.02 g) and rate of tension development (dT/dt for IFN-gamma + LPS, from 1.78 +/- 0.36 to 1.17 +/- 0.28 g/s) compared to untreated controls, and this was prevented by dexamethasone (1 microM) and partly reversed by a non-specific NOS inhibitor, NG-nitro-L-arginine (NOLA, 30 microM).	Nitroarginine	390-409	interferon gamma	Rattus norvegicus	12-21
9618239-4	1998	Exposure to IFN-gamma and LPS for 15 h in vitro significantly decreased the peak tension (PT for IFN-gamma + LPS, from 0.13 +/- 0.03 to 0.07 +/- 0.02 g) and rate of tension development (dT/dt for IFN-gamma + LPS, from 1.78 +/- 0.36 to 1.17 +/- 0.28 g/s) compared to untreated controls, and this was prevented by dexamethasone (1 microM) and partly reversed by a non-specific NOS inhibitor, NG-nitro-L-arginine (NOLA, 30 microM).	Nitroarginine	390-409	interferon gamma	Rattus norvegicus	97-106
9618239-4	1998	Exposure to IFN-gamma and LPS for 15 h in vitro significantly decreased the peak tension (PT for IFN-gamma + LPS, from 0.13 +/- 0.03 to 0.07 +/- 0.02 g) and rate of tension development (dT/dt for IFN-gamma + LPS, from 1.78 +/- 0.36 to 1.17 +/- 0.28 g/s) compared to untreated controls, and this was prevented by dexamethasone (1 microM) and partly reversed by a non-specific NOS inhibitor, NG-nitro-L-arginine (NOLA, 30 microM).	Nitroarginine	390-409	interferon gamma	Rattus norvegicus	97-106
9618239-4	1998	Exposure to IFN-gamma and LPS for 15 h in vitro significantly decreased the peak tension (PT for IFN-gamma + LPS, from 0.13 +/- 0.03 to 0.07 +/- 0.02 g) and rate of tension development (dT/dt for IFN-gamma + LPS, from 1.78 +/- 0.36 to 1.17 +/- 0.28 g/s) compared to untreated controls, and this was prevented by dexamethasone (1 microM) and partly reversed by a non-specific NOS inhibitor, NG-nitro-L-arginine (NOLA, 30 microM).	Nitroarginine	411-415	interferon gamma	Rattus norvegicus	12-21
9618239-4	1998	Exposure to IFN-gamma and LPS for 15 h in vitro significantly decreased the peak tension (PT for IFN-gamma + LPS, from 0.13 +/- 0.03 to 0.07 +/- 0.02 g) and rate of tension development (dT/dt for IFN-gamma + LPS, from 1.78 +/- 0.36 to 1.17 +/- 0.28 g/s) compared to untreated controls, and this was prevented by dexamethasone (1 microM) and partly reversed by a non-specific NOS inhibitor, NG-nitro-L-arginine (NOLA, 30 microM).	Nitroarginine	411-415	interferon gamma	Rattus norvegicus	97-106
9618239-4	1998	Exposure to IFN-gamma and LPS for 15 h in vitro significantly decreased the peak tension (PT for IFN-gamma + LPS, from 0.13 +/- 0.03 to 0.07 +/- 0.02 g) and rate of tension development (dT/dt for IFN-gamma + LPS, from 1.78 +/- 0.36 to 1.17 +/- 0.28 g/s) compared to untreated controls, and this was prevented by dexamethasone (1 microM) and partly reversed by a non-specific NOS inhibitor, NG-nitro-L-arginine (NOLA, 30 microM).	Nitroarginine	411-415	interferon gamma	Rattus norvegicus	97-106
9618239-6	1998	Again, the depressant effects of IFN-gamma and LPS on inotropic responsiveness to isoprenaline were completely prevented by pretreatment with dexamethasone (1 microM), by a specific inhibitor of NOS2, mercaptoethylguanidine (MEG, 30 microM) and by NOLA.	Nitroarginine	248-252	interferon gamma	Rattus norvegicus	33-42
9618239-6	1998	Again, the depressant effects of IFN-gamma and LPS on inotropic responsiveness to isoprenaline were completely prevented by pretreatment with dexamethasone (1 microM), by a specific inhibitor of NOS2, mercaptoethylguanidine (MEG, 30 microM) and by NOLA.	Nitroarginine	248-252	nitric oxide synthase 2	Rattus norvegicus	195-199
9730687-3	1998	The effect of L-NAME in both models is mimicked by L-nitroarginine (L-NNA) and L-nitromethylarginine (L-NMMA), which block constitutive (e and n) forms of NOS, but not by aminoguanidine (which blocks iNOS) or 7-nitroindazole (which specifically blocks nNOS).	Nitroarginine	68-73	nitric oxide synthase 1	Rattus norvegicus	252-256
9593832-9	1998	In opposite, a nitric oxide synthase (NOS) inhibitor, N-nitro-L-arginine (NNA)(25 mg/kg) decreased CBF by about 25% and increased time to seizure to 60+/-16 min.	Nitroarginine	74-77	nitric oxide synthase 2	Homo sapiens	15-36
9546715-6	1998	This production was reversibly inhibited by culture of embryos in medium containing a nonspecific NO synthase (NOS) inhibitor (NG-nitro-L-arginine).	Nitroarginine	127-146	nitric oxide synthase 1, neuronal	Mus musculus	98-109
9605575-4	1998	In the pulmonary artery, human (h)alpha-CGRP-induced relaxation of phenylephrine-evoked tone was abolished either by removal of the endothelium or by NG-nitro-L-arginine (10(-5) M).	Nitroarginine	150-169	calcitonin related polypeptide alpha	Homo sapiens	40-44
9568844-9	1998	In the presence of the NO-synthase inhibitor N(W)-nitro-L-arginine (L-NNA; 5 x 10(-5) mol/l) VEGF/VPF caused only small, transient relaxations (before NNA 109 +/- 5%, after NNA 100%, 15 min with VEGF 95 +/- 2%).	Nitroarginine	68-73	vascular endothelial growth factor A	Rattus norvegicus	93-97
9528932-11	1998	Exposure to IL-1beta resulted in 10-fold higher medium nitrite levels in both subpopulations; this effect was prevented by the iNOS blocker, N(G)-methyl-L-arginine, which also prevented the IL-1beta-induced suppression in the glucose-responsive subpopulation.	Nitroarginine	141-163	interleukin 1 beta	Rattus norvegicus	12-20
9528932-11	1998	Exposure to IL-1beta resulted in 10-fold higher medium nitrite levels in both subpopulations; this effect was prevented by the iNOS blocker, N(G)-methyl-L-arginine, which also prevented the IL-1beta-induced suppression in the glucose-responsive subpopulation.	Nitroarginine	141-163	nitric oxide synthase 2	Rattus norvegicus	127-131
9528932-11	1998	Exposure to IL-1beta resulted in 10-fold higher medium nitrite levels in both subpopulations; this effect was prevented by the iNOS blocker, N(G)-methyl-L-arginine, which also prevented the IL-1beta-induced suppression in the glucose-responsive subpopulation.	Nitroarginine	141-163	interleukin 1 beta	Rattus norvegicus	190-198
9601581-6	1998	Bradykinin (10-100 microM) produced similar dilation of non-collaterals and collaterals which was decreased by nitro-L-arginine but not glibenclamide.	Nitroarginine	111-127	kininogen 1	Canis lupus familiaris	0-10
9568844-9	1998	In the presence of the NO-synthase inhibitor N(W)-nitro-L-arginine (L-NNA; 5 x 10(-5) mol/l) VEGF/VPF caused only small, transient relaxations (before NNA 109 +/- 5%, after NNA 100%, 15 min with VEGF 95 +/- 2%).	Nitroarginine	68-73	vascular endothelial growth factor A	Rattus norvegicus	98-101
9568844-9	1998	In the presence of the NO-synthase inhibitor N(W)-nitro-L-arginine (L-NNA; 5 x 10(-5) mol/l) VEGF/VPF caused only small, transient relaxations (before NNA 109 +/- 5%, after NNA 100%, 15 min with VEGF 95 +/- 2%).	Nitroarginine	68-73	vascular endothelial growth factor A	Rattus norvegicus	195-199
9600661-17	1998	All these treatments except atropine and NG-nitro-L-arginine prevented the endothelin-1-induced lung oedema and reduced the lethality by around 50%.	Nitroarginine	41-60	endothelin 1	Rattus norvegicus	75-87
9530268-7	1998	In contrast, L-NNA (100 microM) enhanced both afferent and efferent arteriolar vasoconstrictor responses to ANG II.	Nitroarginine	13-18	angiotensinogen	Rattus norvegicus	108-114
9570470-4	1998	The effects of alpha1-adrenoceptor blockade and beta2-adrenoceptor stimulation on nerve blood flow and conduction velocity were almost completely (76.7-91.7%) attenuated by NG-nitro-L-arginine co-treatment.	Nitroarginine	173-192	adrenoceptor beta 2	Rattus norvegicus	48-66
9535016-8	1998	LPS/IFN-stimulated NO production was partially inhibited with the nitric oxide synthase (NOS) competitive antagonists; N(omega)-nitro-L-arginine methyl ester and N(omega)-nitro-L-arginine.	Nitroarginine	119-144	toll-like receptor 4	Mus musculus	0-7
9544874-4	1998	In both the AT1 and vehicle groups, nitroarginine infusion significantly decreased the acetylcholine depressor response, glomerular filtration rate, renal plasma flow, and heart rate, and increased arterial pressure and renal vascular resistance in a similar manner, whereas it caused little change in the urinary excretion of sodium and water or in plasma renin activity.	Nitroarginine	36-49	angiotensin II receptor type 1	Canis lupus familiaris	12-15
9570442-7	1998	Both Nomega-nitro-L-arginine methyl ester and NG-nitro-L-arginine increased the tonic CD50 of pentylenetetrazol in mice and Nomega-nitro-L-arginine methyl ester delayed 4-aminopyridine-induced tonus.	Nitroarginine	46-65	intercellular adhesion molecule 5, telencephalin	Mus musculus	86-90
9438562-6	1998	L-NNA treatment enhanced these increases in TBA-reactive substances and MPO activity.	Nitroarginine	0-5	myeloperoxidase	Rattus norvegicus	72-75
9438562-8	1998	Enhancement of ischemia-reperfusion injury by L-NNA treatment was inhibited by injection with anti-neutrophil antibody, anti-platelet activating factor (PAF) antagonist, and anti-leukotriene B4 (LTB4) receptor antagonist.	Nitroarginine	46-51	PCNA clamp associated factor	Rattus norvegicus	153-156
9537834-5	1998	In addition, intraperitoneal administration of NNA inhibited HO-1 immunoreactivity induced by the microinjection of LPS plus IFN-gamma.	Nitroarginine	47-50	heme oxygenase 1	Rattus norvegicus	61-65
9536922-14	1998	After inhibition of nitric oxide synthase with NG-nitro-L-arginine the sensitivity to acetylcholine increased to a similar extent in arteries from embolized pigs and controls.	Nitroarginine	47-66	nitric oxide synthase 2	Sus scrofa	20-41
9517384-8	1998	The contractile response to noradrenaline was unaltered by irradiation throughout the experimental period, but in contrast to control vessels, an increase in the sensitivity to noradrenaline in the presence of the nitric oxide synthase (NOS) inhibitor N(G)-nitro-L-arginine was not observed in the irradiated vessels.	Nitroarginine	252-273	nitric oxide synthase, brain	Oryctolagus cuniculus	214-235
11253783-6	1998	Contractile studies showed that the nitric oxide synthase inhibitor N-nitro-L-arginine (L-NNA) 10 mM increased submaximal (40 Hz) tetanic force (P < 0.0001).	Nitroarginine	68-86	nitric oxide synthase 2	Homo sapiens	36-57
11324518-1	1998	Using extracellular recording technique, the effects of L-arginine (L-arg), SIN-1 and N-nitro-L-arginine (L-NNA) on glutamate-induced discharge of neurons in CA1 area of hippocampal slices were examined to define the role of L-arg:NO pathway in glutamate-induced discharge of hippocampal neurons and its possible underlying mechanism.	Nitroarginine	86-104	carbonic anhydrase 1	Rattus norvegicus	158-161
11324518-1	1998	Using extracellular recording technique, the effects of L-arginine (L-arg), SIN-1 and N-nitro-L-arginine (L-NNA) on glutamate-induced discharge of neurons in CA1 area of hippocampal slices were examined to define the role of L-arg:NO pathway in glutamate-induced discharge of hippocampal neurons and its possible underlying mechanism.	Nitroarginine	106-111	carbonic anhydrase 1	Rattus norvegicus	158-161
9443437-9	1998	VEGF/VPF-induced permeability was significantly attenuated by the nitric oxide (NO) synthase inhibitors N(omega)-nitro-L-arginine (10 mg/kg) or N(omega)-nitro-L-arginine methyl ester (20 mg/kg) and the cyclooxygenase inhibitor indomethacin (5 mg/kg).	Nitroarginine	104-129	vascular endothelial growth factor A	Homo sapiens	0-4
9443437-9	1998	VEGF/VPF-induced permeability was significantly attenuated by the nitric oxide (NO) synthase inhibitors N(omega)-nitro-L-arginine (10 mg/kg) or N(omega)-nitro-L-arginine methyl ester (20 mg/kg) and the cyclooxygenase inhibitor indomethacin (5 mg/kg).	Nitroarginine	104-129	vascular endothelial growth factor A	Homo sapiens	5-8
11253783-6	1998	Contractile studies showed that the nitric oxide synthase inhibitor N-nitro-L-arginine (L-NNA) 10 mM increased submaximal (40 Hz) tetanic force (P < 0.0001).	Nitroarginine	88-93	nitric oxide synthase 2	Homo sapiens	36-57
11253783-8	1998	L-NNA effects were partially reversed by 8-bromo-cGMP 1 mM (8-Br-GMP; a cell-permeable cGMP analogue; P < 0.0001) or dipyridamole 10 microM (DPM; a phosphodiesterase inhibitor; P < 0.0001).	Nitroarginine	0-5	5'-nucleotidase, cytosolic II	Homo sapiens	50-53
11253783-9	1998	8-Br-GMP and DPM produced more-complete L-NNA reversal in combination (P < 0.0001).	Nitroarginine	40-45	5'-nucleotidase, cytosolic II	Homo sapiens	5-8
11253785-3	1998	Endothelial nitric oxide synthase (NOS) activity was inhibited by intraphrenic infusion of L-arginine analogues such as N(G)-nitro-L-arginine, N(G)-nitro-L-arginine methyl ester and argininosuccinic acid.	Nitroarginine	120-141	nitric oxide synthase 3	Canis lupus familiaris	12-33
9585173-5	1998	The lafutidine-induced increase of [3H]-labeled mucin in the corpus was completely blocked by either NG-nitro-L-arginine (10[-5] M) or 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazolne-1-oxyl-3-oxide (10[-5] M).	Nitroarginine	101-120	solute carrier family 13 member 2	Rattus norvegicus	48-53
10806843-6	1998	The inhibitory effect of Al on LTP in CA3 could be enhanced by preinjection of NG-nitro-L-arginine (0.3 mol/L, 1 microliter).	Nitroarginine	79-98	carbonic anhydrase 3	Rattus norvegicus	38-41
9706740-8	1998	Hemoglobin and L-NNA enhanced the ET-1-induced Isc response by about twofold without affecting prostaglandin E2 release or its secretory response.	Nitroarginine	15-20	endothelin-1	Cavia porcellus	34-38
9436821-10	1997	This barbiturate also significantly augmented the hyporeactivity to phenylephrine in carotid arteries exposed to IL-1beta, an effect that was abolished by N(G)-nitro-L-arginine.	Nitroarginine	155-176	interleukin 1 beta	Homo sapiens	113-121
9403543-8	1997	The inhibitory effect of TNF-alpha was partially reversed by N(omega)-nitro-L-arginine, deferoxamine, or alpha-tocopherol and totally reversed by methylene blue.	Nitroarginine	61-86	tumor necrosis factor	Homo sapiens	25-34
9413859-2	1997	Infusion of low (nonpressor) doses of L-NNA or RES-701-1 potentiated systemic and renal vasoconstriction induced by bolus injections of endothelin-1 or sarafotoxin 6c.	Nitroarginine	38-43	endothelin 1	Rattus norvegicus	136-148
9401791-14	1997	Roxatidine-induced stimulation of [3H]glucosamine incorporation into mucin was completely blocked by the addition of either NG-nitro-L-arginine (10(-5) M) or 2-(4-carboxyphenyl)-4,4,5,5,-tetramethylimidazoline-1-oxyl-3-oxide sodium salt (10(-5) M).	Nitroarginine	124-143	solute carrier family 13 member 2	Rattus norvegicus	69-74
9409257-6	1997	Pretreatment with N omega-nitro-L-arginine caused a significant inhibition of VEGF/VPF-induced hypotension.	Nitroarginine	18-42	vascular endothelial growth factor A	Oryctolagus cuniculus	78-82
9354637-6	1997	Nitric oxide production from HEK293 cells ectopically expressing nitric oxide synthases resulted in the stimulation of JNK1 activity, while JNK1 stimulation in nitric oxide synthase-overexpressing cells was abrogated by a nitric oxide synthase inhibitor, NG-nitro-L-arginine.	Nitroarginine	255-274	mitogen-activated protein kinase 8	Homo sapiens	140-144
9425999-2	1997	The AVP-induced relaxation was abolished or reversed to a contraction by removal of the endothelium or treatment with NG-nitro-L-arginine.	Nitroarginine	118-137	arginine vasopressin	Canis lupus familiaris	4-7
9347323-7	1997	Pretreatment with the nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine methylester (L-NAME), but not with D-NAME, significantly reduced the incidence of convulsions and lethality, as well as the increase in cyclic GMP.	Nitroarginine	61-80	nitric oxide synthase 1, neuronal	Mus musculus	22-43
9346432-9	1997	N(omega)-nitro-L-arginine pretreatment partly restored the L-arginine-induced rCBF increase.	Nitroarginine	0-25	CCAAT/enhancer binding protein zeta	Rattus norvegicus	78-82
9385251-9	1997	The relaxations to CGRP and bradykinin were still significant after inhibition of nitric oxide synthase with 10(-4) M N omega-nitro-L-arginine (L-NNA) and inhibition of prostaglandin synthesis with 10(-5) M indomethacin, indicating the existence of an alternative vasorelaxing pathway.	Nitroarginine	118-142	Calcitonin gene-related peptide	Sus scrofa	19-23
9385251-9	1997	The relaxations to CGRP and bradykinin were still significant after inhibition of nitric oxide synthase with 10(-4) M N omega-nitro-L-arginine (L-NNA) and inhibition of prostaglandin synthesis with 10(-5) M indomethacin, indicating the existence of an alternative vasorelaxing pathway.	Nitroarginine	144-149	Calcitonin gene-related peptide	Sus scrofa	19-23
9415273-8	1997	Finally, release of ET-1 was inhibited by NO in normoxia as well as throughout reperfusion as evident from the stimulatory effect of L-NNA.	Nitroarginine	133-138	endothelin 1	Rattus norvegicus	20-24
9321821-5	1997	VEGF produced a highly significant dose-dependent increase in coronary blood flow (maximal 3.51 +/- 0.85-fold) in the absence of significant changes in epicardial artery diameter, a decline in mean arterial pressure (maximal 43%), and a decrease in left ventricular end-diastolic pressure (maximal 52%), all of which could be inhibited by pretreatment with NG-nitro-L-arginine.	Nitroarginine	357-376	vascular endothelial growth factor A	Sus scrofa	0-4
9305973-7	1997	Endothelial nitric oxide synthase readily forms such lower rhombicity complexes, which correlates with the tight binding of NNA to this isoform.	Nitroarginine	124-127	nitric oxide synthase 3	Homo sapiens	0-33
9369345-9	1997	The order of potency for these agonists in the presence of phentolamine, propranolol, guanethidine and L-NNA was: 6-bromo-APB > SKF38393 > dopamine > LY171555.	Nitroarginine	103-108	arginyl aminopeptidase	Homo sapiens	122-125
9313940-12	1997	NG-nitro-L-arginine (5 mg kg-1) potentiated renal responses to regional AII and NA in both groups, but AII responses remained lower in pregnancy.	Nitroarginine	0-19	angiotensinogen	Rattus norvegicus	72-75
9315556-9	1997	L-NNA inhibited iNOS and cNOS activities and plasma NO(x) levels.	Nitroarginine	0-5	nitric oxide synthase, inducible	Oryctolagus cuniculus	16-20
9315556-9	1997	L-NNA inhibited iNOS and cNOS activities and plasma NO(x) levels.	Nitroarginine	0-5	nitric oxide synthase, brain	Oryctolagus cuniculus	25-29
9299360-6	1997	L-NNA increased the release of ET-1 and worsened coronary function, whereas SNAP had opposite effects.	Nitroarginine	0-5	endothelin 1	Rattus norvegicus	31-35
9313890-6	1997	Elevated "OH after MPP+ was blocked stereospecifically by infusion of the nitric oxide synthase (NOS) inhibitor nitro-L-arginine or by the NMDA channel blocker MK801.	Nitroarginine	112-128	nitric oxide synthase 2	Homo sapiens	74-95
9300319-5	1997	The relaxation caused by CGRP was also slightly inhibited at 2 x 10(-8) M by removal of endothelium and in the presence of methylene blue, NG-nitro-L-arginine methylester (L-NAME), or glibenclamide but was not affected by atropine, propranolol, indomethacin, or tetrodotoxin.	Nitroarginine	139-158	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	25-29
9288162-0	1997	Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters.	Nitroarginine	58-79	nitric oxide synthase 1	Homo sapiens	24-54
9288162-1	1997	A series of N omega-nitroarginine (ArgNO2)- and phenylalanine-containing dipeptides and dipeptide esters were synthesized as potential selective inhibitors of neuronal nitric oxide synthase (nNOS).	Nitroarginine	12-33	nitric oxide synthase 1	Homo sapiens	159-189
9288162-1	1997	A series of N omega-nitroarginine (ArgNO2)- and phenylalanine-containing dipeptides and dipeptide esters were synthesized as potential selective inhibitors of neuronal nitric oxide synthase (nNOS).	Nitroarginine	12-33	nitric oxide synthase 1	Homo sapiens	191-195
9283700-12	1997	Endothelium removal increased the contraction to electrical stimulation at 30 degrees C (about 91% for 8 Hz) but not at 37 degrees C. Both L-NOARG and endothelium removal abolished the potentiating effects of endothelin-1 on the response to electrical stimulation found at 30 degrees C. 6.	Nitroarginine	139-146	endothelin-1	Oryctolagus cuniculus	209-221
9257914-13	1997	The nitric oxide (NO) synthase inhibitor N omega-nitro-L-arginine (L-NOARG, 300 microM) attenuated the dilatation induced by adenosine, and by the A1AR and A2AR agonists.	Nitroarginine	41-65	adenosine A2a receptor	Rattus norvegicus	156-160
9257914-13	1997	The nitric oxide (NO) synthase inhibitor N omega-nitro-L-arginine (L-NOARG, 300 microM) attenuated the dilatation induced by adenosine, and by the A1AR and A2AR agonists.	Nitroarginine	67-74	adenosine A2a receptor	Rattus norvegicus	156-160
9263225-10	1997	However, in ischemia gerbils treated with 100 mg kg-1 L-NNA, the average neuronal cell density in the lateral CA1 subfield was 54.4 +/- 19.1, L-NNA (100 mg kg-1) significantly (p < 0.05) reduced the occurrence of neuronal death in the lateral CA1 subfield.	Nitroarginine	54-59	carbonic anhydrase 1	Homo sapiens	110-113
9812867-1	1997	Using extracellular recording technique, the effects of L-arginine (L-arg), N-nitro-L-arginine (L-NNA), SIN-1 and methylene blue (MB) on spontaneous discharges of neurons in CA1 area of hippocampal slices were examined to determine the role of L-arg: NO pathway and the possible underlying mechanism.	Nitroarginine	76-94	carbonic anhydrase 1	Homo sapiens	174-177
9263225-10	1997	However, in ischemia gerbils treated with 100 mg kg-1 L-NNA, the average neuronal cell density in the lateral CA1 subfield was 54.4 +/- 19.1, L-NNA (100 mg kg-1) significantly (p < 0.05) reduced the occurrence of neuronal death in the lateral CA1 subfield.	Nitroarginine	54-59	carbonic anhydrase 1	Homo sapiens	246-249
9180640-5	1997	N omega-nitro-L-arginine (10(-4) mol/L), a nitric oxide synthase inhibitor, elicited a significant decrease in basal arteriolar diameter of fSHR (by approximately 19%) and fSHR-OV+ES (by approximately 17%), thereby eliminating the differences in tone among the various groups.	Nitroarginine	0-24	follicle stimulating hormone receptor	Rattus norvegicus	140-144
9299636-5	1997	L-NNA induced phase III-like contractions in the stomach in the duodenum in association with a significant increase in motilin level.	Nitroarginine	0-5	motilin	Canis lupus familiaris	119-126
9218313-8	1997	RESULTS: In goats in the control group, ET-1 elicited concentration-dependent contraction of the middle cerebral artery that was significantly potentiated after endothelium denudation or during incubation with L-NOArg.	Nitroarginine	210-217	endothelin-1	Capra hircus	40-44
9218313-10	1997	Combined endothelium denudation and incubation with L-NOArg produced a contractile response to ET-1 significantly higher than that induced by each treatment separately.	Nitroarginine	52-59	endothelin-1	Capra hircus	95-99
9227638-10	1997	IL-1 beta-induced protection was reversed with L-NNA.	Nitroarginine	47-52	interleukin 1 beta	Rattus norvegicus	0-9
9201027-8	1997	However, NO blockade with intracoronary NG-nitro-L-arginine blocked the enhanced coronary vasodilation to ACh and BK.	Nitroarginine	40-59	kininogen 1	Canis lupus familiaris	114-116
9227474-3	1997	PACAP, like VIP, increased cytosolic free Ca2+ and the formation of L-[3H]citrulline, NO-3/NO-2, guanosine 3",5"-cyclic monophosphate (cGMP), and adenosine 3"5"-cyclic monophosphate (cAMP) and induced relaxation (mean effective concentration 1.8 +/- 0.1 nM) that was partly inhibited by NG-nitro-L-arginine (L-NNA), VIP-(10-28), and PACAP 6-38.	Nitroarginine	287-306	LOW QUALITY PROTEIN: pituitary adenylate cyclase-activating polypeptide	Oryctolagus cuniculus	0-5
9227474-3	1997	PACAP, like VIP, increased cytosolic free Ca2+ and the formation of L-[3H]citrulline, NO-3/NO-2, guanosine 3",5"-cyclic monophosphate (cGMP), and adenosine 3"5"-cyclic monophosphate (cAMP) and induced relaxation (mean effective concentration 1.8 +/- 0.1 nM) that was partly inhibited by NG-nitro-L-arginine (L-NNA), VIP-(10-28), and PACAP 6-38.	Nitroarginine	308-313	LOW QUALITY PROTEIN: pituitary adenylate cyclase-activating polypeptide	Oryctolagus cuniculus	0-5
9227474-5	1997	PACAP-induced relaxation was inhibited to the same extent (46-49%) by nifedipine, L-NNA, PTx, and the protein kinase G inhibitor KT-5823; the inhibition reflected the component of relaxation mediated by the NO-cGMP pathway.	Nitroarginine	82-87	LOW QUALITY PROTEIN: pituitary adenylate cyclase-activating polypeptide	Oryctolagus cuniculus	0-5
9180640-5	1997	N omega-nitro-L-arginine (10(-4) mol/L), a nitric oxide synthase inhibitor, elicited a significant decrease in basal arteriolar diameter of fSHR (by approximately 19%) and fSHR-OV+ES (by approximately 17%), thereby eliminating the differences in tone among the various groups.	Nitroarginine	0-24	follicle stimulating hormone receptor	Rattus norvegicus	172-176
9105711-13	1997	Human pial arteries from two out of four patients displayed an L-NOARG/indomethacin-resistant relaxation in response to substance P.	Nitroarginine	63-70	tachykinin precursor 1	Homo sapiens	120-131
9185087-5	1997	Inhibition of endothelium-derived nitric oxide synthesis by L-NNA, however, significantly attenuated BK- and SP-induced vascular relaxations, whereas indomethacin had slight influence.	Nitroarginine	60-65	kininogen 1	Bos taurus	101-103
9234666-0	1997	Influence of cytochrome P-450 inhibitors on endothelium-dependent nitro-L-arginine-resistant relaxation and cromakalim-induced relaxation in rat mesenteric arteries.	Nitroarginine	66-82	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	13-29
9176242-0	1997	Endothelin-1 mediates nitro-L-arginine vasoconstriction of hypertensive rat lungs.	Nitroarginine	22-38	endothelin 1	Rattus norvegicus	0-12
9183289-0	1997	[3H]L-NG-nitroarginine binding after transient focal ischemia and NMDA-induced excitotoxicity in type I and type III nitric oxide synthase null mice.	Nitroarginine	6-22	nitric oxide synthase 1, neuronal	Mus musculus	117-138
9183289-1	1997	We investigated the density and distribution of nitric oxide synthase (NOS) binding by quantitative autoradiography using [3H]L-NG-nitroarginine ([3H]L-NNA) after transient focal ischemia or intrastriatal injection of N-methyl-D-aspartate (NMDA) in wild-type (SV-129 and C57black/6) and type I (neuronal) and type III (endothelial) NOS-deficient mice.	Nitroarginine	126-144	nitric oxide synthase 1, neuronal	Mus musculus	48-69
9105232-14	1997	Administration of L-NNA in the knockout mice attenuated the rCBF response to isoflurane at 1.2 and 1.8 vol% but had no effect on the response at 2.4 vol%.	Nitroarginine	18-23	CCAAT/enhancer binding protein zeta	Rattus norvegicus	60-64
9085046-5	1997	However when incubated in conjunction with 400 ng/ml interleukin-6 for 2 h, NG-nitro-L-arginine apparently prevented the increase in cGMP and nitrite induced by 400 ng/ml interleukin-6.	Nitroarginine	76-95	interleukin 6	Rattus norvegicus	53-66
9173873-0	1997	Cysteine-200 of human inducible nitric oxide synthase is essential for dimerization of haem domains and for binding of haem, nitroarginine and tetrahydrobiopterin.	Nitroarginine	125-138	nitric oxide synthase 2	Homo sapiens	22-53
9173873-7	1997	The iNOS 1-504 and 59-504 fusion proteins bound similar amounts of haem, Nomega-nitro-l-arginine (nitroarginine) and tetrahydrobiopterin, showing that the first 58 residues are not required for binding these factors.	Nitroarginine	73-96	nitric oxide synthase 2	Homo sapiens	4-8
9173873-7	1997	The iNOS 1-504 and 59-504 fusion proteins bound similar amounts of haem, Nomega-nitro-l-arginine (nitroarginine) and tetrahydrobiopterin, showing that the first 58 residues are not required for binding these factors.	Nitroarginine	98-111	nitric oxide synthase 2	Homo sapiens	4-8
9049163-3	1997	Nitric oxide production was effectively inhibited by intravenous infusion of 20 mg/kg nitro-L-arginine methylester (L-NAME) as evidenced by a shift of the dose/response curve for the effect of intracoronary administration of bradykinin (0.004-4.0 nmol/min) on coronary blood flow.	Nitroarginine	86-102	kininogen 1	Canis lupus familiaris	225-235
9091643-10	1997	This lysis was suppressed by the specific iNOS inhibitor N(G)-methyl-L-arginine.	Nitroarginine	57-79	nitric oxide synthase 2, inducible	Mus musculus	42-46
9085046-5	1997	However when incubated in conjunction with 400 ng/ml interleukin-6 for 2 h, NG-nitro-L-arginine apparently prevented the increase in cGMP and nitrite induced by 400 ng/ml interleukin-6.	Nitroarginine	76-95	interleukin 6	Rattus norvegicus	171-184
9138678-9	1997	HbO (20 microM) and a combination of HbO (20 microM) and L-NOARG (100 microM) reduced Rmax to bradykinin by 58% (P < 0.05) and 54% (P < 0.05), respectively.	Nitroarginine	57-64	kininogen 1	Homo sapiens	94-104
9087607-4	1997	Intravenous administration of the nonspecific NO synthase (NOS) inhibitor N(omega)-nitro-L-arginine increased mean arterial blood pressure and resting cerebrovascular resistance and attenuated CSD-induced hyperemia.	Nitroarginine	74-99	nitric oxide synthase, brain	Oryctolagus cuniculus	46-57
9138678-10	1997	HbO (20 microM) and L-NOARG (100 microM, combined but not HbO (20 microM) alone, caused a significant 11 fold (P < 0.05) decrease in sensitivity to bradykinin.	Nitroarginine	20-27	kininogen 1	Homo sapiens	151-161
9138678-14	1997	A combination of HbO, L-NOARG and high K+ (30 mM) abolished the response to bradykinin.	Nitroarginine	22-29	kininogen 1	Homo sapiens	76-86
9041554-4	1997	Thus, L-NNA seems to bind the substrate-binding domain in the nNOS with high affinity rather than L-Arg.	Nitroarginine	6-11	nitric oxide synthase 1	Rattus norvegicus	62-66
9074982-6	1997	In addition, treatment of EC with XO and/or L-NNA increased both surface expression of P-selectin and release of von Willebrand factor into media.	Nitroarginine	44-49	selectin P	Homo sapiens	87-97
9041554-9	1997	These results suggest that L-[3H]NNA seems to bind the substrate-binding domain in the nNOS but the binding affinity of L-Arg was lower than the affinity of L-NNA.	Nitroarginine	157-162	nitric oxide synthase 1	Rattus norvegicus	87-91
9067444-0	1997	Enhancement of central pressor effect of AVP in SHR and WKY rats by intracranial N(G)-nitro-L-arginine.	Nitroarginine	81-102	arginine vasopressin	Rattus norvegicus	41-44
9138738-4	1997	N(G)-nitro-L-arginine (L-NNA), an inhibitor of NO synthase (NOS), (5 mg/kg, i.p.)	Nitroarginine	0-21	nitric oxide synthase 1, neuronal	Mus musculus	47-58
9067444-11	1997	pretreatment with L-NNA significantly intensified the pressor response to centrally applied AVP both in WKY (P < 0.01) and in SHR (P < 0.01) rats; the maximum increase of blood pressure to combined administration of L-NNA and AVP being significantly greater in SHR than in WKY rats.	Nitroarginine	18-23	arginine vasopressin	Rattus norvegicus	92-95
9067444-11	1997	pretreatment with L-NNA significantly intensified the pressor response to centrally applied AVP both in WKY (P < 0.01) and in SHR (P < 0.01) rats; the maximum increase of blood pressure to combined administration of L-NNA and AVP being significantly greater in SHR than in WKY rats.	Nitroarginine	18-23	arginine vasopressin	Rattus norvegicus	232-235
9067444-11	1997	pretreatment with L-NNA significantly intensified the pressor response to centrally applied AVP both in WKY (P < 0.01) and in SHR (P < 0.01) rats; the maximum increase of blood pressure to combined administration of L-NNA and AVP being significantly greater in SHR than in WKY rats.	Nitroarginine	222-227	arginine vasopressin	Rattus norvegicus	92-95
8987799-4	1997	Local NOS inhibition by microdialysis delivery of N(G)-nitro-L-arginine (NLA) significantly reduced ACh release in the cholinergic cell body region of the pedunculopontine tegmental nucleus and in the cholinoceptive mPRF.	Nitroarginine	50-71	Spi-C transcription factor (Spi-1/PU.1 related)	Mus musculus	216-220
9040620-4	1997	Data were acquired after treatment with the nitric oxide synthase inhibitor N omega-nitro-L-arginine during hypoxia (inspired oxygen fraction = 0.10) and during inhalation of nitric oxide (100 ppm).	Nitroarginine	76-100	nitric oxide synthase 2	Sus scrofa	44-65
9201555-7	1997	VIP-induced relaxation was antagonized by L-NOArg (50 microM) (from 68 +/- 5 to 46 +/- 2% relaxation of 5-HT-induced tone) but not by D-NOArg.	Nitroarginine	42-49	vasoactive intestinal peptide	Ovis aries	0-3
9201555-9	1997	Exogenous VIP produced an approximately 2.4-fold increase in cyclic GMP content which was prevented by preincubation with L-NOArg (100 microM) but not D-NOArg.	Nitroarginine	122-129	vasoactive intestinal peptide	Ovis aries	10-13
8987799-4	1997	Local NOS inhibition by microdialysis delivery of N(G)-nitro-L-arginine (NLA) significantly reduced ACh release in the cholinergic cell body region of the pedunculopontine tegmental nucleus and in the cholinoceptive mPRF.	Nitroarginine	73-76	Spi-C transcription factor (Spi-1/PU.1 related)	Mus musculus	216-220
9263762-3	1997	Subchronic inhibition of the nitric oxide synthase (NOS) pathway (N omega-nitro-L-arginine, 20 mg.kg-1.d-1 during 7 days) attenuated the systemic and coronary effects of bradykinin.	Nitroarginine	66-90	nitric oxide synthase 3	Canis lupus familiaris	29-50
9416322-1	1997	The involvement of nitric oxide (NO) in the development of ischemic cytotoxic edema was investigated by inhibiting nitric oxide synthase (NOS) activity with N omega-nitro-L-arginine (NLA).	Nitroarginine	157-181	nitric oxide synthase 2	Homo sapiens	115-136
9008461-4	1997	In addition, group 3 received supplemental L-arginine and group 4 received L-arginine and N omega-nitro-L-arginine (L-NA), an inhibitor of NO synthase (NOS).	Nitroarginine	90-114	nitric oxide synthase 1, neuronal	Mus musculus	139-150
9263768-5	1997	Addition of acetylcholine (1 nM-10 microM) or bradykinin (1 nM-10 microM) to precontracted preparations elicited concentration-dependent relaxation responses that were dependent on the presence of the endothelium and were partially inhibited by the NO-synthase inhibitor nitro-L-arginine (0.1 mM).	Nitroarginine	271-287	kininogen 1	Homo sapiens	46-56
9263762-3	1997	Subchronic inhibition of the nitric oxide synthase (NOS) pathway (N omega-nitro-L-arginine, 20 mg.kg-1.d-1 during 7 days) attenuated the systemic and coronary effects of bradykinin.	Nitroarginine	66-90	kininogen 1	Canis lupus familiaris	170-180
8978749-5	1997	Moreover, arginine-induced potentiation, NO production, and cyclic GMP increases were all suppressed after the preincubation of cells with N-methyl-L-arginine or N-nitro-L-arginine, nitric oxide synthase inhibitor.	Nitroarginine	162-180	5'-nucleotidase, cytosolic II	Homo sapiens	67-70
8988010-10	1996	Studies of the association of NG-nitro-L-arginine (L-NNA) to nNOS(BH4+) revealed that excess BH4 increased the amount of bound L-NNA 2-fold.	Nitroarginine	30-49	nitric oxide synthase 1	Homo sapiens	61-65
9150420-0	1997	Potent inhibition of human neuronal nitric oxide synthase by N(G)-nitro-L-arginine methyl ester results from contaminating N(G)-nitro-L-arginine.	Nitroarginine	61-82	nitric oxide synthase 1	Homo sapiens	36-57
9148280-3	1997	The nitric oxide synthase inhibitor N omega-nitro-L-arginine (0.1 mM) also increased the sensitivity to endothelin-1 (0.6 log units) in basilar arteries with endothelium, whereas N omega-nitro-D-arginine (0.1 mM) and indomethacin (3 microM) had no effect, indicating that withdrawal of endothelium-derived nitric oxide may account for the enhancement of the endothelin-1-induced contraction after endothelial denudation.	Nitroarginine	36-60	endothelin-1	Oryctolagus cuniculus	104-116
9148280-3	1997	The nitric oxide synthase inhibitor N omega-nitro-L-arginine (0.1 mM) also increased the sensitivity to endothelin-1 (0.6 log units) in basilar arteries with endothelium, whereas N omega-nitro-D-arginine (0.1 mM) and indomethacin (3 microM) had no effect, indicating that withdrawal of endothelium-derived nitric oxide may account for the enhancement of the endothelin-1-induced contraction after endothelial denudation.	Nitroarginine	36-60	endothelin-1	Oryctolagus cuniculus	358-370
9051783-3	1996	Intrastriatal injection of ET-1 caused seizures and barrel rolling which were prevented by pretreatment with the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 and attenuated by the nitric-oxide synthase inhibitor N omega-nitro-L-arginine (L-NNA).	Nitroarginine	222-246	endothelin 1	Homo sapiens	27-31
9051783-3	1996	Intrastriatal injection of ET-1 caused seizures and barrel rolling which were prevented by pretreatment with the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 and attenuated by the nitric-oxide synthase inhibitor N omega-nitro-L-arginine (L-NNA).	Nitroarginine	248-253	endothelin 1	Homo sapiens	27-31
8988010-10	1996	Studies of the association of NG-nitro-L-arginine (L-NNA) to nNOS(BH4+) revealed that excess BH4 increased the amount of bound L-NNA 2-fold.	Nitroarginine	51-56	nitric oxide synthase 1	Homo sapiens	61-65
8954112-3	1996	Inhibition of nitric oxide (NO) production by N omega-nitro-L-arginine (LNA) canceled such an inhibitory effect of LPS and/or IFN gamma.	Nitroarginine	46-70	interferon gamma	Rattus norvegicus	126-135
8988010-10	1996	Studies of the association of NG-nitro-L-arginine (L-NNA) to nNOS(BH4+) revealed that excess BH4 increased the amount of bound L-NNA 2-fold.	Nitroarginine	127-132	nitric oxide synthase 1	Homo sapiens	61-65
8988010-11	1996	Most of the binding data are explained by a model in which nNOS dimers accommodate two identical BH4- and Arg/L-NNA-binding sites, with cooperativity between Arg- and BH4-binding and anticooperativity between the BH4-binding sites.	Nitroarginine	110-115	nitric oxide synthase 1	Homo sapiens	59-63
8981663-8	1996	The highest IL-6 level and the most advanced histopathological alterations were observed in the rats treated with L-NNA.	Nitroarginine	114-119	interleukin 6	Rattus norvegicus	12-16
9017237-7	1996	Under the hypoxic condition, MK-801, L-NNA, and anti-PAF IgG significantly protected the CA1 neurons from hypoxic injury compared with cortical neurons, while cycloheximide protected both cultures equally.	Nitroarginine	37-42	carbonic anhydrase 1	Rattus norvegicus	89-92
8997279-5	1996	These effects of ST were completely abolished after deendothelization (air bolus maintained for 6 min in vessel lumen) and after local infusion of NG-nitro-L-arginine (L-NNA; 10(-4) M), a nitric oxide (NO) synthesis inhibitor.	Nitroarginine	147-166	somatostatin	Rattus norvegicus	17-19
9394497-4	1996	We found that the enzyme is dependent on the presence of calcium, calmodulin and NADPH and is inhibited by the arginine analog L-NG-nitroarginine.	Nitroarginine	127-145	calmodulin 2	Gallus gallus	66-76
8922738-17	1996	In contrast, NO synthase inhibition with NG-nitro-L-arginine (30 microM) resulted in an attenuated desensitization to vasopressin in intact rings (from 2.46 +/- 0.17 to 2.25 +/- 0.22 g, NS).	Nitroarginine	41-60	arginine vasopressin	Rattus norvegicus	118-129
8945677-7	1996	The hypotension induced by intravenous and intraarterial injections of BK and intravenous injections of des-Arg9-BK was only slightly reduced after nitric oxide (NO) synthase inhibition with NG-nitro-L-arginine (L-NNA).	Nitroarginine	191-210	kininogen 1	Canis lupus familiaris	71-73
8945677-7	1996	The hypotension induced by intravenous and intraarterial injections of BK and intravenous injections of des-Arg9-BK was only slightly reduced after nitric oxide (NO) synthase inhibition with NG-nitro-L-arginine (L-NNA).	Nitroarginine	212-217	kininogen 1	Canis lupus familiaris	71-73
8951973-2	1996	Experiment 1 demonstrated a dose-related decrease in CP-induced solid food intake over a 60-min test period with increasing dose (10, 25, and 50 mg/ kg SC) of the NO-synthase (NOS) inhibitor, L-NG-nitro arginine (L-NOARG), reaching statistical significance at 10 mg/kg L-NOARG when compared to vehicle control.	Nitroarginine	192-211	nitric oxide synthase 1, neuronal	Mus musculus	163-174
8955523-2	1996	Intraventricular injection of 5 microliters of 5.0 mg/ml N omega-nitro-L-arginine (LNNA) significantly preserved neuronal density in the central part of the CA1 region examined 7 days after 5-min ischemia [188.5 +/- 8.5/mm: 90.0% of the 209.5 +/- 11.1/mm density in the sham-operated controls vs. 16.7 +/- 6.4/mm in those injected with artificial cerebrospinal fluid (CSF) only].	Nitroarginine	57-81	carbonic anhydrase 1	Homo sapiens	157-160
8955523-2	1996	Intraventricular injection of 5 microliters of 5.0 mg/ml N omega-nitro-L-arginine (LNNA) significantly preserved neuronal density in the central part of the CA1 region examined 7 days after 5-min ischemia [188.5 +/- 8.5/mm: 90.0% of the 209.5 +/- 11.1/mm density in the sham-operated controls vs. 16.7 +/- 6.4/mm in those injected with artificial cerebrospinal fluid (CSF) only].	Nitroarginine	83-87	carbonic anhydrase 1	Homo sapiens	157-160
8897969-1	1996	The effect of NG-nitro-L-arginine (L-NNA) on regional cerebral blood flow (rCBF) response to hypercapnia (5% CO2 inhalation) was studied in urethan-anesthetized wild-type (SV-129) and type III nitric oxide (NO) synthase (NOS)-deficient mice, using laser-Doppler flowmetry and the closed cranial window technique.	Nitroarginine	35-40	CCAAT/enhancer binding protein zeta	Rattus norvegicus	75-79
8957254-3	1996	Inhibition of nitric oxide synthase by N omega-nitro-L-arginine (100 microM) shifted the vasopressin-induced vasoconstrictor response curve to the left.	Nitroarginine	39-63	arginine vasopressin	Rattus norvegicus	89-100
8859008-14	1996	Hexamethonium or L-NNA (but not atropine) reduced VIP release; CCK8 still enhanced it.	Nitroarginine	17-22	vasoactive intestinal peptide	Canis lupus familiaris	50-53
8833903-8	1996	This decrease was prevented by inhibition of iNOS induction by dexamethasone or by inhibition of iNOS activity by N(G)-methyl-L-arginine.	Nitroarginine	114-136	nitric oxide synthase 2	Rattus norvegicus	97-101
8806587-3	1996	In addition, when slices were incubated in the presence of N-nitro-L-arginine, a nitric oxide (NO) synthase inhibitor, PAF-stimulated cyclic GMP generation was abolished.	Nitroarginine	59-77	PCNA clamp associated factor	Rattus norvegicus	119-122
8843766-5	1996	Velocity was also inhibited in a concentration-dependent fashion by the nitric oxide synthase inhibitor NG-nitro-L-arginine (L-NNA; IC50, 1 microM; maximal inhibition, 96 +/- 2%) and by the vasoactive intestinal peptide (VIP) antagonist VIP-(10-28) (IC50, 30 nM; maximal inhibition, 64 +/- 6%), consistent with involvement of both nitric oxide and VIP in descending relaxation of circular muscle and contraction of longitudinal muscle.	Nitroarginine	125-130	vasoactive intestinal peptide	Homo sapiens	221-224
8843766-5	1996	Velocity was also inhibited in a concentration-dependent fashion by the nitric oxide synthase inhibitor NG-nitro-L-arginine (L-NNA; IC50, 1 microM; maximal inhibition, 96 +/- 2%) and by the vasoactive intestinal peptide (VIP) antagonist VIP-(10-28) (IC50, 30 nM; maximal inhibition, 64 +/- 6%), consistent with involvement of both nitric oxide and VIP in descending relaxation of circular muscle and contraction of longitudinal muscle.	Nitroarginine	125-130	vasoactive intestinal peptide	Homo sapiens	237-240
8843766-5	1996	Velocity was also inhibited in a concentration-dependent fashion by the nitric oxide synthase inhibitor NG-nitro-L-arginine (L-NNA; IC50, 1 microM; maximal inhibition, 96 +/- 2%) and by the vasoactive intestinal peptide (VIP) antagonist VIP-(10-28) (IC50, 30 nM; maximal inhibition, 64 +/- 6%), consistent with involvement of both nitric oxide and VIP in descending relaxation of circular muscle and contraction of longitudinal muscle.	Nitroarginine	125-130	vasoactive intestinal peptide	Homo sapiens	237-240
9048219-6	1996	Thus, in human pulmonary arteries, NA and ACh activities release vasodilator prostanoids and nitroarginine-sensitive EDRF from the endothelium, and initiate direct contractile actions to smooth muscle.	Nitroarginine	93-106	alpha hemoglobin stabilizing protein	Homo sapiens	117-121
9004899-2	1996	It was shown that inhibition of inducible NO-synthase by N(W)-nitro-L-arginine (L-NNA) at 10 mg/kg reduces the mortality of animals due to heat shock, prevents the fall of arterial blood pressure and abnormal inhibition of constriction and stimulation of dilation reactions related to NO hyperproduction.	Nitroarginine	80-85	nitric oxide synthase 2	Homo sapiens	32-53
8853353-5	1996	NG-nitro-L-arginine (L-NNA, 1 mM) superfusion inhibited cortical NOS activity by > 70% and abrogated the response in wild-type mice while blocking the dilation by approximately 50% in eNOS mutant and nNOS mutant mice.	Nitroarginine	0-19	nitric oxide synthase 3, endothelial cell	Mus musculus	187-191
8853353-5	1996	NG-nitro-L-arginine (L-NNA, 1 mM) superfusion inhibited cortical NOS activity by > 70% and abrogated the response in wild-type mice while blocking the dilation by approximately 50% in eNOS mutant and nNOS mutant mice.	Nitroarginine	0-19	nitric oxide synthase 1, neuronal	Mus musculus	203-207
8853353-5	1996	NG-nitro-L-arginine (L-NNA, 1 mM) superfusion inhibited cortical NOS activity by > 70% and abrogated the response in wild-type mice while blocking the dilation by approximately 50% in eNOS mutant and nNOS mutant mice.	Nitroarginine	21-26	nitric oxide synthase 3, endothelial cell	Mus musculus	187-191
8853353-5	1996	NG-nitro-L-arginine (L-NNA, 1 mM) superfusion inhibited cortical NOS activity by > 70% and abrogated the response in wild-type mice while blocking the dilation by approximately 50% in eNOS mutant and nNOS mutant mice.	Nitroarginine	21-26	nitric oxide synthase 1, neuronal	Mus musculus	203-207
8853353-7	1996	The residual dilation after L-NNA in eNOS mutant mice could be blocked completely by TTX-plus L-NNA.	Nitroarginine	28-33	nitric oxide synthase 3, endothelial cell	Mus musculus	37-41
8853353-7	1996	The residual dilation after L-NNA in eNOS mutant mice could be blocked completely by TTX-plus L-NNA.	Nitroarginine	94-99	nitric oxide synthase 3, endothelial cell	Mus musculus	37-41
8853353-8	1996	Our findings indicate that 1) ACh dilates pial arterioles of wild-type mice by NOS-dependent mechanisms as reported in other species, 2) the response in nNOS mutant mice resembles the wild-type response except for enhanced dilation to ACh and reduced L-NNA sensitivity, and 3) surprisingly, the response in eNOS mutant mice is partially NOS dependent and attenuated by both TTX and L-NNA.	Nitroarginine	251-256	nitric oxide synthase 1, neuronal	Mus musculus	153-157
8853353-8	1996	Our findings indicate that 1) ACh dilates pial arterioles of wild-type mice by NOS-dependent mechanisms as reported in other species, 2) the response in nNOS mutant mice resembles the wild-type response except for enhanced dilation to ACh and reduced L-NNA sensitivity, and 3) surprisingly, the response in eNOS mutant mice is partially NOS dependent and attenuated by both TTX and L-NNA.	Nitroarginine	382-387	nitric oxide synthase 1, neuronal	Mus musculus	153-157
8781471-4	1996	The effects of BK and CCh, but not SNAP, were blocked by 10(-4) mol/L NG-nitro-L-arginine, consistent with both BK and CCh stimulating NO biosynthesis and with SNAP decomposing to release NO, respectively.	Nitroarginine	70-89	kininogen 1	Canis lupus familiaris	15-17
8781471-4	1996	The effects of BK and CCh, but not SNAP, were blocked by 10(-4) mol/L NG-nitro-L-arginine, consistent with both BK and CCh stimulating NO biosynthesis and with SNAP decomposing to release NO, respectively.	Nitroarginine	70-89	kininogen 1	Canis lupus familiaris	112-114
8784243-0	1996	Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine.	Nitroarginine	87-103	nitric oxide synthase 3, endothelial cell	Mus musculus	21-54
8784243-4	1996	Unlike the situation in wild-type mice, nitro-L-arginine superfusion (1 mM) dilated pial arterioles of eNOS knockout mice in a closed cranial window preparation.	Nitroarginine	40-56	nitric oxide synthase 3, endothelial cell	Mus musculus	103-107
8784243-7	1996	Systemic administration of nitro-L-arginine decreased infarct size in eNOS mutant mice (24%) but not in the wild-type strain.	Nitroarginine	27-43	nitric oxide synthase 3, endothelial cell	Mus musculus	70-74
8784243-8	1996	This finding complements published data showing that nitro-L-arginine increases infarct size in knockout mice expressing the eNOS but not the neuronal NOS isoform (i.e., neuronal NOS knockout mice).	Nitroarginine	53-69	nitric oxide synthase 3, endothelial cell	Mus musculus	125-129
8770052-4	1996	NG-nitro-L-arginine (L-NMA) abolished NO formation, abolished VIP release and relaxation at low frequencies, and partly inhibited them at higher frequencies.	Nitroarginine	0-19	vasoactive intestinal peptide	Rattus norvegicus	62-65
8706919-1	1996	As our group has shown, the NO-synthase inhibitor L-NNA decreased 2-3 times heat shock-induced synthesis of the heat shock protein HSP70 (FEBS Lett.	Nitroarginine	50-55	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	131-136
8770052-9	1996	Thus 1) inhibition of relaxation by L-NNA reflects suppression of NO and VIP release from nerve terminals and NO formation in muscle cells, 2) inhibition by VIP-(10-28) partly reflects suppression of NO formation in muscle cells, and 3) inhibition by oxy-Hb reflects neutralization of extracellular NO and suppression of VIP release.	Nitroarginine	36-41	vasoactive intestinal peptide	Rattus norvegicus	73-76
8864557-11	1996	The release of CGRP evoked by ETX was enhanced by L-arginine by 43% and inhibited by N omega-nitro-L-arginine (L-NOARG) and methylene blue by 37% and 38%, respectively.	Nitroarginine	85-109	calcitonin-related polypeptide alpha	Rattus norvegicus	15-19
8770168-4	1996	In the presence of L-NNA, 1 nM ANG II decreased afferent diameter by 26% and efferent diameter by 35%.	Nitroarginine	19-24	angiotensinogen	Rattus norvegicus	31-37
8770168-6	1996	L-NNA also augmented vasopressin responses, indicating a lack of agonist specificity in this interaction.	Nitroarginine	0-5	arginine vasopressin	Rattus norvegicus	21-32
8770168-7	1996	ANG II reactivity during L-NNA treatment was not enhanced when tissue NO activity was fixed at basal levels (exposure to 1 microM sodium nitroprusside).	Nitroarginine	25-30	angiotensinogen	Rattus norvegicus	0-6
8756014-8	1996	In vitro, indomethacin blunted the residual relaxation to bradykinin of large coronary arteries taken from L-NNA-treated, but not from control, dogs.	Nitroarginine	107-112	kininogen 1	Canis lupus familiaris	58-68
8756014-9	1996	Bradykinin-induced increase in 6-ketoprostaglandin F1 alpha production was greater in coronary arteries taken from L-NNA-treated dogs (+ 179 +/- 41 pg/mm2) than from control dogs (+ 66 +/- 18 pg/mm2) (P < .05).	Nitroarginine	115-120	kininogen 1	Canis lupus familiaris	0-10
8770115-5	1996	Relaxations to both VEGF and bFGF were inhibited in the presence of either NG-nitro-L-arginine or genistein, suggesting that the relaxations are through the tyrosine kinase-mediated release of endothelium-derived nitric oxide.	Nitroarginine	75-94	vascular endothelial growth factor A	Sus scrofa	20-24
8770120-4	1996	After incubation with 20 or 50 mM K+ for 1 h, the indomethacin- and NG-nitro-L-arginine+ (L-NNA)-resistant relaxation induced by A23187 or bradykinin, which could be further inhibited by tetraethylammonium but not glibenclamide, was significantly reduced.	Nitroarginine	68-87	kininogen 1	Homo sapiens	139-149
8770120-4	1996	After incubation with 20 or 50 mM K+ for 1 h, the indomethacin- and NG-nitro-L-arginine+ (L-NNA)-resistant relaxation induced by A23187 or bradykinin, which could be further inhibited by tetraethylammonium but not glibenclamide, was significantly reduced.	Nitroarginine	90-95	kininogen 1	Homo sapiens	139-149
8864557-11	1996	The release of CGRP evoked by ETX was enhanced by L-arginine by 43% and inhibited by N omega-nitro-L-arginine (L-NOARG) and methylene blue by 37% and 38%, respectively.	Nitroarginine	111-118	calcitonin-related polypeptide alpha	Rattus norvegicus	15-19
8683799-28	1996	per minute N-omega-nitro-L-arginine) endothelin-1 increased renal vascular resistance (1.2 +/- 0.2 mm.	Nitroarginine	11-35	EDN1	Ovis aries	37-49
8886498-5	1996	Purified components of GS, Rb1 and especially Rg1, relaxed pulmonary vessels and this effect was eliminated by nitro-L-arginine, an inhibitor of nitric oxide (NO) synthase.	Nitroarginine	111-127	retinoblastoma-associated protein	Oryctolagus cuniculus	27-30
8886498-5	1996	Purified components of GS, Rb1 and especially Rg1, relaxed pulmonary vessels and this effect was eliminated by nitro-L-arginine, an inhibitor of nitric oxide (NO) synthase.	Nitroarginine	111-127	protein phosphatase 1 regulatory subunit 3A	Oryctolagus cuniculus	46-49
8864303-3	1996	In dentate gyrus, the NMDA-induced glutamate release was inhibited non-significantly by tetrodotoxin, whereas the NO synthase (NOS) inhibitor NG-nitro-L-arginine (L-NNA) blocked the NMDA-induced release of glutamate in a concentration-dependent manner, but not a high K(+)-evoked release of glutamate.	Nitroarginine	142-161	nitric oxide synthase, inducible	Cavia porcellus	114-125
8878249-6	1996	In both tissues L-NNA enhanced the contraction induced by endothelin-1 and lowered the threshold concentration for it.	Nitroarginine	16-21	endothelin 1	Bos taurus	58-70
8864303-3	1996	In dentate gyrus, the NMDA-induced glutamate release was inhibited non-significantly by tetrodotoxin, whereas the NO synthase (NOS) inhibitor NG-nitro-L-arginine (L-NNA) blocked the NMDA-induced release of glutamate in a concentration-dependent manner, but not a high K(+)-evoked release of glutamate.	Nitroarginine	163-168	nitric oxide synthase, inducible	Cavia porcellus	114-125
8695758-8	1996	The dose-dependent vasodilation to BK was diminished (p < 0.01) after treatment with 1.8 mM N omega-nitro-L-arginine (L-NA), a potent inhibitor of nitric oxide synthase.	Nitroarginine	95-119	kininogen 1	Canis lupus familiaris	35-37
8675267-4	1996	Nitro-L-arginine, a nitric oxide synthase inhibitor, also attenuated the relaxations to methacholine, bradykinin, and arachidonic acid and shifted the EC50 (control versus nitro-L-arginine) to each (1 x 10(-7) versus 3 x 10(-7) mo1/L, 3 x 10(-10) versus > 10(-9) mo1/L, and 3 x 10(-7) versus > 10(-6) mo1/L, respectively).	Nitroarginine	0-16	kininogen 1	Bos taurus	102-112
8832069-2	1996	The L-arginine derivatives NG-nitro-L-arginine (L-NOARG) and NG-nitro-L-arginine methyl ester (L-NAME) have been widely used to inhibit constitutive NO synthase (NOS) in different biological systems.	Nitroarginine	27-46	nitric oxide synthase 2	Homo sapiens	149-160
8832083-6	1996	Pretreatment with the NO synthase (NOS) inhibitor, NG-nitro-L-arginine (L-NAME, 200 mg kg-1) given by intravenous injection, inhibited the endotoxin-evoked responses; the AFR was 16.5 +/- 1.9 (n = 8, P < 0.001) and the conjunctival hyperaemia was abolished.	Nitroarginine	51-70	nitric oxide synthase, brain	Oryctolagus cuniculus	22-33
8764352-3	1996	VIP, PACAP-27 and PACAP-38 induced concentration-dependent relaxation that was partly inhibited by the antagonists VIP10-28 and PACAP6-38 and the NO synthase inhibitor NG-nitro-L-arginine (L-NNA).	Nitroarginine	168-187	VIP peptides	Cavia porcellus	0-3
8764352-3	1996	VIP, PACAP-27 and PACAP-38 induced concentration-dependent relaxation that was partly inhibited by the antagonists VIP10-28 and PACAP6-38 and the NO synthase inhibitor NG-nitro-L-arginine (L-NNA).	Nitroarginine	189-194	VIP peptides	Cavia porcellus	0-3
8800364-1	1996	The effects of systemic administration of the nitric oxide synthase inhibitor N omega-nitro-L-arginine on the vasculature of the pig nasal mucosa were compared with the effects of alpha-adrenoceptor agonists and of sympathetic nerve stimulation.	Nitroarginine	78-102	nitric oxide synthase 2	Sus scrofa	46-67
8764264-5	1996	Insulin evoked concentration-dependent increases in control diameter of 13-61%, which were completely inhibited by endothelium removal or L-NNA.	Nitroarginine	138-143	insulin	Homo sapiens	0-7
8636342-9	1996	ACTH-induced reductions in PGF2alpha-induced increases in FAP in the fetal placental circulation were not inhibited by the nitric oxide synthase inhibitor, N omega-nitro-L-arginine (100 micromol/L; n = 5), the cyclooxygenase inhibitor indomethacin (3 micromol/L; n = 5), or a guanylate cyclase inhibitor LY83583(1 micromol/L; n = 5).	Nitroarginine	158-180	proopiomelanocortin	Homo sapiens	0-4
8730755-14	1996	Inhibition of NO synthase with N omega-nitro-L-arginine (L-NOARG, 45 mg kg-1) significantly (P < 0.05) prevented the decrease in CVR but not MAP induced by des-Arg9-BK, whilst responses to BK were not affected by L-NOARG pretreatment.	Nitroarginine	31-55	kininogen 1	Canis lupus familiaris	168-170
8730755-14	1996	Inhibition of NO synthase with N omega-nitro-L-arginine (L-NOARG, 45 mg kg-1) significantly (P < 0.05) prevented the decrease in CVR but not MAP induced by des-Arg9-BK, whilst responses to BK were not affected by L-NOARG pretreatment.	Nitroarginine	31-55	kininogen 1	Canis lupus familiaris	192-194
8730755-14	1996	Inhibition of NO synthase with N omega-nitro-L-arginine (L-NOARG, 45 mg kg-1) significantly (P < 0.05) prevented the decrease in CVR but not MAP induced by des-Arg9-BK, whilst responses to BK were not affected by L-NOARG pretreatment.	Nitroarginine	57-64	kininogen 1	Canis lupus familiaris	168-170
8730755-14	1996	Inhibition of NO synthase with N omega-nitro-L-arginine (L-NOARG, 45 mg kg-1) significantly (P < 0.05) prevented the decrease in CVR but not MAP induced by des-Arg9-BK, whilst responses to BK were not affected by L-NOARG pretreatment.	Nitroarginine	57-64	kininogen 1	Canis lupus familiaris	192-194
8813591-3	1996	Blockade of nitric oxide (NO) synthesis by 1 mM N omega -nitro-L-arginine decreased by 20% the amplitude of the 20 Hz-induced relaxation and changed the pattern of relaxation, making it similar to the sustained relaxation evoked by exogenously applied vasoactive intestinal peptide (VIP).	Nitroarginine	48-73	vasoactive intestinal peptide	Homo sapiens	283-286
8762203-7	1996	Concomitant administration of an angiotensin converting enzyme inhibitor with the kinin antagonist Hoe 140, administered either subcutaneously or via a mini-osmotic pump, or of the nitric oxide synthase inhibitor NG-nitro-L-arginine attenuated the effect of the angiotensin converting enzyme inhibitor on the mesenteric vascular weight and wall:lumen area ratios.	Nitroarginine	213-232	angiotensin I converting enzyme	Rattus norvegicus	262-291
8786424-4	1996	The NOS inhibitor nitro-L-arginine is neuroprotective in wild-type but not nNOS-cultures, confirming the role of nNOS-derived NO in glutamate neurotoxicity.	Nitroarginine	18-34	nitric oxide synthase 1, neuronal	Mus musculus	113-117
8724984-7	1996	The hemoglobin-induced depolarization as well as the suppression of the synaptic transients were present in slices pretreated with 0.1 or 0.5 mM of N omega-nitro-L-arginine, a nitric oxide synthase inhibitor, suggesting that hemoglobin has electrophysiological actions on hippocampal CA1 neurons that are independent of its NO scavenging property.	Nitroarginine	148-172	carbonic anhydrase 1	Rattus norvegicus	284-287
8603867-6	1996	RESULTS: After in vivo treatment, L-NIO was found to be a more potent inhibitor than L-NNA for ocular i-NOS (87% versus 43% inhibition), and L-NNA was more potent than L-NIO for ocular c-NOS (81% versus 39%).	Nitroarginine	85-90	nitric oxide synthase 2	Rattus norvegicus	102-107
8603867-6	1996	RESULTS: After in vivo treatment, L-NIO was found to be a more potent inhibitor than L-NNA for ocular i-NOS (87% versus 43% inhibition), and L-NNA was more potent than L-NIO for ocular c-NOS (81% versus 39%).	Nitroarginine	141-146	nitric oxide synthase 3	Rattus norvegicus	185-190
8613228-8	1996	The effects of angiotensin II and L-arginine were blocked by inhibition of nitric oxide release with N(omega)-nitro-L-arginine.	Nitroarginine	101-126	angiotensinogen	Rattus norvegicus	15-29
8780207-5	1996	After superfusion with topical N omega-nitro-L-arginine (L-NNA; 1 mM), the rCBF response was inhibited by approximately 45% in WT mice (P < 0.05), whereas there was no inhibition in Kn.	Nitroarginine	31-55	CCAAT/enhancer binding protein zeta	Rattus norvegicus	75-79
8780207-5	1996	After superfusion with topical N omega-nitro-L-arginine (L-NNA; 1 mM), the rCBF response was inhibited by approximately 45% in WT mice (P < 0.05), whereas there was no inhibition in Kn.	Nitroarginine	57-62	CCAAT/enhancer binding protein zeta	Rattus norvegicus	75-79
8780207-7	1996	Our results suggest that 1) endothelial NO production does not mediate the rCBF coupling to neuronal activity in Kn, 2) the inhibitory effect of L-NNA on the rCBF response to whisker stimulation in WT is a consequence of type I (neuronal) NOS inhibition, and 3) NO-independent mechanisms couple rCBF and metabolism during whisker stimulation in mice lacking expression of neuronal NOS.	Nitroarginine	145-150	CCAAT/enhancer binding protein zeta	Rattus norvegicus	158-162
8780207-7	1996	Our results suggest that 1) endothelial NO production does not mediate the rCBF coupling to neuronal activity in Kn, 2) the inhibitory effect of L-NNA on the rCBF response to whisker stimulation in WT is a consequence of type I (neuronal) NOS inhibition, and 3) NO-independent mechanisms couple rCBF and metabolism during whisker stimulation in mice lacking expression of neuronal NOS.	Nitroarginine	145-150	CCAAT/enhancer binding protein zeta	Rattus norvegicus	158-162
8882593-2	1996	The role of endothelium-derived hyperpolarizing factor and voltage-operated Ca2+ channels in mediating endothelium-dependent, NG-nitro-L-arginine (L-NOARG; 100 microM) -resistant relaxations to bradykinin (BK), was examined in isolated rings of endothelium-intact bovine left anterior descending coronary artery.	Nitroarginine	126-145	kininogen 1	Bos taurus	194-204
8882593-2	1996	The role of endothelium-derived hyperpolarizing factor and voltage-operated Ca2+ channels in mediating endothelium-dependent, NG-nitro-L-arginine (L-NOARG; 100 microM) -resistant relaxations to bradykinin (BK), was examined in isolated rings of endothelium-intact bovine left anterior descending coronary artery.	Nitroarginine	147-154	kininogen 1	Bos taurus	194-204
8907808-2	1996	N-Nitro-L-arginine (NOLA) and endothelin-1 were used to increase the blood pressure of normotensive rats, sodium nitroprusside (NP) and calcitonin gene-related peptide (CGRP) were used to decrease the blood pressure of spontaneously hypertensive rats (SHR).	Nitroarginine	20-24	calcitonin-related polypeptide alpha	Rattus norvegicus	136-167
8631029-8	1996	Nitrite production from IL-1 alpha/IFN-gamma was sensitive to the nitric oxide synthase inhibitors, NG-methyl-L-arginine or NG-nitro-L-arginine in a dose-dependent manner.	Nitroarginine	124-143	interleukin 1 alpha	Mus musculus	24-34
8631029-8	1996	Nitrite production from IL-1 alpha/IFN-gamma was sensitive to the nitric oxide synthase inhibitors, NG-methyl-L-arginine or NG-nitro-L-arginine in a dose-dependent manner.	Nitroarginine	124-143	interferon gamma	Mus musculus	35-44
8821528-12	1996	In the presence of NG-nitro-L-arginine (an inhibitor of nitric oxide synthases), concentration-relaxation curves to bradykinin were shifted to the right in both types of preparations.	Nitroarginine	19-38	kininogen 1	Canis lupus familiaris	116-126
8619882-5	1996	The amino acid-based NOS inhibitor, NG-nitro-L-arginine, shows a preference for ecNOS and bNOS over iNOS, whereas L-N6-(1-iminoethyl)lysine is selective for iNOS over bNOS.	Nitroarginine	36-55	nitric oxide synthase 3	Homo sapiens	80-85
8619882-5	1996	The amino acid-based NOS inhibitor, NG-nitro-L-arginine, shows a preference for ecNOS and bNOS over iNOS, whereas L-N6-(1-iminoethyl)lysine is selective for iNOS over bNOS.	Nitroarginine	36-55	nitric oxide synthase 1	Homo sapiens	90-94
8619882-5	1996	The amino acid-based NOS inhibitor, NG-nitro-L-arginine, shows a preference for ecNOS and bNOS over iNOS, whereas L-N6-(1-iminoethyl)lysine is selective for iNOS over bNOS.	Nitroarginine	36-55	nitric oxide synthase 2	Homo sapiens	100-104
8619882-5	1996	The amino acid-based NOS inhibitor, NG-nitro-L-arginine, shows a preference for ecNOS and bNOS over iNOS, whereas L-N6-(1-iminoethyl)lysine is selective for iNOS over bNOS.	Nitroarginine	36-55	nitric oxide synthase 1	Homo sapiens	167-171
8646406-16	1996	In contrast to their potent effects on iNOS, some AATUs and MAGs were 20-100 times weaker than NG-methyl-L-arginine and NG-nitro-L-arginine as inhibitors of ecNOS as assessed by their effects on the conversion of L-arginine to L-citrulline in homogenates of bovine endothelial cells and by their pressor effects in anaesthetized rats.	Nitroarginine	120-139	nitric oxide synthase 3	Bos taurus	157-162
8821528-18	1996	The angiotensin converting enzyme (ACE)-inhibitor, perindoprilat, shifted to the left the concentration-relaxation curves to bradykinin obtained under control conditions and in the presence of NG-nitro-L-arginine.	Nitroarginine	193-212	angiotensin I converting enzyme	Canis lupus familiaris	4-33
8821528-18	1996	The angiotensin converting enzyme (ACE)-inhibitor, perindoprilat, shifted to the left the concentration-relaxation curves to bradykinin obtained under control conditions and in the presence of NG-nitro-L-arginine.	Nitroarginine	193-212	angiotensin I converting enzyme	Canis lupus familiaris	35-38
8821528-18	1996	The angiotensin converting enzyme (ACE)-inhibitor, perindoprilat, shifted to the left the concentration-relaxation curves to bradykinin obtained under control conditions and in the presence of NG-nitro-L-arginine.	Nitroarginine	193-212	kininogen 1	Canis lupus familiaris	125-135
8636301-10	1996	N omega-nitro-L-arginine (100 mumol/L) increased placental CRH-IR secretion into fetal perfusate, and this effect was reversed by the infusion of L-arginine (100 mumol/L), which also reduced release below basal levels.	Nitroarginine	0-24	corticotropin releasing hormone	Homo sapiens	59-62
8851629-1	1996	Two potent inhibitors of nitric oxide synthase (NOS), namely, NG-nitro-L-arginine (NNA) and NG-monomethyl-L-arginine (NMMA) were administered intracerebroventricularly (i.c.v.)	Nitroarginine	62-81	nitric oxide synthase 1, neuronal	Mus musculus	25-46
8592142-5	1996	However, the calmodulin antagonists W-5, W-13, and calmidazolium inhibited L-[3H]-NOARG binding with IC50 values in the micromolar range, and calmodulin (10 micrograms/ml) competitively reversed this inhibition.	Nitroarginine	82-87	calmodulin 1	Rattus norvegicus	13-23
8929574-6	1996	During contractions to endothelin-1 or U-46619 (in the presence of indomethacin), acetylcholine and bradykinin induced endothelium-dependent nitro-L-arginine-inhibitable relaxation in arteries and veins.	Nitroarginine	141-157	EDN1	Ovis aries	23-35
8720479-4	1996	Therefore, D-NNA, L-NNA and diphenyleneiodonium, but not di-2-thienyliodonium, inhibit inducible NO synthase in vascular smooth muscles.	Nitroarginine	18-23	nitric oxide synthase 2	Rattus norvegicus	87-108
8769840-6	1996	Responses to ADM were attenuated during inhibition of nitric oxide (NO) synthesis by nitro-L-arginine (50 micrograms.kg-1.min-1).	Nitroarginine	85-101	adrenomedullin	Canis lupus familiaris	13-16
8963690-9	1996	L-NNA and amino-guanidine blocked TNF alpha-induced vasodilation.	Nitroarginine	0-5	tumor necrosis factor	Sus scrofa	34-43
8993670-12	1996	However, in the presence of L-NOARG a significantly higher concentration (IC50 = 860 +/- 300 nM) of Bk was required to relax renal arteries.	Nitroarginine	28-35	kininogen 1	Canis lupus familiaris	100-102
8993670-18	1996	In the presence of L-NOARG, Bk depressed the PE induced vasopressor effects with a maximum of 18 +/- 20%.	Nitroarginine	19-26	kininogen 1	Canis lupus familiaris	28-30
8625365-0	1996	Effects of N(g)-methyl-L-arginine, an inhibitor of nitric oxide synthesis, on interleukin-2-induced capillary leakage and antitumor responses in healthy and tumor-bearing mice.	Nitroarginine	11-33	interleukin 2	Mus musculus	78-91
8789382-6	1996	These cyclic GMP levels were significantly decreased by NG-nitro-L-arginine (100 microM), and completely by methylene blue (10 microM).	Nitroarginine	56-75	5'-nucleotidase, cytosolic II	Homo sapiens	13-16
8521573-5	1995	The effects of both CCh and BK but not SNAP were eliminated by nitro-L-arginine (NLA, 10(-4) mol/L), consistent with SNAP decomposing to release NO and both CCh and BK stimulating endogenous NO production from L-arginine.	Nitroarginine	63-79	kininogen 1	Canis lupus familiaris	165-167
8820084-4	1996	Seven days before operation, and for 39 additional days, one group received 2.25% L-arginine and one group received 0.01% N-omega-nitro-L-arginine in tap water; one group received tap water only.	Nitroarginine	122-146	nuclear RNA export factor 1	Rattus norvegicus	150-153
8804070-6	1996	Pretreatment (30 min earlier) with 7.5 or 15 mg/kg s.c. of the NOS inhibitor nitro-L-arginine (L-NNA) resulted in a significant and dose-dependent alleviation of NPFF-induced abstinence-like signs.	Nitroarginine	77-93	neuropeptide FF-amide peptide precursor	Rattus norvegicus	162-166
8804070-6	1996	Pretreatment (30 min earlier) with 7.5 or 15 mg/kg s.c. of the NOS inhibitor nitro-L-arginine (L-NNA) resulted in a significant and dose-dependent alleviation of NPFF-induced abstinence-like signs.	Nitroarginine	95-100	neuropeptide FF-amide peptide precursor	Rattus norvegicus	162-166
8804070-7	1996	The anti-NPFF activity of 15 mg/kg L-NNA was blocked by 750 mg/kg L-arginine, but not by the same amount of D-arginine, indicating that L-NNA attenuates NPFF activity through a stereospecific inhibition of NOS.	Nitroarginine	35-40	neuropeptide FF-amide peptide precursor	Rattus norvegicus	9-13
8804070-7	1996	The anti-NPFF activity of 15 mg/kg L-NNA was blocked by 750 mg/kg L-arginine, but not by the same amount of D-arginine, indicating that L-NNA attenuates NPFF activity through a stereospecific inhibition of NOS.	Nitroarginine	35-40	neuropeptide FF-amide peptide precursor	Rattus norvegicus	153-157
8804070-7	1996	The anti-NPFF activity of 15 mg/kg L-NNA was blocked by 750 mg/kg L-arginine, but not by the same amount of D-arginine, indicating that L-NNA attenuates NPFF activity through a stereospecific inhibition of NOS.	Nitroarginine	136-141	neuropeptide FF-amide peptide precursor	Rattus norvegicus	9-13
8804070-7	1996	The anti-NPFF activity of 15 mg/kg L-NNA was blocked by 750 mg/kg L-arginine, but not by the same amount of D-arginine, indicating that L-NNA attenuates NPFF activity through a stereospecific inhibition of NOS.	Nitroarginine	136-141	neuropeptide FF-amide peptide precursor	Rattus norvegicus	153-157
9085348-5	1996	L-NNA also significantly attenuated the heat shock-induced accumulation of HSP70 (by 45% in heart).	Nitroarginine	0-5	heat shock protein family A (Hsp70) member 4	Homo sapiens	75-80
9085352-5	1996	In the artery, NG-nitro-L-arginine inhibited both ST and endothelium-dependent nitric oxide (NO) mediated response.	Nitroarginine	15-34	somatostatin	Rattus norvegicus	50-52
8590997-19	1995	Inhibition of the nitric oxide (NO) synthase with NG-nitro-L-arginine (L-NOARG) (30 microM), enhanced sensitivity and maximal contraction to NPY in both PRA and DRA.	Nitroarginine	50-69	neuropeptide Y	Bos taurus	141-144
8666025-10	1995	These results suggest that, in addition to vasoconstriction due to the inhibition of endothelial nitric oxide production, increased activity of the sympathetic nervous and renin-angiotensin systems contributes significantly to the development of pressor responses produced by the intravenous injection of L-NNA in anesthetized dogs.	Nitroarginine	305-310	renin	Canis lupus familiaris	172-177
7498960-11	1995	In conclusion, the present data indicate that long-term N omega-nitro-L-arginine administration to pregnant rats leads to increased blood pressure, reduced plasma volume expansion, lower plasma renin activity, and fetal growth retardation.	Nitroarginine	56-80	renin	Rattus norvegicus	194-199
8770789-11	1995	Insulin and glucagon levels were 2-3 folds increased by F and L-NNA infusion inhibited these responses while the addition of L-Arg partly reversed this inhibition.	Nitroarginine	62-67	insulin	Canis lupus familiaris	0-7
8770789-12	1995	Duodenal nutrient produced several fold increase in plasma insulin and glucagon levels that were significantly reduced by L-NNA and this reduction was partially reversed by L-Arg.	Nitroarginine	122-127	insulin	Canis lupus familiaris	59-66
8770789-13	1995	GRP also caused moderate rise in plasma insulin and glucagon levels which were significantly reduced by L-NNA and this was partially restored by L-Arg.	Nitroarginine	104-109	gastrin releasing peptide	Canis lupus familiaris	0-3
8770789-13	1995	GRP also caused moderate rise in plasma insulin and glucagon levels which were significantly reduced by L-NNA and this was partially restored by L-Arg.	Nitroarginine	104-109	insulin	Canis lupus familiaris	40-47
8619321-0	1995	The NO synthase inhibitor L-NNA depresses neurohypophysial vasopressin but not its precursor amidating enzymes in salt-loaded rats.	Nitroarginine	26-31	arginine vasopressin	Rattus norvegicus	59-70
8590997-19	1995	Inhibition of the nitric oxide (NO) synthase with NG-nitro-L-arginine (L-NOARG) (30 microM), enhanced sensitivity and maximal contraction to NPY in both PRA and DRA.	Nitroarginine	71-78	neuropeptide Y	Bos taurus	141-144
8974667-9	1995	In the presence of L-NNA, CGRP elicited a significant dose-dependent vasodilatory response, and 10 nM CGRP elicited a sizeable response, reversing the L-NNA-induced constriction by 84.3% +/- 15.5%.	Nitroarginine	19-24	calcitonin-related polypeptide alpha	Rattus norvegicus	26-30
7503277-3	1995	Additionally, opioids produce pial vasodilation that is attenuated by the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (L-NNA).	Nitroarginine	111-130	nitric oxide synthase 2	Sus scrofa	74-100
7503277-3	1995	Additionally, opioids produce pial vasodilation that is attenuated by the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (L-NNA).	Nitroarginine	132-137	nitric oxide synthase 2	Sus scrofa	74-100
7591014-5	1995	In rings with endothelium the contractions to Ang II were augmented by nitro-L-arginine (an inhibitor to nitric oxide synthase) but not indomethacin (an inhibitor of cyclooxygenase), to reach a response comparable to that of preparations without endothelium.	Nitroarginine	71-87	angiotensinogen	Rattus norvegicus	46-52
7485529-3	1995	The TNF-induced effects were prevented by co-incubation with the nitric oxide synthase inhibitors NG-monomethyl-L-arginine (1 mM), NG-nitro-L-arginine methyl ester (1 mM), or NG-nitro-L-arginine (1 mM).	Nitroarginine	131-150	tumor necrosis factor	Homo sapiens	4-7
8581287-11	1995	At 6 h, the nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine (L-NOARG, 100 microM), caused a significant 2 fold decrease in pEC50 (9.58 +/- 0.03) but had no effect on Rmax for BK.	Nitroarginine	50-69	kininogen 1	Bos taurus	185-187
8581287-11	1995	At 6 h, the nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine (L-NOARG, 100 microM), caused a significant 2 fold decrease in pEC50 (9.58 +/- 0.03) but had no effect on Rmax for BK.	Nitroarginine	71-78	kininogen 1	Bos taurus	185-187
7593351-3	1995	Nitric oxide synthase (NOS) inhibition by brain topical superfusion with N omega-nitro-L-arginine (L-NA) revealed (a) Addition of L-NA to high-potassium ACSF reduced the rCBF increase from +94 +/- 36% to +21 +/- 18% (p < or = 0.01, n = 7).	Nitroarginine	73-97	nitric oxide synthase 2	Homo sapiens	0-21
7561088-11	1995	Moreover, treatment of wild-type mice with the NO synthase inhibitor N-nitro-L-arginine methylester resulted in increased anti-CD3-induced morbidity and mortality.	Nitroarginine	69-87	CD247 antigen	Mus musculus	127-130
8974667-9	1995	In the presence of L-NNA, CGRP elicited a significant dose-dependent vasodilatory response, and 10 nM CGRP elicited a sizeable response, reversing the L-NNA-induced constriction by 84.3% +/- 15.5%.	Nitroarginine	151-156	calcitonin-related polypeptide alpha	Rattus norvegicus	26-30
8974667-9	1995	In the presence of L-NNA, CGRP elicited a significant dose-dependent vasodilatory response, and 10 nM CGRP elicited a sizeable response, reversing the L-NNA-induced constriction by 84.3% +/- 15.5%.	Nitroarginine	151-156	calcitonin-related polypeptide alpha	Rattus norvegicus	102-106
7559870-5	1995	Vasodilatory responses to CRH were attenuated by the nitric oxide synthase inhibitor, N omega-nitro-L-arginine (100 mumol/L; P < 0.05), and the guanylate cyclase inhibitor, LY 83583 (1 mumol/L; P < 0.05), but not by the cyclooxygenase inhibitor, indomethacin (3 mumol/L; P > 0.05).	Nitroarginine	86-110	corticotropin releasing hormone	Homo sapiens	26-29
7498282-5	1995	The bradykinin-induced artery relaxation was inhibited by endothelium denudation, NG-nitro-L-arginine (L-NA) or indomethacin and abolished by their combined treatment.	Nitroarginine	82-101	kininogen 1	Canis lupus familiaris	4-14
8573240-3	1995	Repetitive ip administration of NG-nitro-L-arginine (L-NNA), a NO synthase (NOS) inhibitor, protected against neuronal necrosis in the gerbil hippocampal CA1 field after transient forebrain ischemia with a bell-shaped response curve, the optimal dose being 3 mg/kg.	Nitroarginine	32-51	carbonic anhydrase 1	Rattus norvegicus	154-157
8573240-3	1995	Repetitive ip administration of NG-nitro-L-arginine (L-NNA), a NO synthase (NOS) inhibitor, protected against neuronal necrosis in the gerbil hippocampal CA1 field after transient forebrain ischemia with a bell-shaped response curve, the optimal dose being 3 mg/kg.	Nitroarginine	53-58	carbonic anhydrase 1	Rattus norvegicus	154-157
8538497-7	1995	Capillary perfusion recovered in L-arg-treated hamsters, where capillary blood flow velocity was lower than in L-NMMA group and the number of adhering leukocytes was lower than in untreated controls, L-NMMA, and L-NNA groups.	Nitroarginine	212-217	Rho guanine nucleotide exchange factor 12	Homo sapiens	33-38
8548301-2	1995	The 3,4-DAP-evoked [3H]overflow was enhanced by the NO synthase substrate L-arginine, but not by D-arginine; it was reduced by the NO synthase inhibitor NG-nitro-L-arginine, which also antagonized the effects of L-arginine.	Nitroarginine	153-172	death-associated protein	Rattus norvegicus	8-11
8548533-7	1995	Pretreatment with dexamethasone (DEX); ibuprofen (IBU), an inhibitor of cyclooxygenase; and NG-nitro-L-arginine, an inhibitor of nitric oxide synthase, significantly reduced survival, while chlorpromazine (CPZ) and TNF did not affect it.	Nitroarginine	92-111	tumor necrosis factor	Mus musculus	215-218
7544743-4	1995	L-NNA also markedly attenuated the heat shock-induced accumulation of HSP70.	Nitroarginine	0-5	heat shock protein family A (Hsp70) member 4	Homo sapiens	70-75
7638750-10	1995	Pretreatment of endotoxemic mice with indomethacin or NNA blunted the increase in mucosal IL-6.	Nitroarginine	54-57	interleukin 6	Mus musculus	90-94
7594769-9	1995	Urecholine and duodenal nutrient also resulted in a marked increment in plasma insulin and glucagon, the insulin (but not glucagon) increment being abolished by the pretreatment with L-NNA and reversed by the addition of L-arg.	Nitroarginine	183-188	insulin	Canis lupus familiaris	79-86
7594769-9	1995	Urecholine and duodenal nutrient also resulted in a marked increment in plasma insulin and glucagon, the insulin (but not glucagon) increment being abolished by the pretreatment with L-NNA and reversed by the addition of L-arg.	Nitroarginine	183-188	insulin	Canis lupus familiaris	105-112
7606802-2	1995	After 6 days of culture with IL-4, human monocytes released detectable amounts of nitrite and L-citrulline that were inhibited in the presence of nitro-L-arginine (1 mM).	Nitroarginine	146-162	interleukin 4	Homo sapiens	29-33
7582516-12	1995	Substance P caused a smooth muscle hyperpolarization (in the presence of L-NOARG and indomethacin), but only when the artery showed an L-NOARG-resistant relaxation.	Nitroarginine	73-80	tachykinin precursor 1	Homo sapiens	0-11
7582516-12	1995	Substance P caused a smooth muscle hyperpolarization (in the presence of L-NOARG and indomethacin), but only when the artery showed an L-NOARG-resistant relaxation.	Nitroarginine	135-142	tachykinin precursor 1	Homo sapiens	0-11
7606802-4	1995	Ligation of membrane-associated CD23 or stimulation with recombinant soluble CD23 elicited monocytes to release nitrite and L-citrulline that was suppressed by nitro-L-arginine.	Nitroarginine	160-176	Fc epsilon receptor II	Homo sapiens	32-36
7606802-4	1995	Ligation of membrane-associated CD23 or stimulation with recombinant soluble CD23 elicited monocytes to release nitrite and L-citrulline that was suppressed by nitro-L-arginine.	Nitroarginine	160-176	Fc epsilon receptor II	Homo sapiens	77-81
7606802-5	1995	Preactivation of human monocytes with IFN-gamma led to subsequent increased IL-4- and CD23-driven nitrite and L-citrulline productions that were also suppressed in the presence of either nitro-L-arginine or the anti-CD23 mAb Fab fragment.	Nitroarginine	187-203	interferon gamma	Homo sapiens	38-47
7606802-5	1995	Preactivation of human monocytes with IFN-gamma led to subsequent increased IL-4- and CD23-driven nitrite and L-citrulline productions that were also suppressed in the presence of either nitro-L-arginine or the anti-CD23 mAb Fab fragment.	Nitroarginine	187-203	interleukin 4	Homo sapiens	76-80
7606802-5	1995	Preactivation of human monocytes with IFN-gamma led to subsequent increased IL-4- and CD23-driven nitrite and L-citrulline productions that were also suppressed in the presence of either nitro-L-arginine or the anti-CD23 mAb Fab fragment.	Nitroarginine	187-203	Fc epsilon receptor II	Homo sapiens	86-90
7606802-5	1995	Preactivation of human monocytes with IFN-gamma led to subsequent increased IL-4- and CD23-driven nitrite and L-citrulline productions that were also suppressed in the presence of either nitro-L-arginine or the anti-CD23 mAb Fab fragment.	Nitroarginine	187-203	FA complementation group B	Homo sapiens	225-228
7758169-3	1995	Inhibition of basal NO production by NG-nitro-L-arginine (L-NAG) upregulates endothelial MCP-1 mRNA expression (250 +/- 20%) and protein secretion.	Nitroarginine	37-56	NBAS subunit of NRZ tethering complex	Homo sapiens	60-63
7540822-1	1995	The ability of NG-nitro-L-arginine (NNA) and NG-methyl-L-arginine (NMMA) to inactivate native neuronal, endothelial cell, and macrophage nitric oxide synthases (nNOS, eNOS, and iNOS, respectively) was investigated.	Nitroarginine	15-34	nitric oxide synthase 1	Homo sapiens	161-165
7540822-1	1995	The ability of NG-nitro-L-arginine (NNA) and NG-methyl-L-arginine (NMMA) to inactivate native neuronal, endothelial cell, and macrophage nitric oxide synthases (nNOS, eNOS, and iNOS, respectively) was investigated.	Nitroarginine	15-34	nitric oxide synthase 2	Homo sapiens	177-181
7540822-12	1995	Since NNA did not inactivate iNOS at concentrations up to 25 microM, NNA is strictly a reversible inhibitor of iNOS (Ki = 8.1 microM).	Nitroarginine	69-72	nitric oxide synthase 2	Homo sapiens	111-115
15714750-5	1995	Preincubation of endothelial cells with bradykinin and superoxide dismutase (SOD) synergistically potentiated the increase in platelet cGMP, but was attenuated by Nomega-nitro-L-arginine, with partial restoration by L-arginine but not by D-arginine.	Nitroarginine	163-186	kininogen 1	Homo sapiens	40-50
7541004-4	1995	METHODS: Gastroprotection by gastrin 17 against ethanol-induced gross and histological damage was studied after capsaicin-induced defunctionalization of afferent neurons, pretreatment with the calcitonin gene-related peptide receptor antagonist human calcitonin gene-related peptide8-37, anti-calcitonin gene-related peptide antibodies, and the NO synthase inhibitor NG-nitro-L-arginine.	Nitroarginine	367-386	gastrin	Rattus norvegicus	29-36
7616452-8	1995	pretreatment with N omega-nitro-L-arginine (2 micrograms) and the attenuation of beta-endorphin-induced antinociception by N omega-nitro-L-arginine was reversed by i.t.	Nitroarginine	18-42	pro-opiomelanocortin-alpha	Mus musculus	81-95
7616452-8	1995	pretreatment with N omega-nitro-L-arginine (2 micrograms) and the attenuation of beta-endorphin-induced antinociception by N omega-nitro-L-arginine was reversed by i.t.	Nitroarginine	123-147	pro-opiomelanocortin-alpha	Mus musculus	81-95
7758169-3	1995	Inhibition of basal NO production by NG-nitro-L-arginine (L-NAG) upregulates endothelial MCP-1 mRNA expression (250 +/- 20%) and protein secretion.	Nitroarginine	37-56	C-C motif chemokine ligand 2	Homo sapiens	89-94
7537754-4	1995	The inhibition of Na+/K(+)-ATPase activity by LPS/IFN gamma was prevented by simultaneous incubation with N omega-nitro L-arginine and markedly blunted by removal of L-arginine from the medium.	Nitroarginine	106-130	toll-like receptor 4	Mus musculus	46-49
7544135-3	1995	In rings previously exposed to the peptide, bradykinin induced relaxations which were augmented in the presence of perindoprilat; this response was not affected by indomethacin, but nitro-L-arginine induced a rightward shift of the relaxation to the peptide without affecting its maximal effect.	Nitroarginine	182-198	kininogen 1	Canis lupus familiaris	44-54
7771524-5	1995	The presence of 0.7 mM N omega-nitro-L-arginine (NNA), an NO synthase inhibitor, in the luminal fluid significantly reduced renin secretion at the lowest Na/Cl concentration ratio to 0.65 +/- 0.32 log nGU/min (P < 0.01 compared with control).	Nitroarginine	23-47	renin	Homo sapiens	124-129
7771524-5	1995	The presence of 0.7 mM N omega-nitro-L-arginine (NNA), an NO synthase inhibitor, in the luminal fluid significantly reduced renin secretion at the lowest Na/Cl concentration ratio to 0.65 +/- 0.32 log nGU/min (P < 0.01 compared with control).	Nitroarginine	49-52	renin	Homo sapiens	124-129
7537754-4	1995	The inhibition of Na+/K(+)-ATPase activity by LPS/IFN gamma was prevented by simultaneous incubation with N omega-nitro L-arginine and markedly blunted by removal of L-arginine from the medium.	Nitroarginine	106-130	interferon gamma	Mus musculus	50-59
8542540-6	1995	The microvascular response to the topical application of C5a (10(-12) M) was recorded in the presence of 2 x 10(-4) M N-Arg.	Nitroarginine	118-123	complement C5	Rattus norvegicus	57-60
8542540-7	1995	Additionally, experiments of C5a-induced response with N-Arg were repeated in the presence of L-arginine (L-Arg; the precursor of nitric oxide synthesis) or with systemic administration of superoxide dismutase (SOD).	Nitroarginine	55-60	complement C5	Rattus norvegicus	29-32
8542540-8	1995	RESULTS: (1) C5a induces a dose-dependent vasodilation in the small intestine, and the maximal vasodilation occurs in A3 arterioles at C5a concentration of 10(-12) M; (2) N-Arg inhibits the Ach-induced vasodilation in the rat small intestine; and (3) L-Arg or SOD partially reverses the inhibitory effect of N-Arg.	Nitroarginine	171-176	complement C5	Rattus norvegicus	13-16
8542540-8	1995	RESULTS: (1) C5a induces a dose-dependent vasodilation in the small intestine, and the maximal vasodilation occurs in A3 arterioles at C5a concentration of 10(-12) M; (2) N-Arg inhibits the Ach-induced vasodilation in the rat small intestine; and (3) L-Arg or SOD partially reverses the inhibitory effect of N-Arg.	Nitroarginine	308-313	complement C5	Rattus norvegicus	13-16
8542540-10	1995	Superoxide is, at least partially, responsible for the vasoconstrictor response to C5a in the presence of N-Arg.	Nitroarginine	106-111	complement C5	Rattus norvegicus	83-86
8614237-3	1995	L-NG-nitro-arginine, an inhibitor of nitric oxide synthetase, and hemoglobin, a NO scavenger, impaired basal and interleukin-1-beta-induced PRL release, while molsidomine, a NO donor, was able to release PRL and to amplify interleukin-1-beta-induced PRL release, confirming a modulatory role for nitric oxide in pituitary hormone secretion.	Nitroarginine	0-19	interleukin 1 beta	Homo sapiens	113-131
7602539-9	1995	The nitric oxide (NO) biosynthesis inhibitor NG-nitro-L-arginine (L-NNA; 100 microM) significantly antagonized the rapid relaxation but had no effect on the delayed relaxation, while vasoactive intestinal polypeptide (VIP) antagonist (1 microM) significantly reduced the delayed relaxation without affecting the rapid relaxation.	Nitroarginine	66-71	vasoactive intestinal peptide	Rattus norvegicus	218-221
7606339-4	1995	In murine cultured neocortical neurones, NMDA (100 microM)-stimulated production of guanosine 3":5"-cyclic monophosphate (cyclic GMP) was blocked by N-1([thienyl]-cyclohexyl)-piperidine (1 microM) and by the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (100 microM).	Nitroarginine	245-264	5'-nucleotidase, cytosolic II	Mus musculus	129-132
7630433-1	1995	Effects of indomethacin, N omega-nitro-L-arginine (NNA) and naloxone, and of pretreatment with cyclophosphamide (CY), on the interleukin (IL)-1 beta induced inhibition of exocytotic noradrenaline release were investigated in the isolated, vascularly perfused spleen of the rat.	Nitroarginine	25-49	interleukin 1 beta	Rattus norvegicus	125-148
7630433-6	1995	The inhibition of evoked overflow by IL-1 beta was not affected by indomethacin but was reduced or even prevented in the presence of NNA or naloxone, or after lymphocyte depletion of spleens by CY.	Nitroarginine	133-136	interleukin 1 beta	Rattus norvegicus	37-46
7570642-5	1995	Pre-incubation of the slices with L-NG-nitroarginine, a competitive inhibitor of nitric oxide synthase, effectively prevented the NMDA-induced reduction in glutamine synthetase and neuron specific enolase, but did not diminish the kainate-induced decrease in the activity of either enzyme.	Nitroarginine	34-52	glutamate-ammonia ligase	Rattus norvegicus	156-176
8614237-3	1995	L-NG-nitro-arginine, an inhibitor of nitric oxide synthetase, and hemoglobin, a NO scavenger, impaired basal and interleukin-1-beta-induced PRL release, while molsidomine, a NO donor, was able to release PRL and to amplify interleukin-1-beta-induced PRL release, confirming a modulatory role for nitric oxide in pituitary hormone secretion.	Nitroarginine	0-19	prolactin	Homo sapiens	140-143
7780824-0	1995	[Effect of NG-nitro-L-arginine methylester on the secretion of endothelin-1 in vivo and in cultured endothelial cells].	Nitroarginine	11-30	endothelin 1	Homo sapiens	63-75
7534807-3	1995	N omega-nitro-L-arginine, an inhibitor of NO synthase, potentiated thrombin-induced aggregation of washed human platelets, whereas L-arginine inhibited it.	Nitroarginine	0-24	coagulation factor II, thrombin	Homo sapiens	67-75
7784479-12	1995	The antiischemic effect of ACE inhibitors and BK were abolished by the addition of L-NNA (1 x 10(-6) mol/l) or icatibant (1 x 10(-9) mol/l).	Nitroarginine	83-88	angiotensin I converting enzyme	Rattus norvegicus	27-30
7780824-3	1995	NG-nitro-L-arginine methylester (L-NAME), an inhibitor of nitric oxide synthase, increased the peak value of mPAP and PVR during hypoxic ventilation to 4.9 +/- 0.6 kPa and 160.9 +/- 34.6kPa.	Nitroarginine	0-19	phospholipid phosphatase 1	Mus musculus	109-113
7864213-6	1995	The curves to bradykinin obtained in the presence of NG-nitro-L-arginine (an NO synthase inhibitor) were depressed, whereas those obtained in arteries contracted with potassium (to eliminate the EDHF-mediated relaxation) were not affected by the desensitization.	Nitroarginine	53-72	kininogen 1	Canis lupus familiaris	14-24
7537683-0	1995	NG-nitro-L-arginine protects against hypoxia/hypoglycemia-induced decrease in CA1 presynaptic spikes in rat hippocampal slices.	Nitroarginine	0-19	carbonic anhydrase 1	Rattus norvegicus	78-81
7752646-7	1995	The decrease in mean PAP induced by 4 Ala ET-1 and IRL 1620 was attenuated by N omega-nitro-L-arginine [an inhibitor of endothelium-derived nitric oxide (EDNO) synthesis] (16.6% +/- 3.5 vs. 5.9% +/- 2.3 and 16.2% +/- 3.4 vs. 6.6% +/- 2.8, p < 0.05) and by glybenclamide (a blocker of ATP-dependent potassium channels) (18.2% +/- 7.9 vs. 7.5% +/- 8.3 and 14.7% +/- 3.6 vs. 6.3% +/- 3.2, p < 0.05).	Nitroarginine	78-102	EDN1	Ovis aries	42-46
7540023-4	1995	The nitric oxide synthase (NOS) inhibitor N omega-nitro-L-arginine (L-NNA) caused a dose-dependent increase in vascular resistance in ex vivo perfused tumours which was greater than that in normal perfused hindlimbs.	Nitroarginine	42-66	nitric oxide synthase 2	Homo sapiens	4-25
7540023-4	1995	The nitric oxide synthase (NOS) inhibitor N omega-nitro-L-arginine (L-NNA) caused a dose-dependent increase in vascular resistance in ex vivo perfused tumours which was greater than that in normal perfused hindlimbs.	Nitroarginine	68-73	nitric oxide synthase 2	Homo sapiens	4-25
8536815-6	1995	Treatment with NG-nitro-L-arginine (L-NNA), an inhibitor of NO synthase, delayed ulcer healing and this was accompanied by a reduction of GBF at the ulcer margin and in angiogenesis in granulation tissue and by a decrease in serum gastrin level and mucosal growth.	Nitroarginine	15-34	gastrin	Homo sapiens	231-238
8536815-6	1995	Treatment with NG-nitro-L-arginine (L-NNA), an inhibitor of NO synthase, delayed ulcer healing and this was accompanied by a reduction of GBF at the ulcer margin and in angiogenesis in granulation tissue and by a decrease in serum gastrin level and mucosal growth.	Nitroarginine	36-41	gastrin	Homo sapiens	231-238
8536815-7	1995	Addition of L-arginine to L-NNA restored ulcer healing, hyperemia at the ulcer margin and angiogenesis and prevented the fall in serum gastrin and mucosal growth caused by L-NNA.	Nitroarginine	172-177	gastrin	Homo sapiens	135-142
7538649-6	1995	The NO synthase inhibitors NG-nitro-L-arginine or NG-monomethyl-L-arginine, or the NO scavenger oxyhaemoglobin prevented the IL-1 beta-induced increase of cGMP.	Nitroarginine	27-46	interleukin 1 beta	Rattus norvegicus	125-134
8531500-4	1995	Nitric oxide (NO) synthase inhibitors, NG-methyl-L-arginine (10-100 microM) and NG-nitro-L-arginine (10-100 microM) reduced cGMP accumulation induced by bradykinin in a concentration-dependent fashion, and the inhibition was reversed by L-arginine.	Nitroarginine	80-99	kininogen 1	Bos taurus	153-163
7884155-3	1994	Electrical field stimulation at 4 Hz caused a 12-fold increase in PACAP release that was inhibited by 53 +/- 6% (P < 0.01) by the nitric oxide synthase inhibitor, NG-nitro-L-arginine (L-NNA).	Nitroarginine	166-185	adenylate cyclase activating polypeptide 1	Homo sapiens	66-71
7884155-3	1994	Electrical field stimulation at 4 Hz caused a 12-fold increase in PACAP release that was inhibited by 53 +/- 6% (P < 0.01) by the nitric oxide synthase inhibitor, NG-nitro-L-arginine (L-NNA).	Nitroarginine	187-192	adenylate cyclase activating polypeptide 1	Homo sapiens	66-71
7698210-7	1994	The endothelin-1-evoked reduction in coronary flow was also significantly enhanced by the nitric oxide synthesis inhibitor NG-nitro-L-arginine but was unaffected by the cyclooxygenase inhibitor diclofenac.	Nitroarginine	123-142	endothelin 1	Rattus norvegicus	4-16
7884155-5	1994	PACAP release induced by 10-g stretch was inhibited by 67 +/- 10% (P < 0.01) by L-NNA.	Nitroarginine	83-88	adenylate cyclase activating polypeptide 1	Homo sapiens	0-5
7884155-8	1994	Physiol., 264 (1993) G334-G340) showed that orad stretch elicits also VIP release and nitric oxide (NO) production and that VIP release is inhibited (59%) by L-NNA.	Nitroarginine	158-163	vasoactive intestinal peptide	Homo sapiens	124-127
7700011-4	1994	Inhibition of NO formation by absence of l-arginine or presence of N omega-nitro-l-arginine caused a marked decrease in cGMP accumulation and a reduction in renin secretion in cocultures.	Nitroarginine	67-91	renin	Homo sapiens	157-162
7889285-2	1994	Experiments were designed to analyse the requirement of myoendothelial junctions by bradykinin-induced endothelium-dependent relaxations resistant to NG-nitro-L-arginine (L-NOARG) and indomethacin porcine coronary arteries.	Nitroarginine	150-169	kininogen 1	Homo sapiens	84-94
7889285-2	1994	Experiments were designed to analyse the requirement of myoendothelial junctions by bradykinin-induced endothelium-dependent relaxations resistant to NG-nitro-L-arginine (L-NOARG) and indomethacin porcine coronary arteries.	Nitroarginine	171-178	kininogen 1	Homo sapiens	84-94
7889285-15	1994	Bradykinin-induced relaxations in endothelium-preserved rings were only slightly suppressed by L-NOARG (86% of control).	Nitroarginine	95-102	kininogen 1	Homo sapiens	0-10
7889285-17	1994	In the presence of L-NOARG, bradykinin failed to relax partially depolarized vessels.	Nitroarginine	19-26	kininogen 1	Homo sapiens	28-38
7738833-5	1994	The concentration-response curve of bradykinin was significantly shifted to the right after inhibition of NO synthesis with NG-nitro-L-arginine (L-NNA, 30 microM), whereas cyclo-oxygenase blockade with diclofenac (1 microM) had no effect.	Nitroarginine	124-143	kininogen 1	Bos taurus	36-46
7738833-5	1994	The concentration-response curve of bradykinin was significantly shifted to the right after inhibition of NO synthesis with NG-nitro-L-arginine (L-NNA, 30 microM), whereas cyclo-oxygenase blockade with diclofenac (1 microM) had no effect.	Nitroarginine	145-150	kininogen 1	Bos taurus	36-46
7863232-7	1994	Endothelial level of cGMP mainly reflected the synthesis of endothelium-derived relaxing factor/nitrogen monoxide (EDRF/NO), since blocking of the endogenous production of EDRF/NO with N-omega-nitro-L-arginine, resulted in about 90% reduction in cGMP-content of the endothelial cells.	Nitroarginine	185-209	alpha hemoglobin stabilizing protein	Homo sapiens	115-119
7532830-1	1994	Under conditions in which NG-nitro-L-arginine (NOArg) treatment prevents morphine tolerance, NOArg induces a slow progressive inhibition of nitric oxide synthase (NOS), starting at approx.	Nitroarginine	93-98	nitric oxide synthase 1, neuronal	Mus musculus	140-161
7863232-7	1994	Endothelial level of cGMP mainly reflected the synthesis of endothelium-derived relaxing factor/nitrogen monoxide (EDRF/NO), since blocking of the endogenous production of EDRF/NO with N-omega-nitro-L-arginine, resulted in about 90% reduction in cGMP-content of the endothelial cells.	Nitroarginine	185-209	alpha hemoglobin stabilizing protein	Homo sapiens	172-176
7529378-0	1994	Nitric oxide synthase in the pig autonomic nervous system in relation to the influence of NG--nitro-L-arginine on sympathetic and parasympathetic vascular control in vivo.	Nitroarginine	90-110	nitric oxide synthase 2	Sus scrofa	0-21
7943398-4	1994	Plasma levels of ET-1, ET-3, NOx, and 6-keto-PGF1 alpha significantly (P < 0.01) increased at 1 h. L-NNA or indomethacin blocked TNF-alpha-induced hypotension and remarkably increased SVRI but did not affect decreased cardiac index.	Nitroarginine	102-107	endothelin 1	Canis lupus familiaris	17-21
7943398-4	1994	Plasma levels of ET-1, ET-3, NOx, and 6-keto-PGF1 alpha significantly (P < 0.01) increased at 1 h. L-NNA or indomethacin blocked TNF-alpha-induced hypotension and remarkably increased SVRI but did not affect decreased cardiac index.	Nitroarginine	102-107	tumor necrosis factor	Canis lupus familiaris	132-141
8063879-7	1994	The relaxant action of ET-3 was abolished in vessels incubated with NG-nitro-L-arginine (10(-5) M), an inhibitor of nitric oxide synthase.	Nitroarginine	68-87	endothelin 3	Rattus norvegicus	23-27
7846293-7	1994	In tests with feeding and bombesin infusion, L-NNA caused a significant and dose-dependent reduction in plasma gastrin levels.	Nitroarginine	45-50	gastrin	Canis lupus familiaris	111-118
7849248-9	1994	However, unlike ANP, bradykinin-stimulated cGMP synthesis was significantly inhibited by prior treatment with oxyhemoglobin (10(-5) M), an inhibitor of soluble guanylate cyclase, and NG-nitro-L-arginine (NO2Arg), a specific inhibitor of endothelial-derived relaxing factor (EDRF).	Nitroarginine	183-202	kininogen 1	Homo sapiens	21-31
7849248-9	1994	However, unlike ANP, bradykinin-stimulated cGMP synthesis was significantly inhibited by prior treatment with oxyhemoglobin (10(-5) M), an inhibitor of soluble guanylate cyclase, and NG-nitro-L-arginine (NO2Arg), a specific inhibitor of endothelial-derived relaxing factor (EDRF).	Nitroarginine	204-210	kininogen 1	Homo sapiens	21-31
7528917-4	1994	Administration of L-NNA (0.5, 5, or 30 mg/kg) did not affect the basal PBF, but at 5 mg/kg it inhibited completely the caerulein-induced increase in PBF.	Nitroarginine	18-23	PTTG1 interacting protein	Rattus norvegicus	149-152
7808838-5	1994	In juvenile sheep, the increase in resting pulmonary arterial pressure produced by ET-1 was inhibited by meclofenamic acid, an inhibitor of prostaglandin synthesis (40.3 +/- 9.9% versus 2.3 +/- 4.7%, p < 0.05); during pulmonary hypertension, the decrease in pulmonary arterial pressure produced by ET-1 was inhibited by N omega-nitro-L-arginine, an inhibitor of endothelium-derived nitric oxide synthesis (21.4 +/- 10.7% versus 8.0 +/- 3.6%, p < 0.05) and by glybenclamide, an ATP-dependent potassium-channel blocker (18.8 +/- 8.4% versus 4.0 +/- 4.4%, p < 0.05).	Nitroarginine	323-347	EDN1	Ovis aries	83-87
7529378-5	1994	The nitric oxide synthase inhibitor NG-nitro-L-arginine reduced cardiac output by 40% and caused profound vasoconstriction in a variety of vascular beds.	Nitroarginine	36-55	nitric oxide synthase 2	Sus scrofa	4-25
7519365-10	1994	Pretreatment with N-nitro-L-arginine increased mortality rate to 74%, decreased NO2/NO3, and substantially increased TNF and IL-6 levels.	Nitroarginine	18-36	interleukin 6	Rattus norvegicus	125-129
8001643-3	1994	injection of vasoactive intestinal polypeptide (VIP) were markedly reduced by NG-nitro-L-arginine.	Nitroarginine	78-97	vasoactive intestinal peptide	Homo sapiens	13-46
8001643-3	1994	injection of vasoactive intestinal polypeptide (VIP) were markedly reduced by NG-nitro-L-arginine.	Nitroarginine	78-97	vasoactive intestinal peptide	Homo sapiens	48-51
8001643-5	1994	Addition of the NO donor, nitroprusside, reversed the NG-nitro-L-arginine evoked attenuation of the response to nerve stimulation and VIP.	Nitroarginine	54-73	vasoactive intestinal peptide	Homo sapiens	134-137
8071871-3	1994	The remaining relaxation in the media containing L-NNA was abolished in the strips made unresponsive to calcitonin gene-related peptide (CGRP) by its repeated application.	Nitroarginine	49-54	calcitonin related polypeptide alpha	Homo sapiens	137-141
8067439-5	1994	Administration of N omega-nitro-L-arginine and its methyl ester reduced vasodilator responses to bradykinin, acetylcholine, and substance P, whereas responses to endothelium-independent vasodilator agents were not attenuated.	Nitroarginine	18-42	kininogen 1	Homo sapiens	97-107
8067439-5	1994	Administration of N omega-nitro-L-arginine and its methyl ester reduced vasodilator responses to bradykinin, acetylcholine, and substance P, whereas responses to endothelium-independent vasodilator agents were not attenuated.	Nitroarginine	18-42	tachykinin precursor 1	Homo sapiens	128-139
7519365-10	1994	Pretreatment with N-nitro-L-arginine increased mortality rate to 74%, decreased NO2/NO3, and substantially increased TNF and IL-6 levels.	Nitroarginine	18-36	tumor necrosis factor-like	Rattus norvegicus	117-120
8037731-5	1994	In the presence of indomethacin (a cyclooxygenase inhibitor), motilin induced an endothelium-dependent relaxation of the coronary strips which was partially inhibited by N omega-nitro-L-arginine (L-NNA; a NO synthase inhibitor).	Nitroarginine	170-194	motilin	Homo sapiens	62-69
8037731-5	1994	In the presence of indomethacin (a cyclooxygenase inhibitor), motilin induced an endothelium-dependent relaxation of the coronary strips which was partially inhibited by N omega-nitro-L-arginine (L-NNA; a NO synthase inhibitor).	Nitroarginine	196-201	motilin	Homo sapiens	62-69
8037731-6	1994	These results thus indicate that motilin induces Ca2+ transients of the endothelial cells while it also induces vasorelaxation, which may be mediated by both L-NNA sensitive and resistant factors that are derived from the endothelium.	Nitroarginine	158-163	motilin	Homo sapiens	33-40
7524106-1	1994	We recently reported that inhibition of nitric oxide (NO) production by the NO synthase (NOS) inhibitor L-NG-nitro arginine (L-NOARG) antagonized the behavioral effects of a benzodiazepine (BZ) in a mouse paradigm for screening anxiolytic drug activity.	Nitroarginine	104-123	nitric oxide synthase 1, neuronal	Mus musculus	76-87
8048578-3	1994	ET-1 caused concentration-dependent contractions in arteries and veins, augmented by the nitric oxide synthase (NOS) inhibitor, N omega-nitro-L-arginine, in pulmonary veins.	Nitroarginine	128-152	endothelin 1	Homo sapiens	0-4
8048578-3	1994	ET-1 caused concentration-dependent contractions in arteries and veins, augmented by the nitric oxide synthase (NOS) inhibitor, N omega-nitro-L-arginine, in pulmonary veins.	Nitroarginine	128-152	nitric oxide synthase 2	Homo sapiens	89-110
8048578-6	1994	Endothelium-dependent relaxations to bradykinin and ET-1 were greater in pulmonary veins compared with arteries, inhibited by N omega-nitro-L-arginine, and reversed by L-arginine.	Nitroarginine	126-150	kininogen 1	Homo sapiens	37-47
8048578-6	1994	Endothelium-dependent relaxations to bradykinin and ET-1 were greater in pulmonary veins compared with arteries, inhibited by N omega-nitro-L-arginine, and reversed by L-arginine.	Nitroarginine	126-150	endothelin 1	Homo sapiens	52-56
7967238-3	1994	Preincubation with either meclofenamate (31 microM), a cyclooxygenase inhibitor, or L-NG-nitroarginine (100 microM), an endothelium-derived relaxing factor (EDRF) production inhibitor, failed to inhibit amurinone-induced pulmonary vasodilation.	Nitroarginine	84-102	alpha hemoglobin stabilizing protein	Homo sapiens	157-161
7524106-1	1994	We recently reported that inhibition of nitric oxide (NO) production by the NO synthase (NOS) inhibitor L-NG-nitro arginine (L-NOARG) antagonized the behavioral effects of a benzodiazepine (BZ) in a mouse paradigm for screening anxiolytic drug activity.	Nitroarginine	125-132	nitric oxide synthase 1, neuronal	Mus musculus	76-87
7517647-0	1994	Comparative effects of L-NNA and alkyl esters of L-NNA on pulmonary vasodilator responses to ACh, BK, and SP.	Nitroarginine	49-54	tachykinin precursor 1	Homo sapiens	106-108
7524120-3	1994	This bradykinin-induced oxidation of DCFH was inhibited by pretreatment with N-(2-mercaptopropionyl)-glycine (MPG) and 1,3-dimethyl-thiourea (DMTU), scavengers of hydroxyl radical, and the removal of extracellular Ca2+ but was unaffected by NG-nitro-L-arginine or NG-monomethyl-L-arginine, both inhibitors of nitric oxide (NO) synthase.	Nitroarginine	241-260	kininogen 1	Bos taurus	5-15
7517647-5	1994	The similar inhibitory effects of L-NNA, L-NAME, and L-NABE on vasodilator responses to ACh, BK, and SP suggest that the L-arginine analogue, L-NNA, as well as the methyl and benzyl esters of L-NNA are useful probes for studying NO-mediated endothelium-dependent responses in the pulmonary vascular bed of the intact-chest cat.	Nitroarginine	142-147	tachykinin precursor 1	Homo sapiens	101-103
7517647-5	1994	The similar inhibitory effects of L-NNA, L-NAME, and L-NABE on vasodilator responses to ACh, BK, and SP suggest that the L-arginine analogue, L-NNA, as well as the methyl and benzyl esters of L-NNA are useful probes for studying NO-mediated endothelium-dependent responses in the pulmonary vascular bed of the intact-chest cat.	Nitroarginine	142-147	tachykinin precursor 1	Homo sapiens	101-103
7517646-5	1994	The nitric oxide (NO) synthase inhibitors N omega-nitro-L-arginine benzyl ester and N omega-nitro-L-arginine reduced vasodilator responses to BK in a selective manner, indicating that responses to BK are mediated in part by the release of NO.	Nitroarginine	42-66	kininogen 1	Homo sapiens	142-144
7517646-5	1994	The nitric oxide (NO) synthase inhibitors N omega-nitro-L-arginine benzyl ester and N omega-nitro-L-arginine reduced vasodilator responses to BK in a selective manner, indicating that responses to BK are mediated in part by the release of NO.	Nitroarginine	42-66	kininogen 1	Homo sapiens	197-199
8156634-8	1994	This effect was abolished by nitric oxide/EDRF pathway inhibitors NG-monomethyl-L-arginine and N-nitro-L-arginine.	Nitroarginine	95-113	alpha hemoglobin stabilizing protein	Homo sapiens	42-46
8024626-6	1994	Nitro-L-arginine (3 x 10(-5) mol/l) increased the basal ANP release (p < 0.01 vs. CRF group) and prolonged the CRF-induced rise of the ANP secretion.	Nitroarginine	0-16	natriuretic peptide A	Rattus norvegicus	56-59
8024626-6	1994	Nitro-L-arginine (3 x 10(-5) mol/l) increased the basal ANP release (p < 0.01 vs. CRF group) and prolonged the CRF-induced rise of the ANP secretion.	Nitroarginine	0-16	natriuretic peptide A	Rattus norvegicus	138-141
7515904-12	1994	This effect was prevented by N(G)-nitro-L-arginine (L-NNA), which also inhibited VIP-stimulated secretion of amylase; however, L-NNA had no effect on amylase secretion stimulated by carbachol.	Nitroarginine	29-50	vasoactive intestinal peptide	Homo sapiens	81-84
8182526-2	1994	In the mouse abdominal constriction test, pretreatment with the nitric oxide synthase (NOS) inhibitor L-NG-nitroarginine (L-NOARG) caused dose-related antagonism of the antinociceptive effect of N2O but not of either morphine or trans(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] benzeneacetamide methane sulfonate.	Nitroarginine	102-120	nitric oxide synthase 1, neuronal	Mus musculus	64-85
8182526-2	1994	In the mouse abdominal constriction test, pretreatment with the nitric oxide synthase (NOS) inhibitor L-NG-nitroarginine (L-NOARG) caused dose-related antagonism of the antinociceptive effect of N2O but not of either morphine or trans(+/-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] benzeneacetamide methane sulfonate.	Nitroarginine	122-129	nitric oxide synthase 1, neuronal	Mus musculus	64-85
8161004-5	1994	This effect may be blocked by the specific inhibitor of EDRF biosynthesis/release NG-nitro-L-arginine (L-NNA).	Nitroarginine	82-101	alpha hemoglobin stabilizing protein	Homo sapiens	56-60
8161004-5	1994	This effect may be blocked by the specific inhibitor of EDRF biosynthesis/release NG-nitro-L-arginine (L-NNA).	Nitroarginine	103-108	alpha hemoglobin stabilizing protein	Homo sapiens	56-60
7515904-12	1994	This effect was prevented by N(G)-nitro-L-arginine (L-NNA), which also inhibited VIP-stimulated secretion of amylase; however, L-NNA had no effect on amylase secretion stimulated by carbachol.	Nitroarginine	52-57	vasoactive intestinal peptide	Homo sapiens	81-84
7516884-8	1994	The similarity in the inhibitory effects of N omega-nitro-L-arginine methyl ester and N omega-nitro-L-arginine on responses to acetylcholine, bradykinin, and substance P suggest that the L-arginine analog, N omega-nitro-L-arginine, as well as the methyl ester of N omega-nitro-L-arginine, are useful probes for studying endothelium-dependent vasodilator responses in the mesenteric vascular bed of the cat.	Nitroarginine	44-68	kininogen 1	Homo sapiens	142-152
7516884-8	1994	The similarity in the inhibitory effects of N omega-nitro-L-arginine methyl ester and N omega-nitro-L-arginine on responses to acetylcholine, bradykinin, and substance P suggest that the L-arginine analog, N omega-nitro-L-arginine, as well as the methyl ester of N omega-nitro-L-arginine, are useful probes for studying endothelium-dependent vasodilator responses in the mesenteric vascular bed of the cat.	Nitroarginine	86-110	kininogen 1	Homo sapiens	142-152
7516884-8	1994	The similarity in the inhibitory effects of N omega-nitro-L-arginine methyl ester and N omega-nitro-L-arginine on responses to acetylcholine, bradykinin, and substance P suggest that the L-arginine analog, N omega-nitro-L-arginine, as well as the methyl ester of N omega-nitro-L-arginine, are useful probes for studying endothelium-dependent vasodilator responses in the mesenteric vascular bed of the cat.	Nitroarginine	86-110	tachykinin precursor 1	Homo sapiens	158-169
7516884-8	1994	The similarity in the inhibitory effects of N omega-nitro-L-arginine methyl ester and N omega-nitro-L-arginine on responses to acetylcholine, bradykinin, and substance P suggest that the L-arginine analog, N omega-nitro-L-arginine, as well as the methyl ester of N omega-nitro-L-arginine, are useful probes for studying endothelium-dependent vasodilator responses in the mesenteric vascular bed of the cat.	Nitroarginine	86-110	kininogen 1	Homo sapiens	142-152
7516884-8	1994	The similarity in the inhibitory effects of N omega-nitro-L-arginine methyl ester and N omega-nitro-L-arginine on responses to acetylcholine, bradykinin, and substance P suggest that the L-arginine analog, N omega-nitro-L-arginine, as well as the methyl ester of N omega-nitro-L-arginine, are useful probes for studying endothelium-dependent vasodilator responses in the mesenteric vascular bed of the cat.	Nitroarginine	86-110	tachykinin precursor 1	Homo sapiens	158-169
7516884-8	1994	The similarity in the inhibitory effects of N omega-nitro-L-arginine methyl ester and N omega-nitro-L-arginine on responses to acetylcholine, bradykinin, and substance P suggest that the L-arginine analog, N omega-nitro-L-arginine, as well as the methyl ester of N omega-nitro-L-arginine, are useful probes for studying endothelium-dependent vasodilator responses in the mesenteric vascular bed of the cat.	Nitroarginine	44-68	tachykinin precursor 1	Homo sapiens	158-169
7515323-4	1994	Bradykinin and the ACE inhibitor ramiprilat concentration-dependently increased the formation of cyclic GMP which was completely prevented by the stereospecific inhibitor of NO synthase, NG-nitro-L-arginine.	Nitroarginine	187-206	kininogen 1	Homo sapiens	0-10
8199652-6	1994	The extent to which inhibition of EDRF resembled GBS sepsis was determined by comparing hemodynamic observations during (1) EDRF inhibition (using a competitive inhibitor of nitric oxide synthase, N-nitro-L-arginine [NNLA], 80 mg/kg) with (2) GBS infusion.	Nitroarginine	217-221	alpha hemoglobin stabilizing protein	Homo sapiens	34-38
8019744-1	1994	The angiotensin I (AI) metabolite, A(1-7), elicited a concentration-dependent dilator response (ED50 > or = 2 microM) in porcine coronary artery rings which was markedly attenuated by the nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine, and abolished after removal of the endothelium.	Nitroarginine	229-248	angiotensinogen	Homo sapiens	4-17
8174163-5	1994	Arginine vasopressin [2(0.6) nM] and endothelin-1 [1.5(1) nM] induced similar reductions of coronary resting flow but the pressure induced flow increases were significantly greater than in the presence of L-NNA.	Nitroarginine	205-210	endothelin-1	Oryctolagus cuniculus	37-49
7515323-4	1994	Bradykinin and the ACE inhibitor ramiprilat concentration-dependently increased the formation of cyclic GMP which was completely prevented by the stereospecific inhibitor of NO synthase, NG-nitro-L-arginine.	Nitroarginine	187-206	angiotensin I converting enzyme	Homo sapiens	19-22
7515323-4	1994	Bradykinin and the ACE inhibitor ramiprilat concentration-dependently increased the formation of cyclic GMP which was completely prevented by the stereospecific inhibitor of NO synthase, NG-nitro-L-arginine.	Nitroarginine	187-206	5'-nucleotidase, cytosolic II	Homo sapiens	104-107
7526629-4	1994	N-nitro-L-arginine (L-NNA), an inhibitor of nitric oxidase synthase (NOS), significantly ameliorated this neuronal injury in a dose dependent manner.	Nitroarginine	0-18	nitric oxide synthase 1	Rattus norvegicus	44-67
8141362-5	1994	Inhibition of EDRF/NO synthesis by NG-nitro-L-arginine (30 microM) completely abolished the ACh-induced cGMP increase, attenuated the cAMP-elevation without affecting PGI2, and caused a 20.5 +/- 5.8% decrease of the phosphorylation state of VASP.	Nitroarginine	35-54	alpha hemoglobin stabilizing protein	Homo sapiens	14-18
8141362-5	1994	Inhibition of EDRF/NO synthesis by NG-nitro-L-arginine (30 microM) completely abolished the ACh-induced cGMP increase, attenuated the cAMP-elevation without affecting PGI2, and caused a 20.5 +/- 5.8% decrease of the phosphorylation state of VASP.	Nitroarginine	35-54	vasodilator stimulated phosphoprotein	Homo sapiens	241-245
7508198-4	1994	VIP-induced relaxation of basal but not carbachol-stimulated tension was accompanied by increase in L-[3H]citrulline production and was inhibited by the NOS inhibitor NG-nitro-L-arginine (L-NNA).	Nitroarginine	167-186	VIP peptides	Oryctolagus cuniculus	0-3
7508198-4	1994	VIP-induced relaxation of basal but not carbachol-stimulated tension was accompanied by increase in L-[3H]citrulline production and was inhibited by the NOS inhibitor NG-nitro-L-arginine (L-NNA).	Nitroarginine	188-193	VIP peptides	Oryctolagus cuniculus	0-3
7508198-5	1994	Preincubation of carbachol-treated muscle strips with calphostin C restored the ability of VIP to stimulate L-[3H]citrulline production and the ability of L-NNA to inhibit VIP-induced relaxation.	Nitroarginine	155-160	VIP peptides	Oryctolagus cuniculus	172-175
7513645-3	1994	Three nitric oxide synthase (NOS) inhibitors affected transmural nerve stimulation induced relaxation responses in the rabbit urethra and the activity of soluble nitric oxide synthase with the same rank order of potency, i.e., NG-nitro-L-arginine (NNA) > NG-methyl-L-arginine (NMA) > canavanine (CAN).	Nitroarginine	227-246	nitric oxide synthase, brain	Oryctolagus cuniculus	6-27
7513645-3	1994	Three nitric oxide synthase (NOS) inhibitors affected transmural nerve stimulation induced relaxation responses in the rabbit urethra and the activity of soluble nitric oxide synthase with the same rank order of potency, i.e., NG-nitro-L-arginine (NNA) > NG-methyl-L-arginine (NMA) > canavanine (CAN).	Nitroarginine	227-246	nitric oxide synthase, brain	Oryctolagus cuniculus	162-183
7513645-3	1994	Three nitric oxide synthase (NOS) inhibitors affected transmural nerve stimulation induced relaxation responses in the rabbit urethra and the activity of soluble nitric oxide synthase with the same rank order of potency, i.e., NG-nitro-L-arginine (NNA) > NG-methyl-L-arginine (NMA) > canavanine (CAN).	Nitroarginine	248-251	nitric oxide synthase, brain	Oryctolagus cuniculus	6-27
7513384-0	1994	N omega-nitro-L-arginine inhibits vasodilations and elevations of both cyclic AMP and cyclic GMP levels in rat aorta induced by calcitonin gene-related peptide (CGRP).	Nitroarginine	0-24	calcitonin-related polypeptide alpha	Rattus norvegicus	128-159
7513384-0	1994	N omega-nitro-L-arginine inhibits vasodilations and elevations of both cyclic AMP and cyclic GMP levels in rat aorta induced by calcitonin gene-related peptide (CGRP).	Nitroarginine	0-24	calcitonin-related polypeptide alpha	Rattus norvegicus	161-165
7513384-3	1994	L-NNA (30 microM, 15 min) inhibited by 84, 76 and 73% the relaxations induced by rCGRP at 1, 10 and 100 nM, respectively.	Nitroarginine	0-5	calcitonin-related polypeptide alpha	Rattus norvegicus	81-86
7513384-5	1994	Addition of L-arginine (3 mM) 5 min before L-NNA completely prevented the L-NNA-inhibition of CGRP-induced relaxations.	Nitroarginine	74-79	calcitonin-related polypeptide alpha	Rattus norvegicus	94-98
7513384-6	1994	L-NNA (30 microM, 15 min) also inhibited the elevations of both cyclic AMP and cyclic GMP levels caused by CGRP (100 nM).	Nitroarginine	0-5	calcitonin-related polypeptide alpha	Rattus norvegicus	107-111
7524267-26	1994	Also the overflow of NPY-LI evoked by parasympathetic nerve stimulation of the submandibular salivary gland was suppressed by L-NNA.	Nitroarginine	126-131	neuropeptide Y	Sus scrofa	21-24
7526629-4	1994	N-nitro-L-arginine (L-NNA), an inhibitor of nitric oxidase synthase (NOS), significantly ameliorated this neuronal injury in a dose dependent manner.	Nitroarginine	20-25	nitric oxide synthase 1	Rattus norvegicus	44-67
8012902-4	1994	Pretreatment with nitric oxide inhibitors also prevented, in part (methylene blue, 1 microM) or in full (N omega-nitro-L-arginine, 100 microM), the relaxant effect of bradykinin.	Nitroarginine	105-129	kininogen 1	Homo sapiens	167-177
7527103-5	1994	In the presence of nitro-L-arginine, an inhibitor of NO synthase, trandolaprilat augmented the endothelium-dependent relaxations evoked by bradykinin.	Nitroarginine	19-35	kininogen 1	Canis lupus familiaris	139-149
7505207-7	1994	Under bioassay conditions, the perfusates from columns containing IL-1 beta-treated smooth muscle cells relaxed rings of rat aorta without endothelium that had been contracted with phenylephrine; these relaxations were reversed by nitro-L-arginine.	Nitroarginine	231-247	interleukin 1 beta	Rattus norvegicus	66-75
8208056-1	1994	We observed that N-nitro-L-arginine (NOLA), a nitric oxide biosynthesis inhibitor, exacerbated necrosis in the rabbit heart during ischemia-reperfusion while 3-morpholino-sydnonimine-hydrochloride (SIN-1) (a nitric oxide donor) reduced myocardial damage in the same model.	Nitroarginine	17-35	MAPK associated protein 1	Homo sapiens	198-203
8274625-4	1994	The NOLA-induced contraction was reversed with indomethacin (8 x 10(-6) M), ridogrel (10(-5) M) and SQ 29548 (10(-6) M) thus confirming the involvement of thromboxane A2/prostaglandin H2 processes.	Nitroarginine	4-8	UDP glucuronosyltransferase 1 family, polypeptide A7C	Rattus norvegicus	167-186
8208056-1	1994	We observed that N-nitro-L-arginine (NOLA), a nitric oxide biosynthesis inhibitor, exacerbated necrosis in the rabbit heart during ischemia-reperfusion while 3-morpholino-sydnonimine-hydrochloride (SIN-1) (a nitric oxide donor) reduced myocardial damage in the same model.	Nitroarginine	37-41	MAPK associated protein 1	Homo sapiens	198-203
8139697-7	1994	This is probably due to the release of EDRF from endothelial cells since blockade of EDRF synthesis by NG-nitro-L-arginine augmented the thrombin-induced contractions in arteries with intact endothelium.	Nitroarginine	103-122	alpha hemoglobin stabilizing protein	Homo sapiens	39-43
8139697-7	1994	This is probably due to the release of EDRF from endothelial cells since blockade of EDRF synthesis by NG-nitro-L-arginine augmented the thrombin-induced contractions in arteries with intact endothelium.	Nitroarginine	103-122	alpha hemoglobin stabilizing protein	Homo sapiens	85-89
8139697-7	1994	This is probably due to the release of EDRF from endothelial cells since blockade of EDRF synthesis by NG-nitro-L-arginine augmented the thrombin-induced contractions in arteries with intact endothelium.	Nitroarginine	103-122	coagulation factor II, thrombin	Homo sapiens	137-145
7535425-11	1994	However, L-NNA (100 microM) decreased VIP-induced relaxation by 45%, whereas it had no effect on galanin-induced relaxation.	Nitroarginine	9-14	VIP peptides	Cavia porcellus	38-41
7700851-6	1994	N omega-Nitro-L-arginine (15 microM) shifted the ET-1 concentration-response curves to the left in rings from both groups of dogs.	Nitroarginine	0-24	endothelin 1	Canis lupus familiaris	49-53
8134185-5	1994	NG-nitro-L-arginine given 1.5 h before the insult also significantly prevented hypoxic-ischemic damage in the five hippocampal structures examined, dentate gyrus, CA4, CA3, CA1, and subiculum.	Nitroarginine	0-19	carbonic anhydrase 4	Rattus norvegicus	163-166
8125855-3	1993	The vasodilation observed after topical administration of 100 ng/ml recombinant TNF-alpha (rTNF-alpha) was partly but significantly inhibited when NO synthesis was inhibited by 2 x 10(-4) M N omega-nitro-L-arginine (L-NNA).	Nitroarginine	190-214	tumor necrosis factor	Rattus norvegicus	80-89
8134185-5	1994	NG-nitro-L-arginine given 1.5 h before the insult also significantly prevented hypoxic-ischemic damage in the five hippocampal structures examined, dentate gyrus, CA4, CA3, CA1, and subiculum.	Nitroarginine	0-19	carbonic anhydrase 3	Rattus norvegicus	168-171
8134185-5	1994	NG-nitro-L-arginine given 1.5 h before the insult also significantly prevented hypoxic-ischemic damage in the five hippocampal structures examined, dentate gyrus, CA4, CA3, CA1, and subiculum.	Nitroarginine	0-19	carbonic anhydrase 1	Rattus norvegicus	173-176
8125855-3	1993	The vasodilation observed after topical administration of 100 ng/ml recombinant TNF-alpha (rTNF-alpha) was partly but significantly inhibited when NO synthesis was inhibited by 2 x 10(-4) M N omega-nitro-L-arginine (L-NNA).	Nitroarginine	190-214	tumor necrosis factor	Rattus norvegicus	91-101
8125855-3	1993	The vasodilation observed after topical administration of 100 ng/ml recombinant TNF-alpha (rTNF-alpha) was partly but significantly inhibited when NO synthesis was inhibited by 2 x 10(-4) M N omega-nitro-L-arginine (L-NNA).	Nitroarginine	216-221	tumor necrosis factor	Rattus norvegicus	80-89
8125855-3	1993	The vasodilation observed after topical administration of 100 ng/ml recombinant TNF-alpha (rTNF-alpha) was partly but significantly inhibited when NO synthesis was inhibited by 2 x 10(-4) M N omega-nitro-L-arginine (L-NNA).	Nitroarginine	216-221	tumor necrosis factor	Rattus norvegicus	91-101
8125855-4	1993	Almost complete inhibition of the acute vasodilatory effect of rTNF-alpha was found when both NO and prostaglandin synthesis were blocked by simultaneous administration of L-NNA and mefanamic acid.	Nitroarginine	172-177	tumor necrosis factor	Rattus norvegicus	63-73
8293768-4	1993	Bradykinin or moexiprilat also significantly increased the cyclic guanosine monophosphate (cGMP) content of these coronary segments, an effect which was abolished by the nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine (NNA), or by removal of the endothelium.	Nitroarginine	208-227	kininogen 1	Bos taurus	0-10
8254041-6	1993	In rings contracted with prostaglandin F2 alpha, the cumulative addition of bradykinin caused a concentration-dependent relaxation during contractions evoked by prostaglandin F2 alpha, which was not abolished by NLA and indomethacin.	Nitroarginine	212-215	kininogen 1	Homo sapiens	76-86
7508575-2	1993	The basal cyclic GMP efflux was concentration-dependently reduced upon local infusion of the nitric oxide synthase inhibitor NG-nitro-L-arginine (10 microM-1 mM).	Nitroarginine	125-144	5'-nucleotidase, cytosolic II	Homo sapiens	17-20
7508575-4	1993	The glutamate receptor agonist N-methyl-D-aspartate (500 microM) produced a cyclic GMP response which was abolished by the selective receptor antagonist D-2-amino-5-phosphonovaleric acid (500 microM) or by NG-nitro-L-arginine (10 microM).	Nitroarginine	206-225	5'-nucleotidase, cytosolic II	Homo sapiens	83-86
8238588-2	1993	In rings of coronary arteries and saphenous veins contracted submaximally with prostaglandin F2 alpha or U46619, alpha-thrombin (0.1-10 nM) caused relaxations that were abolished by treatment with N omega-nitro-L-arginine (L-NNA) or removal of the endothelium, indicating that the relaxations were mediated by endothelium-derived nitric oxide.	Nitroarginine	197-221	coagulation factor II, thrombin	Homo sapiens	119-127
8238588-2	1993	In rings of coronary arteries and saphenous veins contracted submaximally with prostaglandin F2 alpha or U46619, alpha-thrombin (0.1-10 nM) caused relaxations that were abolished by treatment with N omega-nitro-L-arginine (L-NNA) or removal of the endothelium, indicating that the relaxations were mediated by endothelium-derived nitric oxide.	Nitroarginine	223-228	coagulation factor II, thrombin	Homo sapiens	119-127
8293768-5	1993	NNA also diminished the relaxant response to moexiprilat, but only partially inhibited that to bradykinin, suggesting that the ACE inhibitor-induced relaxation was predominantly mediated by endothelial NO release, whereas bradykinin acted in part by another endothelium-dependent mechanism.	Nitroarginine	0-3	kininogen 1	Bos taurus	95-105
7514138-3	1993	Histopathological examination of the brains obtained 6 days after reflow disclosed that N omega-nitro-L-arginine possesses an ability to mitigate neuronal necrosis in the CA1 subfield of the hippocampus with an optimal dosage of 3 mg/kg.	Nitroarginine	88-112	carbonic anhydrase 1	Homo sapiens	171-174
7906075-3	1993	EDRF production was blunted in the absence of extracellular L-arginine and in the presence of N omega-nitro-L-arginine (L-NAG; 200 microM).	Nitroarginine	94-118	alpha hemoglobin stabilizing protein	Mus musculus	0-4
7906075-3	1993	EDRF production was blunted in the absence of extracellular L-arginine and in the presence of N omega-nitro-L-arginine (L-NAG; 200 microM).	Nitroarginine	94-118	neuroblastoma amplified sequence	Mus musculus	122-125
8293768-4	1993	Bradykinin or moexiprilat also significantly increased the cyclic guanosine monophosphate (cGMP) content of these coronary segments, an effect which was abolished by the nitric oxide (NO) synthase inhibitor, NG-nitro-L-arginine (NNA), or by removal of the endothelium.	Nitroarginine	229-232	kininogen 1	Bos taurus	0-10
8293768-5	1993	NNA also diminished the relaxant response to moexiprilat, but only partially inhibited that to bradykinin, suggesting that the ACE inhibitor-induced relaxation was predominantly mediated by endothelial NO release, whereas bradykinin acted in part by another endothelium-dependent mechanism.	Nitroarginine	0-3	angiotensin I converting enzyme	Bos taurus	127-130
8238420-6	1993	The decrease in pulmonary arterial pressure produced by ET-1 (250 ng/kg) was attenuated by N omega-nitro-L-arginine (an inhibitor of endothelium-derived nitric oxide synthesis, 23.7 +/- 3.4 vs. 12.5 +/- 4.7%; P < 0.05) and by glibenclamide (an ATP-gated potassium-channel blocker, 25.2 +/- 5.0 vs. 9.6 +/- 5.3%; P < 0.05) but not by meclofenamic acid (an inhibitor of prostaglandin synthesis).	Nitroarginine	91-115	EDN1	Ovis aries	56-60
7694601-1	1993	At room temperature (23 degrees C-25 degrees C), the induction of long-term potentiation (LTP) in area CA1 of slices from young male Sprague-Dawley rats was depressed by preincubation with the nitric oxide synthase inhibitors NG-nitro-L-arginine (L-NA, 100 microM) and NG-nitro-L-arginine methyl ester (L-NAME, 100 microM).	Nitroarginine	226-245	carbonic anhydrase 1	Rattus norvegicus	103-106
8276081-7	1993	In the presence of N-nitro-L-arginine (50 microM) the responses to [Ala1,3,11,15]endothelin-1 and low concentrations of endothelin-3 were significantly enhanced.	Nitroarginine	19-37	endothelin-1	Sus scrofa	81-93
8276081-7	1993	In the presence of N-nitro-L-arginine (50 microM) the responses to [Ala1,3,11,15]endothelin-1 and low concentrations of endothelin-3 were significantly enhanced.	Nitroarginine	19-37	endothelin 3	Sus scrofa	120-132
8246168-6	1993	L-NG-nitroarginine, an inhibitor of nitric oxide synthetase, prevented the improvement of glomerular filtration rate and blood urea nitrogen by IGF-I at 1 mg/kg, suggesting that the ameliorative action on renal function by IGF-I is mediated via nitric oxide, possibly its vasodilating action.	Nitroarginine	0-18	insulin-like growth factor 1	Rattus norvegicus	144-149
8246168-6	1993	L-NG-nitroarginine, an inhibitor of nitric oxide synthetase, prevented the improvement of glomerular filtration rate and blood urea nitrogen by IGF-I at 1 mg/kg, suggesting that the ameliorative action on renal function by IGF-I is mediated via nitric oxide, possibly its vasodilating action.	Nitroarginine	0-18	insulin-like growth factor 1	Rattus norvegicus	223-228
7689333-1	1993	L-NG-Nitroarginine (NA) inhibited both the L-arginine oxidation and the L-arginine-independent NADPH oxidation reactions catalyzed by the calcium/calmodulin-dependent constitutive nitric oxide synthase (cNOS) from bovine brain.	Nitroarginine	0-18	nitric oxide synthase 3	Bos taurus	203-207
8238376-2	1993	Lungs treated with 200 microM NG-nitro-L-arginine were resistant to the relaxant effects of VIP in these lungs; the 50% inhibitory dose (ID50) for VIP was 32 nmol/kg (95% confidence interval, 16-79), which was approximately 100-fold greater than the ID50 of control lungs which was 0.39 nmol/kg, (0.16-0.79, P < 0.0001).	Nitroarginine	30-49	VIP peptides	Cavia porcellus	92-95
8238376-2	1993	Lungs treated with 200 microM NG-nitro-L-arginine were resistant to the relaxant effects of VIP in these lungs; the 50% inhibitory dose (ID50) for VIP was 32 nmol/kg (95% confidence interval, 16-79), which was approximately 100-fold greater than the ID50 of control lungs which was 0.39 nmol/kg, (0.16-0.79, P < 0.0001).	Nitroarginine	30-49	VIP peptides	Cavia porcellus	147-150
7691341-0	1993	The central effects of a nitric oxide synthase inhibitor (N omega-nitro-L-arginine) on blood pressure and plasma renin.	Nitroarginine	58-82	renin	Rattus norvegicus	113-118
7691341-3	1993	The goal of our study was to determine if the increase in blood pressure following central NO synthase inhibition with N omega-nitro-L-arginine (L-NNA) is caused by the release of renin.	Nitroarginine	119-143	renin	Rattus norvegicus	180-185
7691341-3	1993	The goal of our study was to determine if the increase in blood pressure following central NO synthase inhibition with N omega-nitro-L-arginine (L-NNA) is caused by the release of renin.	Nitroarginine	145-150	renin	Rattus norvegicus	180-185
7691341-26	1993	We conclude that L-NNA acts directly within the central nervous system to increase blood pressure by a renin-independent mechanism.	Nitroarginine	17-22	renin	Rattus norvegicus	103-108
8399986-3	1993	Bradykinin (30 nM), moexiprilat or ramiprilat (0.3 microM) also significantly increased the cyclic GMP content of these coronary segments, an effect which was abolished by the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (L-NNA; 30 microM) or by removal of the endothelium.	Nitroarginine	213-232	kininogen 1	Bos taurus	0-10
8399986-3	1993	Bradykinin (30 nM), moexiprilat or ramiprilat (0.3 microM) also significantly increased the cyclic GMP content of these coronary segments, an effect which was abolished by the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine (L-NNA; 30 microM) or by removal of the endothelium.	Nitroarginine	234-239	kininogen 1	Bos taurus	0-10
8399986-4	1993	L-NNA also strongly reduced the relaxation response to moexiprilat but only partially inhibited that to bradykinin, demonstrating that the ACE inhibitor-induced relaxation was predominantly mediated by endothelial NO release, whereas bradykinin acted in part through another endothelium-dependent mechanism.	Nitroarginine	0-5	kininogen 1	Bos taurus	104-114
8399986-4	1993	L-NNA also strongly reduced the relaxation response to moexiprilat but only partially inhibited that to bradykinin, demonstrating that the ACE inhibitor-induced relaxation was predominantly mediated by endothelial NO release, whereas bradykinin acted in part through another endothelium-dependent mechanism.	Nitroarginine	0-5	angiotensin I converting enzyme	Bos taurus	139-142
8399986-4	1993	L-NNA also strongly reduced the relaxation response to moexiprilat but only partially inhibited that to bradykinin, demonstrating that the ACE inhibitor-induced relaxation was predominantly mediated by endothelial NO release, whereas bradykinin acted in part through another endothelium-dependent mechanism.	Nitroarginine	0-5	kininogen 1	Bos taurus	234-244
8326022-7	1993	Moreover, when the endogenous constitutive levels of NO made by endothelial cells are suppressed using N-omega-nitro-L-arginine, a potent competitive inhibitor of NO synthase, the baseline levels of ET-1 produced in normoxic environments are increased three- to fourfold.	Nitroarginine	103-127	endothelin 1	Homo sapiens	199-203
8357951-5	1993	The production of nitrite evoked by equieffective concentrations of interleukin-1 beta in the presence and absence of eicosapentaenoic acid were inhibited to a similar extent by nitro L-arginine (an inhibitor of nitric oxide synthase), transforming growth factor beta 1, platelet-derived growth factorAB and thrombin.	Nitroarginine	178-194	transforming growth factor beta 1	Homo sapiens	236-269
8357951-5	1993	The production of nitrite evoked by equieffective concentrations of interleukin-1 beta in the presence and absence of eicosapentaenoic acid were inhibited to a similar extent by nitro L-arginine (an inhibitor of nitric oxide synthase), transforming growth factor beta 1, platelet-derived growth factorAB and thrombin.	Nitroarginine	178-194	coagulation factor II, thrombin	Homo sapiens	308-316
8377844-4	1993	NG-nitro-L-arginine (L-NNA), an inhibitor of nitric oxide formation, markedly enhanced the vasoconstriction induced by 30 nmol endothelin-1 in 2- and 6-mo rats but only slightly and non-significantly enhanced that vasoconstriction in 24-mo rats.	Nitroarginine	0-19	endothelin 1	Rattus norvegicus	127-139
8377844-4	1993	NG-nitro-L-arginine (L-NNA), an inhibitor of nitric oxide formation, markedly enhanced the vasoconstriction induced by 30 nmol endothelin-1 in 2- and 6-mo rats but only slightly and non-significantly enhanced that vasoconstriction in 24-mo rats.	Nitroarginine	21-26	endothelin 1	Rattus norvegicus	127-139
8340065-5	1993	This in vitro hyporesponsiveness to angiotensin II in aortic rings of cirrhotic rats with ascites was reversed on endothelium denudation or nitric oxide synthesis inhibition with N omega-nitro-L-arginine but was not influenced by cyclooxygenase inhibition with indomethacin.	Nitroarginine	179-203	angiotensinogen	Rattus norvegicus	36-50
8398001-7	1993	Nitro-L-arginine prevented the inhibitory effect of interleukin-1 beta.	Nitroarginine	0-16	interleukin 1 beta	Rattus norvegicus	52-70
8398001-11	1993	Interleukin-1 beta elicited greater concentration-dependent productions of cyclic GMP and nitrite in rings from spontaneously hypertensive than from Wistar-Kyoto rats, and these were inhibited by methylene blue and nitro-L-arginine, respectively.	Nitroarginine	215-231	interleukin 1 beta	Rattus norvegicus	0-18
8326022-11	1993	PDGF-B expression was suppressed by NO in a hypoxic environment and induced by N-omega-nitro-L-arginine in both normoxic and hypoxic environments.	Nitroarginine	79-103	platelet derived growth factor subunit B	Homo sapiens	0-6
8389325-2	1993	This inhibition of endothelin-1 secretion was reversed by coincubation with 3 x 10(-3) M NG-nitro-L-arginine, an inhibitor of nitric oxide synthesis.	Nitroarginine	89-108	endothelin 1	Homo sapiens	19-31
8358537-16	1993	L-NOARG enhanced mesenteric vascular responses to ES, NA and AII in both pregnant and nonpregnant groups.	Nitroarginine	0-7	angiotensinogen	Rattus norvegicus	61-64
7681412-2	1993	This effect was antagonized by LPS, a well known inducer of nitric oxide synthase (NOS) expression in macrophages, and was inhibited by NG-methyl-L-arginine and N omega-nitro-L-arginine.	Nitroarginine	161-185	nitric oxide synthase 2	Homo sapiens	60-81
8097316-3	1993	Nitric oxide (NO) contributes to gp120 toxicity, since nitroarginine, an inhibitor of NO synthase, prevents toxicity as does deletion of arginine from the incubation medium and hemoglobin, which binds NO.	Nitroarginine	55-68	inter-alpha-trypsin inhibitor heavy chain 4	Homo sapiens	33-38
8358552-4	1993	Cell-free supernatants, sonicates or rapid filtrates of PAF-stimulated PMN suspensions did not induce platelet adhesion to endothelial cells, but the PMN sonicates induced platelet adhesion when endothelial cells were pretreated with both aspirin and NG-nitro-L-arginine (L-NOARG).	Nitroarginine	251-270	PCNA clamp associated factor	Homo sapiens	56-59
8358552-4	1993	Cell-free supernatants, sonicates or rapid filtrates of PAF-stimulated PMN suspensions did not induce platelet adhesion to endothelial cells, but the PMN sonicates induced platelet adhesion when endothelial cells were pretreated with both aspirin and NG-nitro-L-arginine (L-NOARG).	Nitroarginine	272-279	PCNA clamp associated factor	Homo sapiens	56-59
8447417-3	1993	NG-nitro-L-arginine (L-NNA) abolished NO production in both preparations but only partly inhibited VIP release (45 +/- 8% at 8 Hz and 59 +/- 10% at 10 g stretch) and relaxation (62 +/- 5% and 35 +/- 6%); the effect of L-NNA was reversed by L-arginine but not D-arginine.	Nitroarginine	0-19	vasoactive intestinal peptide	Rattus norvegicus	99-102
7682043-8	1993	In addition, L-NOARG in the presence of indomethacin blocked the a-IgE-dependent relaxation.	Nitroarginine	13-20	immunoglobulin heavy constant epsilon	Homo sapiens	67-70
7682782-4	1993	The pattern of inhibition implied that: 1) relaxation was mediated by VIP and NO; 2) VIP release was partly dependent on NO production, since it was strongly inhibited by L-NNA; and 3) NO was largely produced by the action of VIP on muscle cells, since it was strongly inhibited by VIP-(10-28).	Nitroarginine	171-176	VIP peptides	Cavia porcellus	85-88
7682782-4	1993	The pattern of inhibition implied that: 1) relaxation was mediated by VIP and NO; 2) VIP release was partly dependent on NO production, since it was strongly inhibited by L-NNA; and 3) NO was largely produced by the action of VIP on muscle cells, since it was strongly inhibited by VIP-(10-28).	Nitroarginine	171-176	VIP peptides	Cavia porcellus	85-88
7682782-4	1993	The pattern of inhibition implied that: 1) relaxation was mediated by VIP and NO; 2) VIP release was partly dependent on NO production, since it was strongly inhibited by L-NNA; and 3) NO was largely produced by the action of VIP on muscle cells, since it was strongly inhibited by VIP-(10-28).	Nitroarginine	171-176	VIP peptides	Cavia porcellus	85-88
8514709-7	1993	Nitro-L-arginine increased (P < or = 0.05) ANG II-induced vasoconstriction in TNF-alpha-treated rats, but the pulmonary arterial pressure response was still lower (P < or = 0.05) in TNF250 than in control and TNF62 rats.	Nitroarginine	0-16	angiotensinogen	Rattus norvegicus	46-52
7682650-10	1993	Further, the nitric oxide synthase inhibitors NG-monomethyl-L-arginine and NG-nitro-L-arginine attenuated Ang II- and bradykinin-stimulated elevation of cGMP content but not that stimulated by ANF.	Nitroarginine	75-94	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	106-112
8383697-5	1993	The rise of renin secretion in response to a reduction of the renal artery pressure was markedly attenuated with inhibitors of EDRF formation such as NG-nitro-L-arginine (100 mumol/liter) and related compounds.	Nitroarginine	150-169	renin	Rattus norvegicus	12-17
8447447-3	1993	The EDRF inhibitor, N omega-nitro-L-arginine (L-NNA), had potent dose-dependent constrictor effects on the pulmonary vasculature with normal and raised tone.	Nitroarginine	20-44	alpha hemoglobin stabilizing protein	Homo sapiens	4-8
8514709-7	1993	Nitro-L-arginine increased (P < or = 0.05) ANG II-induced vasoconstriction in TNF-alpha-treated rats, but the pulmonary arterial pressure response was still lower (P < or = 0.05) in TNF250 than in control and TNF62 rats.	Nitroarginine	0-16	tumor necrosis factor	Rattus norvegicus	81-90
8514718-6	1993	However, both alpha-chymotrypsin and NG-nitro-L-arginine facilitated contractions induced by TMS, suggesting that both VIP and NO are involved in responses to TMS.	Nitroarginine	37-56	VIP peptides	Cavia porcellus	119-122
8447447-3	1993	The EDRF inhibitor, N omega-nitro-L-arginine (L-NNA), had potent dose-dependent constrictor effects on the pulmonary vasculature with normal and raised tone.	Nitroarginine	46-51	alpha hemoglobin stabilizing protein	Homo sapiens	4-8
8447417-3	1993	NG-nitro-L-arginine (L-NNA) abolished NO production in both preparations but only partly inhibited VIP release (45 +/- 8% at 8 Hz and 59 +/- 10% at 10 g stretch) and relaxation (62 +/- 5% and 35 +/- 6%); the effect of L-NNA was reversed by L-arginine but not D-arginine.	Nitroarginine	21-26	vasoactive intestinal peptide	Rattus norvegicus	99-102
8447447-4	1993	The constrictor effect of L-NNA was greater (P < 0.05) in the 1-day-old than in the 7-day-old lungs and was significantly (P < 0.005) attenuated by pretreatment with the EDRF precursor, L-arginine.	Nitroarginine	26-31	alpha hemoglobin stabilizing protein	Homo sapiens	176-180
8447447-7	1993	Endothelin-1 (ET-1) and bradykinin (BK) elicited dilator responses that were significantly (P < 0.05) reduced in the presence of L-NNA.	Nitroarginine	132-137	endothelin 1	Homo sapiens	0-12
8447447-7	1993	Endothelin-1 (ET-1) and bradykinin (BK) elicited dilator responses that were significantly (P < 0.05) reduced in the presence of L-NNA.	Nitroarginine	132-137	endothelin 1	Homo sapiens	14-18
8447447-7	1993	Endothelin-1 (ET-1) and bradykinin (BK) elicited dilator responses that were significantly (P < 0.05) reduced in the presence of L-NNA.	Nitroarginine	132-137	kininogen 1	Homo sapiens	24-34
8447447-7	1993	Endothelin-1 (ET-1) and bradykinin (BK) elicited dilator responses that were significantly (P < 0.05) reduced in the presence of L-NNA.	Nitroarginine	132-137	kininogen 1	Homo sapiens	36-38
8447456-4	1993	In rings treated with TNF-alpha or LPS, L-arginine caused a concentration-dependent relaxation that was abolished by N omega-nitro-L-arginine [an inhibitor of nitric oxide (NO) synthase].	Nitroarginine	117-141	tumor necrosis factor	Homo sapiens	22-31
8447474-8	1993	Treatment of smooth muscle cells with NG-nitro-L-arginine inhibited the cytokine-mediated effects as well as the potentiating effect of plasmin.	Nitroarginine	38-57	plasminogen	Homo sapiens	136-143
8447417-5	1993	In addition, VIP induced relaxation and stimulated NO production in muscle strips and isolated colonic muscle cells: L-NNA abolished NO production but only partly inhibited relaxation (58 +/- 6%); oxyhemoglobin had no effect.	Nitroarginine	117-122	vasoactive intestinal peptide	Rattus norvegicus	13-16
8102401-15	1993	L-NNA did not modify the amplitude of hyperpolarization due to ATP or NO; however, it antagonized VIP-induced hyperpolarization (P < 0.01).	Nitroarginine	0-5	VIP peptides	Cavia porcellus	98-101
8447456-7	1993	These effects of TNF-alpha and LPS were blocked by N omega-nitro-L-arginine.	Nitroarginine	51-75	tumor necrosis factor	Homo sapiens	17-26
8381608-5	1993	Exposure to 6-25 dyn/cm2 for > or = 6 h dramatically inhibited ET-1 release and led to 0-70% inhibition of cumulative release by 16 h. Pretreatment with N omega-nitro-L-arginine (L-NNA) reversed this suppression in a dose-dependent manner, implicating either nitric oxide (NO) and/or guanosine 3",5"-cyclic monophosphate (cGMP) as a requirement for shear-mediated inhibition of ET-1 release.	Nitroarginine	156-180	endothelin 1	Homo sapiens	66-70
7678741-5	1993	NSE levels after successive incubation in L-N-ARG and NMDA were 95% of controls incubated in Krebs bicarbonate medium only (GS activity 89% of controls).	Nitroarginine	42-49	enolase 2	Rattus norvegicus	0-3
7678741-6	1993	In contrast, pre-incubation with L-N-ARG prior to the addition of KA resulted in neuronal degeneration and significant reductions in NSE levels and GS activities.	Nitroarginine	33-40	enolase 2	Rattus norvegicus	133-136
8381608-5	1993	Exposure to 6-25 dyn/cm2 for > or = 6 h dramatically inhibited ET-1 release and led to 0-70% inhibition of cumulative release by 16 h. Pretreatment with N omega-nitro-L-arginine (L-NNA) reversed this suppression in a dose-dependent manner, implicating either nitric oxide (NO) and/or guanosine 3",5"-cyclic monophosphate (cGMP) as a requirement for shear-mediated inhibition of ET-1 release.	Nitroarginine	156-180	endothelin 1	Homo sapiens	381-385
7828447-5	1993	Progressive inhibition of EDRF was achieved by continuous infusion of the substituted L-arginine analog N-nitro-L-arginine (NNLA).	Nitroarginine	104-122	alpha hemoglobin stabilizing protein	Homo sapiens	26-30
8240032-2	1993	Removal of endothelial cells or pretreatment with nitro-L-arginine, a specific inhibitor of the endothelium-derived relaxing factor (EDRF) synthesis, impaired, although to a small extent, hPTH-induced relaxations.	Nitroarginine	50-66	alpha hemoglobin stabilizing protein	Homo sapiens	96-131
8240032-2	1993	Removal of endothelial cells or pretreatment with nitro-L-arginine, a specific inhibitor of the endothelium-derived relaxing factor (EDRF) synthesis, impaired, although to a small extent, hPTH-induced relaxations.	Nitroarginine	50-66	alpha hemoglobin stabilizing protein	Homo sapiens	133-137
8240032-2	1993	Removal of endothelial cells or pretreatment with nitro-L-arginine, a specific inhibitor of the endothelium-derived relaxing factor (EDRF) synthesis, impaired, although to a small extent, hPTH-induced relaxations.	Nitroarginine	50-66	parathyroid hormone	Homo sapiens	188-192
8430846-7	1993	The role of endothelium-derived relaxing factor (EDRF) in the vasoconstrictor response to RBC was studied by addition of nitric oxide synthase inhibitor, N omega-nitro-L-arginine (L-NNA, 100 microM) to the perfusate.	Nitroarginine	180-185	alpha hemoglobin stabilizing protein	Homo sapiens	49-53
7828447-5	1993	Progressive inhibition of EDRF was achieved by continuous infusion of the substituted L-arginine analog N-nitro-L-arginine (NNLA).	Nitroarginine	124-128	alpha hemoglobin stabilizing protein	Homo sapiens	26-30
7509962-6	1993	In the presence of NOLA, ET-1 (1 pM) enhanced the responses to nerve stimulation (1-8 Hz, 10-s trains) by a significantly greater amount than in the absence of NOLA, suggesting that the enhancement by ET-1 is suppressed by NO release.	Nitroarginine	19-23	endothelin 1	Rattus norvegicus	25-29
8432339-3	1993	In contrast, injection of a nitric oxide synthesis inhibitor, nitro-L-arginine, into the vitreous cavity inhibited the protective effect of SOD+catalase during HIOP-induced ERG extinction.	Nitroarginine	62-78	catalase	Homo sapiens	144-152
7509962-6	1993	In the presence of NOLA, ET-1 (1 pM) enhanced the responses to nerve stimulation (1-8 Hz, 10-s trains) by a significantly greater amount than in the absence of NOLA, suggesting that the enhancement by ET-1 is suppressed by NO release.	Nitroarginine	19-23	endothelin 1	Rattus norvegicus	201-205
7509962-7	1993	The responses to norepinephrine (3-100 pmol) were also enhanced by 1 pM ET-1 in the presence of NOLA.	Nitroarginine	96-100	endothelin 1	Rattus norvegicus	72-76
7690108-1	1993	NG-Nitro-L-arginine, an inhibitor of nitric oxide synthase, does not influence CRH basal release but is able to modify ACTH basal secretion and to block interleukin-1 beta-induced CRH and ACTH release from rat hypothalamic and anterior pituitary cell cultures in vitro.	Nitroarginine	0-19	interleukin 1 beta	Rattus norvegicus	153-171
7510006-6	1993	In vivo, both big ET-1 and ET-1 (0.5-2 nmol/kg) evoked pressor responses that were augmented by indomethacin (15 mg/kg) and L-NNA (1 mg/kg/min).	Nitroarginine	124-129	endothelin 1	Rattus norvegicus	18-22
7510006-6	1993	In vivo, both big ET-1 and ET-1 (0.5-2 nmol/kg) evoked pressor responses that were augmented by indomethacin (15 mg/kg) and L-NNA (1 mg/kg/min).	Nitroarginine	124-129	endothelin 1	Rattus norvegicus	27-31
7690108-1	1993	NG-Nitro-L-arginine, an inhibitor of nitric oxide synthase, does not influence CRH basal release but is able to modify ACTH basal secretion and to block interleukin-1 beta-induced CRH and ACTH release from rat hypothalamic and anterior pituitary cell cultures in vitro.	Nitroarginine	0-19	corticotropin releasing hormone	Rattus norvegicus	180-183
1338816-5	1992	That L-arginine can ameliorate while L-NNA can exacerbate ToS, suggest that NO-LRF do play an adaptive role in the protective mechanism of the organism during ToS.	Nitroarginine	37-42	zinc finger and BTB domain containing 7a	Rattus norvegicus	79-82
1467832-8	1992	Bradykinin and SIN 1 (a donor of nitric oxide) reduced contractions induced by prostaglandin F2 alpha in an additive fashion in the presence of nitro-L-arginine.	Nitroarginine	144-160	kininogen 1	Homo sapiens	0-10
1467832-8	1992	Bradykinin and SIN 1 (a donor of nitric oxide) reduced contractions induced by prostaglandin F2 alpha in an additive fashion in the presence of nitro-L-arginine.	Nitroarginine	144-160	MAPK associated protein 1	Homo sapiens	15-20
1467832-10	1992	Bradykinin (in the presence of nitro-L-arginine) relaxed the tissues contracted with tetraethylammonium, prostaglandin F2 alpha, phorbol 12, 13-diacetate or endothelin, with similar pD2 values.	Nitroarginine	31-47	kininogen 1	Homo sapiens	0-10
1467826-3	1992	The relaxation by ET-3 was not affected by endothelium denudation nor treatment with NG-nitro-L-arginine, but was abolished or reversed to a contraction by treatment with indomethacin and markedly suppressed by tranylcypromine, a PGI2 synthetase inhibitor, or diphloretin phosphate, a prostaglandin receptor antagonist.	Nitroarginine	85-104	endothelin 3	Canis lupus familiaris	18-22
1467832-6	1992	Bradykinin induced comparable endothelium-dependent relaxations of proximal and distal rings of porcine coronary arteries contracted with prostaglandin F2 alpha in the presence of nitro-L-arginine.	Nitroarginine	180-196	kininogen 1	Homo sapiens	0-10
1332506-9	1992	Furthermore, ANG II blockade attenuates the vasoconstriction elicited by L-NNA, suggesting that EDRF interacts with the renin-angiotensin system to control juxtamedullary afferent and efferent arteriolar resistance.	Nitroarginine	73-78	angiotensinogen	Rattus norvegicus	13-19
1491787-2	1992	The same dose of QUIN following ICV pretreatment with the nitric oxide synthase inhibitor N-nitro-L-arginine (NARG), produced extensive hippocampal lesions with complete loss of the pyramidal layer in 50% of the animals, and moderate damage with total neuronal loss in areas CA1 and CA3 in the remainder of the group.	Nitroarginine	90-108	carbonic anhydrase 1	Rattus norvegicus	275-278
1491787-2	1992	The same dose of QUIN following ICV pretreatment with the nitric oxide synthase inhibitor N-nitro-L-arginine (NARG), produced extensive hippocampal lesions with complete loss of the pyramidal layer in 50% of the animals, and moderate damage with total neuronal loss in areas CA1 and CA3 in the remainder of the group.	Nitroarginine	90-108	carbonic anhydrase 3	Rattus norvegicus	283-286
1491787-2	1992	The same dose of QUIN following ICV pretreatment with the nitric oxide synthase inhibitor N-nitro-L-arginine (NARG), produced extensive hippocampal lesions with complete loss of the pyramidal layer in 50% of the animals, and moderate damage with total neuronal loss in areas CA1 and CA3 in the remainder of the group.	Nitroarginine	110-114	carbonic anhydrase 1	Rattus norvegicus	275-278
1491787-2	1992	The same dose of QUIN following ICV pretreatment with the nitric oxide synthase inhibitor N-nitro-L-arginine (NARG), produced extensive hippocampal lesions with complete loss of the pyramidal layer in 50% of the animals, and moderate damage with total neuronal loss in areas CA1 and CA3 in the remainder of the group.	Nitroarginine	110-114	carbonic anhydrase 3	Rattus norvegicus	283-286
1361870-10	1992	NG-nitro-L-arginine (L-NOARG: 10(-5) M), which inhibits nitric oxide synthetase, inhibited the relaxant response to human alpha-CGRP and cyclic GMP accumulation without affecting the cyclic AMP accumulation.	Nitroarginine	0-19	5'-nucleotidase, cytosolic II	Homo sapiens	144-147
1361870-10	1992	NG-nitro-L-arginine (L-NOARG: 10(-5) M), which inhibits nitric oxide synthetase, inhibited the relaxant response to human alpha-CGRP and cyclic GMP accumulation without affecting the cyclic AMP accumulation.	Nitroarginine	21-28	5'-nucleotidase, cytosolic II	Homo sapiens	144-147
1282726-6	1992	Infusion of 1 mumol/l N-nitro-L-arginine, a specific and potent inhibitor of nitric oxide synthesis in endothelial cells, abolished the GFR elevation induced by 250 pmol/l ET-3.	Nitroarginine	22-40	endothelin 3	Rattus norvegicus	172-176
1384487-3	1992	Furthermore, NG-nitro-L-arginine, a nitric oxide (NO) synthase inhibitor, inhibited both activities induced by IFN-gamma.	Nitroarginine	13-32	interferon gamma	Rattus norvegicus	111-120
1329561-3	1992	The effects of CD-349 on Iso-induced relaxation of the aortic strips precontracted with ET-1 were inhibited by treatment with methylene blue (10(-5) M) and oxyhemoglobin (10(-5) M), whereas they were augmented by treatment with N omega-nitro-L-arginine (10(-4) M).	Nitroarginine	228-252	endothelin-1	Oryctolagus cuniculus	88-92
1358391-11	1992	Bradykinin and A23187 induced relaxations in the presence of nitro-L-arginine (30 microM) that were abolished by calmidazolium (10 microM) but not affected by glibenclamide (10 microM), an inhibitor of ATP-sensitive K+ channels.	Nitroarginine	61-77	kininogen 1	Canis lupus familiaris	0-10
1463429-2	1992	To study this effect further, the influence of L-NG-nitro arginine (L-NNA), a specific inhibitor of EDRF-synthesis, on nitrendipine-induced vasorelaxation was examined in different isolated porcine arteries.	Nitroarginine	68-73	alpha hemoglobin stabilizing protein	Homo sapiens	100-104
1280469-5	1992	In addition, induction of PAI was enhanced by isobutyl-methylxanthine, a phosphodiesterase inhibitor, but not, however, by other phosphodiesterase inhibitors, or by forskolin or NG-nitro-L-arginine, suggesting an effect of isobutyl-methylxanthine other than through cyclic nucleotides.	Nitroarginine	178-197	serpin family E member 1	Rattus norvegicus	26-29
1330642-4	1992	The cyclic GMP responses to bradykinin were suppressed with the same potency by L-arginine analogues in control and in forskolin-treated cells (IC50 of NG-monomethyl-L-arginine 2 microM, of nitro-L-arginine 0.7 microM).	Nitroarginine	190-206	kininogen 1	Homo sapiens	28-38
1330166-15	1992	In the presence of L-NOARG (30 microM), NPY (0.1 microM) did not modify the motor responses induced by field stimulation (0.25-0.5 Hz).	Nitroarginine	19-26	neuropeptide Y	Rattus norvegicus	40-43
1282159-12	1992	Cycloheximide and nitro-L-arginine inhibited the relaxations and the production of nitrite evoked by interleukin-1 beta-treated cells.	Nitroarginine	18-34	interleukin 1 beta	Homo sapiens	101-119
1378360-9	1992	The effects of interleukin-1 beta were inhibited by nitro-L-arginine.	Nitroarginine	52-68	interleukin 1 beta	Rattus norvegicus	15-33
1510156-7	1992	In contrast to MB, NG-nitro-L-arginine, a putative inhibitor of EDRF synthesis, diminished vasodilation to BK in cyclooxygenase-inhibited lobes with elevated vascular tone.	Nitroarginine	19-38	kininogen 1	Canis lupus familiaris	107-109
1504743-8	1992	L-NOARG (30 microM) also augmented contractions of endothelium-intact tissues to noradrenaline, prostaglandin F2 alpha, and to a lesser degree endothelin-1.	Nitroarginine	0-7	endothelin-1	Oryctolagus cuniculus	143-155
1590434-5	1992	Finally, after preconstriction with U-46619, L-NNA abolished the pulmonary vasodilator response to bradykinin (1-10 micrograms.kg-1.min-1) but had no effect on the pulmonary vasodilator response to sodium nitroprusside (1-10 micrograms.kg-1.min-1).	Nitroarginine	45-50	kininogen 1	Canis lupus familiaris	99-109
1504748-10	1992	Selective inhibitors of NO synthase, NG-nitro-L-arginine (L-NOARG) and NG-monomethyl-L-arginine (L-NMMA) (both at 100 microM) attenuated the vasodilator response to ACh in control rats, but had no effect on the vasodilator response to CGRP.	Nitroarginine	37-56	calcitonin-related polypeptide alpha	Rattus norvegicus	235-239
1504748-10	1992	Selective inhibitors of NO synthase, NG-nitro-L-arginine (L-NOARG) and NG-monomethyl-L-arginine (L-NMMA) (both at 100 microM) attenuated the vasodilator response to ACh in control rats, but had no effect on the vasodilator response to CGRP.	Nitroarginine	58-65	calcitonin-related polypeptide alpha	Rattus norvegicus	235-239
1318793-4	1992	NG-Nitro-L-arginine (NLA), a nitric oxide synthase inhibitor, impaired relaxations to bradykinin.	Nitroarginine	0-19	kininogen 1	Canis lupus familiaris	86-96
1318793-4	1992	NG-Nitro-L-arginine (NLA), a nitric oxide synthase inhibitor, impaired relaxations to bradykinin.	Nitroarginine	21-24	kininogen 1	Canis lupus familiaris	86-96
1393268-14	1992	Administration of NO (present in acidified solution of NaNO2) induced concentration-dependent relaxations in trigonal preparations contracted by NA, carbachol, or ET-1.L-NOARG (10-5 M) and L-ARG (10-3M) had no effect on these relaxations.	Nitroarginine	168-175	endothelin-1	Sus scrofa	163-167
1379004-7	1992	Hindlimb vasodilator responses to PAF were reduced by N omega-nitro-L-arginine in a dose that blocked the response to acetylcholine but did not decrease responses to prostaglandin E1 or nitroprusside.	Nitroarginine	54-78	PCNA clamp associated factor	Homo sapiens	34-37
1376778-13	1992	Nitric oxide synthesis by IL-1-activated smooth muscle cells is inhibited by NAA, NMA, and N omega-nitro-L-arginine (NNA) with ED50 (i.e., effective dose for 50% inhibition) values of 20, 60, and 1000 microM, respectively; this rank order of inhibition is characteristic of an agonist-unregulated, inducible isoform of nitric oxide synthase.	Nitroarginine	91-115	interleukin 1 beta	Canis lupus familiaris	26-30
1376778-13	1992	Nitric oxide synthesis by IL-1-activated smooth muscle cells is inhibited by NAA, NMA, and N omega-nitro-L-arginine (NNA) with ED50 (i.e., effective dose for 50% inhibition) values of 20, 60, and 1000 microM, respectively; this rank order of inhibition is characteristic of an agonist-unregulated, inducible isoform of nitric oxide synthase.	Nitroarginine	117-120	interleukin 1 beta	Canis lupus familiaris	26-30
1363553-8	1992	14C-sucrose permeability was increased by 10(-7) M bradykinin and this effect was enhanced by the presence of each one of the following compounds: 10(-5) M methylene blue, 4 x 10(-6) M oxyhemoglobin, 5 x 10(-4) M NG-methyl-L-arginine or 5 x 10(-4) M N omega-nitro-L-arginine.	Nitroarginine	250-274	kininogen 1	Bos taurus	51-61
1601779-0	1992	Endothelin-1-induced pulmonary arterial dilation is reduced by N omega-nitro-L-arginine in fetal lambs.	Nitroarginine	63-87	EDN1	Ovis aries	0-12
1381781-8	1992	The inhibitory effect of IL-1 beta was endothelium and prostaglandin independent, but was prevented by a treatment with NG-nitro-L-arginine (a nitric oxide synthesis inhibitor), cycloheximide, dexamethasone, or IRA.	Nitroarginine	120-139	interleukin-1 beta	Oryctolagus cuniculus	25-34
1601779-6	1992	Addition of N omega-nitro-L-arginine (estimated perfusate concentration 2-6 mM), an analogue of L-arginine that inhibits the production of endothelium-derived relaxing factor (EDRF), significantly attenuated the dilator responses to acetylcholine (10 micrograms) and ET-1 (74 ng/kg) by 35 and 56%, respectively.	Nitroarginine	12-36	EDN1	Ovis aries	267-271
1351697-3	1992	We present evidence indicating that these BK-induced reflex phenomena are 1) mediated by the activation of B2 receptors; 2) potentiated by prostaglandin E2 (PGE2) and serotonin (5-HT) the latter acting via sub-type 5-HT3 receptors; 3) reduced by indomethacin and/or NG-nitroarginine, and 4) abolished by methylene blue.	Nitroarginine	266-282	kininogen 1	Canis lupus familiaris	42-44
1567454-5	1992	The decreases in [Ca2+]i and tension induced by ET-1 were inhibited by the mechanical removal of the endothelium or by pretreatment with NG-nitro-L-arginine and were slightly attenuated by indomethacin.	Nitroarginine	137-156	endothelin 1	Homo sapiens	48-52
1566853-2	1992	Field stimulation of gastric muscle strips was accompanied by frequency-dependent relaxation, vasoactive intestinal peptide (VIP) release, and NO production: the NO synthase inhibitor, NG-nitro-L-arginine (L-NNA) completely inhibited NO production and partly inhibited VIP release (52-54%) and relaxation (58-88%); inhibition of all three functions was reversed by L-arginine but not by D-arginine.	Nitroarginine	185-204	vasoactive intestinal peptide	Homo sapiens	125-128
1566853-2	1992	Field stimulation of gastric muscle strips was accompanied by frequency-dependent relaxation, vasoactive intestinal peptide (VIP) release, and NO production: the NO synthase inhibitor, NG-nitro-L-arginine (L-NNA) completely inhibited NO production and partly inhibited VIP release (52-54%) and relaxation (58-88%); inhibition of all three functions was reversed by L-arginine but not by D-arginine.	Nitroarginine	185-204	vasoactive intestinal peptide	Homo sapiens	269-272
1566853-2	1992	Field stimulation of gastric muscle strips was accompanied by frequency-dependent relaxation, vasoactive intestinal peptide (VIP) release, and NO production: the NO synthase inhibitor, NG-nitro-L-arginine (L-NNA) completely inhibited NO production and partly inhibited VIP release (52-54%) and relaxation (58-88%); inhibition of all three functions was reversed by L-arginine but not by D-arginine.	Nitroarginine	206-211	vasoactive intestinal peptide	Homo sapiens	269-272
1560371-0	1992	Pressor and renal vasoconstrictor effects of NG-nitro-L-arginine as affected by blockade of pressor mechanisms mediated by the sympathetic nervous system, angiotensin, prostanoids and vasopressin.	Nitroarginine	45-64	arginine vasopressin	Rattus norvegicus	184-195
1311716-10	1992	When cultures of M-1 and CPAE cells were treated with N-Arg and challenged with Bk, Bk"s effect on cGMP was partially blocked (61.4 +/- 12 fmol/10(-6) M-1 cells; NS).	Nitroarginine	54-59	kininogen 1	Bos taurus	84-86
1374468-2	1992	The endothelium-dependent relaxations evoked by acetylcholine, ATP and the calcium ionophore A23187 (which are mediated by the constitutive nitric oxide synthase) were inhibited by calmodulin inhibitors [calmidazolium, W-7 and (N-(6-aminohexyl)-5-chloro-1-naphthalene-sulfonamide, hydrochloride, fendiline] and by an inhibitor of nitric oxide synthase, nitro L-arginine.	Nitroarginine	353-369	calmodulin 1	Rattus norvegicus	181-191
1374468-8	1992	The production of cyclic GMP evoked by interleukin-1 beta in rings without endothelium was inhibited by nitro L-arginine but not by calmidazolium.	Nitroarginine	104-120	interleukin 1 beta	Rattus norvegicus	39-57
1516274-11	1992	Perfusion with N-nitro-L-arginine (NOLA; 10 mumol/L) had no effect on basal perfusion pressures, but potentiated responses to ET-1 in both groups of kidneys.	Nitroarginine	15-33	endothelin 1	Rattus norvegicus	126-130
1516274-11	1992	Perfusion with N-nitro-L-arginine (NOLA; 10 mumol/L) had no effect on basal perfusion pressures, but potentiated responses to ET-1 in both groups of kidneys.	Nitroarginine	35-39	endothelin 1	Rattus norvegicus	126-130
1516274-12	1992	However, the difference in responses to ET-1 between kidneys from diabetic and non-diabetic rats remained significant in the presence of NOLA.	Nitroarginine	137-141	endothelin 1	Rattus norvegicus	40-44
1522509-5	1992	NOLA (30 mg kg-1 bolus followed by 1 mg kg-1 min-1 infusion) caused an approximately 40 mmHg elevation in the mean arterial blood pressure, a regionally heterogenous increase of the regional cerebrovascular resistance and a decrease in the regional cerebral blood flow 15 and 40 min after the start of its administration.	Nitroarginine	0-4	CD59 molecule (CD59 blood group)	Homo sapiens	45-50
1555637-2	1992	The endothelium-dependent vasorelaxation induced by acetylcholine and CGRP was inhibited by NG-monomethyl-L-arginine (L-NMMA) and NG-nitro-L-arginine (L-NOARG) in a concentration-related fashion.	Nitroarginine	130-149	calcitonin-related polypeptide alpha	Rattus norvegicus	70-74
1555637-2	1992	The endothelium-dependent vasorelaxation induced by acetylcholine and CGRP was inhibited by NG-monomethyl-L-arginine (L-NMMA) and NG-nitro-L-arginine (L-NOARG) in a concentration-related fashion.	Nitroarginine	151-158	calcitonin-related polypeptide alpha	Rattus norvegicus	70-74
1334347-6	1992	The BK"s suppression of the ET-1-induced vasoconstriction was partly reversed by additions of each 10(-5) of Ng-nitro-L-arginine, a substrate inhibitor of nitric oxide, methylene blue, an inhibitor of soluble guanylate cyclase, or indomethacin, an inhibitor of cyclooxygenase.	Nitroarginine	109-128	kininogen 1	Canis lupus familiaris	4-6
1334347-6	1992	The BK"s suppression of the ET-1-induced vasoconstriction was partly reversed by additions of each 10(-5) of Ng-nitro-L-arginine, a substrate inhibitor of nitric oxide, methylene blue, an inhibitor of soluble guanylate cyclase, or indomethacin, an inhibitor of cyclooxygenase.	Nitroarginine	109-128	endothelin 1	Canis lupus familiaris	28-32
1733199-5	1992	RESULTS: Both N-monomethyl-L-arginine and N-nitro-L-arginine (3 x 10(-4) mol/L) increased resting perfusion pressure (p less than 0.06), and N-nitro-L-arginine promptly and significantly increased perfusion pressure in the fetal-placental circulation preconstricted with U46619 (p less than 0.0004) or endothelin-1 (p less than 0.06).	Nitroarginine	42-60	endothelin 1	Homo sapiens	302-314
1282939-0	1992	Bradykinin-induced, N omega-nitro-L-arginine-insensitive endothelium-dependent relaxation of porcine coronary arteries is not mediated by bioassayable relaxing substances.	Nitroarginine	20-44	kininogen 1	Homo sapiens	0-10
1309423-3	1992	This effect was potentiated by superoxide dismutase and reversed by treating EC with NG-nitro-L-arginine or by treating platelets with methylene blue, indicating that the inhibition of platelet aggregation was due to the release of EDRF by EC.	Nitroarginine	85-104	alpha hemoglobin stabilizing protein	Homo sapiens	232-236
1733256-9	1992	Interestingly, the fall in the IAS tension caused by vasoactive intestinal polypeptide (VIP) (an inhibitory neurotransmitter in the IAS) was also inhibited by L-NNA (3 x 10(-5) M).	Nitroarginine	159-164	vasoactive intestinal peptide	Homo sapiens	53-86
1733256-9	1992	Interestingly, the fall in the IAS tension caused by vasoactive intestinal polypeptide (VIP) (an inhibitory neurotransmitter in the IAS) was also inhibited by L-NNA (3 x 10(-5) M).	Nitroarginine	159-164	vasoactive intestinal peptide	Homo sapiens	88-91
1282631-5	1992	In endothelium-intact bovine coronary arteries, moexiprilat (0.3 microM), like bradykinin (30 nM), caused a nearly twofold increase in the vascular cGMP content which was abolished by both NG-nitro-L-arginine (30 microM) and removal of the endothelium.	Nitroarginine	189-208	kininogen 1	Bos taurus	79-89
1282939-1	1992	The effect of the arginine analogue, N omega-nitro-L-arginine (L-NNA) was studied on bradykinin-induced relaxation in porcine coronary arteries.	Nitroarginine	37-61	kininogen 1	Homo sapiens	85-95
1501139-6	1992	The threshold concentration of bradykinin was the same for the nitro-L-arginine-resistant relaxations and the membrane hyperpolarization.	Nitroarginine	63-79	kininogen 1	Homo sapiens	31-41
1501139-8	1992	Nitro-L-arginine-resistant relaxations were evoked by several agents (A23187, thrombin and UK 14304) in addition to bradykinin.	Nitroarginine	0-16	coagulation factor II, thrombin	Homo sapiens	78-86
1501139-8	1992	Nitro-L-arginine-resistant relaxations were evoked by several agents (A23187, thrombin and UK 14304) in addition to bradykinin.	Nitroarginine	0-16	kininogen 1	Homo sapiens	116-126
1501139-11	1992	Thrombin caused more transient relaxations and hyperpolarizations than bradykinin in the presence of nitro-L-arginine.	Nitroarginine	101-117	coagulation factor II, thrombin	Homo sapiens	0-8
1501139-11	1992	Thrombin caused more transient relaxations and hyperpolarizations than bradykinin in the presence of nitro-L-arginine.	Nitroarginine	101-117	kininogen 1	Homo sapiens	71-81
1507574-0	1992	Effect of L-NG-nitro-arginine (L-NOARG) on the relaxation induced by gamma-aminobutyric acid (GABA) and vasoactive intestinal peptide (VIP) in rat isolated duodenum.	Nitroarginine	10-29	vasoactive intestinal peptide	Rattus norvegicus	135-138
1507574-0	1992	Effect of L-NG-nitro-arginine (L-NOARG) on the relaxation induced by gamma-aminobutyric acid (GABA) and vasoactive intestinal peptide (VIP) in rat isolated duodenum.	Nitroarginine	31-38	vasoactive intestinal peptide	Rattus norvegicus	135-138
1738296-4	1992	The ET-1- and ET-3- induced vasorelaxation was blocked by NG-nitro-L-arginine, an inhibitor of nitric oxide synthesis, and methylene blue, an inhibitor of soluble guanylate cyclase.	Nitroarginine	58-77	endothelin 1	Homo sapiens	4-8
1738296-4	1992	The ET-1- and ET-3- induced vasorelaxation was blocked by NG-nitro-L-arginine, an inhibitor of nitric oxide synthesis, and methylene blue, an inhibitor of soluble guanylate cyclase.	Nitroarginine	58-77	endothelin 3	Homo sapiens	14-18
1282939-1	1992	The effect of the arginine analogue, N omega-nitro-L-arginine (L-NNA) was studied on bradykinin-induced relaxation in porcine coronary arteries.	Nitroarginine	63-68	kininogen 1	Homo sapiens	85-95
1282939-3	1992	In contrast to the findings in organ chamber experiments, bradykinin-induced release of endothelium-derived relaxing factor(s) (EDRFs) was abolished after 45 min of treatment of perfused porcine coronary artery segments with L-NNA (10(-4) M) in a superfusion bioassay system.	Nitroarginine	225-230	kininogen 1	Homo sapiens	58-68
1282939-4	1992	These results show that, in addition to the release of nitric oxide, endothelium-dependent relaxation of porcine coronary arteries to bradykinin involves an alternative mechanism(s), which accounts for the relaxation in the presence of L-NNA.	Nitroarginine	236-241	kininogen 1	Homo sapiens	134-144
1656767-5	1991	TNF-alpha-stimulated endothelium-dependent increases in reporter monolayer cGMP content were first evident at 8 h and maximal at 16-24 h. In addition, TNF-alpha-stimulated endothelium-dependent increases in reporter monolayer cGMP content were abrogated by hemoglobin and methylene blue, blunted by N omega-nitro-L-arginine and augmented by superoxide dismutase and the calcium agonist bradykinin.	Nitroarginine	299-323	tumor necrosis factor	Bos taurus	0-9
1661096-4	1991	This effect was potentiated by superoxide dismutase and reversed by incubating the IL-1 beta-treated smooth muscle cells with NG-nitro-L-arginine (L-NNA) or by treating the platelets with methylene blue.	Nitroarginine	126-145	interleukin 1 beta	Rattus norvegicus	83-92
1661096-4	1991	This effect was potentiated by superoxide dismutase and reversed by incubating the IL-1 beta-treated smooth muscle cells with NG-nitro-L-arginine (L-NNA) or by treating the platelets with methylene blue.	Nitroarginine	147-152	interleukin 1 beta	Rattus norvegicus	83-92
1661096-7	1991	The elevation of platelet cGMP induced by the IL-1 beta-treated smooth muscle cells was prevented by exposing the cytokine-treated cells to L-NNA or by treating platelets with methylene blue.	Nitroarginine	140-145	interleukin 1 beta	Rattus norvegicus	46-55
1661096-8	1991	Treatment of smooth muscle cells with IL-1 beta also resulted in an eightfold increase in nitrite production, which was blocked when the cells were incubated with L-NNA.	Nitroarginine	163-168	interleukin 1 beta	Rattus norvegicus	38-47
1662272-3	1991	L-Arginine derivatives, NG-methyl-L-arginine and NG-nitro-L-arginine also inhibited cyclic GMP responses to 10(-8) M ET-1 with IC50 values of 1.2 x 10(-6) M and 7.6 x 10(-8) M, respectively, and the inhibition was prevented with L-arginine.	Nitroarginine	49-68	endothelin-1	Sus scrofa	117-121
1723050-5	1991	In contrast, the vasoconstrictor effects of noradrenaline (NA), angiotensin II (ATII), NKB and [MePhe7]NKB on the venous side of the circulation were enhanced following treatment with L-NNA, methylene blue or CHAPS.	Nitroarginine	184-189	angiotensinogen	Rattus norvegicus	64-78
1723050-5	1991	In contrast, the vasoconstrictor effects of noradrenaline (NA), angiotensin II (ATII), NKB and [MePhe7]NKB on the venous side of the circulation were enhanced following treatment with L-NNA, methylene blue or CHAPS.	Nitroarginine	184-189	tachykinin precursor 3	Rattus norvegicus	87-90
1723050-5	1991	In contrast, the vasoconstrictor effects of noradrenaline (NA), angiotensin II (ATII), NKB and [MePhe7]NKB on the venous side of the circulation were enhanced following treatment with L-NNA, methylene blue or CHAPS.	Nitroarginine	184-189	tachykinin precursor 3	Rattus norvegicus	103-106
1659406-2	1991	In the presence of nitro-L-arginine (100 microM), an inhibitor of NO synthase, the stimulatory effect of bradykinin on L-arginine uptake was partially inhibited while NO release was completely abolished.	Nitroarginine	19-35	kininogen 1	Homo sapiens	105-115
1762073-3	1991	In dogs given LNNA (75 micrograms/kg/min for 25 min), the RBF decreased after intrarenal administration of ET-3 (5 ng/kg/min).	Nitroarginine	14-18	endothelin 3	Canis lupus familiaris	107-111
1655653-5	1991	The ramiprilat-induced cyclic GMP increase was completely abolished by the stereospecific inhibitor of nitric oxide synthase, NG-nitro-L-arginine.	Nitroarginine	126-145	5'-nucleotidase, cytosolic II	Homo sapiens	30-33
1656767-5	1991	TNF-alpha-stimulated endothelium-dependent increases in reporter monolayer cGMP content were first evident at 8 h and maximal at 16-24 h. In addition, TNF-alpha-stimulated endothelium-dependent increases in reporter monolayer cGMP content were abrogated by hemoglobin and methylene blue, blunted by N omega-nitro-L-arginine and augmented by superoxide dismutase and the calcium agonist bradykinin.	Nitroarginine	299-323	tumor necrosis factor	Bos taurus	151-160
1652336-7	1991	NG-nitro-L-arginine (L-NNA), a stereospecific inhibitor of NO-biosynthesis, inhibited the relaxations induced by electrical stimulation but not those by exogenous NO or vasoactive intestinal polypeptide (VIP).	Nitroarginine	21-26	vasoactive intestinal peptide	Canis lupus familiaris	204-207
1991651-5	1991	The action of EDRF was abolished by oxyhemoglobin and methylene blue, and the generation of EDRF in response to shear stress was markedly inhibited or abolished by NG-nitro-L-arginine, by NG-amino-L-arginine, by calcium-free extracellular medium, and by depleting endothelial cells of endogenous L-arginine.	Nitroarginine	164-183	alpha hemoglobin stabilizing protein	Homo sapiens	92-96
1649992-6	1991	Similarly, an increase in the basal coronary perfusion pressure by endothelin-1 (0.3 nM) to the same level as observed with L-NNA did not alter the vasomotor responses to ACh and sodium nitroprusside.	Nitroarginine	124-129	endothelin-1	Oryctolagus cuniculus	67-79
1742764-7	1991	The effects of EDRF were studied by either inactivation with haemoglobin or inhibition of EDRF synthesis with N-omega-nitro-L-arginine.	Nitroarginine	110-134	alpha hemoglobin stabilizing protein	Homo sapiens	90-94
1742764-8	1991	Preconstricted microvessels exposed to either N-omega-nitro-L-arginine or haemoglobin constricted further, consistent with basal release of EDRF.	Nitroarginine	46-70	alpha hemoglobin stabilizing protein	Homo sapiens	140-144
1847208-4	1991	The synthesis of this substance could be stimulated with bradykinin (10 nM) or Ca++ ionophore A23187 (1 microM) and was completely prevented by treatment of the BAE cells with the EDRF/NO synthesis inhibitors NG-nitro-L-arginine (100 microM) or NG-methyl-L-arginine (1 mM).	Nitroarginine	209-228	kininogen 1	Bos taurus	57-67
1646060-5	1991	Pretreatment of the cells with the EDRF inhibitors haemoglobin (1 microM) or L-NG-nitro arginine (50 microM) significantly reduced the cyclic GMP response to thrombin.	Nitroarginine	77-96	coagulation factor II, thrombin	Sus scrofa	158-166
1646060-7	1991	The IP3 response to thrombin was significantly enhanced at all time points by haemoglobin and at 5 min for L-NG-nitro arginine, when compared with the response to thrombin alone.	Nitroarginine	107-126	coagulation factor II, thrombin	Sus scrofa	20-28
1991487-4	1991	We thus investigated if NGmonomethyl-L-arginine and N omega-nitro-L-arginine, two specific inhibitors of inorganic nitrogen oxide synthesis from L-arginine, were able to affect the inhibitory effect of TNF and/or IL 6 in co-cultures.	Nitroarginine	52-76	tumor necrosis factor	Homo sapiens	202-205
2155150-6	1990	The production of the EDRF-like activity was inhibited by the L-arginine analogs, NG-monomethyl-L-arginine and NG-nitro-L-arginine, with apparent Ki values of 1.0 and 0.3 microM, respectively.	Nitroarginine	111-130	alpha hemoglobin stabilizing protein	Mus musculus	22-26
1761183-0	1991	Effect of bradykinin antagonists, NG-monomethyl-L-arginine and L-NG-nitro arginine on phospholipase A2 induced oedema in rat paw.	Nitroarginine	63-82	phospholipase A2 group IB	Rattus norvegicus	86-102
1725372-0	1991	Effects of NG-nitro-L-arginine on renal hemodynamic responses to endothelin-3 in anesthetized dogs.	Nitroarginine	11-30	endothelin 3	Canis lupus familiaris	65-77
1725372-1	1991	The effects of NG-nitro-L-arginine (L-NNA), a nitric oxide (NO) synthase inhibitor, on renal vascular response to endothelin-3 (ET-3) were studied in anesthetized dogs.	Nitroarginine	36-41	endothelin 3	Canis lupus familiaris	114-126
1725372-1	1991	The effects of NG-nitro-L-arginine (L-NNA), a nitric oxide (NO) synthase inhibitor, on renal vascular response to endothelin-3 (ET-3) were studied in anesthetized dogs.	Nitroarginine	36-41	endothelin 3	Canis lupus familiaris	128-132
1725372-4	1991	Marked attenuation of the renal vasodilatory response to ET-3 was observed following the administration of L-NNA (75 micrograms/kg/min i.r.a.	Nitroarginine	107-112	endothelin 3	Canis lupus familiaris	57-61
1725372-11	1991	Pretreatment with L-NNA abolished the ET-3-induced renal vasodilation.	Nitroarginine	18-23	endothelin 3	Canis lupus familiaris	38-42
1725372-12	1991	RBF decreased immediately after the start of ET-3 infusion into animals treated with L-NNA.	Nitroarginine	85-90	endothelin 3	Canis lupus familiaris	45-49
1725333-0	1991	Endothelin modulates L-NG-nitroarginine-induced enhancement of vasoconstriction evoked by norepinephrine.	Nitroarginine	21-39	endothelin 1	Rattus norvegicus	0-10
1725333-1	1991	The interaction of endothelin-1 (ET-1), a novel vasoconstrictor peptide synthesized according to the encoded amino acid sequence, with L-NG-nitroarginine (NOARG), an L-arginine-reversible inhibitor of endothelium-derived relaxing factor (EDRF) on adrenergic receptors, was investigated.	Nitroarginine	135-153	endothelin 1	Rattus norvegicus	19-31
1725333-1	1991	The interaction of endothelin-1 (ET-1), a novel vasoconstrictor peptide synthesized according to the encoded amino acid sequence, with L-NG-nitroarginine (NOARG), an L-arginine-reversible inhibitor of endothelium-derived relaxing factor (EDRF) on adrenergic receptors, was investigated.	Nitroarginine	135-153	endothelin 1	Rattus norvegicus	33-37
1725333-1	1991	The interaction of endothelin-1 (ET-1), a novel vasoconstrictor peptide synthesized according to the encoded amino acid sequence, with L-NG-nitroarginine (NOARG), an L-arginine-reversible inhibitor of endothelium-derived relaxing factor (EDRF) on adrenergic receptors, was investigated.	Nitroarginine	155-160	endothelin 1	Rattus norvegicus	19-31
1725333-1	1991	The interaction of endothelin-1 (ET-1), a novel vasoconstrictor peptide synthesized according to the encoded amino acid sequence, with L-NG-nitroarginine (NOARG), an L-arginine-reversible inhibitor of endothelium-derived relaxing factor (EDRF) on adrenergic receptors, was investigated.	Nitroarginine	155-160	endothelin 1	Rattus norvegicus	33-37
1725333-6	1991	Simultaneous NOARG (10(-5) M) infusion with ET-1 (10(-11) M) into the mesenteric arteries caused further enhancement of the pressor responses to exogenous norepinephrine (200 ng) without affecting the baseline perfusion pressure: 126 +/- 15% to 262 +/- 45% (p less than 0.05, vehicle control: 100%).	Nitroarginine	13-18	endothelin 1	Rattus norvegicus	44-48
34365445-2	2021	In the given study a non-selective NOS inhibitor - N-nitro-L-arginine; a highly selective inhibitor of neuronal NOS - N-propyl-L-arginine and a highly selective competitive inhibitor of inducible NOS - (S)-methylurea were used.	Nitroarginine	49-69	nitric oxide synthase 1	Homo sapiens	103-115
35605060-10	2022	Coadministration of MK-801 and L-NNA at subeffective doses not only decreases the expression of GFAP, but also regulates the oxidative stress imbalance CONCLUSION: Based on these results, it could be hypothesized that blockage of NO/NMDAR pathway might be a novel treatment for PTSD-like behavior in animals by inhibiting the astrocyte and regulating oxidative stress level.	Nitroarginine	31-36	glial fibrillary acidic protein	Mus musculus	96-100
35605060-10	2022	Coadministration of MK-801 and L-NNA at subeffective doses not only decreases the expression of GFAP, but also regulates the oxidative stress imbalance CONCLUSION: Based on these results, it could be hypothesized that blockage of NO/NMDAR pathway might be a novel treatment for PTSD-like behavior in animals by inhibiting the astrocyte and regulating oxidative stress level.	Nitroarginine	31-36	glutamate receptor, ionotropic, NMDA1 (zeta 1)	Mus musculus	233-238
33603336-8	2021	TTX did not block the inhibitory effect of EVO on spontaneous colon contractions, while L-NNA, a selective nNOS synthase inhibitor, did partially abolish this inhibitory effect.	Nitroarginine	88-93	nitric oxide synthase 1	Rattus norvegicus	107-111
35380411-6	2022	Relaxation was partially blocked by the addition of the eNOS blocker Nomega-nitro-L-arginine, or the large conductance potassium channel blocker paxilline.	Nitroarginine	69-92	nitric oxide synthase 3	Homo sapiens	56-60
35328344-5	2022	Active nNOS was also required for Grp94-induced cytoprotection, since its inhibition by L-NNA disrupted the co-immunoprecipitation and co-fractionation of Grp94 with nNOS and SERCA2, and increased apoptosis.	Nitroarginine	88-93	nitric oxide synthase 1, neuronal	Mus musculus	7-11
35328344-5	2022	Active nNOS was also required for Grp94-induced cytoprotection, since its inhibition by L-NNA disrupted the co-immunoprecipitation and co-fractionation of Grp94 with nNOS and SERCA2, and increased apoptosis.	Nitroarginine	88-93	heat shock protein 90, beta (Grp94), member 1	Mus musculus	34-39
35328344-5	2022	Active nNOS was also required for Grp94-induced cytoprotection, since its inhibition by L-NNA disrupted the co-immunoprecipitation and co-fractionation of Grp94 with nNOS and SERCA2, and increased apoptosis.	Nitroarginine	88-93	heat shock protein 90, beta (Grp94), member 1	Mus musculus	155-160
35328344-5	2022	Active nNOS was also required for Grp94-induced cytoprotection, since its inhibition by L-NNA disrupted the co-immunoprecipitation and co-fractionation of Grp94 with nNOS and SERCA2, and increased apoptosis.	Nitroarginine	88-93	nitric oxide synthase 1, neuronal	Mus musculus	166-170
35328344-5	2022	Active nNOS was also required for Grp94-induced cytoprotection, since its inhibition by L-NNA disrupted the co-immunoprecipitation and co-fractionation of Grp94 with nNOS and SERCA2, and increased apoptosis.	Nitroarginine	88-93	ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	Mus musculus	175-181
2634248-3	1989	N omega-Nitro-L-arginine and NG-monomethyl-L-arginine, two inhibitors of EDRF synthesis, markedly attenuated the relaxations.	Nitroarginine	0-24	alpha hemoglobin stabilizing protein	Mus musculus	73-77
33662571-8	2021	Inhibition of iNOS by Nomega-nitro-L-arginine however led to a massive lipid peroxidation upon exposure to pro-inflammatory cytokines.	Nitroarginine	22-45	nitric oxide synthase 2	Rattus norvegicus	14-18
34021781-8	2021	L-NNA, an NO synthase (NOS) inhibitor, increased the ET-1-induced contractions in both the control and indoxyl sulfate groups, whereas L-NPA (10-6 M), a specific neuronal NOS inhibitor, did not affect the ET-1-induced contraction in both groups.	Nitroarginine	0-5	endothelin 1	Rattus norvegicus	53-57
34021781-8	2021	L-NNA, an NO synthase (NOS) inhibitor, increased the ET-1-induced contractions in both the control and indoxyl sulfate groups, whereas L-NPA (10-6 M), a specific neuronal NOS inhibitor, did not affect the ET-1-induced contraction in both groups.	Nitroarginine	0-5	endothelin 1	Rattus norvegicus	205-209
33643042-7	2020	In mouse coronary arteries, pirfenidone relaxation was inhibited in the presence of a nitric oxide (NO) synthase inhibitor, NG-nitro-l-arginine (L-NOARG), a blocker of large-conductance calcium-activated potassium channels (BKCa), iberiotoxin, and a blocker of KV7 channels, XE991.	Nitroarginine	124-143	potassium large conductance calcium-activated channel, subfamily M, alpha member 1	Mus musculus	224-228
32542595-10	2020	ErbB4 overexpression in GABAergic neurons promoted neurite outgrowth, an effect that was potentiated by Nrg treatment.	Nitroarginine	104-107	erb-b2 receptor tyrosine kinase 4	Rattus norvegicus	0-5
33203296-5	2021	The nitric oxide synthase (NOS) inhibitor Nomega-nitro-L-arginine abolished rCBF response to diazoxide suggesting NO was involved in the mediation of vasorelaxation.	Nitroarginine	42-65	nitric oxide synthase 1, neuronal	Mus musculus	4-25
32343709-9	2020	Treatment of A53T alpha-syn transgenic mice with Nomega-Nitro-L-arginine (L-NNA) significantly reduced the S-nitrosylation of GRK6 and CK2alpha in the brain.	Nitroarginine	49-72	synuclein, alpha	Mus musculus	18-27
32343709-9	2020	Treatment of A53T alpha-syn transgenic mice with Nomega-Nitro-L-arginine (L-NNA) significantly reduced the S-nitrosylation of GRK6 and CK2alpha in the brain.	Nitroarginine	49-72	G protein-coupled receptor kinase 6	Mus musculus	126-130
32343709-9	2020	Treatment of A53T alpha-syn transgenic mice with Nomega-Nitro-L-arginine (L-NNA) significantly reduced the S-nitrosylation of GRK6 and CK2alpha in the brain.	Nitroarginine	74-79	synuclein, alpha	Mus musculus	18-27
32343709-9	2020	Treatment of A53T alpha-syn transgenic mice with Nomega-Nitro-L-arginine (L-NNA) significantly reduced the S-nitrosylation of GRK6 and CK2alpha in the brain.	Nitroarginine	74-79	G protein-coupled receptor kinase 6	Mus musculus	126-130
30886586-9	2019	By contrast, neither diabetes nor tocomin treatment influenced EDH-type relaxation as, in the presence of L-NNA, an inhibitor of eNOS, and ODQ, to inhibit soluble guanylate cyclase, responses to ACh were similar in all treatment groups.	Nitroarginine	106-111	nitric oxide synthase 3	Rattus norvegicus	129-133
31252063-0	2019	N -nitro-l-arginine methyl model of pre-eclampsia elicits differential IBA1 and EAAT1 expressions in brain.	Nitroarginine	0-19	allograft inflammatory factor 1	Rattus norvegicus	71-75
31252063-0	2019	N -nitro-l-arginine methyl model of pre-eclampsia elicits differential IBA1 and EAAT1 expressions in brain.	Nitroarginine	0-19	solute carrier family 1 member 3	Rattus norvegicus	80-85
31349085-3	2019	Inhibition of nitric oxide synthase (NOS) with Nomega-nitro-L-arginine (L-NAME) potentiates vasoconstriction by phenylephrine and the trace amine, beta-phenylethylamine (PEA), indicating underlying opposing vasodilatation.	Nitroarginine	47-70	nitric oxide synthase, inducible	Cavia porcellus	14-35
30947567-5	2019	At the same time, high dose silibinin increased NO levels in A431 cells and the endothelial nitric oxide synthase (eNOS) inhibitor NG-nitro-L-arginine methylester (L-NAME) attenuated silibinin-induced cell growth inhibition.	Nitroarginine	131-150	nitric oxide synthase 3	Homo sapiens	80-113
31230218-6	2020	Moreover, the role of endothelial nitric oxide synthase (eNOS) was confirmed by coadministration of nitro-omega-L-arginine (L-NNA) (25 mg/kg/day) for 5 days.	Nitroarginine	124-129	nitric oxide synthase 3	Homo sapiens	57-61
31286027-6	2019	Enhanced angiogenesis was NO-mediated, as addition of the NO synthase (NOS) inhibitor L-NNA to the culture media abolished differences in tubule formation across conditions (0 wk: 71.3 +- 1.8 mm, Acute HT: 71.6 +- 1.9 mm, 8 wk: 70.5 +- 1.6 mm, p = 0.69).	Nitroarginine	86-91	nitric oxide synthase 2	Homo sapiens	58-69
30867452-5	2019	Ano1 antagonists, benzbromarone and Ani9 inhibited the effects of TTX, L-NNA and ODQ.	Nitroarginine	71-76	anoctamin 1, calcium activated chloride channel	Mus musculus	0-4
30867452-6	2019	Ano1 channels are activated by Ca2+ release from the endoplasmic reticulum (ER) in ICC, and blocking Ca2+ release with a SERCA inhibitor (thapsigargin) or a store-operated Ca2+ entry blocker (GSK 7975 A) reversed the effects of TTX, L-NNA and ODQ.	Nitroarginine	233-238	anoctamin 1, calcium activated chloride channel	Mus musculus	0-4
30508636-8	2019	The effect of GLP-1(7-36) amide was partly inhibited by the neuronal blocker tetrodotoxin and nitric oxide (NO) synthase inhibitor l-NNA suggesting both NO-dependent neural and NO-independent direct effects on smooth muscle.	Nitroarginine	131-136	glucagon	Mus musculus	14-19
29773582-6	2018	In isolated endothelial cells, apelin caused an increase in 4,5-diaminofluorescein fluorescence that was abolished by nitro-l-arginine (NLA) and F13A (H-Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Ala-OH), an APJ receptor antagonist, consistent with increased nitric oxide (NO) production.	Nitroarginine	118-134	apelin	Rattus norvegicus	31-37
30254407-9	2018	The effects of ADPN were no longer observed in the presence of the nitric oxide (NO) synthesis inhibitor L-NG-nitro arginine (L-NNA) (P > 0.05).	Nitroarginine	105-124	adiponectin, C1Q and collagen domain containing	Mus musculus	15-19
30254407-9	2018	The effects of ADPN were no longer observed in the presence of the nitric oxide (NO) synthesis inhibitor L-NG-nitro arginine (L-NNA) (P > 0.05).	Nitroarginine	126-131	adiponectin, C1Q and collagen domain containing	Mus musculus	15-19
29655978-15	2018	The protective effect of sitagliptin was abrogated by coadministartion of L-NNA, a selective inhibitor of both endothelial NOS (eNOS) and neuronal NOS (nNOS).	Nitroarginine	74-79	nitric oxide synthase 3	Rattus norvegicus	111-126
29655978-15	2018	The protective effect of sitagliptin was abrogated by coadministartion of L-NNA, a selective inhibitor of both endothelial NOS (eNOS) and neuronal NOS (nNOS).	Nitroarginine	74-79	nitric oxide synthase 1	Rattus norvegicus	138-150
29655978-15	2018	The protective effect of sitagliptin was abrogated by coadministartion of L-NNA, a selective inhibitor of both endothelial NOS (eNOS) and neuronal NOS (nNOS).	Nitroarginine	74-79	nitric oxide synthase 1	Rattus norvegicus	152-156
29380056-7	2018	In the presence of L-NNA and indomethacin, TRPV4 blockade attenuated ACh-induced vasodilation in arteries from CH rats.	Nitroarginine	19-24	transient receptor potential cation channel, subfamily V, member 4	Rattus norvegicus	43-48
28856444-6	2018	Curcumin downregulated Cdx-2 and Hif-1alpha mRNA expression and upregulated HO-1 and SOD 2, and these effects were reversed by L-NNA and further restored by co-treatment of L-NNA with L-arginine.	Nitroarginine	127-132	heme oxygenase 1	Rattus norvegicus	76-80
28856444-6	2018	Curcumin downregulated Cdx-2 and Hif-1alpha mRNA expression and upregulated HO-1 and SOD 2, and these effects were reversed by L-NNA and further restored by co-treatment of L-NNA with L-arginine.	Nitroarginine	127-132	superoxide dismutase 2	Rattus norvegicus	85-90
28856444-6	2018	Curcumin downregulated Cdx-2 and Hif-1alpha mRNA expression and upregulated HO-1 and SOD 2, and these effects were reversed by L-NNA and further restored by co-treatment of L-NNA with L-arginine.	Nitroarginine	173-178	caudal type homeo box 2	Rattus norvegicus	23-28
28856444-6	2018	Curcumin downregulated Cdx-2 and Hif-1alpha mRNA expression and upregulated HO-1 and SOD 2, and these effects were reversed by L-NNA and further restored by co-treatment of L-NNA with L-arginine.	Nitroarginine	173-178	hypoxia inducible factor 1 subunit alpha	Rattus norvegicus	33-43
28856444-6	2018	Curcumin downregulated Cdx-2 and Hif-1alpha mRNA expression and upregulated HO-1 and SOD 2, and these effects were reversed by L-NNA and further restored by co-treatment of L-NNA with L-arginine.	Nitroarginine	173-178	heme oxygenase 1	Rattus norvegicus	76-80
28856444-6	2018	Curcumin downregulated Cdx-2 and Hif-1alpha mRNA expression and upregulated HO-1 and SOD 2, and these effects were reversed by L-NNA and further restored by co-treatment of L-NNA with L-arginine.	Nitroarginine	173-178	superoxide dismutase 2	Rattus norvegicus	85-90
26846374-13	2016	A high dose of ET-1 (400 nm) co-infused with l-NNA further attenuated CVC during 0.25, 5 and 100 mm MCh administration relative to the ET-1 site (all P < 0.05).	Nitroarginine	45-50	endothelin 1	Homo sapiens	15-19
28899928-5	2017	Murine hypertension models, induced by high-salt diet, N(G)-nitro-l-arginine intake, or angiotensin II delivery, showed decreased TRPV4-KCa2.3 interaction in ECs.	Nitroarginine	55-76	transient receptor potential cation channel, subfamily V, member 4	Mus musculus	130-135
28899928-5	2017	Murine hypertension models, induced by high-salt diet, N(G)-nitro-l-arginine intake, or angiotensin II delivery, showed decreased TRPV4-KCa2.3 interaction in ECs.	Nitroarginine	55-76	potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3	Mus musculus	136-142
28966669-6	2017	Sal B reversed the inhibitory effect of N-nitro L-arginine methylester on the MSCs and increased ALP activity, OCN content and the OPG/RANKL ratio.	Nitroarginine	40-58	TNF receptor superfamily member 11B	Rattus norvegicus	131-134
28966669-6	2017	Sal B reversed the inhibitory effect of N-nitro L-arginine methylester on the MSCs and increased ALP activity, OCN content and the OPG/RANKL ratio.	Nitroarginine	40-58	TNF superfamily member 11	Rattus norvegicus	135-140
28656320-11	2017	Pretreatment with Nomega-nitro-L-arginine (L-NAME), an NO synthase inhibitor, significantly enhanced Ang II-induced contraction and Y27632-induced relaxation in the control basilar arteries but not in the STZ-induced diabetic mice arteries.	Nitroarginine	18-41	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	101-107
28324019-7	2017	We also found that l-arginine upregulated GLUT-1/GLUT-4 expression and translocation, which were related to increased glucose uptake; however, these responses were significantly blocked by N(G)-nitro-l-arginine methylester.	Nitroarginine	189-210	solute carrier family 2 member 1	Rattus norvegicus	42-48
28324019-7	2017	We also found that l-arginine upregulated GLUT-1/GLUT-4 expression and translocation, which were related to increased glucose uptake; however, these responses were significantly blocked by N(G)-nitro-l-arginine methylester.	Nitroarginine	189-210	solute carrier family 2 member 4	Rattus norvegicus	49-55
28334039-6	2017	Finally, the effects of sodium nitroprusside (SNP, a NO donor) and Nomega-nitro-L-arginine (NNA, an iNOS inhibitor) on IL-1beta-mediated NF-kappaB-activation were examined.	Nitroarginine	67-90	interleukin 1 beta	Homo sapiens	119-127
28334039-6	2017	Finally, the effects of sodium nitroprusside (SNP, a NO donor) and Nomega-nitro-L-arginine (NNA, an iNOS inhibitor) on IL-1beta-mediated NF-kappaB-activation were examined.	Nitroarginine	92-95	interleukin 1 beta	Homo sapiens	119-127
28334039-9	2017	SNP attenuated the IL-1beta-induced increase in NF-kappaB luciferase activity and expression, whereas NNA diminished the inhibitory effects of L-Arg on IL-1beta-inducible NF- kappaB luciferase activity.	Nitroarginine	102-105	interleukin 1 beta	Homo sapiens	152-160
29142468-8	2017	In the presence of the nitric oxide (NO) synthesis inhibitor L-NNA, GLP-2 no longer influenced the neurally-evoked contractile responses (P > 0.05).	Nitroarginine	61-66	glucagon-like peptide 2 receptor	Mus musculus	68-73
29070471-6	2017	Combined treatment with L-NNA and METH, compared with METH alone, resulted in significantly lowered expression of NOS, NO, PDI-SNO and alphaSN in the hippocampus and striatum of the mice (all P<0.05).	Nitroarginine	24-29	prolyl 4-hydroxylase, beta polypeptide	Mus musculus	123-126
29070471-6	2017	Combined treatment with L-NNA and METH, compared with METH alone, resulted in significantly lowered expression of NOS, NO, PDI-SNO and alphaSN in the hippocampus and striatum of the mice (all P<0.05).	Nitroarginine	24-29	synuclein, alpha	Mus musculus	135-142
25543171-8	2015	The following receptor blockers diminished the action of PACAP-38: PACAP 6-38,haloperidol, methysergide, naloxone and nitro-l-arginine.	Nitroarginine	118-134	adenylate cyclase activating polypeptide 1	Rattus norvegicus	57-62
26486177-8	2016	However, relaxation responses were reduced by Nomega-nitro-L-arginine (L-NNA; 100 muM), an inhibitor of nitric oxide synthesis (40-50% reduction), zinc protoprophyrin IX (10 muM), an inhibitor of carbon monoxide synthesis (20-40% reduction), and also propargylglycine (30 muM) and aminooxyacetic acid (30 muM), inhibitors of hydrogen sulphide synthesis (15-20% reduction).	Nitroarginine	46-69	latexin	Homo sapiens	82-85
26486177-8	2016	However, relaxation responses were reduced by Nomega-nitro-L-arginine (L-NNA; 100 muM), an inhibitor of nitric oxide synthesis (40-50% reduction), zinc protoprophyrin IX (10 muM), an inhibitor of carbon monoxide synthesis (20-40% reduction), and also propargylglycine (30 muM) and aminooxyacetic acid (30 muM), inhibitors of hydrogen sulphide synthesis (15-20% reduction).	Nitroarginine	71-76	latexin	Homo sapiens	82-85
26138467-8	2015	The excitatory effects of LY-83583 were found to resemble those with neuronal nitric oxide synthase (nNOS) inhibition by l-NNA, since it produced a significant increase in the IAS tone and attenuated NANC relaxation.	Nitroarginine	121-126	nitric oxide synthase 1	Rattus norvegicus	69-99
26138467-8	2015	The excitatory effects of LY-83583 were found to resemble those with neuronal nitric oxide synthase (nNOS) inhibition by l-NNA, since it produced a significant increase in the IAS tone and attenuated NANC relaxation.	Nitroarginine	121-126	nitric oxide synthase 1	Rattus norvegicus	101-105
26108095-7	2015	Interestingly, inhibition of nitric oxide synthase by N-nitro-L-arginine completely prevented the decrease in prolactin release without acute neurotoxic effects of methylmercury.	Nitroarginine	54-72	prolactin	Homo sapiens	110-119
25818700-7	2015	Furthermore, salt stress stimulated NO accumulation, whereas blocking NO production with the inhibitor N(omega)-nitro-l-arginine-methylester compromised the salt-mediated reduction of root meristem size, PIN down-regulation, and stabilization of AXR3/IAA17, indicating that NO is involved in salt-mediated inhibition of root meristem growth.	Nitroarginine	103-128	AUX/IAA transcriptional regulator family protein	Arabidopsis thaliana	246-250
25818700-7	2015	Furthermore, salt stress stimulated NO accumulation, whereas blocking NO production with the inhibitor N(omega)-nitro-l-arginine-methylester compromised the salt-mediated reduction of root meristem size, PIN down-regulation, and stabilization of AXR3/IAA17, indicating that NO is involved in salt-mediated inhibition of root meristem growth.	Nitroarginine	103-128	AUX/IAA transcriptional regulator family protein	Arabidopsis thaliana	251-256
26486177-8	2016	However, relaxation responses were reduced by Nomega-nitro-L-arginine (L-NNA; 100 muM), an inhibitor of nitric oxide synthesis (40-50% reduction), zinc protoprophyrin IX (10 muM), an inhibitor of carbon monoxide synthesis (20-40% reduction), and also propargylglycine (30 muM) and aminooxyacetic acid (30 muM), inhibitors of hydrogen sulphide synthesis (15-20% reduction).	Nitroarginine	71-76	latexin	Homo sapiens	174-177
26486177-8	2016	However, relaxation responses were reduced by Nomega-nitro-L-arginine (L-NNA; 100 muM), an inhibitor of nitric oxide synthesis (40-50% reduction), zinc protoprophyrin IX (10 muM), an inhibitor of carbon monoxide synthesis (20-40% reduction), and also propargylglycine (30 muM) and aminooxyacetic acid (30 muM), inhibitors of hydrogen sulphide synthesis (15-20% reduction).	Nitroarginine	71-76	latexin	Homo sapiens	174-177
26486177-8	2016	However, relaxation responses were reduced by Nomega-nitro-L-arginine (L-NNA; 100 muM), an inhibitor of nitric oxide synthesis (40-50% reduction), zinc protoprophyrin IX (10 muM), an inhibitor of carbon monoxide synthesis (20-40% reduction), and also propargylglycine (30 muM) and aminooxyacetic acid (30 muM), inhibitors of hydrogen sulphide synthesis (15-20% reduction).	Nitroarginine	71-76	latexin	Homo sapiens	174-177
25151131-10	2015	The single dose of NNLA (60 mg/kg) applied on the 10th day after SCI or Baclofen therapy reduced nNOS expression in alpha-motoneurons and suppressed symptoms of increased reflex activity.	Nitroarginine	19-23	nitric oxide synthase 1	Rattus norvegicus	97-101
25554985-32	2014	Inhibition of NO synthase by L-NNA significantly reduced the LI and the rise in EBF caused by Ang-(1-7).	Nitroarginine	29-34	EBF transcription factor 1	Rattus norvegicus	80-83
25666964-0	2015	Renal effects of glucose transporter 4 in Nomega-nitro-L-arginine/ /high salt-induced hypertensive rats.	Nitroarginine	42-65	solute carrier family 2 member 4	Rattus norvegicus	17-38
25666964-3	2015	METHODS: Hypertensive nephropathy was induced by Nomega-nitro-L-arginine (L-NNA), a nitric oxide (NO) synthase inhibitor, 100 mg/ml in drinking water and high salt (HS) diet (4 % NaCl), for 15 days in the presence of insulin, a GLUT 4 agonist (1 U/day) and indinavir, a GLUT4 inhibitor (80 mg/kg/day).	Nitroarginine	74-79	solute carrier family 2 member 4	Rattus norvegicus	228-234
25666964-3	2015	METHODS: Hypertensive nephropathy was induced by Nomega-nitro-L-arginine (L-NNA), a nitric oxide (NO) synthase inhibitor, 100 mg/ml in drinking water and high salt (HS) diet (4 % NaCl), for 15 days in the presence of insulin, a GLUT 4 agonist (1 U/day) and indinavir, a GLUT4 inhibitor (80 mg/kg/day).	Nitroarginine	74-79	solute carrier family 2 member 4	Rattus norvegicus	270-275
25090657-7	2014	And when we knocked down the PDI gene, the L-NNA did not have this effect.	Nitroarginine	43-48	prolyl 4-hydroxylase subunit beta	Rattus norvegicus	29-32
25109425-4	2014	KEY RESULTS: Patients with DS presented decreased spontaneous rhythmic contractions (SRC) that were significantly enhanced after incubation with L-NNA (1 mM) and TTX (1 muM), and unaffected by the P2Y1 antagonist MRS2500 (1 muM).	Nitroarginine	145-150	latexin	Homo sapiens	169-172
24814612-4	2014	Haloperidol, phenoxybenzamine, bicuculline, atropine, nitro-L-arginine and astressin 2B prevented the action of Ucn 3, in both sexes, whereas antalarmin exerted no action in either male or female animals.	Nitroarginine	54-70	urocortin 3	Mus musculus	112-117
24425765-12	2014	N(omega)-nitro-l-arginine and copper prevented the deleterious effect of interleukin-1beta on COX activity and GSIS.	Nitroarginine	0-25	interleukin 1 beta	Rattus norvegicus	73-90
25360396-2	2014	The reported utility of aminoguanidine and nitroarginine in iNOS inhibition points to a potential similar utility for analogs of nitro-guanidine.	Nitroarginine	43-56	nitric oxide synthase 2	Homo sapiens	60-64
25033468-12	2014	By means of this UPLC-MS/MS (15)N-citrulline assay, N(G)-nitro-arginine (100 muM) was found to inhibit recombinant inducible NOS (iNOS) activity (by 38%), whereas nitrite and GSSG (each at 500 muM) did not affect iNOS activity at all.	Nitroarginine	52-71	nitric oxide synthase 2	Homo sapiens	115-128
25033468-12	2014	By means of this UPLC-MS/MS (15)N-citrulline assay, N(G)-nitro-arginine (100 muM) was found to inhibit recombinant inducible NOS (iNOS) activity (by 38%), whereas nitrite and GSSG (each at 500 muM) did not affect iNOS activity at all.	Nitroarginine	52-71	nitric oxide synthase 2	Homo sapiens	130-134
25033468-12	2014	By means of this UPLC-MS/MS (15)N-citrulline assay, N(G)-nitro-arginine (100 muM) was found to inhibit recombinant inducible NOS (iNOS) activity (by 38%), whereas nitrite and GSSG (each at 500 muM) did not affect iNOS activity at all.	Nitroarginine	52-71	nitric oxide synthase 2	Homo sapiens	213-217
24874709-8	2014	Our results show that orexin A decreases significantly the time spent in the arms (open/open+closed) and this action is reversed by bicuculline, phenoxybenzamine and propranolol, but not by atropine, haloperidol or nitro-l-arginine.	Nitroarginine	215-231	hypocretin	Mus musculus	22-30
24425765-12	2014	N(omega)-nitro-l-arginine and copper prevented the deleterious effect of interleukin-1beta on COX activity and GSIS.	Nitroarginine	0-25	coproporphyrinogen oxidase	Rattus norvegicus	94-97
24365975-7	2014	When L-NNA+mitochondrial inhibitors (cyanide, rotenone or myxothiazol) were added, the increase in tone was similar in normoxic and hypoxic vessels, which suggests that inhibition of the binding of NO to reduced CcO restored the action of NO on sGC.	Nitroarginine	5-10	serglycin	Mus musculus	245-248
24361899-5	2014	Ang-(1-7) (2, 3 and 4 mug/paw) elicited a local peripheral antinociceptive effect that was antagonized by the nonselective NO synthase (NOS) inhibitor L-NOarg and the selective neuronal NOS (nNOS) inhibitor L-NPA.	Nitroarginine	151-158	angiogenin	Rattus norvegicus	0-8
24372768-9	2014	Both responses were blocked by tissue incubation with the nitric oxide synthase inhibitor (Nomega-nitro-l-arginine 1 mM) and the P2Y1 receptor blocker 2"-deoxy-N(6) -methyladenosine 3",5"-bisphosphate tetrasodium salt (MRS2179; 10 muM).	Nitroarginine	91-114	latexin	Homo sapiens	231-234
25194201-6	2014	Half of the animals in both groups received the nNOS inhibitor-L-NNA (2mM) in the drinking water throughout the study (N=8 for all groups).	Nitroarginine	62-68	nitric oxide synthase 1	Rattus norvegicus	48-52
24246145-4	2014	Finally, Nomega-nitro-l-arginine greatly potentiated the induction of basic fibroblast growth factor (FGF2) by pilocarpine.	Nitroarginine	9-32	fibroblast growth factor 2	Rattus norvegicus	70-100
24246145-4	2014	Finally, Nomega-nitro-l-arginine greatly potentiated the induction of basic fibroblast growth factor (FGF2) by pilocarpine.	Nitroarginine	9-32	fibroblast growth factor 2	Rattus norvegicus	102-106
23480366-8	2013	L-NNA and capsaicin that augmented LI and decreased EBF, also significantly reduced melatonin-induced protection and hyperemia; both were restored with L-arginine and calcitonin gene-related peptide (CGRP) added to melatonin.	Nitroarginine	0-5	calcitonin-related polypeptide alpha	Rattus norvegicus	167-198
24113588-1	2013	N(G),N(G)-dimethyl-L-arginine (ADMA) and N(G)-methyl-L-arginine (NMMA) are endogenous inhibitors of nitric oxide synthase (NOS).	Nitroarginine	41-63	nitric oxide synthase 2	Homo sapiens	100-121
23642043-10	2013	The administration of either Nomega-nitro-l-arginine or 1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one potentiated sustained HPV and partly abolished the differences in sustained HPV between WT and DDAH1(tg) mice.	Nitroarginine	29-52	dimethylarginine dimethylaminohydrolase 1	Mus musculus	196-201
24041741-7	2013	Combining the statin pretreatment with the eNOS inhibitor L-NNA as well as bypassing the HMG-CoA reductase (EC number: 1.1.1.34) by adding mevalonic acid or geranyl pyrophosphate restored the exocytotic effect of PMA.	Nitroarginine	58-63	nitric oxide synthase 3	Homo sapiens	43-47
23978788-6	2013	Nesfatin-1-induced protection was attenuated by suppression of COX-1 and COX-2 activity, the inhibition of NOS with L-NNA, the deactivation of afferent nerves with neurotoxic doses of capsaicin, and the pretreatment with capsazepine to inhibit vanilloid VR1 receptors.	Nitroarginine	116-121	nucleobindin 2	Rattus norvegicus	0-10
23480366-8	2013	L-NNA and capsaicin that augmented LI and decreased EBF, also significantly reduced melatonin-induced protection and hyperemia; both were restored with L-arginine and calcitonin gene-related peptide (CGRP) added to melatonin.	Nitroarginine	0-5	calcitonin-related polypeptide alpha	Rattus norvegicus	200-204
23812222-3	2013	MATERIALS AND METHODS: On gestation day 8, mice were injected with a non-teratogenic dose (20 mg/kg) of the nitric oxide synthase (NOS) inhibitor N(G)-nitro-L-arginine methyl esther (L-NAME).	Nitroarginine	146-167	nitric oxide synthase 1, neuronal	Mus musculus	108-129
23348803-4	2013	ODQ, L-NNA, and L-NMMA also prevented CNP-induced elevations in cGMP concentrations, and L-NNA or L-NMMA blocked CNP-induced decreases in myosin light phosphorylation.	Nitroarginine	89-94	natriuretic peptide type C	Mus musculus	113-116
23348107-9	2013	Phenoxybenzamine, yohimbine, propranolol, methysergide, cyproheptadine, atropine, bicuculline and nitro-l-arginine prevented the action of kisspeptin-13 on passive avoidance learning, but haloperidol and naloxone did not block the effects of kisspeptin-13.	Nitroarginine	98-114	KiSS-1 metastasis-suppressor	Mus musculus	139-149
23348107-9	2013	Phenoxybenzamine, yohimbine, propranolol, methysergide, cyproheptadine, atropine, bicuculline and nitro-l-arginine prevented the action of kisspeptin-13 on passive avoidance learning, but haloperidol and naloxone did not block the effects of kisspeptin-13.	Nitroarginine	98-114	KiSS-1 metastasis-suppressor	Mus musculus	242-252
23043510-8	2013	Blocking NO generation with the NOS inhibitor N-nitro-L-arginine attenuated the S-nitrosylation of PDI and inhibited the formation of mutant SOD1 aggregates.	Nitroarginine	46-64	prolyl 4-hydroxylase subunit beta	Homo sapiens	99-102
23243147-7	2013	In the presence of L-NOARG and indomethacin, a novel K(Ca)2 and K(Ca)3.1 channel activator, NS4591, induced concentration- and endothelium-dependent relaxations, which were markedly reduced in arteries from chronically hypoxic rats compared with arteries from normoxic rats.	Nitroarginine	19-26	potassium calcium-activated channel subfamily N member 4	Rattus norvegicus	64-72
23323764-6	2013	In P2Y(1)(-/-) mice, a nitrergic IJP (N(omega) -nitro-l-arginine-sensitive), but not a purinergic IJP was recorded.	Nitroarginine	38-64	purinergic receptor P2Y, G-protein coupled 1	Mus musculus	3-9
23043510-8	2013	Blocking NO generation with the NOS inhibitor N-nitro-L-arginine attenuated the S-nitrosylation of PDI and inhibited the formation of mutant SOD1 aggregates.	Nitroarginine	46-64	superoxide dismutase 1	Homo sapiens	141-145
22814938-12	2012	Morphine significantly upregulated the expression of DREAM, and the formalin-induced upregulation was significantly attenuated by l-NNA.	Nitroarginine	130-135	potassium voltage-gated channel interacting protein 3	Rattus norvegicus	53-58
21720771-1	2012	The activity of the angiotensin-converting enzyme (ACE) of the inner surface (the endothelium surface) of rat aorta sections has been studied depending on their distance from the aortic arch, age of rats, and the duration of treatment of rats with the NO synthase inhibitor, N (omega)-nitro-L-arginine (L-NAME).	Nitroarginine	275-301	angiotensin I converting enzyme	Rattus norvegicus	51-54
22718118-6	2012	Treatment of SCCs in vitro with the inducible nitric oxide synthase (iNOS) inhibitor N(omega)-nitro-L-arginine(L-NNA) induced E-selectin expression at levels comparable to imiquimod-treated SCCs undergoing immunologic destruction.	Nitroarginine	85-110	nitric oxide synthase 2	Homo sapiens	36-67
22718118-6	2012	Treatment of SCCs in vitro with the inducible nitric oxide synthase (iNOS) inhibitor N(omega)-nitro-L-arginine(L-NNA) induced E-selectin expression at levels comparable to imiquimod-treated SCCs undergoing immunologic destruction.	Nitroarginine	85-110	nitric oxide synthase 2	Homo sapiens	69-73
22718118-6	2012	Treatment of SCCs in vitro with the inducible nitric oxide synthase (iNOS) inhibitor N(omega)-nitro-L-arginine(L-NNA) induced E-selectin expression at levels comparable to imiquimod-treated SCCs undergoing immunologic destruction.	Nitroarginine	85-110	selectin E	Homo sapiens	126-136
22718118-6	2012	Treatment of SCCs in vitro with the inducible nitric oxide synthase (iNOS) inhibitor N(omega)-nitro-L-arginine(L-NNA) induced E-selectin expression at levels comparable to imiquimod-treated SCCs undergoing immunologic destruction.	Nitroarginine	111-116	nitric oxide synthase 2	Homo sapiens	36-67
22718118-6	2012	Treatment of SCCs in vitro with the inducible nitric oxide synthase (iNOS) inhibitor N(omega)-nitro-L-arginine(L-NNA) induced E-selectin expression at levels comparable to imiquimod-treated SCCs undergoing immunologic destruction.	Nitroarginine	111-116	nitric oxide synthase 2	Homo sapiens	69-73
22718118-6	2012	Treatment of SCCs in vitro with the inducible nitric oxide synthase (iNOS) inhibitor N(omega)-nitro-L-arginine(L-NNA) induced E-selectin expression at levels comparable to imiquimod-treated SCCs undergoing immunologic destruction.	Nitroarginine	111-116	selectin E	Homo sapiens	126-136
21973085-6	2012	Similarly, in 3-month-old mice, caveolin-1 KO reduced contractility to noradrenaline by an L-NNA-sensitive mechanism.	Nitroarginine	91-96	caveolin 1, caveolae protein	Mus musculus	32-42
22401765-16	2012	RESULTS: VCLT prevented the increase of SBP and plasma angiotensin II in l-NNA treated rats.	Nitroarginine	73-78	angiotensinogen	Rattus norvegicus	55-69
22659627-12	2012	In contrast, intravenous infusion of the eNOS inhibitor L-NNA (10 mg kg(-1)) completely abrogated the SIM-induced cardioprotection and eNOS phosphorylation during ischemia and reperfusion, but did not affect the activity of PKA.	Nitroarginine	56-61	nitric oxide synthase 3	Sus scrofa	41-45
22659627-12	2012	In contrast, intravenous infusion of the eNOS inhibitor L-NNA (10 mg kg(-1)) completely abrogated the SIM-induced cardioprotection and eNOS phosphorylation during ischemia and reperfusion, but did not affect the activity of PKA.	Nitroarginine	56-61	nitric oxide synthase 3	Sus scrofa	135-139
22659627-12	2012	In contrast, intravenous infusion of the eNOS inhibitor L-NNA (10 mg kg(-1)) completely abrogated the SIM-induced cardioprotection and eNOS phosphorylation during ischemia and reperfusion, but did not affect the activity of PKA.	Nitroarginine	56-61	protein kinase cAMP-activated catalytic subunit alpha	Sus scrofa	224-227
22128174-7	2012	Treatment of cells with N(G)-nitro-L-arginine, a slowly reversible competitive inhibitor that stabilizes nNOS, decreases both nNOS ubiquitination and binding of Hsp90, Hsp70, and CHIP.	Nitroarginine	24-45	nitric oxide synthase 1	Homo sapiens	105-109
22378773-6	2012	ANG II-induced ROS production was enhanced by PD123319, the NOS inhibitor N(G)-nitro-l-arginine (LNNA), or in nNOS-null mice.	Nitroarginine	74-95	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	0-6
22378773-6	2012	ANG II-induced ROS production was enhanced by PD123319, the NOS inhibitor N(G)-nitro-l-arginine (LNNA), or in nNOS-null mice.	Nitroarginine	97-101	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	0-6
22217882-2	2012	Acetylcholine-induced endothelium-dependent relaxation of small mesenteric arteries of eNOS-/- was resistant to N-nitro-L-arginine and indomethacin and the guanylyl cyclase inhibitor, 1H-(1,2,4) oxadiazolo (4,3-a) quinoxalin-1-one.	Nitroarginine	112-130	nitric oxide synthase 3, endothelial cell	Mus musculus	87-91
22371472-7	2012	In P2Y(1)(-/-) mice, EFS responses were completely blocked by L-NNA.	Nitroarginine	62-67	purinergic receptor P2Y, G-protein coupled 1	Mus musculus	3-9
22128174-7	2012	Treatment of cells with N(G)-nitro-L-arginine, a slowly reversible competitive inhibitor that stabilizes nNOS, decreases both nNOS ubiquitination and binding of Hsp90, Hsp70, and CHIP.	Nitroarginine	24-45	nitric oxide synthase 1	Homo sapiens	126-130
22128174-7	2012	Treatment of cells with N(G)-nitro-L-arginine, a slowly reversible competitive inhibitor that stabilizes nNOS, decreases both nNOS ubiquitination and binding of Hsp90, Hsp70, and CHIP.	Nitroarginine	24-45	heat shock protein 90 alpha family class A member 1	Homo sapiens	161-166
22128174-7	2012	Treatment of cells with N(G)-nitro-L-arginine, a slowly reversible competitive inhibitor that stabilizes nNOS, decreases both nNOS ubiquitination and binding of Hsp90, Hsp70, and CHIP.	Nitroarginine	24-45	heat shock protein family A (Hsp70) member 4	Homo sapiens	168-173
21326108-6	2011	In addition, N-nitro-l-arginine blunted big ET-1-induced suppression of norepinephrine overflow and improvement of cardiac dysfunction after ischemia/reperfusion.	Nitroarginine	13-31	endothelin 1	Rattus norvegicus	44-48
21713068-4	2011	The primary findings of this study were that NG-nitro-l-Arginine, an inhibitor of endothelial and neuronal nitric oxide synthase, attenuated AIMs induced by chronic and acute l-DOPA.	Nitroarginine	45-64	nitric oxide synthase 1	Rattus norvegicus	98-128
22011436-8	2012	Moreover, norepinephrine release and AT1 receptor expression were increased by the nitric oxide (NO) synthase inhibitor N(G)-methyl-L-arginine and the protein kinase C activator phorbol myristate acetate.	Nitroarginine	120-142	angiotensin II receptor, type 1a	Rattus norvegicus	37-40
22029733-8	2011	Additionally, N-nitro l-arginine methylester slightly potentiated the contractions induced by motilin.	Nitroarginine	14-32	motilin	Canis lupus familiaris	94-101
22110764-6	2011	Hypo-reactivity was associated with up-regulation of inducible NO-synthase and increased production of NO, and was reversed by the NO-synthase inhibitor (N(G)-nitro-L-arginine).	Nitroarginine	154-175	nitric oxide synthase 2	Homo sapiens	53-74
20978518-7	2011	Vasoconstrictive response of isolated rat carotid artery rings, after phenylephrine was attenuated at 24  hours following preincubation with leptin, was unaffected by removal of endothelium but abrogated by coculture with N-(omega)-nitro-L-arginine methylester, pointing toward an inducible nitric oxide synthase-mediated mechanism.	Nitroarginine	222-248	leptin	Rattus norvegicus	141-147
22553677-2	2011	METHODS: CRNV was induced by alkali injury in mice, nitric oxide synthetase (NOS) was inhibited by NG-nitro-L-arginine (L-NAME) and inducible nitric oxide synthetase (iNOS) was inhibited by aminoguanidine hemisulfate salt (AG).	Nitroarginine	99-118	nitric oxide synthase 1, neuronal	Mus musculus	52-75
21277991-5	2011	The role of nitric oxide synthase (NOS) and NADPH oxidase (NOX) in hypoxia-induced Mst3 up-regulation was also demonstrated by the inhibitory effect of N(G)-nitro-l-arginine and apocynin, which inhibits NOS and NOX, respectively.	Nitroarginine	152-173	nitric oxide synthase 2	Homo sapiens	12-33
21277991-5	2011	The role of nitric oxide synthase (NOS) and NADPH oxidase (NOX) in hypoxia-induced Mst3 up-regulation was also demonstrated by the inhibitory effect of N(G)-nitro-l-arginine and apocynin, which inhibits NOS and NOX, respectively.	Nitroarginine	152-173	serine/threonine kinase 24	Homo sapiens	83-87
21317305-7	2011	Treatment with the NOS inhibitor N(G)-nitro-L-arginine (L-NNA) before ischemia suppressed the protection induced by Hsp22.	Nitroarginine	33-54	heat shock protein 8	Mus musculus	116-121
21317305-7	2011	Treatment with the NOS inhibitor N(G)-nitro-L-arginine (L-NNA) before ischemia suppressed the protection induced by Hsp22.	Nitroarginine	56-61	heat shock protein 8	Mus musculus	116-121
20637185-7	2010	Of note, some commercially available inhibitors for iNOS and/or COX-2, such as ibuprofen, dextromethorphan, and N(G)-methyl-l-arginine (l-NMA), show negligible effects on microglial Abeta phagocytosis.	Nitroarginine	112-134	nitric oxide synthase 2, inducible	Mus musculus	52-56
21647438-1	2011	This study tests whether the nitric oxide synthase (NOS) inhibitor, N(G)-nitro-L-arginine (L-NNA), combines favorably with ionizing radiation (IR) in controlling squamous carcinoma tumor growth.	Nitroarginine	68-89	nitric oxide synthase 2	Homo sapiens	29-50
21647438-1	2011	This study tests whether the nitric oxide synthase (NOS) inhibitor, N(G)-nitro-L-arginine (L-NNA), combines favorably with ionizing radiation (IR) in controlling squamous carcinoma tumor growth.	Nitroarginine	91-96	nitric oxide synthase 2	Homo sapiens	29-50
21043515-2	2010	Aiming at the design of innovative (99m)Tc(I) complexes for targeting inducible NOS (iNOS) in vivo by SPECT imaging, herein we describe a set of novel (99m)Tc(CO)3 complexes (2-5) and the corresponding rhenium surrogates (2a-5a) containing the NOS inhibitor N(omega)-nitro-l-arginine.	Nitroarginine	258-283	nitric oxide synthase 2, inducible	Mus musculus	85-89
20709731-5	2010	In acutely instrumented, late-gestation ovine fetuses, eNOS was inhibited by nitro-l-arginine infusion into the left PA (LPA).	Nitroarginine	77-93	nitric oxide synthase, endothelial	Ovis aries	55-59
21059996-9	2010	In vitro treatment with BH4, polyethylene glycol-superoxide dismutase (PEG-SOD), or Nomega-nitro-L-arginine (L-NNA) significantly augmented NO and reduced TSP-1 and O2- levels from EPCs of WT DOCA-salt mice.	Nitroarginine	84-107	thrombospondin 1	Mus musculus	155-160
21059996-9	2010	In vitro treatment with BH4, polyethylene glycol-superoxide dismutase (PEG-SOD), or Nomega-nitro-L-arginine (L-NNA) significantly augmented NO and reduced TSP-1 and O2- levels from EPCs of WT DOCA-salt mice.	Nitroarginine	109-114	thrombospondin 1	Mus musculus	155-160
20729196-6	2010	The involvement of the altered heme cleft in regulating ubiquitination is confirmed by the finding that the slowly reversible inhibitor of nNOS, N(G)-nitro-L-arginine, but not its inactive D-isomer, protects the C331A nNOS from ubiquitination in all these experimental systems.	Nitroarginine	145-166	nitric oxide synthase 1	Homo sapiens	139-143
20729196-6	2010	The involvement of the altered heme cleft in regulating ubiquitination is confirmed by the finding that the slowly reversible inhibitor of nNOS, N(G)-nitro-L-arginine, but not its inactive D-isomer, protects the C331A nNOS from ubiquitination in all these experimental systems.	Nitroarginine	145-166	nitric oxide synthase 1	Homo sapiens	218-222
20637185-7	2010	Of note, some commercially available inhibitors for iNOS and/or COX-2, such as ibuprofen, dextromethorphan, and N(G)-methyl-l-arginine (l-NMA), show negligible effects on microglial Abeta phagocytosis.	Nitroarginine	112-134	prostaglandin-endoperoxide synthase 2	Mus musculus	64-69
20540939-10	2010	Results obtained with L-NNA, 1400W, 7-NI, OxyHb, ODQ or Tiron showed that this response was mediated by products from endothelial NOS (eNOS) different from NO and without soluble guanylate cyclase activation, but it involved superoxide anions.	Nitroarginine	22-27	nitric oxide synthase 3	Homo sapiens	118-133
20540939-10	2010	Results obtained with L-NNA, 1400W, 7-NI, OxyHb, ODQ or Tiron showed that this response was mediated by products from endothelial NOS (eNOS) different from NO and without soluble guanylate cyclase activation, but it involved superoxide anions.	Nitroarginine	22-27	nitric oxide synthase 3	Homo sapiens	135-139
20307563-5	2010	The inhibition of prostaglandin and nitric oxide (NO) synthesis (by indomethacin and by N-omega-Nitro-l-arginine, respectively) and the use of K(+) channel inhibitors (apamin and charybdotoxin) showed that melittin evoked relaxation via an endothelium-dependent mechanism (NO production), and by activation of charybdotoxin-sensitive K(+) channels of smooth muscle.	Nitroarginine	88-112	melittin	Apis mellifera	206-214
20451534-5	2010	Moreover, pre-administration of NG-nitro-l-arginine (l-NOArg) in the hippocampus partially prevented the Ghr-induced memory improvement, abolished the increase in NOS activity, and prevented the decreased threshold to generate LTP induced by Ghr.	Nitroarginine	32-51	ghrelin and obestatin prepropeptide	Rattus norvegicus	105-108
20451534-5	2010	Moreover, pre-administration of NG-nitro-l-arginine (l-NOArg) in the hippocampus partially prevented the Ghr-induced memory improvement, abolished the increase in NOS activity, and prevented the decreased threshold to generate LTP induced by Ghr.	Nitroarginine	32-51	ghrelin and obestatin prepropeptide	Rattus norvegicus	242-245
20451534-5	2010	Moreover, pre-administration of NG-nitro-l-arginine (l-NOArg) in the hippocampus partially prevented the Ghr-induced memory improvement, abolished the increase in NOS activity, and prevented the decreased threshold to generate LTP induced by Ghr.	Nitroarginine	53-60	ghrelin and obestatin prepropeptide	Rattus norvegicus	105-108
20451534-5	2010	Moreover, pre-administration of NG-nitro-l-arginine (l-NOArg) in the hippocampus partially prevented the Ghr-induced memory improvement, abolished the increase in NOS activity, and prevented the decreased threshold to generate LTP induced by Ghr.	Nitroarginine	53-60	ghrelin and obestatin prepropeptide	Rattus norvegicus	242-245
20543087-5	2010	In normal rats, N-nitro-l-arginine (100 microM) plus 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (10 microM), to inhibit NOS and soluble guanylate cyclase (sGC), respectively, abolished ACh-induced relaxation, whereas in diabetic rats, the maximum relaxation to ACh was attenuated (maximum relaxation: 25 + or - 5%), but not abolished, by that treatment.	Nitroarginine	16-34	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	130-155
20638384-4	2010	The inhibitor of Ca2+-dependent NOS (N-nitro-L-arginine, 100 microM) prevented ASN-evoked caspase-3 activation and PARP-1 degradation.	Nitroarginine	37-55	caspase 3	Mus musculus	90-99
20638384-4	2010	The inhibitor of Ca2+-dependent NOS (N-nitro-L-arginine, 100 microM) prevented ASN-evoked caspase-3 activation and PARP-1 degradation.	Nitroarginine	37-55	poly (ADP-ribose) polymerase family, member 1	Mus musculus	115-121
20543087-5	2010	In normal rats, N-nitro-l-arginine (100 microM) plus 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (10 microM), to inhibit NOS and soluble guanylate cyclase (sGC), respectively, abolished ACh-induced relaxation, whereas in diabetic rats, the maximum relaxation to ACh was attenuated (maximum relaxation: 25 + or - 5%), but not abolished, by that treatment.	Nitroarginine	16-34	guanylate cyclase 1 soluble subunit beta 2	Rattus norvegicus	157-160
20564560-5	2010	In addition, after D-NNA was incubated with the pure enzyme of DAO in vitro without tissue homogenates, L-NNA was not produced, even though D-NNA was disposed.	Nitroarginine	104-109	D-amino acid oxidase	Mus musculus	63-66
20482699-4	2010	Nicotine-induced oxidation currents were blocked by the nitric oxide synthase (NOS) inhibitor, nitro-l-arginine (NLA, 100 micromol L(-1)).	Nitroarginine	95-111	nitric oxide synthase, inducible	Cavia porcellus	56-77
20482699-4	2010	Nicotine-induced oxidation currents were blocked by the nitric oxide synthase (NOS) inhibitor, nitro-l-arginine (NLA, 100 micromol L(-1)).	Nitroarginine	113-116	nitric oxide synthase, inducible	Cavia porcellus	56-77
20466848-8	2010	The effects of GLP-1 on myocardial glucose uptake were blocked by pretreatment with the p38alpha MAP kinase inhibitor or the nonspecific nitric oxide synthase inhibitor nitro-l-arginine.	Nitroarginine	169-185	glucagon	Canis lupus familiaris	15-20
20335378-5	2010	Compared with controls, coronary arteries from dex-exposed lambs demonstrated enhanced vasoconstriction to endothelin-1 and ACh that was abolished by endothelial removal or preincubation with the nitric oxide synthase inhibitor L-NNA, membrane-permeable superoxide dismutase + catalase, or apamin + charybdotoxin, but not indomethacin.	Nitroarginine	228-233	EDN1	Ovis aries	107-119
20564560-8	2010	Furthermore, the ability to produce L-NNA from D-NNA-corresponding alpha-keto acids (N(G)-nitroguanidino-2-oxopentanoic acid) produced by porcine kidney-derived DAO (pkDAO) was also studied in the DAO inhibitor-pretreated rats.	Nitroarginine	36-41	D-amino acid oxidase	Mus musculus	161-164
20564560-8	2010	Furthermore, the ability to produce L-NNA from D-NNA-corresponding alpha-keto acids (N(G)-nitroguanidino-2-oxopentanoic acid) produced by porcine kidney-derived DAO (pkDAO) was also studied in the DAO inhibitor-pretreated rats.	Nitroarginine	36-41	D-amino-acid oxidase	Rattus norvegicus	168-171
20125033-9	2010	L-NNA and propofol, respectively, reduced TNF-induced nitrative stress and attenuated TNF cellular toxicity.	Nitroarginine	0-5	tumor necrosis factor	Homo sapiens	42-45
20125033-9	2010	L-NNA and propofol, respectively, reduced TNF-induced nitrative stress and attenuated TNF cellular toxicity.	Nitroarginine	0-5	tumor necrosis factor	Homo sapiens	86-89
19628271-7	2010	The attenuation of EFS-induced amplitudes by l-NOARG but not ODQ was, in part, reversed by GH.	Nitroarginine	45-52	growth hormone 1	Homo sapiens	91-93
20091049-7	2010	Ang II-induced hypertension was associated with blunted endothelium-dependent relaxations and induction of endothelium-dependent contractions in the presence of nitro-L-arginine in response to acetylcholine (Ach).	Nitroarginine	161-177	angiotensinogen	Rattus norvegicus	0-6
19734318-11	2009	N(omega)-nitro-l-arginine treatment inhibited VEGF-augmented growth in RA and hyperoxia.	Nitroarginine	0-25	vascular endothelial growth factor A	Homo sapiens	46-50
19673702-6	2010	Induction of iNOS expression in RAW264.7 cells with LPS (lipopolysaccharide; 1 microg/ml) causes a significant increase in PMA-induced chemiluminescence, which could be enhanced by the NOS substrate, L-arginine, and could be abolished by the NOS inhibitor, L-NNA (NG-nitro-L-arginine).	Nitroarginine	257-262	nitric oxide synthase 2, inducible	Mus musculus	13-17
19673702-6	2010	Induction of iNOS expression in RAW264.7 cells with LPS (lipopolysaccharide; 1 microg/ml) causes a significant increase in PMA-induced chemiluminescence, which could be enhanced by the NOS substrate, L-arginine, and could be abolished by the NOS inhibitor, L-NNA (NG-nitro-L-arginine).	Nitroarginine	264-283	nitric oxide synthase 2, inducible	Mus musculus	13-17
20004705-9	2010	Next, we also showed that either an IL-1 receptor antagonist or NOS inhibitor Nomega-nitro-L-arginine (L-NNA) attenuated the NE-induced CRH release.	Nitroarginine	78-101	corticotropin releasing hormone	Rattus norvegicus	136-139
20004705-9	2010	Next, we also showed that either an IL-1 receptor antagonist or NOS inhibitor Nomega-nitro-L-arginine (L-NNA) attenuated the NE-induced CRH release.	Nitroarginine	103-108	corticotropin releasing hormone	Rattus norvegicus	136-139
20004705-11	2010	Moreover, we found that application of L-NNA attenuated IL-1beta-induced CRH release, indicating that NO likely mediates this process.	Nitroarginine	39-44	interleukin 1 beta	Rattus norvegicus	56-64
20004705-11	2010	Moreover, we found that application of L-NNA attenuated IL-1beta-induced CRH release, indicating that NO likely mediates this process.	Nitroarginine	39-44	corticotropin releasing hormone	Rattus norvegicus	73-76
19912999-3	2010	In DOCA-salt and L-NNA hypertensive rats, the mean systolic blood pressure (MSBB) was 185.3+/-4.7 and 170.2+/-4.1 mmHg, whereas after administration of NOX-1 to hypertensive rats, MSBB was 127.8+/-4.5 and 120.2+/-5.1 mmHg, respectively.	Nitroarginine	17-22	NADPH oxidase 1	Rattus norvegicus	152-157
19398659-8	2009	Mechanical ablation of the endothelium or inhibition of eNOS with N(omega)-nitro-L-arginine inhibited the reduction in contractility caused by ENaC blockers.	Nitroarginine	66-91	sodium channel epithelial 1 subunit gamma	Rattus norvegicus	143-147
19650107-1	2009	The methyl ester prodrug of N(omega)-nitro-L-arginine (L-NAME) has been reported to exert anticancer effects against several human tumors, including thyroid carcinoma, by inhibiting nitric oxide synthase (NOS).	Nitroarginine	28-53	nitric oxide synthase 2	Homo sapiens	182-203
19692538-6	2009	The inducible nitric oxide synthase (iNOS) inhibitors N(G)-methyl-L-arginine and 1,4-PBIT attenuated TEC-induced apoptosis of DP thymic cells.	Nitroarginine	54-76	nitric oxide synthase 2	Homo sapiens	4-35
19692538-6	2009	The inducible nitric oxide synthase (iNOS) inhibitors N(G)-methyl-L-arginine and 1,4-PBIT attenuated TEC-induced apoptosis of DP thymic cells.	Nitroarginine	54-76	nitric oxide synthase 2	Homo sapiens	37-41
19586904-8	2009	Treating the cells with the broad NOS inhibitor N(G)-methyl-l-arginine, the free radical scavenger N-acetyl-l-cysteine, or the NOS substrate l-arginine partially inhibits UV-induced eIF2alpha phosphorylation.	Nitroarginine	48-70	eukaryotic translation initiation factor 2A	Homo sapiens	182-191
19130224-5	2009	Furthermore, SK-MS10 enhanced the mucosal expression of the CGRP gene and its serum levels.N(G)-methyl L-arginine (L-NMMA) or capsaicin desensitization reversed the SK-MS10-induced gastroprotection effect.	Nitroarginine	91-113	calcitonin-related polypeptide alpha	Rattus norvegicus	60-64
19535675-6	2009	Nitric oxide synthase (NOS) inhibition [N(omega)-nitro-L-arginine (L-NNA), 100 microM] and endothelium inactivation augmented ET-1 responses in arteries from Air but not DE rats so that after either treatment responses were not different between groups.	Nitroarginine	40-65	endothelin 1	Rattus norvegicus	126-130
19535675-6	2009	Nitric oxide synthase (NOS) inhibition [N(omega)-nitro-L-arginine (L-NNA), 100 microM] and endothelium inactivation augmented ET-1 responses in arteries from Air but not DE rats so that after either treatment responses were not different between groups.	Nitroarginine	67-72	endothelin 1	Rattus norvegicus	126-130
19540892-6	2009	In both groups, the PAR2-AP-induced relaxation was largely blocked by endothelial denudation or by N(G)-nitro-L-arginine [nitric oxide (NO) synthase inhibitor] treatment, but it was unaffected by indomethacin (cyclooxygenase inhibitor) treatment.	Nitroarginine	99-120	F2R like trypsin receptor 1	Rattus norvegicus	20-24
19320775-10	2009	eNOS(++) lung cytosols showed an increase of ecSOD protein level of 142 +/- 10.5% as compared with transgene-negative littermates (P < 0.05), which was abolished by N(omega)-nitro-L-arginine treatment.	Nitroarginine	168-193	superoxide dismutase 3, extracellular	Mus musculus	45-50
19416632-10	2009	In this setting,NO2-Arg-Trim but not trimebutine, significantly down-regulated the spinal cFOS mRNA expression and increased blood concentrations of NO2 +NO3.	Nitroarginine	16-23	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	90-94
19299569-10	2009	Addition of l-NNA abolished the effect of exogenous SOD in old Sed arteries.	Nitroarginine	12-17	superoxide dismutase 1	Rattus norvegicus	52-55
19416632-11	2009	Moreover, the expression of several genes involved in inflammation and pain, as IL-1beta, TNFalpha, COX2 and iNOS, was up-regulated in colonic tissue from post-colitis rats and NO2-Arg-Trim, but not trimebutine, effectively reversed this effect.	Nitroarginine	177-184	interleukin 1 beta	Rattus norvegicus	80-88
19416632-11	2009	Moreover, the expression of several genes involved in inflammation and pain, as IL-1beta, TNFalpha, COX2 and iNOS, was up-regulated in colonic tissue from post-colitis rats and NO2-Arg-Trim, but not trimebutine, effectively reversed this effect.	Nitroarginine	177-184	tumor necrosis factor	Rattus norvegicus	90-98
19416632-11	2009	Moreover, the expression of several genes involved in inflammation and pain, as IL-1beta, TNFalpha, COX2 and iNOS, was up-regulated in colonic tissue from post-colitis rats and NO2-Arg-Trim, but not trimebutine, effectively reversed this effect.	Nitroarginine	177-184	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	100-104
19416632-11	2009	Moreover, the expression of several genes involved in inflammation and pain, as IL-1beta, TNFalpha, COX2 and iNOS, was up-regulated in colonic tissue from post-colitis rats and NO2-Arg-Trim, but not trimebutine, effectively reversed this effect.	Nitroarginine	177-184	nitric oxide synthase 2	Rattus norvegicus	109-113
19171133-2	2009	N(G)-nitro-L-arginine (L-NOARG; 1-100 microM), a steriospecific inhibitor of nitric oxide synthase (NOS), completely inhibited the relaxations induced by KCl but not those induced by vasoactive intestinal polypeptide (VIP) antagonist.	Nitroarginine	0-21	nitric oxide synthase 2	Homo sapiens	77-98
19171133-2	2009	N(G)-nitro-L-arginine (L-NOARG; 1-100 microM), a steriospecific inhibitor of nitric oxide synthase (NOS), completely inhibited the relaxations induced by KCl but not those induced by vasoactive intestinal polypeptide (VIP) antagonist.	Nitroarginine	0-21	vasoactive intestinal peptide	Homo sapiens	218-221
19171133-2	2009	N(G)-nitro-L-arginine (L-NOARG; 1-100 microM), a steriospecific inhibitor of nitric oxide synthase (NOS), completely inhibited the relaxations induced by KCl but not those induced by vasoactive intestinal polypeptide (VIP) antagonist.	Nitroarginine	23-30	nitric oxide synthase 2	Homo sapiens	77-98
19171133-2	2009	N(G)-nitro-L-arginine (L-NOARG; 1-100 microM), a steriospecific inhibitor of nitric oxide synthase (NOS), completely inhibited the relaxations induced by KCl but not those induced by vasoactive intestinal polypeptide (VIP) antagonist.	Nitroarginine	23-30	vasoactive intestinal peptide	Homo sapiens	183-216
19171133-2	2009	N(G)-nitro-L-arginine (L-NOARG; 1-100 microM), a steriospecific inhibitor of nitric oxide synthase (NOS), completely inhibited the relaxations induced by KCl but not those induced by vasoactive intestinal polypeptide (VIP) antagonist.	Nitroarginine	23-30	vasoactive intestinal peptide	Homo sapiens	218-221
18851959-4	2008	hPP relaxation was reduced by endothelial cell removal and abolished in the presence of a nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine-methylester (L-NAME).	Nitroarginine	128-149	familial progressive hyperpigmentation 1	Homo sapiens	0-3
18930832-3	2009	The amnesic effect of L-NNA was not state-dependent and was mimicked by the soluble guanylyl cyclase inhibitor LY83583 and the PKG inhibitor KT-5823.	Nitroarginine	22-27	protein kinase cGMP-dependent 1	Homo sapiens	127-130
19813144-8	2009	An inhibitor of constitutive NOS isoform, N(G)-nitro-L-arginine (NNLA, 100 microM), partially prevented ASN-evoked PARP-1 inhibition.	Nitroarginine	42-63	synuclein alpha	Rattus norvegicus	104-107
19813144-8	2009	An inhibitor of constitutive NOS isoform, N(G)-nitro-L-arginine (NNLA, 100 microM), partially prevented ASN-evoked PARP-1 inhibition.	Nitroarginine	42-63	poly (ADP-ribose) polymerase 1	Rattus norvegicus	115-121
19813144-8	2009	An inhibitor of constitutive NOS isoform, N(G)-nitro-L-arginine (NNLA, 100 microM), partially prevented ASN-evoked PARP-1 inhibition.	Nitroarginine	65-69	synuclein alpha	Rattus norvegicus	104-107
19813144-8	2009	An inhibitor of constitutive NOS isoform, N(G)-nitro-L-arginine (NNLA, 100 microM), partially prevented ASN-evoked PARP-1 inhibition.	Nitroarginine	65-69	poly (ADP-ribose) polymerase 1	Rattus norvegicus	115-121
19010435-11	2009	In conclusion, 3-week treatment with l-NAME yields low serum Nomega-nitro-L-arginine concentrations, causing preferential inhibition of cNOS activity.	Nitroarginine	61-84	nitric oxide synthase 3, endothelial cell	Mus musculus	136-140
19081984-4	2009	The complexes bearing guanidino substituted analogues of l-arginine still present considerable inhibitory action (N(omega)-monomethyl-l-arginine, K(i) = 36 microM; N(omega)-nitro-l-arginine, K(i) = 84 microM), being the first examples of organometallic complexes able to inhibit the iNOS.	Nitroarginine	164-189	nitric oxide synthase 2	Homo sapiens	283-287
18436224-7	2009	Moreover, apocynin, endothelium denudation and N(G)-nitro-l-arginine methylester (l-NAME, nitric oxide synthase inhibitor) suppressed the ET-1-induced increase in A23187-stimulated O(2*)(-) generation.	Nitroarginine	47-68	endothelin 1	Homo sapiens	138-142
19155632-5	2009	RESULTS: GSE-induced endothelium-dependent relaxations were abolished by N(G)-nitro-L-arginine (an eNOS inhibitor) and ODQ (a soluble guanylyl cyclase inhibitor), and they were reduced by MnTMPyP, polyethyleneglycol catalase, PP2 (an inhibitor of Src kinase) and wortmannin (an inhibitor of phosphoinositide 3-kinase).	Nitroarginine	73-94	nitric oxide synthase 3	Homo sapiens	99-103
18957814-5	2008	This relaxation was abolished by N(G)-nitro-L-arginine, an NO synthase (NOS) inhibitor.	Nitroarginine	33-54	nitric oxide synthase 3	Canis lupus familiaris	59-70
18534254-6	2008	N-Omega-nitro-L-arginine, which inhibits kynurenine aminotransferase I and II, abolished this neuroprotective effect.	Nitroarginine	0-24	kynurenine aminotransferase 1	Rattus norvegicus	41-77
18378017-5	2008	Orexin-A-induced protection was abolished by selective OX-1 receptor antagonist, vagotomy and attenuated by suppression of COX-1 and COX-2, deactivation of afferent nerves with neurotoxic dose of capsaicin, pretreatment with CCK(2)/gastrin antagonist, CGRP(8-37) or capsazepine and by inhibition of NOS with L-NNA.	Nitroarginine	308-313	hypocretin neuropeptide precursor	Rattus norvegicus	0-8
18411251-3	2008	In the RAW264.7 macrophage cell line and in rat primary alveolar macrophages, LPS was found to inhibit Notch1 intracellular domain (Notch1-IC) transcription activity, which could then be rescued by treatment with N(G)-nitro-l-arginine, a nitric oxide synthase (NOS) inhibitor.	Nitroarginine	213-234	notch receptor 1	Rattus norvegicus	103-109
17960557-6	2008	Chemotaxis to PTN was blocked by the NOS inhibitors L-NNA and L-NMMA, the NO scavenger PTIO, the phosphoinositide-3 kinase inhibitor wortmannin, and the guanylyl cyclase inhibitor ODQ, suggesting dependence of EPC chemotaxis on these pathways.	Nitroarginine	52-57	pleiotrophin	Homo sapiens	14-17
17960557-9	2008	While L-NNA abolished PTN-induced migration in EPCs and HUVECs, it did not inhibit PTN- and VEGF-enhanced proliferation and also caused proliferation by itself.	Nitroarginine	6-11	pleiotrophin	Homo sapiens	22-25
18411251-3	2008	In the RAW264.7 macrophage cell line and in rat primary alveolar macrophages, LPS was found to inhibit Notch1 intracellular domain (Notch1-IC) transcription activity, which could then be rescued by treatment with N(G)-nitro-l-arginine, a nitric oxide synthase (NOS) inhibitor.	Nitroarginine	213-234	notch receptor 1	Rattus norvegicus	132-138
18299991-3	2008	In cultured human aortic endothelial cells (HAEC), arterial shear stress of 10 dyne/cm(2) blocked by >80% the induction by 5 ng/mL TNFalpha of interleukin-8 (IL-8) and IL-6 secretion (50 and 90% reduction, respectively, in the presence of nitric oxide synthase antagonism with 200 microM nitro-L-arginine methylester, L-NAME).	Nitroarginine	291-307	tumor necrosis factor	Homo sapiens	134-142
18299991-3	2008	In cultured human aortic endothelial cells (HAEC), arterial shear stress of 10 dyne/cm(2) blocked by >80% the induction by 5 ng/mL TNFalpha of interleukin-8 (IL-8) and IL-6 secretion (50 and 90% reduction, respectively, in the presence of nitric oxide synthase antagonism with 200 microM nitro-L-arginine methylester, L-NAME).	Nitroarginine	291-307	C-X-C motif chemokine ligand 8	Homo sapiens	146-159
17989504-3	2008	NOS inhibitors included: non-specific inhibitor N(G)-nitro-L-arginine and L-N(6)-(1-iminoethyl)lysine preferentially acting on inducible NOS (iNOS) as well as 7-nitroindazole relatively specific inhibitor neuronal NOS (nNOS).	Nitroarginine	48-69	nitric oxide synthase 2	Rattus norvegicus	127-140
18222959-7	2008	Co-administration of L-NNA abrogated the improvement in myocardial function induced by adiponectin.	Nitroarginine	21-26	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	87-98
18222959-10	2008	L-NNA did not affect infarct size per se but abolished the protective effect of adiponectin (infarct size 40 +/- 5%).	Nitroarginine	0-5	adiponectin, C1Q and collagen domain containing	Rattus norvegicus	80-91
18336903-7	2008	In the presence of the nitric oxide synthase (NOS) inhibitor l-NNA (100 microM) the amplitude was significantly reduced (40+/-13% to 18+/-8%, P<0.05, n=6), frequency was unaltered and the bradykinin-dependent vasodilator response was reduced (68+/-13% to 40+/-19%, P<0.05, n=6).	Nitroarginine	61-66	nitric oxide synthase 2	Homo sapiens	23-44
18336903-7	2008	In the presence of the nitric oxide synthase (NOS) inhibitor l-NNA (100 microM) the amplitude was significantly reduced (40+/-13% to 18+/-8%, P<0.05, n=6), frequency was unaltered and the bradykinin-dependent vasodilator response was reduced (68+/-13% to 40+/-19%, P<0.05, n=6).	Nitroarginine	61-66	kininogen 1	Homo sapiens	191-201
18321097-8	2008	Starting with the nitroarginine-containing dipeptide inhibitors we developed previously, a small organic molecule with a totally different chemical structure was designed, which showed nanomolar nNOS inhibitory potency and more than 1000-fold nNOS selectivity.	Nitroarginine	18-31	nitric oxide synthase 1	Homo sapiens	195-199
18321097-8	2008	Starting with the nitroarginine-containing dipeptide inhibitors we developed previously, a small organic molecule with a totally different chemical structure was designed, which showed nanomolar nNOS inhibitory potency and more than 1000-fold nNOS selectivity.	Nitroarginine	18-31	nitric oxide synthase 1	Homo sapiens	243-247
19097389-4	2008	The aim of this work was to observe the effect of two NO synthase (NOS) inhibitors (N omega-Nitro-L-arginine, NA; 7-nitroindazole, NI) on spontaneous behaviour, spatial learning and motor functions in Lurcher (+/Lc) and wild type (+/+) mice, derived from the B6CBA strain.	Nitroarginine	84-108	nitric oxide synthase 1, neuronal	Mus musculus	54-65
17993594-3	2008	Furthermore, if the action of ANG II is dependent on NO, then the NO synthase inhibitor nitro-L-arginine (NLA) would reverse this improvement.	Nitroarginine	88-104	angiotensinogen	Homo sapiens	30-36
17993594-3	2008	Furthermore, if the action of ANG II is dependent on NO, then the NO synthase inhibitor nitro-L-arginine (NLA) would reverse this improvement.	Nitroarginine	106-109	angiotensinogen	Homo sapiens	30-36
18354258-6	2008	Ang II-induced MMP-2 activation is inhibited by N(G)-nitro-L-arginine and MnTMPyP.	Nitroarginine	48-69	angiotensinogen	Rattus norvegicus	0-6
18354258-6	2008	Ang II-induced MMP-2 activation is inhibited by N(G)-nitro-L-arginine and MnTMPyP.	Nitroarginine	48-69	matrix metallopeptidase 2	Rattus norvegicus	15-20
17989504-3	2008	NOS inhibitors included: non-specific inhibitor N(G)-nitro-L-arginine and L-N(6)-(1-iminoethyl)lysine preferentially acting on inducible NOS (iNOS) as well as 7-nitroindazole relatively specific inhibitor neuronal NOS (nNOS).	Nitroarginine	48-69	nitric oxide synthase 2	Rattus norvegicus	142-146
17631366-7	2007	In the second experiment, leptin was coinjected ICV with NG-nitro-arginine methyl ester HC1 (L-NNA), a NOS inhibitor.	Nitroarginine	93-98	leptin	Gallus gallus	26-32
17660395-4	2007	During local heating we showed that when the selective neuronal nNO synthase (nNOS) inhibitor N(omega)-nitro-L-arginine-2,4-L-diaminobutyric amide (N(omega), 10 mM) was delivered by intradermal microdialysis, cutaneous vascular conductance (CVC) decreased by an amount equivalent to the largest reduction produced by the nonselective NO synthase (NOS) inhibitor nitro-L-arginine (NLA, 10 mM).	Nitroarginine	103-119	nitric oxide synthase 1	Homo sapiens	64-76
17614291-6	2007	Previously, we reported a series of nitroarginine-containing dipeptide amides as potent and selective nNOS inhibitors.	Nitroarginine	36-49	nitric oxide synthase 1	Homo sapiens	102-106
17660395-4	2007	During local heating we showed that when the selective neuronal nNO synthase (nNOS) inhibitor N(omega)-nitro-L-arginine-2,4-L-diaminobutyric amide (N(omega), 10 mM) was delivered by intradermal microdialysis, cutaneous vascular conductance (CVC) decreased by an amount equivalent to the largest reduction produced by the nonselective NO synthase (NOS) inhibitor nitro-L-arginine (NLA, 10 mM).	Nitroarginine	103-119	nitric oxide synthase 1	Homo sapiens	78-82
17660395-4	2007	During local heating we showed that when the selective neuronal nNO synthase (nNOS) inhibitor N(omega)-nitro-L-arginine-2,4-L-diaminobutyric amide (N(omega), 10 mM) was delivered by intradermal microdialysis, cutaneous vascular conductance (CVC) decreased by an amount equivalent to the largest reduction produced by the nonselective NO synthase (NOS) inhibitor nitro-L-arginine (NLA, 10 mM).	Nitroarginine	103-119	nitric oxide synthase 1	Homo sapiens	65-76
17660395-4	2007	During local heating we showed that when the selective neuronal nNO synthase (nNOS) inhibitor N(omega)-nitro-L-arginine-2,4-L-diaminobutyric amide (N(omega), 10 mM) was delivered by intradermal microdialysis, cutaneous vascular conductance (CVC) decreased by an amount equivalent to the largest reduction produced by the nonselective NO synthase (NOS) inhibitor nitro-L-arginine (NLA, 10 mM).	Nitroarginine	380-383	nitric oxide synthase 1	Homo sapiens	64-76
17660395-4	2007	During local heating we showed that when the selective neuronal nNO synthase (nNOS) inhibitor N(omega)-nitro-L-arginine-2,4-L-diaminobutyric amide (N(omega), 10 mM) was delivered by intradermal microdialysis, cutaneous vascular conductance (CVC) decreased by an amount equivalent to the largest reduction produced by the nonselective NO synthase (NOS) inhibitor nitro-L-arginine (NLA, 10 mM).	Nitroarginine	380-383	nitric oxide synthase 1	Homo sapiens	78-82
17660395-4	2007	During local heating we showed that when the selective neuronal nNO synthase (nNOS) inhibitor N(omega)-nitro-L-arginine-2,4-L-diaminobutyric amide (N(omega), 10 mM) was delivered by intradermal microdialysis, cutaneous vascular conductance (CVC) decreased by an amount equivalent to the largest reduction produced by the nonselective NO synthase (NOS) inhibitor nitro-L-arginine (NLA, 10 mM).	Nitroarginine	380-383	nitric oxide synthase 1	Homo sapiens	65-76
17868368-4	2007	LTD(DHPG) required nitric oxide (NO) synthesis as it was blocked by the broad-spectrum NO synthase (NOS) inhibitor Nomega-nitro-l-arginine (NL-Arg) and impaired under blockade of neuronal NOS and in endothelial NOS-deficient mice.	Nitroarginine	115-138	nitric oxide synthase 1, neuronal	Mus musculus	87-98
17868368-4	2007	LTD(DHPG) required nitric oxide (NO) synthesis as it was blocked by the broad-spectrum NO synthase (NOS) inhibitor Nomega-nitro-l-arginine (NL-Arg) and impaired under blockade of neuronal NOS and in endothelial NOS-deficient mice.	Nitroarginine	140-146	nitric oxide synthase 1, neuronal	Mus musculus	87-98
17868368-6	2007	The NO synthesis necessary for LTD(DHPG) induction occurred downstream of CB1 activation as ACEA-evoked LTD was also abolished by NL-Arg.	Nitroarginine	130-136	cannabinoid receptor 1 (brain)	Mus musculus	74-77
17785957-9	2007	Urocortin-induced relaxation was not affected by the combination of a guanylyl cyclase inhibitor, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 1 microM), indomethacin and N(omega)-nitro-L-arginine.	Nitroarginine	176-201	urocortin	Rattus norvegicus	0-9
17439405-11	2007	Endothelial NOS inhibitor Nomega-nitro-L-arginine prevented vasodilatation, whereas neuronal NOS inhibitor 7-nitroindazole did not show significant influence on the vessel relaxation of astragaloside IV.	Nitroarginine	26-49	nitric oxide synthase 3	Rattus norvegicus	0-15
17377806-3	2007	Under basal conditions, Rp-8-Br-PET-cGMPS, a specific PKG inhibitor, evoked a significant contraction of isolated porcine coronary arteries, which was prevented by nitro-L: -arginine or the removal of the endothelium.	Nitroarginine	164-182	protein kinase cGMP-dependent 1	Homo sapiens	54-57
17377806-6	2007	The basal activity of PKG but not that of cyclic adenosine monophosphate-dependent protein kinase (PKA) was inhibited by nitro-L: -arginine, ODQ, or Rp-8-Br-PET-cGMPS.	Nitroarginine	121-139	protein kinase cGMP-dependent 1	Homo sapiens	22-25
17616485-7	2007	L-NNA-sensitive and -resistant relaxation to ACh were also inhibited in AHL aortas.	Nitroarginine	0-5	cadherin 23 (otocadherin)	Mus musculus	72-75
17638882-6	2007	When the effects of TNF-alpha and iNOS were neutralized through the use of neutralizing antibody and N(G)-methyl-L-arginine, respectively, the enhanced cytotoxicity of TbetaRIIDN-RAW cells was partially reversed.	Nitroarginine	101-123	tumor necrosis factor	Mus musculus	20-29
17638882-6	2007	When the effects of TNF-alpha and iNOS were neutralized through the use of neutralizing antibody and N(G)-methyl-L-arginine, respectively, the enhanced cytotoxicity of TbetaRIIDN-RAW cells was partially reversed.	Nitroarginine	101-123	nitric oxide synthase 2, inducible	Mus musculus	34-38
17525359-7	2007	VIP relaxation was almost completely abolished by 4-aminopyridine, and was partly inhibited by N(G)-nitro-L-arginine, but was not affected by indomethacin.	Nitroarginine	95-116	vasoactive intestinal peptide	Homo sapiens	0-3
17568429-2	2007	At P4-P6, the L-NNA treatment produced a significant decrease of the dendritic length and dendritic-spine density of the pyramidal cells of the CA1 hippocampus.	Nitroarginine	14-19	carbonic anhydrase 1	Rattus norvegicus	144-147
17568429-3	2007	In addition, the dendritic length of the pyramidal neurons of the CA1 hippocampus decreased because of the L-NNA treatment at P1-P3.	Nitroarginine	107-112	carbonic anhydrase 1	Rattus norvegicus	66-69
17499220-4	2007	The HO-1 inducting effect of LCY-2-CHO was inhibited by SB203580, N(G)-nitro-l-arginine methylester (l-NAME), and wortmannin, but was not affected by U0126 or SP600125.	Nitroarginine	66-87	heme oxygenase 1	Rattus norvegicus	4-8
17622703-9	2007	Inhibition of COX/PG and NOS/NO systems by indomethacin and L-NNA, respectively, or inactivation of sensory nerves by capsaicin, that manifested in further increase of esophageal injury, reduced the levels of EBF, markedly raised the levels TNF-alpha and reduced mucosal PGE(2), but the pretreatment with MT prevented significantly esophageal injury, improved EBF and raised mucosal PGE(2) contents.	Nitroarginine	60-65	coproporphyrinogen oxidase	Rattus norvegicus	14-20
17406074-1	2007	The aim of this study was to investigate the effect of an inhibitor of nitric oxide production, N(omega)-nitro-L-arginine methyl esther (L-NAME) on Cu-Zn/SOD (superoxide dismutase) enzyme activity and copper and zinc concentrations in diabetes-induced rats.	Nitroarginine	96-121	superoxide dismutase 1	Rattus norvegicus	148-157
17652825-2	2007	administration of N(G)-nitro-L-arginine (NNA, 10, 20 and 40 mg/kg), a non-selective nitric oxide synthase (NOS) inhibitor, significantly and dose-dependently decreased the incidence of convulsions induced by i.p.	Nitroarginine	18-39	nitric oxide synthase 1, neuronal	Mus musculus	84-105
17652825-2	2007	administration of N(G)-nitro-L-arginine (NNA, 10, 20 and 40 mg/kg), a non-selective nitric oxide synthase (NOS) inhibitor, significantly and dose-dependently decreased the incidence of convulsions induced by i.p.	Nitroarginine	41-44	nitric oxide synthase 1, neuronal	Mus musculus	84-105
17481557-6	2007	In addition, pre-treatment with the NO synthase inhibitor, L-NOARG, significantly enhanced the contractions induced by LTB(4).	Nitroarginine	59-66	prostaglandin reductase 1	Cavia porcellus	119-125
17174609-8	2007	INDO+L-NNA+HbO reduced the VEGF-induced relaxation to 20.8+/-4.6% in RA vs. 4.8+/-1.6% in IMA (P=0.01).	Nitroarginine	5-10	vascular endothelial growth factor A	Homo sapiens	27-31
17208221-5	2007	The application of cholecystokinin octapeptide sulphate (cholecystokinin-8S) to colonic preparations induced concentration-dependent contractions which were prevented by devazepide (CCK1 receptor antagonist), enhanced by GV150013 (CCK2 receptor antagonist) or N(omega)-nitro-L-arginine methylester (L-NAME, nitric oxide synthase inhibitor), and unaffected by tetrodotoxin.	Nitroarginine	260-285	cholecystokinin	Cavia porcellus	19-34
17208221-5	2007	The application of cholecystokinin octapeptide sulphate (cholecystokinin-8S) to colonic preparations induced concentration-dependent contractions which were prevented by devazepide (CCK1 receptor antagonist), enhanced by GV150013 (CCK2 receptor antagonist) or N(omega)-nitro-L-arginine methylester (L-NAME, nitric oxide synthase inhibitor), and unaffected by tetrodotoxin.	Nitroarginine	260-285	cholecystokinin	Cavia porcellus	57-72
17075027-7	2007	l-NNA induced a rapid increase in ROS formation, subsequent activation of p38 MAP kinase, and p38 MAP kinase-dependent increases in the expression of transforming growth factor-beta and tumor necrosis factor-alpha.	Nitroarginine	0-5	mitogen-activated protein kinase 14	Mus musculus	74-77
17075027-7	2007	l-NNA induced a rapid increase in ROS formation, subsequent activation of p38 MAP kinase, and p38 MAP kinase-dependent increases in the expression of transforming growth factor-beta and tumor necrosis factor-alpha.	Nitroarginine	0-5	mitogen-activated protein kinase 14	Mus musculus	94-97
17075027-8	2007	Similar changes (increased ROS formation, p38 MAP kinase phosphorylation, and cytokine induction) were also observed in cardiomyocytes derived from eNOS+/+ mice when exposed to l-NNA.	Nitroarginine	177-182	mitogen-activated protein kinase 14	Mus musculus	42-45
17075027-7	2007	l-NNA induced a rapid increase in ROS formation, subsequent activation of p38 MAP kinase, and p38 MAP kinase-dependent increases in the expression of transforming growth factor-beta and tumor necrosis factor-alpha.	Nitroarginine	0-5	tumor necrosis factor	Mus musculus	150-213
16753316-4	2006	Inhibition of nitric oxide synthase (NOS) activity by N(omega)-nitro-L-arginine (L-NNA) or scavenging NO by 2-phenyl-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxyde (PTIO) partially blocked the US-induced H(2)O(2) production and cell death.	Nitroarginine	54-79	nitric oxide synthase 2	Homo sapiens	14-35
17266136-5	2007	These responses were potently reduced by the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine (L-NOARG, 30 microM) and further reversed by the NO synthesis substrate L-arginine (L-ARG, 3 mM).	Nitroarginine	83-102	nitric oxide synthase 2	Sus scrofa	45-66
17266136-5	2007	These responses were potently reduced by the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine (L-NOARG, 30 microM) and further reversed by the NO synthesis substrate L-arginine (L-ARG, 3 mM).	Nitroarginine	104-111	nitric oxide synthase 2	Sus scrofa	45-66
17054907-4	2006	The interferon-gamma-induced suppression of JNK1 activation in BV-2 cells was prevented completely by treatment with N(G)-nitro-l-arginine, an inhibitor of NO synthase.	Nitroarginine	117-138	interferon gamma	Mus musculus	4-20
17054907-4	2006	The interferon-gamma-induced suppression of JNK1 activation in BV-2 cells was prevented completely by treatment with N(G)-nitro-l-arginine, an inhibitor of NO synthase.	Nitroarginine	117-138	mitogen-activated protein kinase 8	Mus musculus	44-48
16753316-4	2006	Inhibition of nitric oxide synthase (NOS) activity by N(omega)-nitro-L-arginine (L-NNA) or scavenging NO by 2-phenyl-4,4,5,5-tetramethyl-imidazoline-1-oxyl-3-oxyde (PTIO) partially blocked the US-induced H(2)O(2) production and cell death.	Nitroarginine	81-86	nitric oxide synthase 2	Homo sapiens	14-35
16997880-2	2006	Fetal NOS-3 activity, measured as NO production with 0.5-0.9 microM 4-amino-5-methylamino-2,7-difluorofluorescein, was decreased in hypoxia by 14.4% (P < 0.01), inhibitable by the NOS inhibitor N-nitro-L-arginine, and dependent on extracellular arginine.	Nitroarginine	197-215	nitric oxide synthase 3	Homo sapiens	6-11
17085343-9	2006	Seven or 15 days of L-NNA treatment reduced COX-1 mRNA expression in these vessels and the small intestine, concomitant with a significant decrease in the concentration of plasma PGI(2) and serum NO in IHPH and PHPH rats (P<0.05).	Nitroarginine	20-25	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	44-49
16931799-7	2006	The activities of Ras and ERK-1,-2 were markedly increased in collateral vessels of the shunt experiment, and infusions of L-NAME and L-NNA strongly inhibited MAPK activity as well as shunt-induced arteriogenesis.	Nitroarginine	134-139	mitogen-activated protein kinase 3	Homo sapiens	26-34
16982927-10	2006	Coadministration of LPS with the NO synthase inhibitor nitro-L-arginine in Cav-1(-/-) mice prevented the suppression of NF-kappaB activity and restored lung polymorphonuclear leukocyte sequestration in response to LPS challenge.	Nitroarginine	55-71	caveolin 1, caveolae protein	Mus musculus	75-80
16931799-7	2006	The activities of Ras and ERK-1,-2 were markedly increased in collateral vessels of the shunt experiment, and infusions of L-NAME and L-NNA strongly inhibited MAPK activity as well as shunt-induced arteriogenesis.	Nitroarginine	134-139	mitogen-activated protein kinase 3	Homo sapiens	159-163
16546300-13	2006	Potent antioxidants: Trolox and 4-hydroxy-Tempo had no effect on DAT function but NOS inhibitor Nomega-nitro-L-arginine (100 microM), prevented ASN-evoked DAT down-regulation.	Nitroarginine	96-119	synuclein alpha	Rattus norvegicus	144-147
17033098-12	2006	The carbachol-induced corticosterone response was significantly increased by pretreatment with nNOS inhibitor L-NNA and was considerably reduced by indomethacin, a general COX inhibitor.	Nitroarginine	110-115	nitric oxide synthase 1	Rattus norvegicus	95-99
16546300-13	2006	Potent antioxidants: Trolox and 4-hydroxy-Tempo had no effect on DAT function but NOS inhibitor Nomega-nitro-L-arginine (100 microM), prevented ASN-evoked DAT down-regulation.	Nitroarginine	96-119	solute carrier family 6 member 3	Rattus norvegicus	155-158
16837587-6	2006	The predominantly presynaptic LTP in the GluR1 knock-outs was blocked by postsynaptic antagonism of nitric oxide synthase (NOS), either with intracellular N-omega-nitro-L-arginine methyl ester or N-nitro-L-arginine, providing the first evidence for a retrograde transmitter role for NO at this synapse.	Nitroarginine	196-214	glutamate receptor, ionotropic, AMPA1 (alpha 1)	Mus musculus	41-46
16626307-15	2006	EFS (1-32 Hz) caused l-NG-nitroarginine-sensitive relaxations of pig urethral muscle that were increased in amplitude and duration by PDE-5 inhibition.	Nitroarginine	21-39	phosphodiesterase 5A	Sus scrofa	134-139
16725109-4	2006	Inhibition of endothelial nitric oxide synthase (eNOS) using l-NNA blocked VEGF-E-induced NO release and angiogenesis.	Nitroarginine	61-66	nitric oxide synthase 3	Homo sapiens	14-47
16725109-4	2006	Inhibition of endothelial nitric oxide synthase (eNOS) using l-NNA blocked VEGF-E-induced NO release and angiogenesis.	Nitroarginine	61-66	platelet derived growth factor C	Homo sapiens	75-81
16837587-6	2006	The predominantly presynaptic LTP in the GluR1 knock-outs was blocked by postsynaptic antagonism of nitric oxide synthase (NOS), either with intracellular N-omega-nitro-L-arginine methyl ester or N-nitro-L-arginine, providing the first evidence for a retrograde transmitter role for NO at this synapse.	Nitroarginine	196-214	nitric oxide synthase 1, neuronal	Mus musculus	100-121
17569362-7	2006	(3) N.-Nitro-L-arginine (L-NNA) significantly decreased the content of iNOS, NO and SOD in all above tissues and serum, and also decreased the content of cNOS in lung and kidney tissues and serum.	Nitroarginine	4-23	nitric oxide synthase 2, inducible	Mus musculus	71-75
16461370-7	2006	Injection of the NOS inhibitor Nomega-nitro-L-arginine (15 mg/kg im), but not the cyclooxygenase inhibitor indomethacin (5 mg/kg im), 45 min preoperatively completely abolished the increase in skin flap blood flow and viability induced by Ad.VEGF-165 injected subdermally into the mapped skin flap 7 days preoperatively.	Nitroarginine	31-54	vascular endothelial growth factor A	Rattus norvegicus	242-246
16861823-8	2006	A nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine (10(-4) M and 3 x 10(-4) M, in SO and gallbladder strips, respectively), significantly increased all EFS-induced contractions of SO and gallbladder strips.	Nitroarginine	41-60	nitric oxide synthase, inducible	Cavia porcellus	2-23
16567131-2	2006	The NK1 receptor agonist septide (1-100 nM) induced dose-dependent contractions which were reduced by atropine and augmented by L-NNA.	Nitroarginine	128-133	tachykinin receptor 1	Mus musculus	4-16
16819295-7	2006	Similarly KT-5823 (1 microM) or RP-8-CPT-cGMPS (10 microM), inhibitors of protein kinase G (PKG) blocked the effect of VIP (50 nM) on pacemaker potentials as did N-nitro-L-arginine (L-NA, 100 mM), a non-selective nitric oxide synthase (NOS) inhibitor.	Nitroarginine	162-180	vasoactive intestinal polypeptide	Mus musculus	119-122
17569362-7	2006	(3) N.-Nitro-L-arginine (L-NNA) significantly decreased the content of iNOS, NO and SOD in all above tissues and serum, and also decreased the content of cNOS in lung and kidney tissues and serum.	Nitroarginine	4-23	nitric oxide synthase 3, endothelial cell	Mus musculus	154-158
17569362-7	2006	(3) N.-Nitro-L-arginine (L-NNA) significantly decreased the content of iNOS, NO and SOD in all above tissues and serum, and also decreased the content of cNOS in lung and kidney tissues and serum.	Nitroarginine	25-30	nitric oxide synthase 2, inducible	Mus musculus	71-75
17569362-7	2006	(3) N.-Nitro-L-arginine (L-NNA) significantly decreased the content of iNOS, NO and SOD in all above tissues and serum, and also decreased the content of cNOS in lung and kidney tissues and serum.	Nitroarginine	25-30	nitric oxide synthase 3, endothelial cell	Mus musculus	154-158
17569362-12	2006	L-NNA, non-selective inhibitor of NOS, aggravates damage of tissues and increases mortality, though it can reduce the increase of iNOS and NO induced by lipopolysaccharide.	Nitroarginine	0-5	nitric oxide synthase 2, inducible	Mus musculus	130-134
16628357-7	2006	However, compared with the model group, L-NNA-induced cardiac hypertrophy of rats was significantly relieved in simvastatin treatment groups, associated with improved left ventricular function, decreased LVMI, lower BNP levels in plasma and myocardium, lower content of myocardial hydroxyproline, and increased myocardial heme oxygenase (HO) activity.	Nitroarginine	40-45	natriuretic peptide B	Rattus norvegicus	216-219
16612843-3	2006	Endothelium removal or N(G)-nitro-L-arginine (L-NOARG) enhanced contractions to endothelin-1 either in control and diabetic arteries.	Nitroarginine	23-44	endothelin-1	Oryctolagus cuniculus	80-92
16581065-10	2006	Deactivation of sensory nerves with capsaicin or inhibition of cNOS by L-NNA significantly attenuated the protective activity of ghrelin and accompanying increase in the GBF.	Nitroarginine	71-76	nitric oxide synthase 3	Rattus norvegicus	63-67
16581065-10	2006	Deactivation of sensory nerves with capsaicin or inhibition of cNOS by L-NNA significantly attenuated the protective activity of ghrelin and accompanying increase in the GBF.	Nitroarginine	71-76	ghrelin and obestatin prepropeptide	Rattus norvegicus	129-136
16612843-3	2006	Endothelium removal or N(G)-nitro-L-arginine (L-NOARG) enhanced contractions to endothelin-1 either in control and diabetic arteries.	Nitroarginine	46-53	endothelin-1	Oryctolagus cuniculus	80-92
16612843-5	2006	In contrast to that observed in rubbed and in L-NOARG treated arteries, in the presence of indomethacin the contractile action of endothelin-1 was higher in diabetic arteries than in control arteries.	Nitroarginine	46-53	endothelin-1	Oryctolagus cuniculus	130-142
16278821-9	2006	In vitro, in the A431 human squamous carcinoma cell line, exogenous and endogenous stimulation of the iNOS pathway led to up-regulation of VEGF-C, which was blocked by the NOS inhibitor L-NNA.	Nitroarginine	186-191	nitric oxide synthase 2	Homo sapiens	102-106
16470315-5	2006	Nomeganitro-L-arginine (L-NOARG) reduced CCK-8S- and cerulein-induced relaxation (IC50: 5.2; 95% CI: 2.5-18 microM) in a concentration-dependent manner.	Nitroarginine	0-22	cholecystokinin	Rattus norvegicus	41-44
16470315-5	2006	Nomeganitro-L-arginine (L-NOARG) reduced CCK-8S- and cerulein-induced relaxation (IC50: 5.2; 95% CI: 2.5-18 microM) in a concentration-dependent manner.	Nitroarginine	24-31	cholecystokinin	Rattus norvegicus	41-44
16470315-6	2006	The magnitude of 300 nM CCK-8S-induced relaxation was reduced by 100 microM L-NOARG from 73 +/- 5.1 to 19 +/- 3.5% in an L-arginine but not D-arginine preventable manner.	Nitroarginine	76-83	cholecystokinin	Rattus norvegicus	24-27
16278821-9	2006	In vitro, in the A431 human squamous carcinoma cell line, exogenous and endogenous stimulation of the iNOS pathway led to up-regulation of VEGF-C, which was blocked by the NOS inhibitor L-NNA.	Nitroarginine	186-191	vascular endothelial growth factor C	Homo sapiens	139-145
16288975-5	2006	The selective constitutive NOS (cNOS) inhibitor N(G)-nitro-L-arginine (L-NNA; 20 mg/kg, ip; 1 h after endotoxin) partially attenuated endotoxin-induced decrease in MAP.	Nitroarginine	48-69	nitric oxide synthase 3	Rattus norvegicus	14-30
16288975-5	2006	The selective constitutive NOS (cNOS) inhibitor N(G)-nitro-L-arginine (L-NNA; 20 mg/kg, ip; 1 h after endotoxin) partially attenuated endotoxin-induced decrease in MAP.	Nitroarginine	48-69	nitric oxide synthase 3	Rattus norvegicus	32-36
16288975-5	2006	The selective constitutive NOS (cNOS) inhibitor N(G)-nitro-L-arginine (L-NNA; 20 mg/kg, ip; 1 h after endotoxin) partially attenuated endotoxin-induced decrease in MAP.	Nitroarginine	71-76	nitric oxide synthase 3	Rattus norvegicus	14-30
16288975-5	2006	The selective constitutive NOS (cNOS) inhibitor N(G)-nitro-L-arginine (L-NNA; 20 mg/kg, ip; 1 h after endotoxin) partially attenuated endotoxin-induced decrease in MAP.	Nitroarginine	71-76	nitric oxide synthase 3	Rattus norvegicus	32-36
16212982-6	2005	The ir-ADM content in plasma, ventricles and aortas in L-NNA-treated animals increased by 80%, 72% and 57% (all p<0.01), respectively.	Nitroarginine	55-60	adrenomedullin	Rattus norvegicus	7-10
16226251-6	2005	Pretreatment with a NO synthase inhibitor, NG-nitro-L-arginine (L-NNA), significantly inhibited urotensin II-induced vasodilatation in young rats, but not in aged rats.	Nitroarginine	43-62	urotensin 2	Rattus norvegicus	96-108
16216381-3	2005	In the course of studies on the ubiquitylation of neuronal NOS (nNOS), we have found that certain substrate analogs, such as N(G)-nitro-L-arginine, stabilize the dimeric form of nNOS and protect the enzyme from ubiquitylation.	Nitroarginine	125-146	nitric oxide synthase 1	Homo sapiens	50-62
16216381-3	2005	In the course of studies on the ubiquitylation of neuronal NOS (nNOS), we have found that certain substrate analogs, such as N(G)-nitro-L-arginine, stabilize the dimeric form of nNOS and protect the enzyme from ubiquitylation.	Nitroarginine	125-146	nitric oxide synthase 1	Homo sapiens	64-68
16216381-3	2005	In the course of studies on the ubiquitylation of neuronal NOS (nNOS), we have found that certain substrate analogs, such as N(G)-nitro-L-arginine, stabilize the dimeric form of nNOS and protect the enzyme from ubiquitylation.	Nitroarginine	125-146	nitric oxide synthase 1	Homo sapiens	178-182
16087201-3	2005	VGF(588-617)-induced nitric oxide production was reduced by N(G)-nitro-l-arginine methylester (l-NAME) (20 microg), a nitric oxide synthase inhibitor, which also reduced penile erection when injected in the paraventricular nucleus 15 min before the VGF peptide.	Nitroarginine	60-81	VGF nerve growth factor inducible	Rattus norvegicus	0-3
16087201-3	2005	VGF(588-617)-induced nitric oxide production was reduced by N(G)-nitro-l-arginine methylester (l-NAME) (20 microg), a nitric oxide synthase inhibitor, which also reduced penile erection when injected in the paraventricular nucleus 15 min before the VGF peptide.	Nitroarginine	60-81	VGF nerve growth factor inducible	Rattus norvegicus	249-252
16226251-6	2005	Pretreatment with a NO synthase inhibitor, NG-nitro-L-arginine (L-NNA), significantly inhibited urotensin II-induced vasodilatation in young rats, but not in aged rats.	Nitroarginine	64-69	urotensin 2	Rattus norvegicus	96-108
15702482-10	2005	NOS inhibitors aminoguanidine or N(G)-nitro-L-arginine, simultaneously injected with LPS, reduced the iNOS immunoreactivity and infarct volume, especially in penumbra regions.	Nitroarginine	33-54	nitric oxide synthase 2	Rattus norvegicus	102-106
15964921-7	2005	Although inhibition of nitric oxide synthase (NOS) with N(omega)-nitro-l-arginine (l-NNA) did not alter basal HO-2 catalytic activity or CO production, l-NNA blocked glutamate stimulation of HO-2 activity and CO production.	Nitroarginine	56-81	nitric oxide synthase 2	Homo sapiens	23-44
15964921-7	2005	Although inhibition of nitric oxide synthase (NOS) with N(omega)-nitro-l-arginine (l-NNA) did not alter basal HO-2 catalytic activity or CO production, l-NNA blocked glutamate stimulation of HO-2 activity and CO production.	Nitroarginine	152-157	heme oxygenase 2	Homo sapiens	191-195
15792990-1	2005	Smooth muscle membrane potential (E(m)) depends on K(+) channels, and arteries from rats made hypertensive with N(omega)-nitro-l-arginine (LHR) are depolarized compared with control.	Nitroarginine	112-137	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	139-142
16101009-9	2005	These substrate preferences were used in the design of novel reverse hydroxamate TACE inhibitors with phenethyl and 5-methyl-thiophene-methyl side-chains at P1", and threonine and nitro-arginine at P2".	Nitroarginine	180-194	ADAM metallopeptidase domain 17	Homo sapiens	81-85
16039037-1	2005	BACKGROUND: We have demonstrated previously that the nitric oxide synthase (NOS) inhibitor N(G)-nitro-L-arginine (L-NNA) decreases free radical generation and nitrosative injury via peroxynitrite formation after epicardial dc shocks.	Nitroarginine	91-112	nitric oxide synthase 2	Sus scrofa	53-74
16039037-1	2005	BACKGROUND: We have demonstrated previously that the nitric oxide synthase (NOS) inhibitor N(G)-nitro-L-arginine (L-NNA) decreases free radical generation and nitrosative injury via peroxynitrite formation after epicardial dc shocks.	Nitroarginine	114-119	nitric oxide synthase 2	Sus scrofa	53-74
16120196-14	2005	The relaxant effect of adrenomedullin was also significantly diminished by 2",5"-dideoxyadenosine, an inhibitor of adenylate cyclase, N(G)-nitro-L-arginine, an inhibitor of nitric oxide synthesis, or 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, an inhibitor of soluble guanylate cyclase.	Nitroarginine	134-155	adrenomedullin	Bos taurus	23-37
15806312-9	2005	Addition of the NOS inhibitor, L-NNA, prevented the LPS-induced decrease in Na+,K+ATPase activity, suggesting that NO is involved in the decrease of Na+,K+-ATPase activity observed in the IEC-6 cells incubated with LPS.	Nitroarginine	31-36	interferon regulatory factor 6	Homo sapiens	52-55
15806312-9	2005	Addition of the NOS inhibitor, L-NNA, prevented the LPS-induced decrease in Na+,K+ATPase activity, suggesting that NO is involved in the decrease of Na+,K+-ATPase activity observed in the IEC-6 cells incubated with LPS.	Nitroarginine	31-36	interferon regulatory factor 6	Homo sapiens	215-218
15766572-5	2005	The arginine-induced insulin release is via the production of nitric oxide, since treatment with N(G)-nitro-l-arginine, an inhibitor of nitric oxide synthase, blocks insulin secretion induced by l-arginine.	Nitroarginine	97-118	insulin	Homo sapiens	21-28
15721868-6	2005	RESULTS: Benidipine significantly inhibited protein synthesis by cardiac myocytes stimulated with phenylephrine (PE), and this effect was partially abolished by cotreatment with a nitric oxide synthase (NOS) inhibitor [N(G)-nitro-l-arginine methylester (l-NAME)].	Nitroarginine	219-240	nitric oxide synthase 1, neuronal	Mus musculus	180-201
15680470-6	2005	The following receptor blockers diminished the action of PACAP-38 on the facilitation of extinction: propranolol, haloperidol, naloxone, bicuculline and nitro-L-arginine, the latter by blocking nitric oxide formation.	Nitroarginine	153-169	adenylate cyclase activating polypeptide 1	Rattus norvegicus	57-62
15818117-14	2005	Pretreatment with L-NNA completely inhibited VEGF and PlGF vasodilation and prevented the increase in cGMP seen with both agonists.	Nitroarginine	18-23	vascular endothelial growth factor A	Homo sapiens	45-49
15818117-14	2005	Pretreatment with L-NNA completely inhibited VEGF and PlGF vasodilation and prevented the increase in cGMP seen with both agonists.	Nitroarginine	18-23	placental growth factor	Homo sapiens	54-58
15721872-8	2005	Relaxations to urocortin in endothelium-intact rings were attenuated to the same extent after treatment with N(G)-nitro-l-arginine (l-NNA) and 1H-[1,2,4]oxadizolo[4,3-a]quinoxalin-1-one (ODQ).	Nitroarginine	109-130	urocortin	Homo sapiens	15-24
15721872-8	2005	Relaxations to urocortin in endothelium-intact rings were attenuated to the same extent after treatment with N(G)-nitro-l-arginine (l-NNA) and 1H-[1,2,4]oxadizolo[4,3-a]quinoxalin-1-one (ODQ).	Nitroarginine	132-137	urocortin	Homo sapiens	15-24
15496613-3	2005	We examined the possible role of renal d-amino acid oxidase (DAAO) in the chiral inversion of d-NNA to l-NNA.	Nitroarginine	103-108	D-amino-acid oxidase	Rattus norvegicus	39-59
15816458-8	2005	Both tetrodotoxin and L-NNA inhibited the relaxation reaction in response to IL-1beta in the human colon.	Nitroarginine	22-27	interleukin 1 beta	Homo sapiens	77-85
15496613-3	2005	We examined the possible role of renal d-amino acid oxidase (DAAO) in the chiral inversion of d-NNA to l-NNA.	Nitroarginine	103-108	D-amino-acid oxidase	Rattus norvegicus	61-65
15588145-8	2005	L-NNA treatment (2 x 25 mg/kg) caused aggravation of edematous AP to the necrotizing situation, and increased IL-6 and hematocrit levels.	Nitroarginine	0-5	interleukin 6	Homo sapiens	110-114
16259727-11	2005	Ghrelin-induced protection was abolished by vagotomy and significantly attenuated by L-NNA and deactivation of afferent nerves with neurotoxic dose of capsaicin.	Nitroarginine	85-90	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
15637440-5	2005	VEGF signaling was probed using NO synthase inhibition (L-NNA), calcium channel blockade (lanthanum chloride) and withdrawal (calcium-free solution), and inhibitors of the PLC-PKC cascade (U-73122 and chelerythrine chloride, respectively).	Nitroarginine	56-61	vascular endothelial growth factor A	Rattus norvegicus	0-4
15807279-10	2005	However, in group LIR+L-NNA, the pulmonary edema was even more severe, the MPO activity and MDA content were significantly higher those that in group LIR or group LIR+L-Arg (P<0.01).	Nitroarginine	22-27	myeloperoxidase	Oryctolagus cuniculus	75-78
15984155-7	2005	Both Nomega-nitro-L-arginine (L-NNA) and Nomega-nitro-L-arginine methyl ester (L-NAME), inhibitors for both iNOS and eNOS, delayed cumulus expansion, inhibited cumulus cell DNA fragmentation and inhibited CEOs to resume meiosis.	Nitroarginine	5-28	nitric oxide synthase 2	Homo sapiens	108-112
16259750-10	2005	Indomethacin which suppressed PG generation by about 90%, while augmenting WRS damage, and L-NNA, that suppressed NO-synthase activity, significantly attenuated the protective and hyperaemic activity of this PPAR-gamma ligand.	Nitroarginine	91-96	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	208-218
15841719-3	2005	MATERIAL AND METHODS: The collateral vascular responsiveness to graded concentrations of AVP (10(-10) - 3 x 10(-7) M) was tested by an in situ collateral perfusion system pretreated with Nomega-nitro-L-arginine (L-NNA, 100 microM), indomethacin (INDO, 10 microM), or both.	Nitroarginine	187-210	arginine vasopressin	Rattus norvegicus	89-92
15841719-3	2005	MATERIAL AND METHODS: The collateral vascular responsiveness to graded concentrations of AVP (10(-10) - 3 x 10(-7) M) was tested by an in situ collateral perfusion system pretreated with Nomega-nitro-L-arginine (L-NNA, 100 microM), indomethacin (INDO, 10 microM), or both.	Nitroarginine	212-217	arginine vasopressin	Rattus norvegicus	89-92
15841719-7	2005	Incubation with L-NNA or L-NNA plus INDO, but not INDO alone, significantly potentiated the constrictive effects of AVP.	Nitroarginine	16-21	arginine vasopressin	Rattus norvegicus	116-119
15841719-7	2005	Incubation with L-NNA or L-NNA plus INDO, but not INDO alone, significantly potentiated the constrictive effects of AVP.	Nitroarginine	25-30	arginine vasopressin	Rattus norvegicus	116-119
15265762-9	2004	Inhibition of NOS with N(omega)-nitro-l-arginine and N(omega)-methyl-l-arginine reduced AICAR-stimulated glucose uptake by 21 +/- 3% (P < 0.05) and 25 +/- 4% (P < 0.05), respectively.	Nitroarginine	23-48	5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase	Homo sapiens	88-93
15319202-1	2004	We reported previously that endothelium-intact superior mesenteric arteries (SMA) from N(omega)-nitro-L-arginine (L-NNA)-treated hypertensive rats (LHR) contract more to norepinephrine (NE) than SMA from control rats.	Nitroarginine	87-112	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	148-151
15319202-1	2004	We reported previously that endothelium-intact superior mesenteric arteries (SMA) from N(omega)-nitro-L-arginine (L-NNA)-treated hypertensive rats (LHR) contract more to norepinephrine (NE) than SMA from control rats.	Nitroarginine	114-119	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	148-151
15613736-5	2004	The nicotine-induced increase in ACTH and corticosterone response was significantly supressed by piroxicam, and diminished by indomethacin, but was significantly augmented by L-NAME and L-NNA.	Nitroarginine	186-191	proopiomelanocortin	Homo sapiens	33-37
15613736-17	2004	COX blockers did not significantly affect the CRH-induced HPA response and the inhibition of NO synthesis by L-NNA markedly intensified ACTH response.	Nitroarginine	109-114	proopiomelanocortin	Homo sapiens	136-140
16359238-5	2005	L-tryptophan, an inhibitor of IDO, completely blocked the antiviral activity of IFN-gamma against vaccinia virus in 143B cells, an human osteosarcoma cell line, whereas N(G)-methyl-L-arginine, a NOS2 inhibitor, did not.	Nitroarginine	169-191	nitric oxide synthase 2	Homo sapiens	195-199
15610479-4	2004	Contrary to this, N(G)-nitro-L-arginine (L-NOARG) (10(-5) M) inhibited relaxation is evoked by VIP.	Nitroarginine	18-39	vasoactive intestinal peptide	Canis lupus familiaris	95-98
15610479-4	2004	Contrary to this, N(G)-nitro-L-arginine (L-NOARG) (10(-5) M) inhibited relaxation is evoked by VIP.	Nitroarginine	41-48	vasoactive intestinal peptide	Canis lupus familiaris	95-98
15610479-6	2004	In the presence of both L-NOARG and L-NOARG + indomethacin, 4-AP led to the further inhibition of VIP-induced relaxation of canine uterine artery.	Nitroarginine	24-31	vasoactive intestinal peptide	Canis lupus familiaris	98-101
15610479-6	2004	In the presence of both L-NOARG and L-NOARG + indomethacin, 4-AP led to the further inhibition of VIP-induced relaxation of canine uterine artery.	Nitroarginine	36-43	vasoactive intestinal peptide	Canis lupus familiaris	98-101
15610930-0	2004	Litter has an effect on the behavioural changes caused by the administration of the nitric oxide synthase inhibitor NG-nitro-L-arginine and ethanol in mice.	Nitroarginine	116-135	nitric oxide synthase 1, neuronal	Mus musculus	84-105
15644939-7	2004	The relaxing response of nociceptin in coronary arteries was significantly reduced by removal of endothelium and by the presence of L-NNA, cGMP, and [Nphe1]NC(1-13)NH2, the selective nociceptin receptor antagonist, but not by naloxone, the nonselestive opioid receptor blocker or propranolol, which blocks the adrenergic beta-receptor.	Nitroarginine	132-137	prepronociceptin	Homo sapiens	25-35
15501531-2	2004	In basilar arteries isolated from diabetic rats: (a) the ET-1-induced contraction was enhanced, (b) the contraction induced by N(G)-nitro-l-arginine [a nitric oxide synthase (NOS) inhibitor] was weaker, and (c) the levels of the mRNAs for ET(A)/ET(B) receptors and prepro-ET-1, but not for NOS, were significantly elevated (all versus age-matched controls).	Nitroarginine	127-148	endothelin receptor type A	Rattus norvegicus	239-244
15501531-2	2004	In basilar arteries isolated from diabetic rats: (a) the ET-1-induced contraction was enhanced, (b) the contraction induced by N(G)-nitro-l-arginine [a nitric oxide synthase (NOS) inhibitor] was weaker, and (c) the levels of the mRNAs for ET(A)/ET(B) receptors and prepro-ET-1, but not for NOS, were significantly elevated (all versus age-matched controls).	Nitroarginine	127-148	endothelin 1	Rattus norvegicus	272-276
15451549-6	2004	Cytotoxicity assay showed that nicotine enhanced LPS (20 ng/ml) and IFN-gamma (10 ng/ml)-induced cytotoxicity, which was inhibited by an NOS inhibitor N-nitro-L-arginine (NLA) in RAW264.7 cells.	Nitroarginine	151-169	interferon gamma	Mus musculus	68-77
15505501-8	2004	Pretreatment of INDO or L-NNA + HbO significantly (P < 0.001) inhibited the relaxation by VEGF (21.2 +/- 3.9% or 23.3 +/- 4.3%) and KDR-SM (9.8 +/- 8.2% or 10.1 +/- 17.8%).	Nitroarginine	24-29	vascular endothelial growth factor A	Homo sapiens	93-97
15505501-8	2004	Pretreatment of INDO or L-NNA + HbO significantly (P < 0.001) inhibited the relaxation by VEGF (21.2 +/- 3.9% or 23.3 +/- 4.3%) and KDR-SM (9.8 +/- 8.2% or 10.1 +/- 17.8%).	Nitroarginine	24-29	kinase insert domain receptor	Homo sapiens	135-138
15610930-1	2004	The aim of the work was to study the effects of litter and the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine (L-NOARG) on the behaviour of mice after acute and chronic ethanol administration and withdrawal.	Nitroarginine	101-120	nitric oxide synthase 1, neuronal	Mus musculus	63-84
15610930-1	2004	The aim of the work was to study the effects of litter and the nitric oxide synthase (NOS) inhibitor NG-nitro-L-arginine (L-NOARG) on the behaviour of mice after acute and chronic ethanol administration and withdrawal.	Nitroarginine	122-129	nitric oxide synthase 1, neuronal	Mus musculus	63-84
15453990-4	2004	Topical uPA (10(-9), 10(-7) M) elicited pial artery dilation that was blunted by the NO synthase inhibitor, L-NNA (10(-6) M) (8 +/- 1% and 13 +/- 1 vs. 3 +/- 1% and 7 +/- 2%, respectively).	Nitroarginine	108-113	plasminogen activator, urokinase	Sus scrofa	8-11
15595686-6	2004	But L-NNA could significantly inhibit the abstinent syndrome, decrease NOS positive cells and apoptosis, and increase CaM content and the activity of SOD and GSHPx in the testis.	Nitroarginine	4-9	glutathione peroxidase 1	Rattus norvegicus	158-163
15655306-7	2004	In the presence of nitroarginine, SIN-1 (10(-9)-10(-7) M) reduced the amplitude and frequency of slow potentials: low concentrations (<10(-8) M) reduced only the frequency of slow potentials, while higher concentrations (10(-8)-10(-7) M) reduced both the amplitude and frequency of slow potentials, in a concentration-dependent manner, before abolishing the slow potentials.	Nitroarginine	19-32	MAPK associated protein 1	Homo sapiens	34-39
15339862-4	2004	Pretreatment with indomethacin or N(G) nitro-l-arginine methylester (l-NAME) reduced the mesenteric vasodilator response to hUII, and abolished the late tachycardia and hindquarters vasodilatation.	Nitroarginine	34-55	urotensin 2	Homo sapiens	124-128
15235101-7	2004	Treatment of nNOS with NG-nitro-L-arginine or 7-nitroindazole led to stabilization of the dimeric nNOS and decreased proteasomal degradation of the enzyme, consistent with that observed in cells.	Nitroarginine	23-42	nitric oxide synthase 1	Homo sapiens	13-17
15235101-7	2004	Treatment of nNOS with NG-nitro-L-arginine or 7-nitroindazole led to stabilization of the dimeric nNOS and decreased proteasomal degradation of the enzyme, consistent with that observed in cells.	Nitroarginine	23-42	nitric oxide synthase 1	Homo sapiens	98-102
15177919-5	2004	Ghrelin-induced protection was abolished by vagotomy and attenuated by suppression of COX, deactivation of afferent nerves with neurotoxic dose of capsaicin or CGRP(8-37) and by inhibition of NOS with L-NNA but not influenced by medullectomy and administration of 6-hydroxydopamine.	Nitroarginine	201-206	ghrelin and obestatin prepropeptide	Rattus norvegicus	0-7
15297024-4	2004	N-Nitro-L-arginine, an inhibitor of nitric oxide synthase, inhibited NAG-ST-induced rise in nitric oxide level and also calcium influx.	Nitroarginine	0-18	sodium voltage-gated channel alpha subunit 7	Rattus norvegicus	69-72
15186217-7	2004	Addition of the nitric oxide inhibitor nitroarginine to FRK/RAK knockout islets exposed to cytokines decreased cell death to a basal level.	Nitroarginine	39-52	fyn-related kinase	Mus musculus	56-59
15186217-7	2004	Addition of the nitric oxide inhibitor nitroarginine to FRK/RAK knockout islets exposed to cytokines decreased cell death to a basal level.	Nitroarginine	39-52	fyn-related kinase	Mus musculus	60-63
15153526-5	2004	N(G)-nitro-L-arginine methylester further stimulated this immune reaction to IFN-gamma and TNF-alpha, but the brain of these mice failed to exhibit signs of neurodegeneration and demyelination.	Nitroarginine	0-21	interferon gamma	Mus musculus	77-86
15283756-7	2004	Pre-treatment with N(G)-Nitro-L-arginine-methylester (l-NAME) (10(-4) mol L(-1)) increased the Ang II sensitivity in retrograde (17 +/- 9%) and orthograde perfused Ef (19 +/- 9%).	Nitroarginine	19-40	angiotensinogen (serpin peptidase inhibitor, clade A, member 8)	Mus musculus	95-101
15253725-3	2004	METHODS: In anesthetized rats, N-nitro-L-arginine methylester (L-NAME) was used for nonselective inhibition of nitric oxide synthesis and 7-nitroindazole (7-NI) for inactivation of neuronal isoform of nitric oxide synthase (nNOS).	Nitroarginine	31-49	nitric oxide synthase 1	Rattus norvegicus	224-228
14962849-5	2004	l-NNA and eNOS deletion, but not nNOS or iNOS deletion, increased pancreatic trypsin activity and serum lipase during the initiation phase of in vivo caerulein-induced AP.	Nitroarginine	0-5	lipase, endothelial	Mus musculus	104-110
15213268-10	2004	Rats treated with Nomega-nitro-L-arginine-methyl-esther and losartan presented a decreased local AngII formation, in contrast to its known effect on plasma AngII.	Nitroarginine	18-41	angiotensinogen	Rattus norvegicus	97-102
15213268-10	2004	Rats treated with Nomega-nitro-L-arginine-methyl-esther and losartan presented a decreased local AngII formation, in contrast to its known effect on plasma AngII.	Nitroarginine	18-41	angiotensinogen	Rattus norvegicus	156-161
15136793-5	2004	Pretreatment with the NO synthase (NOS) inhibitor L-NG-nitro arginine antagonized the effects of both chlordiazepoxide and THIP; similar pretreatment with the D-isomer, D-NG-nitro arginine, which is inactive as an NOS inhibitor, was without effect on chlordiazepoxide and THIP.	Nitroarginine	50-69	nitric oxide synthase 1, neuronal	Mus musculus	22-33
15167278-5	2004	The BK-induced hyperpolarization was significantly reduced by N-nitro-L-arginine, indomethacin, and hemoglobin in both arteries and veins and was greater in the arteries.	Nitroarginine	62-80	kininogen 1	Homo sapiens	4-6
15153526-5	2004	N(G)-nitro-L-arginine methylester further stimulated this immune reaction to IFN-gamma and TNF-alpha, but the brain of these mice failed to exhibit signs of neurodegeneration and demyelination.	Nitroarginine	0-21	tumor necrosis factor	Mus musculus	91-100
15108356-10	2004	TNF-alpha-induced decrease in the number of wild-type cells was significantly prevented by culture with N omega-nitro-L-arginine (10(-4) M), an inhibitor of caspase.	Nitroarginine	104-128	tumor necrosis factor	Rattus norvegicus	0-9
14759550-5	2004	Since relaxation was also significantly inhibited by NG-nitro-L-arginine (N5-nitro-amidino-L-2,5-diamino-pentanoic acid: L-NOARG), the neurogenic effect of PACAP seems to be mediated mainly through nitric oxide neurons.	Nitroarginine	53-72	adenylate cyclase activating polypeptide 1	Rattus norvegicus	156-161
14759550-5	2004	Since relaxation was also significantly inhibited by NG-nitro-L-arginine (N5-nitro-amidino-L-2,5-diamino-pentanoic acid: L-NOARG), the neurogenic effect of PACAP seems to be mediated mainly through nitric oxide neurons.	Nitroarginine	74-119	adenylate cyclase activating polypeptide 1	Rattus norvegicus	156-161
14751407-3	2004	Endothelium removal or N(G)-nitro-L-arginine enhanced contractions in response to endothelin-1 only in control arteries, without modifying the endothelin-1 response in diabetic arteries.	Nitroarginine	23-44	endothelin-1	Oryctolagus cuniculus	82-94
14668338-4	2004	The interferon-gamma-induced inhibition of ASK1 activity was blocked by N(G)-nitro-l-arginine, an inhibitor of NO synthase.	Nitroarginine	72-93	interferon gamma	Mus musculus	4-20
14668338-4	2004	The interferon-gamma-induced inhibition of ASK1 activity was blocked by N(G)-nitro-l-arginine, an inhibitor of NO synthase.	Nitroarginine	72-93	mitogen-activated protein kinase kinase kinase 5	Mus musculus	43-47
14985051-4	2004	N(G)-nitro-L-arginine (L-NOArg) enhanced the maximal contraction induced by endothelin-1 in control rabbits and potentiated this response in diabetic rabbits.	Nitroarginine	0-21	endothelin-1	Oryctolagus cuniculus	76-88
14985051-4	2004	N(G)-nitro-L-arginine (L-NOArg) enhanced the maximal contraction induced by endothelin-1 in control rabbits and potentiated this response in diabetic rabbits.	Nitroarginine	23-30	endothelin-1	Oryctolagus cuniculus	76-88
15086361-10	2004	Pretreatment of NNA or NNA plus INDO equivalently enhanced the response of ET-1 while pretreatment of INDO alone exerted no effect.	Nitroarginine	16-19	endothelin 1	Rattus norvegicus	75-79
15086361-10	2004	Pretreatment of NNA or NNA plus INDO equivalently enhanced the response of ET-1 while pretreatment of INDO alone exerted no effect.	Nitroarginine	23-26	endothelin 1	Rattus norvegicus	75-79
14701803-3	2004	A NOS inhibitor, N(G)-methyl-l-arginine, enhanced the tumor necrosis factor-alpha (TNF-alpha)-induced cleavage of procaspase-9, procaspase-3, and poly-(ADP-ribose) polymerase, as well as the level of apoptosis.	Nitroarginine	17-39	tumor necrosis factor	Homo sapiens	54-81
14701803-3	2004	A NOS inhibitor, N(G)-methyl-l-arginine, enhanced the tumor necrosis factor-alpha (TNF-alpha)-induced cleavage of procaspase-9, procaspase-3, and poly-(ADP-ribose) polymerase, as well as the level of apoptosis.	Nitroarginine	17-39	tumor necrosis factor	Homo sapiens	83-92
14701803-3	2004	A NOS inhibitor, N(G)-methyl-l-arginine, enhanced the tumor necrosis factor-alpha (TNF-alpha)-induced cleavage of procaspase-9, procaspase-3, and poly-(ADP-ribose) polymerase, as well as the level of apoptosis.	Nitroarginine	17-39	caspase 3	Homo sapiens	128-140
15019645-6	2004	EDHF-mediated hyperpolarization was elicited by BK (-6.5 log M) in the presence of Indo, l-NNA and HbO.	Nitroarginine	89-94	kininogen 1	Homo sapiens	48-50
15061157-0	2004	The nitric oxide synthase inhibitor N(G)-nitro-L-arginine decreases defibrillation-induced free radical generation.	Nitroarginine	36-57	nitric oxide synthase 3	Canis lupus familiaris	4-25
15061157-1	2004	OBJECTIVES: to demonstrate that nitric oxide (NO) contributes to free radical generation after epicardial shocks and to determinethe effect of a nitric oxide synthase (NOS) inhibitor, N(G)-nitro-L-arginine (L-NNA), on free radical generation.	Nitroarginine	184-205	nitric oxide synthase 3	Canis lupus familiaris	145-166
15170073-5	2004	The ET-1 content of the perfusate was significantly increased following combined pretreatment with L-NOARG, MB, TEA, and indomethacin at a high flow rate.	Nitroarginine	99-106	endothelin 1	Rattus norvegicus	4-8
14597853-9	2003	L-NNA, valsartan and PD-123319 also abolished endothelium-dependent vasorelaxant responses to ACh and Ca(2+) ionophore A23187 in the presence of ang II.	Nitroarginine	0-5	angiotensinogen	Rattus norvegicus	145-151
14736250-2	2004	We previously reported nitroarginine-containing dipeptide amides and some peptidomimetic analogues as potent and selective inhibitors of neuronal NOS (nNOS).	Nitroarginine	23-36	nitric oxide synthase 1	Homo sapiens	137-149
14736250-2	2004	We previously reported nitroarginine-containing dipeptide amides and some peptidomimetic analogues as potent and selective inhibitors of neuronal NOS (nNOS).	Nitroarginine	23-36	nitric oxide synthase 1	Homo sapiens	151-155
12966154-4	2003	Descending relaxation was accompanied by vasoactive intestinal peptide (VIP) release, a marker for inhibitory neurotransmitter release, into the caudad compartment, and was partly inhibited by VIP10-28 and NG-nitro-L-arginine, and abolished by a combination of the two agents.	Nitroarginine	206-225	vasoactive intestinal polypeptide	Mus musculus	72-75
15003711-6	2004	PACAP antiserum, a PACAP antagonist (PACAP 6-38), haloperidol, phenoxybenzamine, propranolol and naloxone each prevented the changes observed at 30 min and 3 h. Atropine, nitro-l-arginine, bicuculline and methysergide were ineffective.	Nitroarginine	171-187	adenylate cyclase activating polypeptide 1	Rattus norvegicus	0-5
14662737-9	2004	However, the PACAP 38 relaxations were reduced by omega-CgTX, capsaicin, l-NOARG and ODQ.	Nitroarginine	73-80	adenylate cyclase activating polypeptide 1	Sus scrofa	13-18
14515363-3	2003	Studies were performed in piglets, 3-5 days old, divided into normoxic (n = 5), hypoxic (n = 5), and NO synthase (NOS) inhibitor N-nitro-L-arginine (NNLA)-treated hypoxic (n = 5) groups.	Nitroarginine	129-147	nitric oxide synthase 2	Homo sapiens	101-112
14597982-5	2003	The insulin-induced inhibition of aggregation was accompanied by a decreased Ca(2+) response to thrombin and was also prevented by N(omega) nitro-L-arginine.	Nitroarginine	131-156	insulin	Homo sapiens	4-11
12730058-6	2003	In the presence of superoxide dismutase and catalase, l-NNA-induced vasoconstriction is reduced, and the dilation observed after addition of MA in presence of the reactive oxygen species is no longer present.	Nitroarginine	54-59	catalase	Rattus norvegicus	44-52
12890708-4	2003	(3) The potency of ANP and CNP in aortae from WT animals was increased in the presence of the NOS inhibitor, N(G)-nitro-L-arginine (3 x 10(-4) M) and the soluble guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolol[4,3,a]quinoxalin-1-one (5 x 10(-6) M).	Nitroarginine	109-130	2',3'-cyclic nucleotide 3' phosphodiesterase	Mus musculus	27-30
12938164-10	2003	Introducing the nitric oxide synthase (NOS) inhibitors N(G)-methyl-l-arginine or N-omega nitro-l-arginine diminished the effects of CTS on the production of nitrite oxide and proteoglycans.	Nitroarginine	55-77	nitric oxide synthase, brain	Oryctolagus cuniculus	16-37
12938164-10	2003	Introducing the nitric oxide synthase (NOS) inhibitors N(G)-methyl-l-arginine or N-omega nitro-l-arginine diminished the effects of CTS on the production of nitrite oxide and proteoglycans.	Nitroarginine	81-105	nitric oxide synthase, brain	Oryctolagus cuniculus	16-37
12907314-6	2003	The nitric oxide synthase (NOS) substrate, L-arginine (60 mg/kg), inhibited the anticonvulsant property of agmatine and this effect was significantly reversed by NOS inhibitor N(G)-nitro-L-arginine (L-NAME, 30 mg/kg), implying an NO-dependent mechanism for L-arginine effect.	Nitroarginine	176-197	nitric oxide synthase 1, neuronal	Mus musculus	4-25
12829651-7	2003	L-NNA abolished C-peptide effects on nerve conduction.	Nitroarginine	0-5	insulin 2	Rattus norvegicus	16-25
12829651-9	2003	C-peptide partially (57-66%) corrected these defects, an effect markedly attenuated by L-NNA co-treatment.	Nitroarginine	87-92	insulin 2	Rattus norvegicus	0-9
12824821-8	2003	The ACTH response to acute intragastric alcohol injection was significantly (p < 0.01) decreased by the arginine derivative N omega-nitro-L-arginine-methylester, which nonspecifically blocks NOS activity, as well as by the specific neuronal NOS antagonist 7-nitroindazole.	Nitroarginine	127-151	proopiomelanocortin	Homo sapiens	4-8
12781340-4	2003	Inhibition of endogenous nitric oxide formation using N(omega)-nitro-L-arginine resulted in a 20% increase in leptin release over 48 hr, which suggests that the nitric oxide/cyclic GMP pathway might play a small role in the regulation of endogenous leptin release.	Nitroarginine	54-79	5'-nucleotidase, cytosolic II	Homo sapiens	181-184
12763764-3	2003	METHODS AND RESULTS: Isometric tension and membrane-potential recordings demonstrated that bradykinin and substance P caused EDHF-mediated relaxations and hyperpolarizations of porcine coronary microvessels in the presence of indomethacin and Nomega-nitro-L-arginine.	Nitroarginine	243-266	kininogen 1	Homo sapiens	91-101
12763764-3	2003	METHODS AND RESULTS: Isometric tension and membrane-potential recordings demonstrated that bradykinin and substance P caused EDHF-mediated relaxations and hyperpolarizations of porcine coronary microvessels in the presence of indomethacin and Nomega-nitro-L-arginine.	Nitroarginine	243-266	tachykinin precursor 1	Homo sapiens	106-117
12827025-3	2003	In the presence of indomethacin (10 microM) and Nomega-nitro-L-arginine (100 microM), irbesartan, valsartan, and EXP3174 induced a rightward shift of U46619- and angiotensin II-induced contraction.	Nitroarginine	48-71	angiotensinogen	Homo sapiens	162-176
12895429-5	2003	ET-1 produced dose-dependent contraction of aorta from eNOS+/+ mice that was increased twofold following acute inhibition of all NOS isoforms with N(G)-nitro-L-arginine (L-NNA).	Nitroarginine	147-168	endothelin 1	Mus musculus	0-4
12895429-5	2003	ET-1 produced dose-dependent contraction of aorta from eNOS+/+ mice that was increased twofold following acute inhibition of all NOS isoforms with N(G)-nitro-L-arginine (L-NNA).	Nitroarginine	170-175	endothelin 1	Mus musculus	0-4
12704544-5	2003	In vitro, VEGF produced dose-dependent relaxation of myocardial and systemic arterioles and venules (arterioles: 60-100 mm and venules: 120-200 mm in internal diameter) that was partially inhibited by L-NNA, but had no effect on epicardial coronary arteries, systemic arteries, or veins.	Nitroarginine	201-206	vascular endothelial growth factor A	Sus scrofa	10-14
12628584-6	2003	Further, we found that nitric oxide synthase inhibitor N(G)-nitro-L-arginine prevented deltamethrin-induced neuronal apoptosis and altered expression of p53, Bax, and Bcl-2.	Nitroarginine	55-76	tumor protein p53	Homo sapiens	153-156
12808474-7	2003	Pretreatment of tracheal rings with the inhibitor of NO synthase (NOS) N(omega)-nitro-L-arginine (L-NOARG; 100 microM) for 20 min prior to exposure to ROS GE-KHS decreased the ROS GE-KHS-induced relaxation.	Nitroarginine	71-96	nitric oxide synthase, inducible	Cavia porcellus	53-64
12808474-7	2003	Pretreatment of tracheal rings with the inhibitor of NO synthase (NOS) N(omega)-nitro-L-arginine (L-NOARG; 100 microM) for 20 min prior to exposure to ROS GE-KHS decreased the ROS GE-KHS-induced relaxation.	Nitroarginine	98-105	nitric oxide synthase, inducible	Cavia porcellus	53-64
12505875-7	2003	Inhibition of nitric oxide synthase (NOS) with nitro-l-arginine augmented HPV in PKC-epsilon +/+ but not -/- mice.	Nitroarginine	47-63	nitric oxide synthase 1, neuronal	Mus musculus	14-35
12505875-7	2003	Inhibition of nitric oxide synthase (NOS) with nitro-l-arginine augmented HPV in PKC-epsilon +/+ but not -/- mice.	Nitroarginine	47-63	protein kinase C, epsilon	Mus musculus	81-92
12618272-8	2003	PP1 and Nitro-L-arginine methylester (L-NAME) inhibited HGF-stimulated HUVEC growth by 51 and by 71%.	Nitroarginine	8-24	hepatocyte growth factor	Homo sapiens	56-59
12711621-8	2003	In the aortas from LDLR(-/-) mice treated with L-NNA (100 micro M), ACh induced a contractile effect.	Nitroarginine	47-52	low density lipoprotein receptor	Mus musculus	19-23
12668306-0	2003	The nitric oxide synthase inhibitor N(G)-nitro-L-arginine decreases defibrillation-induced free radical generation.	Nitroarginine	36-57	nitric oxide synthase 3	Canis lupus familiaris	4-25
12668306-1	2003	OBJECTIVES: To demonstrate that nitric oxide (NO) contributes to free radical generation after epicardial shocks and to determine the effect of a nitric oxide synthase (NOS) inhibitor, N(G)-nitro-L-arginine (L-NNA), on free radical generation.	Nitroarginine	185-206	nitric oxide synthase 3	Canis lupus familiaris	146-167
12524425-7	2003	Chronic inhibition of NO synthesis in N(omega)-nitro-l-arginine-treated rats induced a strong decrease in RhoA mRNA and protein expression in aorta and pulmonary artery associated with inhibition of RhoA-mediated Ca(2+) sensitization.	Nitroarginine	38-63	ras homolog family member A	Rattus norvegicus	106-110
12524425-7	2003	Chronic inhibition of NO synthesis in N(omega)-nitro-l-arginine-treated rats induced a strong decrease in RhoA mRNA and protein expression in aorta and pulmonary artery associated with inhibition of RhoA-mediated Ca(2+) sensitization.	Nitroarginine	38-63	ras homolog family member A	Rattus norvegicus	199-203
12605012-8	2003	The NK(1) receptor-mediated relaxations were abolished by removing the endothelium or by a combination of -nitro-L-arginine and indomethacin, whereas each compound exerted a partial inhibitory effect.	Nitroarginine	106-123	tachykinin receptor 1	Homo sapiens	4-18
12628584-6	2003	Further, we found that nitric oxide synthase inhibitor N(G)-nitro-L-arginine prevented deltamethrin-induced neuronal apoptosis and altered expression of p53, Bax, and Bcl-2.	Nitroarginine	55-76	BCL2 associated X, apoptosis regulator	Homo sapiens	158-161
12628584-6	2003	Further, we found that nitric oxide synthase inhibitor N(G)-nitro-L-arginine prevented deltamethrin-induced neuronal apoptosis and altered expression of p53, Bax, and Bcl-2.	Nitroarginine	55-76	BCL2 apoptosis regulator	Homo sapiens	167-172
12527143-10	2003	L-NNA reversed this vascular effect of somatostatin.	Nitroarginine	0-5	somatostatin	Rattus norvegicus	39-51
12560128-6	2003	Pretreatment with N(G)-methyl-L-arginine (L-NMMA), an inhibitor of NO synthase, attenuated the increases in the BP and HR induced by direct perfusion of 0.45 M saline, while direct infusion of 3-morpholinosyndnonimine (SIN-1, a NO donor) in the PVN region induced increases in the BP and HR.	Nitroarginine	18-40	MAPK associated protein 1	Homo sapiens	219-224
12445887-4	2002	Non-selective antagonism of endothelin receptors, with PD-142893, uncovered insulin-induced vasodilatation (25+/-8% from baseline at 3.4 mU/ml), which was abolished by inhibition of NO synthesis with N(G)-nitro-L-arginine (L-NA).	Nitroarginine	200-221	insulin	Homo sapiens	76-83
12522071-10	2003	5 The present study demonstrates that in femoral artery rings from young piglets, despite an L-NOARG/IM-resistant component sensitive to K(+) channel blockade with CTX and apamin, ACh-induced relaxation is abolished by sGC-inhibition or a combination of L-NOARG and HbO.	Nitroarginine	254-261	sarcoglycan beta	Homo sapiens	219-222
14509925-2	2003	Modulations of the activities of neuronal NO-synthase (nNOS) in the populations of the cardiovascular neurons within the medullary nuclei which are involved in the reflector cardiovascular control were induced by intramedullary injections of sodium nitroprusside as NO donor, L-arginine as NO precursor, L-NNA as an inhibitor of NOS, as well as by intraperetoneal injections of 7-nitroindazol (nNOS inhibitor).	Nitroarginine	304-309	nitric oxide synthase 1	Homo sapiens	33-53
14509925-2	2003	Modulations of the activities of neuronal NO-synthase (nNOS) in the populations of the cardiovascular neurons within the medullary nuclei which are involved in the reflector cardiovascular control were induced by intramedullary injections of sodium nitroprusside as NO donor, L-arginine as NO precursor, L-NNA as an inhibitor of NOS, as well as by intraperetoneal injections of 7-nitroindazol (nNOS inhibitor).	Nitroarginine	304-309	nitric oxide synthase 1	Homo sapiens	55-59
12576092-4	2003	In the presence of the NOS inhibitor N(G)-nitro-L-arginine, the responsiveness to 5-hydroxytryptamine in gastric arteries from rats treated with reserpine + adrenomedullin was enhanced to the same level of rats treated with reserpine alone.	Nitroarginine	37-58	adrenomedullin	Rattus norvegicus	157-171
12388232-2	2003	We showed previously that denuded aortic rings from N(omega)-nitro-l-arginine-treated hypertensive rats (LHR) contract more to CaCl(2) and to the alpha(2)-AR agonist UK-14304 than do rings from normotensive rats (NR).	Nitroarginine	52-77	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	105-108
12450573-3	2002	N(G)-nitro-L-arginine methylester (L-NAME), a nitric oxide (NO) synthase inhibitor, depressed or abolished the relaxation induced by low frequency stimulation, but only slightly attenuated the response to high frequency stimulation.	Nitroarginine	0-21	nitric oxide synthase 2	Sus scrofa	46-72
12527483-9	2002	Nomega-Nitro-L-arginine (L-NNA) (1.5 microg/kg) injected into the NRL/RVLM prevented the hypotensive effect of both alpha-MNA and the higher dose of brimonidine injected into the NTS.	Nitroarginine	0-23	neural retina-specific leucine zipper protein	Oryctolagus cuniculus	66-69
12444497-10	2002	L-NNA potentiated vasoconstriction to vasopressin particularly in Ficoll 400-perfused kidneys, although additional inhibition of cyclooxygenase and/or cytochrome P(450) was without effect.	Nitroarginine	0-5	arginine vasopressin	Rattus norvegicus	38-49
12527483-9	2002	Nomega-Nitro-L-arginine (L-NNA) (1.5 microg/kg) injected into the NRL/RVLM prevented the hypotensive effect of both alpha-MNA and the higher dose of brimonidine injected into the NTS.	Nitroarginine	25-30	neural retina-specific leucine zipper protein	Oryctolagus cuniculus	66-69
12535701-3	2002	Results of behavioral studies (step-down test) showed that MCH administration reverts the amnesic effects induced by N(G)-nitro-L-arginine (L-NOArg).	Nitroarginine	117-138	pro-melanin concentrating hormone	Homo sapiens	59-62
12438669-10	2002	We found that pretreatment with either nitro-L-arginine or LY294002 completely inhibited the vasodilator response to recombinant human VEGF (p < 0.005).	Nitroarginine	39-55	vascular endothelial growth factor A	Homo sapiens	135-139
12535701-3	2002	Results of behavioral studies (step-down test) showed that MCH administration reverts the amnesic effects induced by N(G)-nitro-L-arginine (L-NOArg).	Nitroarginine	140-147	pro-melanin concentrating hormone	Homo sapiens	59-62
12392504-9	2002	The decreased sensitivity to Ang II after 1 week of 7-NI treatment compared with control rats persisted after l-NNA infusion.	Nitroarginine	110-115	angiotensinogen	Rattus norvegicus	29-35
12381676-8	2002	L-NOARG, but not apamin, further inhibited the relaxation which persisted after the desensitization to neurotensin.	Nitroarginine	0-7	neurotensin	Rattus norvegicus	103-114
12381678-2	2002	Bradykinin-induced changes in isometric force or smooth muscle membrane potential were assessed in rings of porcine renal interlobar artery preconstricted with the thromboxane analogue U46619 in the continuous presence of N(omega)-nitro-L-arginine and diclofenac to inhibit NO synthases and cyclo-oxygenases.	Nitroarginine	222-247	kininogen 1	Homo sapiens	0-10
12216068-11	2002	LPS exposure resulted in increased numbers of 4T1-GFP cells in mouse lung tissue compared to saline controls, an effect blocked by the competitive NOS inhibitor, N(G) methyl-L-arginine (NMA).	Nitroarginine	162-184	toll-like receptor 4	Mus musculus	0-3
12216068-11	2002	LPS exposure resulted in increased numbers of 4T1-GFP cells in mouse lung tissue compared to saline controls, an effect blocked by the competitive NOS inhibitor, N(G) methyl-L-arginine (NMA).	Nitroarginine	186-189	toll-like receptor 4	Mus musculus	0-3
12358795-11	2002	AEBSF or N-nitro-l-arginine (NNA) reduced BDNF-mediated PARP activation.	Nitroarginine	9-27	brain derived neurotrophic factor	Homo sapiens	42-46
12091378-2	2002	While guanidino-methylated arginines (MA) including asymmetric dimethylarginine (ADMA) and N(G)-methyl-l-arginine (NMA) are potent competitive inhibitors of nitric oxide synthase (NOS) and are released upon protein degradation, it is unknown whether their intracellular concentrations are sufficient to critically regulate neuronal NO production and secondary cellular function or injury.	Nitroarginine	91-113	nitric oxide synthase 2	Homo sapiens	157-178
12091378-2	2002	While guanidino-methylated arginines (MA) including asymmetric dimethylarginine (ADMA) and N(G)-methyl-l-arginine (NMA) are potent competitive inhibitors of nitric oxide synthase (NOS) and are released upon protein degradation, it is unknown whether their intracellular concentrations are sufficient to critically regulate neuronal NO production and secondary cellular function or injury.	Nitroarginine	115-118	nitric oxide synthase 2	Homo sapiens	157-178
12169650-4	2002	Pretreatment with N(omega)-nitro-L-arginine, a nitric oxide synthase inhibitor, or chelerythrine, a protein kinase C inhibitor (both given at doses that block late PC in this model), prevented the increase in AR protein 24 hours later, demonstrating that ischemic PC upregulates AR via nitric oxide- and protein kinase C-dependent signaling pathways.	Nitroarginine	18-43	aldo-keto reductase family 1 member B1	Oryctolagus cuniculus	209-211
12169650-4	2002	Pretreatment with N(omega)-nitro-L-arginine, a nitric oxide synthase inhibitor, or chelerythrine, a protein kinase C inhibitor (both given at doses that block late PC in this model), prevented the increase in AR protein 24 hours later, demonstrating that ischemic PC upregulates AR via nitric oxide- and protein kinase C-dependent signaling pathways.	Nitroarginine	18-43	aldo-keto reductase family 1 member B1	Oryctolagus cuniculus	279-281
12114200-5	2002	The dilation was partially inhibited by nitro-L-arginine (L-NA), an inhibitor of nitric oxide synthase (NOS), but was unaffected by indomethacin, a cyclooxygenase (COX) inhibitor.	Nitroarginine	40-56	nitric oxide synthase 2	Homo sapiens	81-102
12358795-11	2002	AEBSF or N-nitro-l-arginine (NNA) reduced BDNF-mediated PARP activation.	Nitroarginine	29-32	brain derived neurotrophic factor	Homo sapiens	42-46
12358795-11	2002	AEBSF or N-nitro-l-arginine (NNA) reduced BDNF-mediated PARP activation.	Nitroarginine	29-32	poly(ADP-ribose) polymerase 1	Homo sapiens	56-60
12193470-6	2002	Aortic homogenates from L-NNA rats also had elevated p110beta protein density, but neither L-NNA nor DOCA-salt had differences in p85alpha and p110alpha.	Nitroarginine	24-29	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta	Rattus norvegicus	53-61
12195285-0	2002	[Changes in adrenomedullin and receptor activity-modifying protein 2 mRNA in myocardium and vessels during L-NNA-induced hypertension in rats].	Nitroarginine	107-112	adrenomedullin	Rattus norvegicus	12-26
12195285-0	2002	[Changes in adrenomedullin and receptor activity-modifying protein 2 mRNA in myocardium and vessels during L-NNA-induced hypertension in rats].	Nitroarginine	107-112	receptor activity modifying protein 2	Rattus norvegicus	31-68
12358795-11	2002	AEBSF or N-nitro-l-arginine (NNA) reduced BDNF-mediated PARP activation.	Nitroarginine	9-27	poly(ADP-ribose) polymerase 1	Homo sapiens	56-60
11900796-7	2002	Nitric oxide synthase (NOS) inhibitor N(G)-nitro-L-arginine (LNNA; 10, 40 and 80 mg/kg i.p.)	Nitroarginine	38-59	nitric oxide synthase 1, neuronal	Mus musculus	0-21
12065311-6	2002	The nitric oxide synthase (NOS) inhibitor N(omega)-nitro-L-arginine (L-NNA) increased phasic pressures at all sites and ICS tone but did not abolish colonic relaxation during ileal distension in innervated loops.	Nitroarginine	42-67	nitric oxide synthase 3	Canis lupus familiaris	4-25
12065311-6	2002	The nitric oxide synthase (NOS) inhibitor N(omega)-nitro-L-arginine (L-NNA) increased phasic pressures at all sites and ICS tone but did not abolish colonic relaxation during ileal distension in innervated loops.	Nitroarginine	69-74	nitric oxide synthase 3	Canis lupus familiaris	4-25
12079003-5	2002	The nitric oxide synthase (NOS) inhibitor, N(G)-nitro-L-arginine (L-NOARG; 3 x 10(-5) M) abolished the vasodilatation by NECA but not CGS21680, indicating that nitric oxide (NO) of a non-endothelial source mediated the NECA response.	Nitroarginine	43-64	nitric oxide synthase, inducible	Cavia porcellus	4-25
12079003-5	2002	The nitric oxide synthase (NOS) inhibitor, N(G)-nitro-L-arginine (L-NOARG; 3 x 10(-5) M) abolished the vasodilatation by NECA but not CGS21680, indicating that nitric oxide (NO) of a non-endothelial source mediated the NECA response.	Nitroarginine	66-73	nitric oxide synthase, inducible	Cavia porcellus	4-25
12031632-1	2002	BACKGROUND: The objective of the study was to investigate the effects of the nitric oxide synthase (NOS) inhibitors 7-nitroindazole (7-NI), N(G)-nitro-L-arginine (L-NOARG), and N(G)-nitro-L-arginine methyl ester (L-NAME) on the behavior of mice in the staircase test.	Nitroarginine	163-170	nitric oxide synthase 1, neuronal	Mus musculus	77-98
12009388-4	2002	RESULTS: Renal arteries responded to thrombin with relaxation, which was inhibited by N(G)-nitro-L-arginine or indomethacin and reversed to contractions by the combination.	Nitroarginine	86-107	coagulation factor II, thrombin	Homo sapiens	37-45
12086980-13	2002	In the absence of Delta(9)-THC, neither PD98059 nor U0126 affected the NO-mediated relaxation of coronary artery rings but both substances induced a leftward shift in the concentration - relaxation curve to bradykinin when diclofenac and N(omega)nitro-L-arginine were present.	Nitroarginine	238-262	kininogen 1	Homo sapiens	207-217
12047915-6	2002	Pretreatment with the nitric oxide (NO) synthase inhibitor N(omega)-nitro-L-arginine (L-NNA) partly blocked the action of both LY315902 and GLP-1.	Nitroarginine	59-84	glucagon	Rattus norvegicus	140-145
12047915-6	2002	Pretreatment with the nitric oxide (NO) synthase inhibitor N(omega)-nitro-L-arginine (L-NNA) partly blocked the action of both LY315902 and GLP-1.	Nitroarginine	86-91	glucagon	Rattus norvegicus	140-145
11959627-1	2002	Nitric oxide (NO) synthase (NOS) inhibition with N(omega)-nitro-L-arginine (L-NNA) produces L-NNA hypertensive rats (LHR), which exhibit increased sensitivity to voltage-dependent Ca(2+) channel-mediated vasoconstriction.	Nitroarginine	49-74	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	92-115
11959627-1	2002	Nitric oxide (NO) synthase (NOS) inhibition with N(omega)-nitro-L-arginine (L-NNA) produces L-NNA hypertensive rats (LHR), which exhibit increased sensitivity to voltage-dependent Ca(2+) channel-mediated vasoconstriction.	Nitroarginine	49-74	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	117-120
11959627-1	2002	Nitric oxide (NO) synthase (NOS) inhibition with N(omega)-nitro-L-arginine (L-NNA) produces L-NNA hypertensive rats (LHR), which exhibit increased sensitivity to voltage-dependent Ca(2+) channel-mediated vasoconstriction.	Nitroarginine	76-81	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	92-115
11959627-1	2002	Nitric oxide (NO) synthase (NOS) inhibition with N(omega)-nitro-L-arginine (L-NNA) produces L-NNA hypertensive rats (LHR), which exhibit increased sensitivity to voltage-dependent Ca(2+) channel-mediated vasoconstriction.	Nitroarginine	76-81	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	117-120
11959627-5	2002	Superfused L-arginine hyperpolarized VSMCs from both the control and LHR groups and reversed L-NNA-induced depolarization (-44.5 +/- 1.0 vs. -45.8 +/- 2.1 mV).	Nitroarginine	93-98	luteinizing hormone/choriogonadotropin receptor	Rattus norvegicus	69-72
11900796-7	2002	Nitric oxide synthase (NOS) inhibitor N(G)-nitro-L-arginine (LNNA; 10, 40 and 80 mg/kg i.p.)	Nitroarginine	61-65	nitric oxide synthase 1, neuronal	Mus musculus	0-21
12007924-5	2002	In the presence of N(G)-nitro-L-arginine, the noradrenaline-induced contraction of aorta from diabetic rats, but not from controls, was inhibited by catalase treatment.	Nitroarginine	19-40	catalase	Rattus norvegicus	149-157
11841991-0	2002	N(omega)-nitro-L-arginine inhibits inducible HSP-70 via Ca(2+), PKC, and PKA in human intestinal epithelial T84 cells.	Nitroarginine	0-25	heat shock protein family A (Hsp70) member 4	Homo sapiens	45-51
11884382-7	2002	NOS-inhibition with N(G)-nitro-L-arginine decreased superoxide in vessels from angiotensin II-treated animals, compatible with NOS-uncoupling.	Nitroarginine	20-41	angiotensinogen	Rattus norvegicus	79-93
11841991-0	2002	N(omega)-nitro-L-arginine inhibits inducible HSP-70 via Ca(2+), PKC, and PKA in human intestinal epithelial T84 cells.	Nitroarginine	0-25	proline rich transmembrane protein 2	Homo sapiens	64-67
11841991-1	2002	The nitric oxide (NO) synthase inhibitor N(omega)-nitro-L-arginine (L-NNA) inhibits heat stress (HS)-induced NO production and the inducible 70-kDa heat shock protein (HSP-70i) in many rodent organs.	Nitroarginine	41-66	heat shock protein family A (Hsp70) member 1A	Homo sapiens	168-175
11841991-1	2002	The nitric oxide (NO) synthase inhibitor N(omega)-nitro-L-arginine (L-NNA) inhibits heat stress (HS)-induced NO production and the inducible 70-kDa heat shock protein (HSP-70i) in many rodent organs.	Nitroarginine	68-73	heat shock protein family A (Hsp70) member 1A	Homo sapiens	168-175
11841991-2	2002	We used human intestinal epithelial T84 cells to characterize the inhibitory effect of L-NNA on HS-induced HSP-70i expression.	Nitroarginine	87-92	heat shock protein family A (Hsp70) member 1A	Homo sapiens	107-114
11841991-4	2002	HS increased HSP-70i mRNA and protein in T84 cells exposed to 45 degrees C for 10 min and allowed to recover for 6 h. L-NNA treatment for 1 h before HS inhibited the induction of HSP-70i mRNA and protein, with an IC(50) of 0.0471 +/- 0.0007 microM.	Nitroarginine	118-123	heat shock protein family A (Hsp70) member 1A	Homo sapiens	13-20
11841991-4	2002	HS increased HSP-70i mRNA and protein in T84 cells exposed to 45 degrees C for 10 min and allowed to recover for 6 h. L-NNA treatment for 1 h before HS inhibited the induction of HSP-70i mRNA and protein, with an IC(50) of 0.0471 +/- 0.0007 microM.	Nitroarginine	118-123	heat shock protein family A (Hsp70) member 1A	Homo sapiens	179-186
11841991-5	2002	Because the HS-induced increase in HSP-70i mRNA and protein is Ca(2+) dependent, we measured [Ca(2+)](i) after treating cells with L-NNA.	Nitroarginine	131-136	heat shock protein family A (Hsp70) member 1A	Homo sapiens	35-42
11841991-9	2002	L-NNA effectively blocked heat shock factor-1 (HSF1) translocation from the cytosol to the nucleus, a process requiring PKC phosphorylation.	Nitroarginine	0-5	heat shock transcription factor 1	Homo sapiens	26-45
11841991-9	2002	L-NNA effectively blocked heat shock factor-1 (HSF1) translocation from the cytosol to the nucleus, a process requiring PKC phosphorylation.	Nitroarginine	0-5	heat shock transcription factor 1	Homo sapiens	47-51
11841991-9	2002	L-NNA effectively blocked heat shock factor-1 (HSF1) translocation from the cytosol to the nucleus, a process requiring PKC phosphorylation.	Nitroarginine	0-5	proline rich transmembrane protein 2	Homo sapiens	120-123
11841991-10	2002	These results suggest that L-NNA inhibits HSP-70i by reducing [Ca(2+)](i) and decreasing PKC and PKA activity, thereby blocking HSF1 translocation from the cytosol to the nucleus.	Nitroarginine	27-32	heat shock protein family A (Hsp70) member 1A	Homo sapiens	42-49
11841991-10	2002	These results suggest that L-NNA inhibits HSP-70i by reducing [Ca(2+)](i) and decreasing PKC and PKA activity, thereby blocking HSF1 translocation from the cytosol to the nucleus.	Nitroarginine	27-32	proline rich transmembrane protein 2	Homo sapiens	89-92
11841991-10	2002	These results suggest that L-NNA inhibits HSP-70i by reducing [Ca(2+)](i) and decreasing PKC and PKA activity, thereby blocking HSF1 translocation from the cytosol to the nucleus.	Nitroarginine	27-32	heat shock transcription factor 1	Homo sapiens	128-132
11882637-7	2002	Because such a vasodilation is prevented by nonvasoconstricting microdoses of N(G)-nitro-L-arginine methylester, nitric oxide--endothelin balance controls substantially renal hemodynamics under angiotensin II blockade.	Nitroarginine	78-99	angiotensinogen	Homo sapiens	194-208
11827697-9	2002	RESULTS: CM treated with TNFalpha exhibited decreased levels of alphaMHC transcripts (69 +/- 8% of control), the effect of TNFalpha was reversed by L-NNA (94 +/- 14% of control).	Nitroarginine	148-153	tumor necrosis factor	Mus musculus	25-33
11827697-9	2002	RESULTS: CM treated with TNFalpha exhibited decreased levels of alphaMHC transcripts (69 +/- 8% of control), the effect of TNFalpha was reversed by L-NNA (94 +/- 14% of control).	Nitroarginine	148-153	tumor necrosis factor	Mus musculus	123-131
11899958-7	2002	The relaxant responses to VEGF were significantly attenuated by pretreatment with Nomega-nitro-L-arginine (L-NNA) alone and indomethacin + L-NNA, and totally abolished by removal of the endothelium or pretreatment with indomethacin + L-NNA + oxyhemoglobin.	Nitroarginine	82-105	vascular endothelial growth factor A	Homo sapiens	26-30
11899958-7	2002	The relaxant responses to VEGF were significantly attenuated by pretreatment with Nomega-nitro-L-arginine (L-NNA) alone and indomethacin + L-NNA, and totally abolished by removal of the endothelium or pretreatment with indomethacin + L-NNA + oxyhemoglobin.	Nitroarginine	107-112	vascular endothelial growth factor A	Homo sapiens	26-30
11899958-7	2002	The relaxant responses to VEGF were significantly attenuated by pretreatment with Nomega-nitro-L-arginine (L-NNA) alone and indomethacin + L-NNA, and totally abolished by removal of the endothelium or pretreatment with indomethacin + L-NNA + oxyhemoglobin.	Nitroarginine	139-144	vascular endothelial growth factor A	Homo sapiens	26-30
11899958-7	2002	The relaxant responses to VEGF were significantly attenuated by pretreatment with Nomega-nitro-L-arginine (L-NNA) alone and indomethacin + L-NNA, and totally abolished by removal of the endothelium or pretreatment with indomethacin + L-NNA + oxyhemoglobin.	Nitroarginine	139-144	vascular endothelial growth factor A	Homo sapiens	26-30
11903508-2	2002	The present study was undertaken to clarify whether the renin-angiotensin system contributes to the development of this pressor response to L-NNA.	Nitroarginine	140-145	renin	Canis lupus familiaris	56-61
11903508-5	2002	The acute pressor response produced by the intravenous administration of L-NNA was accompanied by reduced renin activity in both systemic and renal vascular beds.	Nitroarginine	73-78	renin	Canis lupus familiaris	106-111
11903508-7	2002	The counteraction by captopril of the L-NNA-induced pressor response was likely to be attributable to enhancement by captopril of depressor responses to bradykinin, as HOE-140, a bradykinin B2 receptor antagonist, neutralised the effect of captopril.	Nitroarginine	38-43	kininogen 1	Canis lupus familiaris	153-163
11903508-7	2002	The counteraction by captopril of the L-NNA-induced pressor response was likely to be attributable to enhancement by captopril of depressor responses to bradykinin, as HOE-140, a bradykinin B2 receptor antagonist, neutralised the effect of captopril.	Nitroarginine	38-43	kininogen 1	Canis lupus familiaris	179-189
11719508-5	2002	Interestingly, ROS generation in response to VEGF is not blocked but rather potentiated by endothelial nitric-oxide synthase inhibitors diphenyleneiodonium and N(G)methyl-l-arginine, ruling out the possibility of nitric oxide being the oxidant species here detected in VEGF-stimulated cells.	Nitroarginine	160-181	vascular endothelial growth factor A	Homo sapiens	45-49